TW202302152A - 多醣及其多肽結合物之純化方法 - Google Patents
多醣及其多肽結合物之純化方法 Download PDFInfo
- Publication number
- TW202302152A TW202302152A TW111105554A TW111105554A TW202302152A TW 202302152 A TW202302152 A TW 202302152A TW 111105554 A TW111105554 A TW 111105554A TW 111105554 A TW111105554 A TW 111105554A TW 202302152 A TW202302152 A TW 202302152A
- Authority
- TW
- Taiwan
- Prior art keywords
- seq
- polypeptide
- polysaccharide
- kda
- mol
- Prior art date
Links
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 612
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 612
- 150000004676 glycans Chemical class 0.000 title claims abstract description 473
- 229920001184 polypeptide Polymers 0.000 title claims description 323
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 321
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 321
- 238000000746 purification Methods 0.000 title description 34
- 238000000034 method Methods 0.000 claims abstract description 197
- 239000000203 mixture Substances 0.000 claims abstract description 141
- 230000002163 immunogen Effects 0.000 claims abstract description 135
- 230000001580 bacterial effect Effects 0.000 claims abstract description 89
- 210000002421 cell wall Anatomy 0.000 claims abstract description 42
- 241001505901 Streptococcus sp. 'group A' Species 0.000 claims description 223
- 108010075210 streptolysin O Proteins 0.000 claims description 184
- 102000036639 antigens Human genes 0.000 claims description 173
- 108091007433 antigens Proteins 0.000 claims description 173
- 239000000427 antigen Substances 0.000 claims description 166
- 150000001413 amino acids Chemical class 0.000 claims description 165
- 239000012634 fragment Substances 0.000 claims description 147
- GAJBPZXIKZXTCG-VIFPVBQESA-N (2s)-2-amino-3-[4-(azidomethyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(CN=[N+]=[N-])C=C1 GAJBPZXIKZXTCG-VIFPVBQESA-N 0.000 claims description 130
- 210000004027 cell Anatomy 0.000 claims description 95
- 239000006166 lysate Substances 0.000 claims description 93
- 238000009739 binding Methods 0.000 claims description 89
- 230000027455 binding Effects 0.000 claims description 88
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 claims description 39
- 108010013639 Peptidoglycan Proteins 0.000 claims description 39
- 108010059574 C5a peptidase Proteins 0.000 claims description 37
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 36
- 229940024606 amino acid Drugs 0.000 claims description 34
- 150000004804 polysaccharides Polymers 0.000 claims description 34
- 239000003638 chemical reducing agent Substances 0.000 claims description 31
- 230000005875 antibody response Effects 0.000 claims description 28
- 238000001914 filtration Methods 0.000 claims description 28
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 26
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 26
- 238000009295 crossflow filtration Methods 0.000 claims description 25
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 25
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical group CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 claims description 24
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 24
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 24
- 108010014251 Muramidase Proteins 0.000 claims description 23
- 102000016943 Muramidase Human genes 0.000 claims description 23
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 23
- 229960000274 lysozyme Drugs 0.000 claims description 23
- 235000010335 lysozyme Nutrition 0.000 claims description 23
- 239000004325 lysozyme Substances 0.000 claims description 23
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 23
- 108010082340 Arginine deiminase Proteins 0.000 claims description 21
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 241000894006 Bacteria Species 0.000 claims description 20
- 239000004365 Protease Substances 0.000 claims description 20
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 18
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 17
- -1 2-amino-3-(4-(azido Nitromethyl)pyridin-2-yl)propionic acid Chemical compound 0.000 claims description 16
- 102000035195 Peptidases Human genes 0.000 claims description 16
- 108091005804 Peptidases Proteins 0.000 claims description 16
- 235000019419 proteases Nutrition 0.000 claims description 16
- 238000010979 pH adjustment Methods 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 14
- 238000004587 chromatography analysis Methods 0.000 claims description 13
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 12
- 230000003301 hydrolyzing effect Effects 0.000 claims description 12
- 230000028993 immune response Effects 0.000 claims description 12
- 230000001681 protective effect Effects 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims description 11
- 238000005119 centrifugation Methods 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 10
- 239000012279 sodium borohydride Substances 0.000 claims description 10
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 10
- 108010067770 Endopeptidase K Proteins 0.000 claims description 9
- 238000005571 anion exchange chromatography Methods 0.000 claims description 9
- 238000011118 depth filtration Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 238000001556 precipitation Methods 0.000 claims description 8
- 238000011146 sterile filtration Methods 0.000 claims description 8
- GAJBPZXIKZXTCG-UHFFFAOYSA-N 2-amino-3-[4-(azidomethyl)phenyl]propanoic acid Chemical compound [NH3+]C(CC1=CC=C(CN=[N+]=[N-])C=C1)C([O-])=O GAJBPZXIKZXTCG-UHFFFAOYSA-N 0.000 claims description 7
- SJHUEOARVQCKOH-UHFFFAOYSA-N 2-amino-3-[5-(azidomethyl)pyridin-2-yl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=C(CN=[N+]=[N-])C=N1 SJHUEOARVQCKOH-UHFFFAOYSA-N 0.000 claims description 7
- PIVPBUHWDALSQO-UHFFFAOYSA-N 2-amino-3-[6-(azidomethyl)pyridin-3-yl]propanoic acid Chemical compound NC(C(=O)O)CC=1C=NC(=CC=1)CN=[N+]=[N-] PIVPBUHWDALSQO-UHFFFAOYSA-N 0.000 claims description 7
- CIFCKCQAKQRJFC-UHFFFAOYSA-N 2-amino-3-azidopropanoic acid Chemical compound OC(=O)C(N)CN=[N+]=[N-] CIFCKCQAKQRJFC-UHFFFAOYSA-N 0.000 claims description 7
- AUARUCAREKTRCL-UHFFFAOYSA-N 2-amino-5-azidopentanoic acid Chemical compound OC(=O)C(N)CCCN=[N+]=[N-] AUARUCAREKTRCL-UHFFFAOYSA-N 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 238000005277 cation exchange chromatography Methods 0.000 claims description 7
- 229940088598 enzyme Drugs 0.000 claims description 7
- 108010009719 mutanolysin Proteins 0.000 claims description 7
- NEMHIKRLROONTL-UHFFFAOYSA-N 2-amino-3-(4-azidophenyl)propanoic acid Chemical compound OC(=O)C(N)CC1=CC=C(N=[N+]=[N-])C=C1 NEMHIKRLROONTL-UHFFFAOYSA-N 0.000 claims description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 6
- 241000194017 Streptococcus Species 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- DIFYSVZHVRAXAV-UHFFFAOYSA-N 2-azido-3-phenylpropanoic acid Chemical compound [N-]=[N+]=NC(C(=O)O)CC1=CC=CC=C1 DIFYSVZHVRAXAV-UHFFFAOYSA-N 0.000 claims description 5
- 241000193403 Clostridium Species 0.000 claims description 5
- 241000194033 Enterococcus Species 0.000 claims description 5
- 241000606790 Haemophilus Species 0.000 claims description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 5
- 241000186781 Listeria Species 0.000 claims description 5
- 239000000919 ceramic Substances 0.000 claims description 5
- CUVGUPIVTLGRGI-UHFFFAOYSA-N 4-(3-phosphonopropyl)piperazine-2-carboxylic acid Chemical compound OC(=O)C1CN(CCCP(O)(O)=O)CCN1 CUVGUPIVTLGRGI-UHFFFAOYSA-N 0.000 claims description 4
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 4
- 102100032488 Acylamino-acid-releasing enzyme Human genes 0.000 claims description 4
- 108010061216 Acylaminoacyl-peptidase Proteins 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 4
- 108090000087 Carboxypeptidase B Proteins 0.000 claims description 4
- 102000003670 Carboxypeptidase B Human genes 0.000 claims description 4
- 108010080937 Carboxypeptidases A Proteins 0.000 claims description 4
- 102000000496 Carboxypeptidases A Human genes 0.000 claims description 4
- 108010059081 Cathepsin A Proteins 0.000 claims description 4
- 102000005572 Cathepsin A Human genes 0.000 claims description 4
- 108090000317 Chymotrypsin Proteins 0.000 claims description 4
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims description 4
- 102000008857 Ferritin Human genes 0.000 claims description 4
- 108050000784 Ferritin Proteins 0.000 claims description 4
- 238000008416 Ferritin Methods 0.000 claims description 4
- 102000004157 Hydrolases Human genes 0.000 claims description 4
- 108090000604 Hydrolases Proteins 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 241000588653 Neisseria Species 0.000 claims description 4
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 4
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 4
- 108090000526 Papain Proteins 0.000 claims description 4
- 108090000284 Pepsin A Proteins 0.000 claims description 4
- 102000057297 Pepsin A Human genes 0.000 claims description 4
- 108010030544 Peptidyl-Lys metalloendopeptidase Proteins 0.000 claims description 4
- 101710188053 Protein D Proteins 0.000 claims description 4
- 241000589516 Pseudomonas Species 0.000 claims description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 4
- 101710132893 Resolvase Proteins 0.000 claims description 4
- 241000191940 Staphylococcus Species 0.000 claims description 4
- 241000194019 Streptococcus mutans Species 0.000 claims description 4
- 241001312524 Streptococcus viridans Species 0.000 claims description 4
- 108090000787 Subtilisin Proteins 0.000 claims description 4
- 108090000631 Trypsin Proteins 0.000 claims description 4
- 102000004142 Trypsin Human genes 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 108010054847 carboxypeptidase P Proteins 0.000 claims description 4
- 229960002376 chymotrypsin Drugs 0.000 claims description 4
- 108090001092 clostripain Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 229940055729 papain Drugs 0.000 claims description 4
- 235000019834 papain Nutrition 0.000 claims description 4
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 4
- 229940111202 pepsin Drugs 0.000 claims description 4
- 229940043131 pyroglutamate Drugs 0.000 claims description 4
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 4
- 239000012588 trypsin Substances 0.000 claims description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 4
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 claims description 3
- 108090001109 Thermolysin Proteins 0.000 claims description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 2
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 claims 2
- 108010051815 Glutamyl endopeptidase Proteins 0.000 claims 1
- 108010003914 endoproteinase Asp-N Proteins 0.000 claims 1
- 108010059339 submandibular proteinase A Proteins 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 26
- 239000000243 solution Substances 0.000 description 97
- 238000003776 cleavage reaction Methods 0.000 description 46
- 230000007017 scission Effects 0.000 description 46
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 35
- 239000002585 base Substances 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- QRZUPJILJVGUFF-UHFFFAOYSA-N 2,8-dibenzylcyclooctan-1-one Chemical compound C1CCCCC(CC=2C=CC=CC=2)C(=O)C1CC1=CC=CC=C1 QRZUPJILJVGUFF-UHFFFAOYSA-N 0.000 description 17
- KTIOBJVNCOFWCL-UHFFFAOYSA-N dbco-peg4-amine Chemical compound NCCOCCOCCOCCOCCC(=O)NCCC(=O)N1CC2=CC=CC=C2C#CC2=CC=CC=C12 KTIOBJVNCOFWCL-UHFFFAOYSA-N 0.000 description 17
- 230000003053 immunization Effects 0.000 description 17
- 238000002649 immunization Methods 0.000 description 17
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 16
- 208000034628 Celiac artery compression syndrome Diseases 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- 238000000569 multi-angle light scattering Methods 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 238000010348 incorporation Methods 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- 229960005486 vaccine Drugs 0.000 description 15
- 230000021615 conjugation Effects 0.000 description 13
- 230000005847 immunogenicity Effects 0.000 description 13
- 108010092854 aspartyllysine Proteins 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 108010047495 alanylglycine Proteins 0.000 description 10
- 108010057821 leucylproline Proteins 0.000 description 10
- 108010003700 lysyl aspartic acid Proteins 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 101710118538 Protease Proteins 0.000 description 9
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- 108010053725 prolylvaline Proteins 0.000 description 9
- 102000014914 Carrier Proteins Human genes 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 108010045350 alanyl-tyrosyl-alanine Proteins 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 8
- 239000001488 sodium phosphate Substances 0.000 description 8
- 229910000162 sodium phosphate Inorganic materials 0.000 description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 8
- 108010078791 Carrier Proteins Proteins 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000006227 byproduct Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000007912 intraperitoneal administration Methods 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 6
- XIKYNVKEUINBGL-IUCAKERBSA-N Glu-His-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)NCC(O)=O XIKYNVKEUINBGL-IUCAKERBSA-N 0.000 description 6
- FXGRXIATVXUAHO-WEDXCCLWSA-N Gly-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN FXGRXIATVXUAHO-WEDXCCLWSA-N 0.000 description 6
- LLWQVJNHMYBLLK-CDMKHQONSA-N Gly-Thr-Phe Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LLWQVJNHMYBLLK-CDMKHQONSA-N 0.000 description 6
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 6
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 6
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 238000001212 derivatisation Methods 0.000 description 6
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 6
- 108010089804 glycyl-threonine Proteins 0.000 description 6
- 108010050848 glycylleucine Proteins 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 108010012058 leucyltyrosine Proteins 0.000 description 6
- 108010079317 prolyl-tyrosine Proteins 0.000 description 6
- 108010026333 seryl-proline Proteins 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 108010031491 threonyl-lysyl-glutamic acid Proteins 0.000 description 6
- LSFLSTKLVZEYDR-UHFFFAOYSA-N 2-amino-3-[4-(azidomethyl)pyridin-2-yl]propanoic acid Chemical compound NC(C(=O)O)CC1=NC=CC(=C1)CN=[N+]=[N-] LSFLSTKLVZEYDR-UHFFFAOYSA-N 0.000 description 5
- NNWQLZWAZSJGLY-UHFFFAOYSA-N 2-azaniumyl-4-azidobutanoate Chemical compound OC(=O)C(N)CCN=[N+]=[N-] NNWQLZWAZSJGLY-UHFFFAOYSA-N 0.000 description 5
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 5
- 101710085938 Matrix protein Proteins 0.000 description 5
- 101710127721 Membrane protein Proteins 0.000 description 5
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 5
- GNHRVXYZKWSJTF-HJGDQZAQSA-N Thr-Asp-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O GNHRVXYZKWSJTF-HJGDQZAQSA-N 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 229960002725 isoflurane Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 108010036211 5-HT-moduline Proteins 0.000 description 4
- CVGNCMIULZNYES-WHFBIAKZSA-N Ala-Asn-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O CVGNCMIULZNYES-WHFBIAKZSA-N 0.000 description 4
- NXSFUECZFORGOG-CIUDSAMLSA-N Ala-Asn-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NXSFUECZFORGOG-CIUDSAMLSA-N 0.000 description 4
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 4
- VCSABYLVNWQYQE-SRVKXCTJSA-N Ala-Lys-Lys Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O VCSABYLVNWQYQE-SRVKXCTJSA-N 0.000 description 4
- BFMIRJBURUXDRG-DLOVCJGASA-N Ala-Phe-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 BFMIRJBURUXDRG-DLOVCJGASA-N 0.000 description 4
- IETUUAHKCHOQHP-KZVJFYERSA-N Ala-Thr-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)N)[C@@H](C)O)C(O)=O IETUUAHKCHOQHP-KZVJFYERSA-N 0.000 description 4
- LYILPUNCKACNGF-NAKRPEOUSA-N Ala-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N LYILPUNCKACNGF-NAKRPEOUSA-N 0.000 description 4
- JEOCWTUOMKEEMF-RHYQMDGZSA-N Arg-Leu-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JEOCWTUOMKEEMF-RHYQMDGZSA-N 0.000 description 4
- KZXPVYVSHUJCEO-ULQDDVLXSA-N Arg-Phe-Lys Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=CC=C1 KZXPVYVSHUJCEO-ULQDDVLXSA-N 0.000 description 4
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 4
- VPPXTHJNTYDNFJ-CIUDSAMLSA-N Asp-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N VPPXTHJNTYDNFJ-CIUDSAMLSA-N 0.000 description 4
- UGIBTKGQVWFTGX-BIIVOSGPSA-N Asp-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)N)C(=O)O UGIBTKGQVWFTGX-BIIVOSGPSA-N 0.000 description 4
- XACXDSRQIXRMNS-OLHMAJIHSA-N Asp-Asn-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)N)O XACXDSRQIXRMNS-OLHMAJIHSA-N 0.000 description 4
- JUWZKMBALYLZCK-WHFBIAKZSA-N Asp-Gly-Asn Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O JUWZKMBALYLZCK-WHFBIAKZSA-N 0.000 description 4
- PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 4
- JNNVNVRBYUJYGS-CIUDSAMLSA-N Asp-Leu-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O JNNVNVRBYUJYGS-CIUDSAMLSA-N 0.000 description 4
- CTWCFPWFIGRAEP-CIUDSAMLSA-N Asp-Lys-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O CTWCFPWFIGRAEP-CIUDSAMLSA-N 0.000 description 4
- JUWISGAGWSDGDH-KKUMJFAQSA-N Asp-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=CC=C1 JUWISGAGWSDGDH-KKUMJFAQSA-N 0.000 description 4
- PLNJUJGNLDSFOP-UWJYBYFXSA-N Asp-Tyr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O PLNJUJGNLDSFOP-UWJYBYFXSA-N 0.000 description 4
- ZUHQCDZJPTXVCU-UHFFFAOYSA-N C1#CCCC2=CC=CC=C2C2=CC=CC=C21 Chemical compound C1#CCCC2=CC=CC=C2C2=CC=CC=C21 ZUHQCDZJPTXVCU-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- KZEUVLLVULIPNX-GUBZILKMSA-N Gln-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N KZEUVLLVULIPNX-GUBZILKMSA-N 0.000 description 4
- JFSNBQJNDMXMQF-XHNCKOQMSA-N Gln-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N)C(=O)O JFSNBQJNDMXMQF-XHNCKOQMSA-N 0.000 description 4
- UHVIQGKBMXEVGN-WDSKDSINSA-N Glu-Gly-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UHVIQGKBMXEVGN-WDSKDSINSA-N 0.000 description 4
- WGYHAAXZWPEBDQ-IFFSRLJSSA-N Glu-Val-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WGYHAAXZWPEBDQ-IFFSRLJSSA-N 0.000 description 4
- JRDYDYXZKFNNRQ-XPUUQOCRSA-N Gly-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN JRDYDYXZKFNNRQ-XPUUQOCRSA-N 0.000 description 4
- BGVYNAQWHSTTSP-BYULHYEWSA-N Gly-Asn-Ile Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BGVYNAQWHSTTSP-BYULHYEWSA-N 0.000 description 4
- TWTPDFFBLQEBOE-IUCAKERBSA-N Gly-Leu-Gln Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O TWTPDFFBLQEBOE-IUCAKERBSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- SACHLUOUHCVIKI-GMOBBJLQSA-N Ile-Arg-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N SACHLUOUHCVIKI-GMOBBJLQSA-N 0.000 description 4
- GLYJPWIRLBAIJH-UHFFFAOYSA-N Ile-Lys-Pro Natural products CCC(C)C(N)C(=O)NC(CCCCN)C(=O)N1CCCC1C(O)=O GLYJPWIRLBAIJH-UHFFFAOYSA-N 0.000 description 4
- JNLSTRPWUXOORL-MMWGEVLESA-N Ile-Ser-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N JNLSTRPWUXOORL-MMWGEVLESA-N 0.000 description 4
- WXLYNEHOGRYNFU-URLPEUOOSA-N Ile-Thr-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N WXLYNEHOGRYNFU-URLPEUOOSA-N 0.000 description 4
- OMDWJWGZGMCQND-CFMVVWHZSA-N Ile-Tyr-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N OMDWJWGZGMCQND-CFMVVWHZSA-N 0.000 description 4
- 108010065920 Insulin Lispro Proteins 0.000 description 4
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 4
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 4
- SUPVSFFZWVOEOI-CQDKDKBSSA-N Leu-Ala-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 SUPVSFFZWVOEOI-CQDKDKBSSA-N 0.000 description 4
- SUPVSFFZWVOEOI-UHFFFAOYSA-N Leu-Ala-Tyr Natural products CC(C)CC(N)C(=O)NC(C)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 SUPVSFFZWVOEOI-UHFFFAOYSA-N 0.000 description 4
- MYGQXVYRZMKRDB-SRVKXCTJSA-N Leu-Asp-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN MYGQXVYRZMKRDB-SRVKXCTJSA-N 0.000 description 4
- HQUXQAMSWFIRET-AVGNSLFASA-N Leu-Glu-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN HQUXQAMSWFIRET-AVGNSLFASA-N 0.000 description 4
- HGFGEMSVBMCFKK-MNXVOIDGSA-N Leu-Ile-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O HGFGEMSVBMCFKK-MNXVOIDGSA-N 0.000 description 4
- LXKNSJLSGPNHSK-KKUMJFAQSA-N Leu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N LXKNSJLSGPNHSK-KKUMJFAQSA-N 0.000 description 4
- WXUOJXIGOPMDJM-SRVKXCTJSA-N Leu-Lys-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O WXUOJXIGOPMDJM-SRVKXCTJSA-N 0.000 description 4
- PKKMDPNFGULLNQ-AVGNSLFASA-N Leu-Met-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O PKKMDPNFGULLNQ-AVGNSLFASA-N 0.000 description 4
- HDHQQEDVWQGBEE-DCAQKATOSA-N Leu-Met-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O HDHQQEDVWQGBEE-DCAQKATOSA-N 0.000 description 4
- PWPBLZXWFXJFHE-RHYQMDGZSA-N Leu-Pro-Thr Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O PWPBLZXWFXJFHE-RHYQMDGZSA-N 0.000 description 4
- RGUXWMDNCPMQFB-YUMQZZPRSA-N Leu-Ser-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RGUXWMDNCPMQFB-YUMQZZPRSA-N 0.000 description 4
- VHXMZJGOKIMETG-CQDKDKBSSA-N Lys-Ala-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CCCCN)N VHXMZJGOKIMETG-CQDKDKBSSA-N 0.000 description 4
- AAORVPFVUIHEAB-YUMQZZPRSA-N Lys-Asp-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O AAORVPFVUIHEAB-YUMQZZPRSA-N 0.000 description 4
- GGNOBVSOZPHLCE-GUBZILKMSA-N Lys-Gln-Asp Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O GGNOBVSOZPHLCE-GUBZILKMSA-N 0.000 description 4
- LLSUNJYOSCOOEB-GUBZILKMSA-N Lys-Glu-Asp Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O LLSUNJYOSCOOEB-GUBZILKMSA-N 0.000 description 4
- WBSCNDJQPKSPII-KKUMJFAQSA-N Lys-Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O WBSCNDJQPKSPII-KKUMJFAQSA-N 0.000 description 4
- PLDJDCJLRCYPJB-VOAKCMCISA-N Lys-Lys-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PLDJDCJLRCYPJB-VOAKCMCISA-N 0.000 description 4
- PLOUVAYOMTYJRG-JXUBOQSCSA-N Lys-Thr-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O PLOUVAYOMTYJRG-JXUBOQSCSA-N 0.000 description 4
- DRRXXZBXDMLGFC-IHRRRGAJSA-N Lys-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN DRRXXZBXDMLGFC-IHRRRGAJSA-N 0.000 description 4
- WIVCOAKLPICYGY-KKUMJFAQSA-N Phe-Asp-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N WIVCOAKLPICYGY-KKUMJFAQSA-N 0.000 description 4
- WPTYDQPGBMDUBI-QWRGUYRKSA-N Phe-Gly-Asn Chemical compound N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O WPTYDQPGBMDUBI-QWRGUYRKSA-N 0.000 description 4
- QTDBZORPVYTRJU-KKXDTOCCSA-N Phe-Tyr-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O QTDBZORPVYTRJU-KKXDTOCCSA-N 0.000 description 4
- DZZCICYRSZASNF-FXQIFTODSA-N Pro-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 DZZCICYRSZASNF-FXQIFTODSA-N 0.000 description 4
- VJLJGKQAOQJXJG-CIUDSAMLSA-N Pro-Asp-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VJLJGKQAOQJXJG-CIUDSAMLSA-N 0.000 description 4
- IOVHBRCQOGWAQH-ZKWXMUAHSA-N Ser-Gly-Ile Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IOVHBRCQOGWAQH-ZKWXMUAHSA-N 0.000 description 4
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 4
- PPNPDKGQRFSCAC-CIUDSAMLSA-N Ser-Lys-Asp Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPNPDKGQRFSCAC-CIUDSAMLSA-N 0.000 description 4
- OZPDGESCTGGNAD-CIUDSAMLSA-N Ser-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CO OZPDGESCTGGNAD-CIUDSAMLSA-N 0.000 description 4
- 241000607768 Shigella Species 0.000 description 4
- NJEMRSFGDNECGF-GCJQMDKQSA-N Thr-Ala-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O NJEMRSFGDNECGF-GCJQMDKQSA-N 0.000 description 4
- XOTBWOCSLMBGMF-SUSMZKCASA-N Thr-Glu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOTBWOCSLMBGMF-SUSMZKCASA-N 0.000 description 4
- YUPVPKZBKCLFLT-QTKMDUPCSA-N Thr-His-Val Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](C(C)C)C(=O)O)N)O YUPVPKZBKCLFLT-QTKMDUPCSA-N 0.000 description 4
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 4
- MGJLBZFUXUGMML-VOAKCMCISA-N Thr-Lys-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MGJLBZFUXUGMML-VOAKCMCISA-N 0.000 description 4
- VBMOVTMNHWPZJR-SUSMZKCASA-N Thr-Thr-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VBMOVTMNHWPZJR-SUSMZKCASA-N 0.000 description 4
- LVRFMARKDGGZMX-IZPVPAKOSA-N Thr-Tyr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=C(O)C=C1 LVRFMARKDGGZMX-IZPVPAKOSA-N 0.000 description 4
- ZWZOCUWOXSDYFZ-CQDKDKBSSA-N Tyr-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 ZWZOCUWOXSDYFZ-CQDKDKBSSA-N 0.000 description 4
- AOIZTZRWMSPPAY-KAOXEZKKSA-N Tyr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)O AOIZTZRWMSPPAY-KAOXEZKKSA-N 0.000 description 4
- ASQFIHTXXMFENG-XPUUQOCRSA-N Val-Ala-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O ASQFIHTXXMFENG-XPUUQOCRSA-N 0.000 description 4
- LABUITCFCAABSV-UHFFFAOYSA-N Val-Ala-Tyr Natural products CC(C)C(N)C(=O)NC(C)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LABUITCFCAABSV-UHFFFAOYSA-N 0.000 description 4
- VUTHNLMCXKLLFI-LAEOZQHASA-N Val-Asp-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N VUTHNLMCXKLLFI-LAEOZQHASA-N 0.000 description 4
- VCAWFLIWYNMHQP-UKJIMTQDSA-N Val-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N VCAWFLIWYNMHQP-UKJIMTQDSA-N 0.000 description 4
- OFTXTCGQJXTNQS-XGEHTFHBSA-N Val-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)N)O OFTXTCGQJXTNQS-XGEHTFHBSA-N 0.000 description 4
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 4
- 108010081404 acein-2 Proteins 0.000 description 4
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 4
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 4
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 4
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 4
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 4
- 108010047857 aspartylglycine Proteins 0.000 description 4
- 108010068265 aspartyltyrosine Proteins 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 108010069898 fibrinogen fragment X Proteins 0.000 description 4
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 4
- 108010072405 glycyl-aspartyl-glycine Proteins 0.000 description 4
- 108010028188 glycyl-histidyl-serine Proteins 0.000 description 4
- 108010015792 glycyllysine Proteins 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 108010044348 lysyl-glutamyl-aspartic acid Proteins 0.000 description 4
- 108010017391 lysylvaline Proteins 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 108010074082 phenylalanyl-alanyl-lysine Proteins 0.000 description 4
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 4
- 108010051242 phenylalanylserine Proteins 0.000 description 4
- 108010025488 pinealon Proteins 0.000 description 4
- 229910000160 potassium phosphate Inorganic materials 0.000 description 4
- 235000011009 potassium phosphates Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108010070643 prolylglutamic acid Proteins 0.000 description 4
- 108010015796 prolylisoleucine Proteins 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 208000004124 rheumatic heart disease Diseases 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 108010072986 threonyl-seryl-lysine Proteins 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108010003137 tyrosyltyrosine Proteins 0.000 description 4
- 108010073969 valyllysine Proteins 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 3
- APHUDFFMXFYRKP-CIUDSAMLSA-N Asn-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N APHUDFFMXFYRKP-CIUDSAMLSA-N 0.000 description 3
- MYLZFUMPZCPJCJ-NHCYSSNCSA-N Asp-Lys-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O MYLZFUMPZCPJCJ-NHCYSSNCSA-N 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- ZOXBSICWUDAOHX-GUBZILKMSA-N Glu-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCC(O)=O ZOXBSICWUDAOHX-GUBZILKMSA-N 0.000 description 3
- JMQFHZWESBGPFC-WDSKDSINSA-N Gly-Gln-Asp Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O JMQFHZWESBGPFC-WDSKDSINSA-N 0.000 description 3
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 3
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 3
- GVKKVHNRTUFCCE-BJDJZHNGSA-N Ile-Leu-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)O)N GVKKVHNRTUFCCE-BJDJZHNGSA-N 0.000 description 3
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 3
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 3
- RXWPLVRJQNWXRQ-IHRRRGAJSA-N Met-His-His Chemical compound C([C@H](NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)C1=CNC=N1 RXWPLVRJQNWXRQ-IHRRRGAJSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- YDTUEBLEAVANFH-RCWTZXSCSA-N Pro-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 YDTUEBLEAVANFH-RCWTZXSCSA-N 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- PMTWIUBUQRGCSB-FXQIFTODSA-N Ser-Val-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O PMTWIUBUQRGCSB-FXQIFTODSA-N 0.000 description 3
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 description 3
- 206010044248 Toxic shock syndrome Diseases 0.000 description 3
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- BBWBEZAMXFGUGK-UHFFFAOYSA-N bis(dodecylsulfanyl)-methylarsane Chemical compound CCCCCCCCCCCCS[As](C)SCCCCCCCCCCCC BBWBEZAMXFGUGK-UHFFFAOYSA-N 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229940001442 combination vaccine Drugs 0.000 description 3
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011026 diafiltration Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 2
- PIPTUBPKYFRLCP-NHCYSSNCSA-N Ala-Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PIPTUBPKYFRLCP-NHCYSSNCSA-N 0.000 description 2
- JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 2
- DVWVZSJAYIJZFI-FXQIFTODSA-N Ala-Arg-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O DVWVZSJAYIJZFI-FXQIFTODSA-N 0.000 description 2
- YAXNATKKPOWVCP-ZLUOBGJFSA-N Ala-Asn-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O YAXNATKKPOWVCP-ZLUOBGJFSA-N 0.000 description 2
- FXKNPWNXPQZLES-ZLUOBGJFSA-N Ala-Asn-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O FXKNPWNXPQZLES-ZLUOBGJFSA-N 0.000 description 2
- LZRNYBIJOSKKRJ-XVYDVKMFSA-N Ala-Asp-His Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N LZRNYBIJOSKKRJ-XVYDVKMFSA-N 0.000 description 2
- LSLIRHLIUDVNBN-CIUDSAMLSA-N Ala-Asp-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LSLIRHLIUDVNBN-CIUDSAMLSA-N 0.000 description 2
- BTYTYHBSJKQBQA-GCJQMDKQSA-N Ala-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N)O BTYTYHBSJKQBQA-GCJQMDKQSA-N 0.000 description 2
- KUDREHRZRIVKHS-UWJYBYFXSA-N Ala-Asp-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KUDREHRZRIVKHS-UWJYBYFXSA-N 0.000 description 2
- LGFCAXJBAZESCF-ACZMJKKPSA-N Ala-Gln-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O LGFCAXJBAZESCF-ACZMJKKPSA-N 0.000 description 2
- CRWFEKLFPVRPBV-CIUDSAMLSA-N Ala-Gln-Met Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O CRWFEKLFPVRPBV-CIUDSAMLSA-N 0.000 description 2
- OMMDTNGURYRDAC-NRPADANISA-N Ala-Glu-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OMMDTNGURYRDAC-NRPADANISA-N 0.000 description 2
- ZVFVBBGVOILKPO-WHFBIAKZSA-N Ala-Gly-Ala Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O ZVFVBBGVOILKPO-WHFBIAKZSA-N 0.000 description 2
- NHLAEBFGWPXFGI-WHFBIAKZSA-N Ala-Gly-Asn Chemical compound C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N NHLAEBFGWPXFGI-WHFBIAKZSA-N 0.000 description 2
- BLIMFWGRQKRCGT-YUMQZZPRSA-N Ala-Gly-Lys Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN BLIMFWGRQKRCGT-YUMQZZPRSA-N 0.000 description 2
- OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 2
- NYDBKUNVSALYPX-NAKRPEOUSA-N Ala-Ile-Arg Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NYDBKUNVSALYPX-NAKRPEOUSA-N 0.000 description 2
- VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 description 2
- RUQBGIMJQUWXPP-CYDGBPFRSA-N Ala-Leu-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O RUQBGIMJQUWXPP-CYDGBPFRSA-N 0.000 description 2
- AJBVYEYZVYPFCF-CIUDSAMLSA-N Ala-Lys-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O AJBVYEYZVYPFCF-CIUDSAMLSA-N 0.000 description 2
- PIXQDIGKDNNOOV-GUBZILKMSA-N Ala-Lys-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O PIXQDIGKDNNOOV-GUBZILKMSA-N 0.000 description 2
- MFMDKJIPHSWSBM-GUBZILKMSA-N Ala-Lys-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O MFMDKJIPHSWSBM-GUBZILKMSA-N 0.000 description 2
- PMQXMXAASGFUDX-SRVKXCTJSA-N Ala-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CCCCN PMQXMXAASGFUDX-SRVKXCTJSA-N 0.000 description 2
- NINQYGGNRIBFSC-CIUDSAMLSA-N Ala-Lys-Ser Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CO)C(O)=O NINQYGGNRIBFSC-CIUDSAMLSA-N 0.000 description 2
- DEWWPUNXRNGMQN-LPEHRKFASA-N Ala-Met-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@@H]1C(=O)O)N DEWWPUNXRNGMQN-LPEHRKFASA-N 0.000 description 2
- ADSGHMXEAZJJNF-DCAQKATOSA-N Ala-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N ADSGHMXEAZJJNF-DCAQKATOSA-N 0.000 description 2
- BTRULDJUUVGRNE-DCAQKATOSA-N Ala-Pro-Lys Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O BTRULDJUUVGRNE-DCAQKATOSA-N 0.000 description 2
- XWFWAXPOLRTDFZ-FXQIFTODSA-N Ala-Pro-Ser Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O XWFWAXPOLRTDFZ-FXQIFTODSA-N 0.000 description 2
- DCVYRWFAMZFSDA-ZLUOBGJFSA-N Ala-Ser-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DCVYRWFAMZFSDA-ZLUOBGJFSA-N 0.000 description 2
- VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 description 2
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 2
- MMLHRUJLOUSRJX-CIUDSAMLSA-N Ala-Ser-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN MMLHRUJLOUSRJX-CIUDSAMLSA-N 0.000 description 2
- SYIFFFHSXBNPMC-UWJYBYFXSA-N Ala-Ser-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N SYIFFFHSXBNPMC-UWJYBYFXSA-N 0.000 description 2
- OEVCHROQUIVQFZ-YTLHQDLWSA-N Ala-Thr-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O OEVCHROQUIVQFZ-YTLHQDLWSA-N 0.000 description 2
- JJHBEVZAZXZREW-LFSVMHDDSA-N Ala-Thr-Phe Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](Cc1ccccc1)C(O)=O JJHBEVZAZXZREW-LFSVMHDDSA-N 0.000 description 2
- QOIGKCBMXUCDQU-KDXUFGMBSA-N Ala-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C)N)O QOIGKCBMXUCDQU-KDXUFGMBSA-N 0.000 description 2
- AENHOIXXHKNIQL-AUTRQRHGSA-N Ala-Tyr-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H]([NH3+])C)CC1=CC=C(O)C=C1 AENHOIXXHKNIQL-AUTRQRHGSA-N 0.000 description 2
- JNJHNBXBGNJESC-KKXDTOCCSA-N Ala-Tyr-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JNJHNBXBGNJESC-KKXDTOCCSA-N 0.000 description 2
- JPOQZCHGOTWRTM-FQPOAREZSA-N Ala-Tyr-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPOQZCHGOTWRTM-FQPOAREZSA-N 0.000 description 2
- MUGAESARFRGOTQ-IGNZVWTISA-N Ala-Tyr-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N MUGAESARFRGOTQ-IGNZVWTISA-N 0.000 description 2
- XSLGWYYNOSUMRM-ZKWXMUAHSA-N Ala-Val-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O XSLGWYYNOSUMRM-ZKWXMUAHSA-N 0.000 description 2
- VHAQSYHSDKERBS-XPUUQOCRSA-N Ala-Val-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O VHAQSYHSDKERBS-XPUUQOCRSA-N 0.000 description 2
- XCIGOVDXZULBBV-DCAQKATOSA-N Ala-Val-Lys Chemical compound CC(C)[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCCN)C(O)=O XCIGOVDXZULBBV-DCAQKATOSA-N 0.000 description 2
- OTUQSEPIIVBYEM-IHRRRGAJSA-N Arg-Asn-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OTUQSEPIIVBYEM-IHRRRGAJSA-N 0.000 description 2
- FBLMOFHNVQBKRR-IHRRRGAJSA-N Arg-Asp-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FBLMOFHNVQBKRR-IHRRRGAJSA-N 0.000 description 2
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
- SYAUZLVLXCDRSH-IUCAKERBSA-N Arg-Gly-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N SYAUZLVLXCDRSH-IUCAKERBSA-N 0.000 description 2
- UBCPNBUIQNMDNH-NAKRPEOUSA-N Arg-Ile-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O UBCPNBUIQNMDNH-NAKRPEOUSA-N 0.000 description 2
- YKZJPIPFKGYHKY-DCAQKATOSA-N Arg-Leu-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YKZJPIPFKGYHKY-DCAQKATOSA-N 0.000 description 2
- OTZMRMHZCMZOJZ-SRVKXCTJSA-N Arg-Leu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTZMRMHZCMZOJZ-SRVKXCTJSA-N 0.000 description 2
- NMRHDSAOIURTNT-RWMBFGLXSA-N Arg-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NMRHDSAOIURTNT-RWMBFGLXSA-N 0.000 description 2
- DPLFNLDACGGBAK-KKUMJFAQSA-N Arg-Phe-Glu Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N DPLFNLDACGGBAK-KKUMJFAQSA-N 0.000 description 2
- CTAPSNCVKPOOSM-KKUMJFAQSA-N Arg-Tyr-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O CTAPSNCVKPOOSM-KKUMJFAQSA-N 0.000 description 2
- IZSMEUDYADKZTJ-KJEVXHAQSA-N Arg-Tyr-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IZSMEUDYADKZTJ-KJEVXHAQSA-N 0.000 description 2
- ISVACHFCVRKIDG-SRVKXCTJSA-N Arg-Val-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O ISVACHFCVRKIDG-SRVKXCTJSA-N 0.000 description 2
- SLKLLQWZQHXYSV-CIUDSAMLSA-N Asn-Ala-Lys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O SLKLLQWZQHXYSV-CIUDSAMLSA-N 0.000 description 2
- NUHQMYUWLUSRJX-BIIVOSGPSA-N Asn-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N NUHQMYUWLUSRJX-BIIVOSGPSA-N 0.000 description 2
- IARGXWMWRFOQPG-GCJQMDKQSA-N Asn-Ala-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IARGXWMWRFOQPG-GCJQMDKQSA-N 0.000 description 2
- GXMSVVBIAMWMKO-BQBZGAKWSA-N Asn-Arg-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCN=C(N)N GXMSVVBIAMWMKO-BQBZGAKWSA-N 0.000 description 2
- NVGWESORMHFISY-SRVKXCTJSA-N Asn-Asn-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O NVGWESORMHFISY-SRVKXCTJSA-N 0.000 description 2
- QISZHYWZHJRDAO-CIUDSAMLSA-N Asn-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N QISZHYWZHJRDAO-CIUDSAMLSA-N 0.000 description 2
- ZDOQDYFZNGASEY-BIIVOSGPSA-N Asn-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N)C(=O)O ZDOQDYFZNGASEY-BIIVOSGPSA-N 0.000 description 2
- HJRBIWRXULGMOA-ACZMJKKPSA-N Asn-Gln-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HJRBIWRXULGMOA-ACZMJKKPSA-N 0.000 description 2
- HCAUEJAQCXVQQM-ACZMJKKPSA-N Asn-Glu-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HCAUEJAQCXVQQM-ACZMJKKPSA-N 0.000 description 2
- HYQYLOSCICEYTR-YUMQZZPRSA-N Asn-Gly-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O HYQYLOSCICEYTR-YUMQZZPRSA-N 0.000 description 2
- UDSVWSUXKYXSTR-QWRGUYRKSA-N Asn-Gly-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O UDSVWSUXKYXSTR-QWRGUYRKSA-N 0.000 description 2
- XVBDDUPJVQXDSI-PEFMBERDSA-N Asn-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N XVBDDUPJVQXDSI-PEFMBERDSA-N 0.000 description 2
- IBLAOXSULLECQZ-IUKAMOBKSA-N Asn-Ile-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC(N)=O IBLAOXSULLECQZ-IUKAMOBKSA-N 0.000 description 2
- NCFJQJRLQJEECD-NHCYSSNCSA-N Asn-Leu-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O NCFJQJRLQJEECD-NHCYSSNCSA-N 0.000 description 2
- QJMCHPGWFZZRID-BQBZGAKWSA-N Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O QJMCHPGWFZZRID-BQBZGAKWSA-N 0.000 description 2
- RCFGLXMZDYNRSC-CIUDSAMLSA-N Asn-Lys-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O RCFGLXMZDYNRSC-CIUDSAMLSA-N 0.000 description 2
- COWITDLVHMZSIW-CIUDSAMLSA-N Asn-Lys-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O COWITDLVHMZSIW-CIUDSAMLSA-N 0.000 description 2
- KEUNWIXNKVWCFL-FXQIFTODSA-N Asn-Met-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O KEUNWIXNKVWCFL-FXQIFTODSA-N 0.000 description 2
- BKFXFUPYETWGGA-XVSYOHENSA-N Asn-Phe-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BKFXFUPYETWGGA-XVSYOHENSA-N 0.000 description 2
- SNYCNNPOFYBCEK-ZLUOBGJFSA-N Asn-Ser-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O SNYCNNPOFYBCEK-ZLUOBGJFSA-N 0.000 description 2
- AMGQTNHANMRPOE-LKXGYXEUSA-N Asn-Thr-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O AMGQTNHANMRPOE-LKXGYXEUSA-N 0.000 description 2
- RTFXPCYMDYBZNQ-SRVKXCTJSA-N Asn-Tyr-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O RTFXPCYMDYBZNQ-SRVKXCTJSA-N 0.000 description 2
- JZLFYAAGGYMRIK-BYULHYEWSA-N Asn-Val-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O JZLFYAAGGYMRIK-BYULHYEWSA-N 0.000 description 2
- PQKSVQSMTHPRIB-ZKWXMUAHSA-N Asn-Val-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O PQKSVQSMTHPRIB-ZKWXMUAHSA-N 0.000 description 2
- HPNDBHLITCHRSO-WHFBIAKZSA-N Asp-Ala-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(O)=O HPNDBHLITCHRSO-WHFBIAKZSA-N 0.000 description 2
- NJIKKGUVGUBICV-ZLUOBGJFSA-N Asp-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O NJIKKGUVGUBICV-ZLUOBGJFSA-N 0.000 description 2
- GVPSCJQLUGIKAM-GUBZILKMSA-N Asp-Arg-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O GVPSCJQLUGIKAM-GUBZILKMSA-N 0.000 description 2
- VPSHHQXIWLGVDD-ZLUOBGJFSA-N Asp-Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VPSHHQXIWLGVDD-ZLUOBGJFSA-N 0.000 description 2
- QXHVOUSPVAWEMX-ZLUOBGJFSA-N Asp-Asp-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXHVOUSPVAWEMX-ZLUOBGJFSA-N 0.000 description 2
- HRGGPWBIMIQANI-GUBZILKMSA-N Asp-Gln-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O HRGGPWBIMIQANI-GUBZILKMSA-N 0.000 description 2
- SPKRHJOVRVDJGG-CIUDSAMLSA-N Asp-Gln-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N SPKRHJOVRVDJGG-CIUDSAMLSA-N 0.000 description 2
- XAJRHVUUVUPFQL-ACZMJKKPSA-N Asp-Glu-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O XAJRHVUUVUPFQL-ACZMJKKPSA-N 0.000 description 2
- KHBLRHKVXICFMY-GUBZILKMSA-N Asp-Glu-Lys Chemical compound N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O KHBLRHKVXICFMY-GUBZILKMSA-N 0.000 description 2
- WBDWQKRLTVCDSY-WHFBIAKZSA-N Asp-Gly-Asp Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O WBDWQKRLTVCDSY-WHFBIAKZSA-N 0.000 description 2
- QCVXMEHGFUMKCO-YUMQZZPRSA-N Asp-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O QCVXMEHGFUMKCO-YUMQZZPRSA-N 0.000 description 2
- UBPMOJLRVMGTOQ-GARJFASQSA-N Asp-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(=O)O)N)C(=O)O UBPMOJLRVMGTOQ-GARJFASQSA-N 0.000 description 2
- KQBVNNAPIURMPD-PEFMBERDSA-N Asp-Ile-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O KQBVNNAPIURMPD-PEFMBERDSA-N 0.000 description 2
- UJGRZQYSNYTCAX-SRVKXCTJSA-N Asp-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UJGRZQYSNYTCAX-SRVKXCTJSA-N 0.000 description 2
- IVPNEDNYYYFAGI-GARJFASQSA-N Asp-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N IVPNEDNYYYFAGI-GARJFASQSA-N 0.000 description 2
- HJCGDIGVVWETRO-ZPFDUUQYSA-N Asp-Lys-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC(O)=O)C(O)=O HJCGDIGVVWETRO-ZPFDUUQYSA-N 0.000 description 2
- NZWDWXSWUQCNMG-GARJFASQSA-N Asp-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N)C(=O)O NZWDWXSWUQCNMG-GARJFASQSA-N 0.000 description 2
- DONWIPDSZZJHHK-HJGDQZAQSA-N Asp-Lys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N)O DONWIPDSZZJHHK-HJGDQZAQSA-N 0.000 description 2
- SARSTIZOZFBDOM-FXQIFTODSA-N Asp-Met-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O SARSTIZOZFBDOM-FXQIFTODSA-N 0.000 description 2
- WOPJVEMFXYHZEE-SRVKXCTJSA-N Asp-Phe-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O WOPJVEMFXYHZEE-SRVKXCTJSA-N 0.000 description 2
- USNJAPJZSGTTPX-XVSYOHENSA-N Asp-Phe-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O USNJAPJZSGTTPX-XVSYOHENSA-N 0.000 description 2
- VNXQRBXEQXLERQ-CIUDSAMLSA-N Asp-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N VNXQRBXEQXLERQ-CIUDSAMLSA-N 0.000 description 2
- GXHDGYOXPNQCKM-XVSYOHENSA-N Asp-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O GXHDGYOXPNQCKM-XVSYOHENSA-N 0.000 description 2
- PDIYGFYAMZZFCW-JIOCBJNQSA-N Asp-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N)O PDIYGFYAMZZFCW-JIOCBJNQSA-N 0.000 description 2
- BYLPQJAWXJWUCJ-YDHLFZDLSA-N Asp-Tyr-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O BYLPQJAWXJWUCJ-YDHLFZDLSA-N 0.000 description 2
- UXRVDHVARNBOIO-QSFUFRPTSA-N Asp-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)N UXRVDHVARNBOIO-QSFUFRPTSA-N 0.000 description 2
- GGBQDSHTXKQSLP-NHCYSSNCSA-N Asp-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N GGBQDSHTXKQSLP-NHCYSSNCSA-N 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- NVEASDQHBRZPSU-BQBZGAKWSA-N Gln-Gln-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O NVEASDQHBRZPSU-BQBZGAKWSA-N 0.000 description 2
- PNENQZWRFMUZOM-DCAQKATOSA-N Gln-Glu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O PNENQZWRFMUZOM-DCAQKATOSA-N 0.000 description 2
- MAGNEQBFSBREJL-DCAQKATOSA-N Gln-Glu-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N MAGNEQBFSBREJL-DCAQKATOSA-N 0.000 description 2
- VSXBYIJUAXPAAL-WDSKDSINSA-N Gln-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O VSXBYIJUAXPAAL-WDSKDSINSA-N 0.000 description 2
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 2
- XFAUJGNLHIGXET-AVGNSLFASA-N Gln-Leu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O XFAUJGNLHIGXET-AVGNSLFASA-N 0.000 description 2
- MLSKFHLRFVGNLL-WDCWCFNPSA-N Gln-Leu-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MLSKFHLRFVGNLL-WDCWCFNPSA-N 0.000 description 2
- LVRKAFPPFJRIOF-GARJFASQSA-N Gln-Met-Pro Chemical compound CSCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N LVRKAFPPFJRIOF-GARJFASQSA-N 0.000 description 2
- HHRAEXBUNGTOGZ-IHRRRGAJSA-N Gln-Phe-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O HHRAEXBUNGTOGZ-IHRRRGAJSA-N 0.000 description 2
- YPFFHGRJCUBXPX-NHCYSSNCSA-N Gln-Pro-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCC(N)=O)C(O)=O YPFFHGRJCUBXPX-NHCYSSNCSA-N 0.000 description 2
- VOUSELYGTNGEPB-NUMRIWBASA-N Gln-Thr-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O VOUSELYGTNGEPB-NUMRIWBASA-N 0.000 description 2
- WIMVKDYAKRAUCG-IHRRRGAJSA-N Gln-Tyr-Glu Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O WIMVKDYAKRAUCG-IHRRRGAJSA-N 0.000 description 2
- HNAUFGBKJLTWQE-IFFSRLJSSA-N Gln-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)N)O HNAUFGBKJLTWQE-IFFSRLJSSA-N 0.000 description 2
- SZXSSXUNOALWCH-ACZMJKKPSA-N Glu-Ala-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O SZXSSXUNOALWCH-ACZMJKKPSA-N 0.000 description 2
- OGMQXTXGLDNBSS-FXQIFTODSA-N Glu-Ala-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O OGMQXTXGLDNBSS-FXQIFTODSA-N 0.000 description 2
- LKDIBBOKUAASNP-FXQIFTODSA-N Glu-Ala-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LKDIBBOKUAASNP-FXQIFTODSA-N 0.000 description 2
- RSUVOPBMWMTVDI-XEGUGMAKSA-N Glu-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C)C(O)=O)=CNC2=C1 RSUVOPBMWMTVDI-XEGUGMAKSA-N 0.000 description 2
- VTTSANCGJWLPNC-ZPFDUUQYSA-N Glu-Arg-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VTTSANCGJWLPNC-ZPFDUUQYSA-N 0.000 description 2
- KKCUFHUTMKQQCF-SRVKXCTJSA-N Glu-Arg-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O KKCUFHUTMKQQCF-SRVKXCTJSA-N 0.000 description 2
- QPRZKNOOOBWXSU-CIUDSAMLSA-N Glu-Asp-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N QPRZKNOOOBWXSU-CIUDSAMLSA-N 0.000 description 2
- JPHYJQHPILOKHC-ACZMJKKPSA-N Glu-Asp-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O JPHYJQHPILOKHC-ACZMJKKPSA-N 0.000 description 2
- XXCDTYBVGMPIOA-FXQIFTODSA-N Glu-Asp-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XXCDTYBVGMPIOA-FXQIFTODSA-N 0.000 description 2
- JVSBYEDSSRZQGV-GUBZILKMSA-N Glu-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O JVSBYEDSSRZQGV-GUBZILKMSA-N 0.000 description 2
- GZWOBWMOMPFPCD-CIUDSAMLSA-N Glu-Asp-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N GZWOBWMOMPFPCD-CIUDSAMLSA-N 0.000 description 2
- HTTSBEBKVNEDFE-AUTRQRHGSA-N Glu-Gln-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)N HTTSBEBKVNEDFE-AUTRQRHGSA-N 0.000 description 2
- CGOHAEBMDSEKFB-FXQIFTODSA-N Glu-Glu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O CGOHAEBMDSEKFB-FXQIFTODSA-N 0.000 description 2
- AIGROOHQXCACHL-WDSKDSINSA-N Glu-Gly-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(O)=O AIGROOHQXCACHL-WDSKDSINSA-N 0.000 description 2
- ZWQVYZXPYSYPJD-RYUDHWBXSA-N Glu-Gly-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZWQVYZXPYSYPJD-RYUDHWBXSA-N 0.000 description 2
- DWBBKNPKDHXIAC-SRVKXCTJSA-N Glu-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCC(O)=O DWBBKNPKDHXIAC-SRVKXCTJSA-N 0.000 description 2
- UGSVSNXPJJDJKL-SDDRHHMPSA-N Glu-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N UGSVSNXPJJDJKL-SDDRHHMPSA-N 0.000 description 2
- IOUQWHIEQYQVFD-JYJNAYRXSA-N Glu-Leu-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IOUQWHIEQYQVFD-JYJNAYRXSA-N 0.000 description 2
- OQXDUSZKISQQSS-GUBZILKMSA-N Glu-Lys-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OQXDUSZKISQQSS-GUBZILKMSA-N 0.000 description 2
- FMBWLLMUPXTXFC-SDDRHHMPSA-N Glu-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)N)C(=O)O FMBWLLMUPXTXFC-SDDRHHMPSA-N 0.000 description 2
- UMHRCVCZUPBBQW-GARJFASQSA-N Glu-Met-Pro Chemical compound CSCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N UMHRCVCZUPBBQW-GARJFASQSA-N 0.000 description 2
- CBOVGULVQSVMPT-CIUDSAMLSA-N Glu-Pro-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O CBOVGULVQSVMPT-CIUDSAMLSA-N 0.000 description 2
- ARIORLIIMJACKZ-KKUMJFAQSA-N Glu-Pro-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ARIORLIIMJACKZ-KKUMJFAQSA-N 0.000 description 2
- ALMBZBOCGSVSAI-ACZMJKKPSA-N Glu-Ser-Asn Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N ALMBZBOCGSVSAI-ACZMJKKPSA-N 0.000 description 2
- HZISRJBYZAODRV-XQXXSGGOSA-N Glu-Thr-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O HZISRJBYZAODRV-XQXXSGGOSA-N 0.000 description 2
- MWTGQXBHVRTCOR-GLLZPBPUSA-N Glu-Thr-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MWTGQXBHVRTCOR-GLLZPBPUSA-N 0.000 description 2
- DTLLNDVORUEOTM-WDCWCFNPSA-N Glu-Thr-Lys Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DTLLNDVORUEOTM-WDCWCFNPSA-N 0.000 description 2
- ZGXGVBYEJGVJMV-HJGDQZAQSA-N Glu-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O ZGXGVBYEJGVJMV-HJGDQZAQSA-N 0.000 description 2
- MIWJDJAMMKHUAR-ZVZYQTTQSA-N Glu-Trp-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)N MIWJDJAMMKHUAR-ZVZYQTTQSA-N 0.000 description 2
- KIEICAOUSNYOLM-NRPADANISA-N Glu-Val-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O KIEICAOUSNYOLM-NRPADANISA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 2
- JBRBACJPBZNFMF-YUMQZZPRSA-N Gly-Ala-Lys Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN JBRBACJPBZNFMF-YUMQZZPRSA-N 0.000 description 2
- PHONXOACARQMPM-BQBZGAKWSA-N Gly-Ala-Met Chemical compound [H]NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O PHONXOACARQMPM-BQBZGAKWSA-N 0.000 description 2
- QSDKBRMVXSWAQE-BFHQHQDPSA-N Gly-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN QSDKBRMVXSWAQE-BFHQHQDPSA-N 0.000 description 2
- UXJHNZODTMHWRD-WHFBIAKZSA-N Gly-Asn-Ala Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O UXJHNZODTMHWRD-WHFBIAKZSA-N 0.000 description 2
- DWUKOTKSTDWGAE-BQBZGAKWSA-N Gly-Asn-Arg Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DWUKOTKSTDWGAE-BQBZGAKWSA-N 0.000 description 2
- AIJAPFVDBFYNKN-WHFBIAKZSA-N Gly-Asn-Asp Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN)C(=O)N AIJAPFVDBFYNKN-WHFBIAKZSA-N 0.000 description 2
- JVWPPCWUDRJGAE-YUMQZZPRSA-N Gly-Asn-Leu Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JVWPPCWUDRJGAE-YUMQZZPRSA-N 0.000 description 2
- XBWMTPAIUQIWKA-BYULHYEWSA-N Gly-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CN XBWMTPAIUQIWKA-BYULHYEWSA-N 0.000 description 2
- QITBQGJOXQYMOA-ZETCQYMHSA-N Gly-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CN QITBQGJOXQYMOA-ZETCQYMHSA-N 0.000 description 2
- LPCKHUXOGVNZRS-YUMQZZPRSA-N Gly-His-Ser Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O LPCKHUXOGVNZRS-YUMQZZPRSA-N 0.000 description 2
- PAWIVEIWWYGBAM-YUMQZZPRSA-N Gly-Leu-Ala Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O PAWIVEIWWYGBAM-YUMQZZPRSA-N 0.000 description 2
- LOEANKRDMMVOGZ-YUMQZZPRSA-N Gly-Lys-Asp Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CC(O)=O)C(O)=O LOEANKRDMMVOGZ-YUMQZZPRSA-N 0.000 description 2
- PTIIBFKSLCYQBO-NHCYSSNCSA-N Gly-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)CN PTIIBFKSLCYQBO-NHCYSSNCSA-N 0.000 description 2
- WDEHMRNSGHVNOH-VHSXEESVSA-N Gly-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)CN)C(=O)O WDEHMRNSGHVNOH-VHSXEESVSA-N 0.000 description 2
- OQQKUTVULYLCDG-ONGXEEELSA-N Gly-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)CN)C(O)=O OQQKUTVULYLCDG-ONGXEEELSA-N 0.000 description 2
- FXLVSYVJDPCIHH-STQMWFEESA-N Gly-Phe-Arg Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FXLVSYVJDPCIHH-STQMWFEESA-N 0.000 description 2
- IEGFSKKANYKBDU-QWHCGFSZSA-N Gly-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN)C(=O)O IEGFSKKANYKBDU-QWHCGFSZSA-N 0.000 description 2
- VDCRBJACQKOSMS-JSGCOSHPSA-N Gly-Phe-Val Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O VDCRBJACQKOSMS-JSGCOSHPSA-N 0.000 description 2
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 2
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 2
- MYXNLWDWWOTERK-BHNWBGBOSA-N Gly-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN)O MYXNLWDWWOTERK-BHNWBGBOSA-N 0.000 description 2
- FOKISINOENBSDM-WLTAIBSBSA-N Gly-Thr-Tyr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O FOKISINOENBSDM-WLTAIBSBSA-N 0.000 description 2
- SYOJVRNQCXYEOV-XVKPBYJWSA-N Gly-Val-Glu Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SYOJVRNQCXYEOV-XVKPBYJWSA-N 0.000 description 2
- BAYQNCWLXIDLHX-ONGXEEELSA-N Gly-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN BAYQNCWLXIDLHX-ONGXEEELSA-N 0.000 description 2
- KSOBNUBCYHGUKH-UWVGGRQHSA-N Gly-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CN KSOBNUBCYHGUKH-UWVGGRQHSA-N 0.000 description 2
- MJNWEIMBXKKCSF-XVYDVKMFSA-N His-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N MJNWEIMBXKKCSF-XVYDVKMFSA-N 0.000 description 2
- IDNNYVGVSZMQTK-IHRRRGAJSA-N His-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N IDNNYVGVSZMQTK-IHRRRGAJSA-N 0.000 description 2
- LYSVCKOXIDKEEL-SRVKXCTJSA-N His-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CN=CN1 LYSVCKOXIDKEEL-SRVKXCTJSA-N 0.000 description 2
- LBHOVGUGOBINDL-KKUMJFAQSA-N His-Asp-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2=CN=CN2)N)O LBHOVGUGOBINDL-KKUMJFAQSA-N 0.000 description 2
- HIAHVKLTHNOENC-HGNGGELXSA-N His-Glu-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O HIAHVKLTHNOENC-HGNGGELXSA-N 0.000 description 2
- PGTISAJTWZPFGN-PEXQALLHSA-N His-Gly-Ile Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O PGTISAJTWZPFGN-PEXQALLHSA-N 0.000 description 2
- JENKOCSDMSVWPY-SRVKXCTJSA-N His-Leu-Asn Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O JENKOCSDMSVWPY-SRVKXCTJSA-N 0.000 description 2
- SAPLASXFNUYUFE-CQDKDKBSSA-N His-Phe-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC2=CN=CN2)N SAPLASXFNUYUFE-CQDKDKBSSA-N 0.000 description 2
- HIJIJPFILYPTFR-ACRUOGEOSA-N His-Tyr-Tyr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O HIJIJPFILYPTFR-ACRUOGEOSA-N 0.000 description 2
- LQSBBHNVAVNZSX-GHCJXIJMSA-N Ile-Ala-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)O)N LQSBBHNVAVNZSX-GHCJXIJMSA-N 0.000 description 2
- HGNUKGZQASSBKQ-PCBIJLKTSA-N Ile-Asp-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HGNUKGZQASSBKQ-PCBIJLKTSA-N 0.000 description 2
- KIMHKBDJQQYLHU-PEFMBERDSA-N Ile-Glu-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N KIMHKBDJQQYLHU-PEFMBERDSA-N 0.000 description 2
- LPXHYGGZJOCAFR-MNXVOIDGSA-N Ile-Glu-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N LPXHYGGZJOCAFR-MNXVOIDGSA-N 0.000 description 2
- SPQWWEZBHXHUJN-KBIXCLLPSA-N Ile-Glu-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O SPQWWEZBHXHUJN-KBIXCLLPSA-N 0.000 description 2
- AREBLHSMLMRICD-PYJNHQTQSA-N Ile-His-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N AREBLHSMLMRICD-PYJNHQTQSA-N 0.000 description 2
- CSQNHSGHAPRGPQ-YTFOTSKYSA-N Ile-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)O)N CSQNHSGHAPRGPQ-YTFOTSKYSA-N 0.000 description 2
- UIEZQYNXCYHMQS-BJDJZHNGSA-N Ile-Lys-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)N UIEZQYNXCYHMQS-BJDJZHNGSA-N 0.000 description 2
- GLYJPWIRLBAIJH-FQUUOJAGSA-N Ile-Lys-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N GLYJPWIRLBAIJH-FQUUOJAGSA-N 0.000 description 2
- FJWALBCCVIHZBS-QXEWZRGKSA-N Ile-Met-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)O)N FJWALBCCVIHZBS-QXEWZRGKSA-N 0.000 description 2
- HQEPKOFULQTSFV-JURCDPSOSA-N Ile-Phe-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)O)N HQEPKOFULQTSFV-JURCDPSOSA-N 0.000 description 2
- IITVUURPOYGCTD-NAKRPEOUSA-N Ile-Pro-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IITVUURPOYGCTD-NAKRPEOUSA-N 0.000 description 2
- JHNJNTMTZHEDLJ-NAKRPEOUSA-N Ile-Ser-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O JHNJNTMTZHEDLJ-NAKRPEOUSA-N 0.000 description 2
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 2
- COWHUQXTSYTKQC-RWRJDSDZSA-N Ile-Thr-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N COWHUQXTSYTKQC-RWRJDSDZSA-N 0.000 description 2
- HJDZMPFEXINXLO-QPHKQPEJSA-N Ile-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N HJDZMPFEXINXLO-QPHKQPEJSA-N 0.000 description 2
- DGTOKVBDZXJHNZ-WZLNRYEVSA-N Ile-Thr-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N DGTOKVBDZXJHNZ-WZLNRYEVSA-N 0.000 description 2
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 2
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 2
- MJOZZTKJZQFKDK-GUBZILKMSA-N Leu-Ala-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(N)=O MJOZZTKJZQFKDK-GUBZILKMSA-N 0.000 description 2
- KWTVLKBOQATPHJ-SRVKXCTJSA-N Leu-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N KWTVLKBOQATPHJ-SRVKXCTJSA-N 0.000 description 2
- HBJZFCIVFIBNSV-DCAQKATOSA-N Leu-Arg-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(O)=O HBJZFCIVFIBNSV-DCAQKATOSA-N 0.000 description 2
- VCSBGUACOYUIGD-CIUDSAMLSA-N Leu-Asn-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VCSBGUACOYUIGD-CIUDSAMLSA-N 0.000 description 2
- ZTLGVASZOIKNIX-DCAQKATOSA-N Leu-Gln-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZTLGVASZOIKNIX-DCAQKATOSA-N 0.000 description 2
- FQZPTCNSNPWHLJ-AVGNSLFASA-N Leu-Gln-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O FQZPTCNSNPWHLJ-AVGNSLFASA-N 0.000 description 2
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 2
- JNDYEOUZBLOVOF-AVGNSLFASA-N Leu-Leu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JNDYEOUZBLOVOF-AVGNSLFASA-N 0.000 description 2
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 2
- VULJUQZPSOASBZ-SRVKXCTJSA-N Leu-Pro-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O VULJUQZPSOASBZ-SRVKXCTJSA-N 0.000 description 2
- ZJZNLRVCZWUONM-JXUBOQSCSA-N Leu-Thr-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O ZJZNLRVCZWUONM-JXUBOQSCSA-N 0.000 description 2
- QWWPYKKLXWOITQ-VOAKCMCISA-N Leu-Thr-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QWWPYKKLXWOITQ-VOAKCMCISA-N 0.000 description 2
- GZRABTMNWJXFMH-UVOCVTCTSA-N Leu-Thr-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZRABTMNWJXFMH-UVOCVTCTSA-N 0.000 description 2
- ISSAURVGLGAPDK-KKUMJFAQSA-N Leu-Tyr-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O ISSAURVGLGAPDK-KKUMJFAQSA-N 0.000 description 2
- VJGQRELPQWNURN-JYJNAYRXSA-N Leu-Tyr-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O VJGQRELPQWNURN-JYJNAYRXSA-N 0.000 description 2
- RVOMPSJXSRPFJT-DCAQKATOSA-N Lys-Ala-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RVOMPSJXSRPFJT-DCAQKATOSA-N 0.000 description 2
- XFIHDSBIPWEYJJ-YUMQZZPRSA-N Lys-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN XFIHDSBIPWEYJJ-YUMQZZPRSA-N 0.000 description 2
- KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 2
- UWKNTTJNVSYXPC-CIUDSAMLSA-N Lys-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN UWKNTTJNVSYXPC-CIUDSAMLSA-N 0.000 description 2
- KNKHAVVBVXKOGX-JXUBOQSCSA-N Lys-Ala-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KNKHAVVBVXKOGX-JXUBOQSCSA-N 0.000 description 2
- HQVDJTYKCMIWJP-YUMQZZPRSA-N Lys-Asn-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O HQVDJTYKCMIWJP-YUMQZZPRSA-N 0.000 description 2
- HIIZIQUUHIXUJY-GUBZILKMSA-N Lys-Asp-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HIIZIQUUHIXUJY-GUBZILKMSA-N 0.000 description 2
- IWWMPCPLFXFBAF-SRVKXCTJSA-N Lys-Asp-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O IWWMPCPLFXFBAF-SRVKXCTJSA-N 0.000 description 2
- LMVOVCYVZBBWQB-SRVKXCTJSA-N Lys-Asp-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LMVOVCYVZBBWQB-SRVKXCTJSA-N 0.000 description 2
- RZHLIPMZXOEJTL-AVGNSLFASA-N Lys-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)N RZHLIPMZXOEJTL-AVGNSLFASA-N 0.000 description 2
- IRRZDAIFYHNIIN-JYJNAYRXSA-N Lys-Gln-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IRRZDAIFYHNIIN-JYJNAYRXSA-N 0.000 description 2
- NDORZBUHCOJQDO-GVXVVHGQSA-N Lys-Gln-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O NDORZBUHCOJQDO-GVXVVHGQSA-N 0.000 description 2
- GRADYHMSAUIKPS-DCAQKATOSA-N Lys-Glu-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O GRADYHMSAUIKPS-DCAQKATOSA-N 0.000 description 2
- PBIPLDMFHAICIP-DCAQKATOSA-N Lys-Glu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PBIPLDMFHAICIP-DCAQKATOSA-N 0.000 description 2
- VQXAVLQBQJMENB-SRVKXCTJSA-N Lys-Glu-Met Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O VQXAVLQBQJMENB-SRVKXCTJSA-N 0.000 description 2
- PAMDBWYMLWOELY-SDDRHHMPSA-N Lys-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N)C(=O)O PAMDBWYMLWOELY-SDDRHHMPSA-N 0.000 description 2
- PBLLTSKBTAHDNA-KBPBESRZSA-N Lys-Gly-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PBLLTSKBTAHDNA-KBPBESRZSA-N 0.000 description 2
- HAUUXTXKJNVIFY-ONGXEEELSA-N Lys-Gly-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HAUUXTXKJNVIFY-ONGXEEELSA-N 0.000 description 2
- ZMMDPRTXLAEMOD-BZSNNMDCSA-N Lys-His-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ZMMDPRTXLAEMOD-BZSNNMDCSA-N 0.000 description 2
- SLQJJFAVWSZLBL-BJDJZHNGSA-N Lys-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN SLQJJFAVWSZLBL-BJDJZHNGSA-N 0.000 description 2
- NCZIQZYZPUPMKY-PPCPHDFISA-N Lys-Ile-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NCZIQZYZPUPMKY-PPCPHDFISA-N 0.000 description 2
- WRODMZBHNNPRLN-SRVKXCTJSA-N Lys-Leu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O WRODMZBHNNPRLN-SRVKXCTJSA-N 0.000 description 2
- UQRZFMQQXXJTTF-AVGNSLFASA-N Lys-Lys-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O UQRZFMQQXXJTTF-AVGNSLFASA-N 0.000 description 2
- QQPSCXKFDSORFT-IHRRRGAJSA-N Lys-Lys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN QQPSCXKFDSORFT-IHRRRGAJSA-N 0.000 description 2
- JYVCOTWSRGFABJ-DCAQKATOSA-N Lys-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCCN)N JYVCOTWSRGFABJ-DCAQKATOSA-N 0.000 description 2
- WGILOYIKJVQUPT-DCAQKATOSA-N Lys-Pro-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O WGILOYIKJVQUPT-DCAQKATOSA-N 0.000 description 2
- SVSQSPICRKBMSZ-SRVKXCTJSA-N Lys-Pro-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O SVSQSPICRKBMSZ-SRVKXCTJSA-N 0.000 description 2
- MIROMRNASYKZNL-ULQDDVLXSA-N Lys-Pro-Tyr Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 MIROMRNASYKZNL-ULQDDVLXSA-N 0.000 description 2
- TVHCDSBMFQYPNA-RHYQMDGZSA-N Lys-Thr-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O TVHCDSBMFQYPNA-RHYQMDGZSA-N 0.000 description 2
- RPWTZTBIFGENIA-VOAKCMCISA-N Lys-Thr-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O RPWTZTBIFGENIA-VOAKCMCISA-N 0.000 description 2
- RMOKGALPSPOYKE-KATARQTJSA-N Lys-Thr-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O RMOKGALPSPOYKE-KATARQTJSA-N 0.000 description 2
- RPWQJSBMXJSCPD-XUXIUFHCSA-N Lys-Val-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(O)=O RPWQJSBMXJSCPD-XUXIUFHCSA-N 0.000 description 2
- IKXQOBUBZSOWDY-AVGNSLFASA-N Lys-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCCCN)N IKXQOBUBZSOWDY-AVGNSLFASA-N 0.000 description 2
- GODBLDDYHFTUAH-CIUDSAMLSA-N Met-Asp-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O GODBLDDYHFTUAH-CIUDSAMLSA-N 0.000 description 2
- MYAPQOBHGWJZOM-UWVGGRQHSA-N Met-Gly-Leu Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C MYAPQOBHGWJZOM-UWVGGRQHSA-N 0.000 description 2
- RDLSEGZJMYGFNS-FXQIFTODSA-N Met-Ser-Asp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O RDLSEGZJMYGFNS-FXQIFTODSA-N 0.000 description 2
- FIZZULTXMVEIAA-IHRRRGAJSA-N Met-Ser-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FIZZULTXMVEIAA-IHRRRGAJSA-N 0.000 description 2
- MIXPUVSPPOWTCR-FXQIFTODSA-N Met-Ser-Ser Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MIXPUVSPPOWTCR-FXQIFTODSA-N 0.000 description 2
- MUDYEFAKNSTFAI-JYJNAYRXSA-N Met-Tyr-Val Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O MUDYEFAKNSTFAI-JYJNAYRXSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 2
- MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 description 2
- 108010079364 N-glycylalanine Proteins 0.000 description 2
- 206010028885 Necrotising fasciitis Diseases 0.000 description 2
- SKGLAZSLOGYCCA-PEFXOJROSA-N Neuromedin N (1-4) Chemical compound CC[C@@H](C)[C@@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H]([C@H](C)CC)C(O)=O)CC1=CC=C(O)C=C1 SKGLAZSLOGYCCA-PEFXOJROSA-N 0.000 description 2
- 101100068676 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) gln-1 gene Proteins 0.000 description 2
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 2
- 206010033078 Otitis media Diseases 0.000 description 2
- FPTXMUIBLMGTQH-ONGXEEELSA-N Phe-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 FPTXMUIBLMGTQH-ONGXEEELSA-N 0.000 description 2
- CGOMLCQJEMWMCE-STQMWFEESA-N Phe-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 CGOMLCQJEMWMCE-STQMWFEESA-N 0.000 description 2
- PSKRILMFHNIUAO-JYJNAYRXSA-N Phe-Glu-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N PSKRILMFHNIUAO-JYJNAYRXSA-N 0.000 description 2
- CSDMCMITJLKBAH-SOUVJXGZSA-N Phe-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O CSDMCMITJLKBAH-SOUVJXGZSA-N 0.000 description 2
- CWFGECHCRMGPPT-MXAVVETBSA-N Phe-Ile-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O CWFGECHCRMGPPT-MXAVVETBSA-N 0.000 description 2
- KDYPMIZMXDECSU-JYJNAYRXSA-N Phe-Leu-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 KDYPMIZMXDECSU-JYJNAYRXSA-N 0.000 description 2
- OQTDZEJJWWAGJT-KKUMJFAQSA-N Phe-Lys-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O OQTDZEJJWWAGJT-KKUMJFAQSA-N 0.000 description 2
- IPFXYNKCXYGSSV-KKUMJFAQSA-N Phe-Ser-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N IPFXYNKCXYGSSV-KKUMJFAQSA-N 0.000 description 2
- QSWKNJAPHQDAAS-MELADBBJSA-N Phe-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O QSWKNJAPHQDAAS-MELADBBJSA-N 0.000 description 2
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 2
- IAOZOFPONWDXNT-IXOXFDKPSA-N Phe-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IAOZOFPONWDXNT-IXOXFDKPSA-N 0.000 description 2
- VGTJSEYTVMAASM-RPTUDFQQSA-N Phe-Thr-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O VGTJSEYTVMAASM-RPTUDFQQSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- DBALDZKOTNSBFM-FXQIFTODSA-N Pro-Ala-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O DBALDZKOTNSBFM-FXQIFTODSA-N 0.000 description 2
- OBVCYFIHIIYIQF-CIUDSAMLSA-N Pro-Asn-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O OBVCYFIHIIYIQF-CIUDSAMLSA-N 0.000 description 2
- XROLYVMNVIKVEM-BQBZGAKWSA-N Pro-Asn-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O XROLYVMNVIKVEM-BQBZGAKWSA-N 0.000 description 2
- AHXPYZRZRMQOAU-QXEWZRGKSA-N Pro-Asn-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1)C(O)=O AHXPYZRZRMQOAU-QXEWZRGKSA-N 0.000 description 2
- XKHCJJPNXFBADI-DCAQKATOSA-N Pro-Asp-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O XKHCJJPNXFBADI-DCAQKATOSA-N 0.000 description 2
- QVIZLAUEAMQKGS-GUBZILKMSA-N Pro-Asp-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1 QVIZLAUEAMQKGS-GUBZILKMSA-N 0.000 description 2
- DEDANIDYQAPTFI-IHRRRGAJSA-N Pro-Asp-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O DEDANIDYQAPTFI-IHRRRGAJSA-N 0.000 description 2
- LHALYDBUDCWMDY-CIUDSAMLSA-N Pro-Glu-Ala Chemical compound C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1)C(O)=O LHALYDBUDCWMDY-CIUDSAMLSA-N 0.000 description 2
- AQGUSRZKDZYGGV-GMOBBJLQSA-N Pro-Ile-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O AQGUSRZKDZYGGV-GMOBBJLQSA-N 0.000 description 2
- UREQLMJCKFLLHM-NAKRPEOUSA-N Pro-Ile-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UREQLMJCKFLLHM-NAKRPEOUSA-N 0.000 description 2
- RYJRPPUATSKNAY-STECZYCISA-N Pro-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@@H]2CCCN2 RYJRPPUATSKNAY-STECZYCISA-N 0.000 description 2
- FMLRRBDLBJLJIK-DCAQKATOSA-N Pro-Leu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FMLRRBDLBJLJIK-DCAQKATOSA-N 0.000 description 2
- MRYUJHGPZQNOAD-IHRRRGAJSA-N Pro-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1 MRYUJHGPZQNOAD-IHRRRGAJSA-N 0.000 description 2
- WFIVLLFYUZZWOD-RHYQMDGZSA-N Pro-Lys-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WFIVLLFYUZZWOD-RHYQMDGZSA-N 0.000 description 2
- WOIFYRZPIORBRY-AVGNSLFASA-N Pro-Lys-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O WOIFYRZPIORBRY-AVGNSLFASA-N 0.000 description 2
- SEZGGSHLMROBFX-CIUDSAMLSA-N Pro-Ser-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O SEZGGSHLMROBFX-CIUDSAMLSA-N 0.000 description 2
- FNGOXVQBBCMFKV-CIUDSAMLSA-N Pro-Ser-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O FNGOXVQBBCMFKV-CIUDSAMLSA-N 0.000 description 2
- KIDXAAQVMNLJFQ-KZVJFYERSA-N Pro-Thr-Ala Chemical compound C[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](C)C(O)=O KIDXAAQVMNLJFQ-KZVJFYERSA-N 0.000 description 2
- VBZXFFYOBDLLFE-HSHDSVGOSA-N Pro-Trp-Thr Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H]([C@H](O)C)C(O)=O)C(=O)[C@@H]1CCCN1 VBZXFFYOBDLLFE-HSHDSVGOSA-N 0.000 description 2
- KHRLUIPIMIQFGT-AVGNSLFASA-N Pro-Val-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHRLUIPIMIQFGT-AVGNSLFASA-N 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- BRKHVZNDAOMAHX-BIIVOSGPSA-N Ser-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N BRKHVZNDAOMAHX-BIIVOSGPSA-N 0.000 description 2
- JPIDMRXXNMIVKY-VZFHVOOUSA-N Ser-Ala-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPIDMRXXNMIVKY-VZFHVOOUSA-N 0.000 description 2
- DKKGAAJTDKHWOD-BIIVOSGPSA-N Ser-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N)C(=O)O DKKGAAJTDKHWOD-BIIVOSGPSA-N 0.000 description 2
- KNZQGAUEYZJUSQ-ZLUOBGJFSA-N Ser-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)N KNZQGAUEYZJUSQ-ZLUOBGJFSA-N 0.000 description 2
- BQWCDDAISCPDQV-XHNCKOQMSA-N Ser-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N)C(=O)O BQWCDDAISCPDQV-XHNCKOQMSA-N 0.000 description 2
- HVKMTOIAYDOJPL-NRPADANISA-N Ser-Gln-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O HVKMTOIAYDOJPL-NRPADANISA-N 0.000 description 2
- BRGQQXQKPUCUJQ-KBIXCLLPSA-N Ser-Glu-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BRGQQXQKPUCUJQ-KBIXCLLPSA-N 0.000 description 2
- GZBKRJVCRMZAST-XKBZYTNZSA-N Ser-Glu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZBKRJVCRMZAST-XKBZYTNZSA-N 0.000 description 2
- OHKFXGKHSJKKAL-NRPADANISA-N Ser-Glu-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OHKFXGKHSJKKAL-NRPADANISA-N 0.000 description 2
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 2
- BPMRXBZYPGYPJN-WHFBIAKZSA-N Ser-Gly-Asn Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O BPMRXBZYPGYPJN-WHFBIAKZSA-N 0.000 description 2
- WEQAYODCJHZSJZ-KKUMJFAQSA-N Ser-His-Tyr Chemical compound C([C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CN=CN1 WEQAYODCJHZSJZ-KKUMJFAQSA-N 0.000 description 2
- MOINZPRHJGTCHZ-MMWGEVLESA-N Ser-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N MOINZPRHJGTCHZ-MMWGEVLESA-N 0.000 description 2
- DOSZISJPMCYEHT-NAKRPEOUSA-N Ser-Ile-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O DOSZISJPMCYEHT-NAKRPEOUSA-N 0.000 description 2
- GZSZPKSBVAOGIE-CIUDSAMLSA-N Ser-Lys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O GZSZPKSBVAOGIE-CIUDSAMLSA-N 0.000 description 2
- OWCVUSJMEBGMOK-YUMQZZPRSA-N Ser-Lys-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O OWCVUSJMEBGMOK-YUMQZZPRSA-N 0.000 description 2
- PMCMLDNPAZUYGI-DCAQKATOSA-N Ser-Lys-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O PMCMLDNPAZUYGI-DCAQKATOSA-N 0.000 description 2
- XKFJENWJGHMDLI-QWRGUYRKSA-N Ser-Phe-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O XKFJENWJGHMDLI-QWRGUYRKSA-N 0.000 description 2
- NUEHQDHDLDXCRU-GUBZILKMSA-N Ser-Pro-Arg Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NUEHQDHDLDXCRU-GUBZILKMSA-N 0.000 description 2
- PJIQEIFXZPCWOJ-FXQIFTODSA-N Ser-Pro-Asp Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O PJIQEIFXZPCWOJ-FXQIFTODSA-N 0.000 description 2
- GYDFRTRSSXOZCR-ACZMJKKPSA-N Ser-Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GYDFRTRSSXOZCR-ACZMJKKPSA-N 0.000 description 2
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 2
- ILZAUMFXKSIUEF-SRVKXCTJSA-N Ser-Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ILZAUMFXKSIUEF-SRVKXCTJSA-N 0.000 description 2
- OLKICIBQRVSQMA-SRVKXCTJSA-N Ser-Ser-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OLKICIBQRVSQMA-SRVKXCTJSA-N 0.000 description 2
- RXUOAOOZIWABBW-XGEHTFHBSA-N Ser-Thr-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RXUOAOOZIWABBW-XGEHTFHBSA-N 0.000 description 2
- SQHKXWODKJDZRC-LKXGYXEUSA-N Ser-Thr-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQHKXWODKJDZRC-LKXGYXEUSA-N 0.000 description 2
- KKKVOZNCLALMPV-XKBZYTNZSA-N Ser-Thr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O KKKVOZNCLALMPV-XKBZYTNZSA-N 0.000 description 2
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 2
- FZNNGIHSIPKFRE-QEJZJMRPSA-N Ser-Trp-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZNNGIHSIPKFRE-QEJZJMRPSA-N 0.000 description 2
- BCAVNDNYOGTQMQ-AAEUAGOBSA-N Ser-Trp-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(O)=O BCAVNDNYOGTQMQ-AAEUAGOBSA-N 0.000 description 2
- VVKVHAOOUGNDPJ-SRVKXCTJSA-N Ser-Tyr-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VVKVHAOOUGNDPJ-SRVKXCTJSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- BSNZTJXVDOINSR-JXUBOQSCSA-N Thr-Ala-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O BSNZTJXVDOINSR-JXUBOQSCSA-N 0.000 description 2
- VFEHSAJCWWHDBH-RHYQMDGZSA-N Thr-Arg-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VFEHSAJCWWHDBH-RHYQMDGZSA-N 0.000 description 2
- VOGXLRKCWFLJBY-HSHDSVGOSA-N Thr-Arg-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O VOGXLRKCWFLJBY-HSHDSVGOSA-N 0.000 description 2
- IRKWVRSEQFTGGV-VEVYYDQMSA-N Thr-Asn-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IRKWVRSEQFTGGV-VEVYYDQMSA-N 0.000 description 2
- KRPKYGOFYUNIGM-XVSYOHENSA-N Thr-Asp-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N)O KRPKYGOFYUNIGM-XVSYOHENSA-N 0.000 description 2
- RCEHMXVEMNXRIW-IRIUXVKKSA-N Thr-Gln-Tyr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N)O RCEHMXVEMNXRIW-IRIUXVKKSA-N 0.000 description 2
- GKWNLDNXMMLRMC-GLLZPBPUSA-N Thr-Glu-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O GKWNLDNXMMLRMC-GLLZPBPUSA-N 0.000 description 2
- LKEKWDJCJSPXNI-IRIUXVKKSA-N Thr-Glu-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LKEKWDJCJSPXNI-IRIUXVKKSA-N 0.000 description 2
- WPAKPLPGQNUXGN-OSUNSFLBSA-N Thr-Ile-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WPAKPLPGQNUXGN-OSUNSFLBSA-N 0.000 description 2
- RFKVQLIXNVEOMB-WEDXCCLWSA-N Thr-Leu-Gly Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N)O RFKVQLIXNVEOMB-WEDXCCLWSA-N 0.000 description 2
- NCXVJIQMWSGRHY-KXNHARMFSA-N Thr-Leu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O NCXVJIQMWSGRHY-KXNHARMFSA-N 0.000 description 2
- KRDSCBLRHORMRK-JXUBOQSCSA-N Thr-Lys-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O KRDSCBLRHORMRK-JXUBOQSCSA-N 0.000 description 2
- SCSVNSNWUTYSFO-WDCWCFNPSA-N Thr-Lys-Glu Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O SCSVNSNWUTYSFO-WDCWCFNPSA-N 0.000 description 2
- MCDVZTRGHNXTGK-HJGDQZAQSA-N Thr-Met-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O MCDVZTRGHNXTGK-HJGDQZAQSA-N 0.000 description 2
- WVVOFCVMHAXGLE-LFSVMHDDSA-N Thr-Phe-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(O)=O WVVOFCVMHAXGLE-LFSVMHDDSA-N 0.000 description 2
- NZRUWPIYECBYRK-HTUGSXCWSA-N Thr-Phe-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O NZRUWPIYECBYRK-HTUGSXCWSA-N 0.000 description 2
- MXNAOGFNFNKUPD-JHYOHUSXSA-N Thr-Phe-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MXNAOGFNFNKUPD-JHYOHUSXSA-N 0.000 description 2
- XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 description 2
- KERCOYANYUPLHJ-XGEHTFHBSA-N Thr-Pro-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O KERCOYANYUPLHJ-XGEHTFHBSA-N 0.000 description 2
- FWTFAZKJORVTIR-VZFHVOOUSA-N Thr-Ser-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O FWTFAZKJORVTIR-VZFHVOOUSA-N 0.000 description 2
- ZESGVALRVJIVLZ-VFCFLDTKSA-N Thr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O ZESGVALRVJIVLZ-VFCFLDTKSA-N 0.000 description 2
- PELIQFPESHBTMA-WLTAIBSBSA-N Thr-Tyr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 PELIQFPESHBTMA-WLTAIBSBSA-N 0.000 description 2
- CURFABYITJVKEW-QTKMDUPCSA-N Thr-Val-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O CURFABYITJVKEW-QTKMDUPCSA-N 0.000 description 2
- PWONLXBUSVIZPH-RHYQMDGZSA-N Thr-Val-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O PWONLXBUSVIZPH-RHYQMDGZSA-N 0.000 description 2
- VYVBSMCZNHOZGD-RCWTZXSCSA-N Thr-Val-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O VYVBSMCZNHOZGD-RCWTZXSCSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- PXYJUECTGMGIDT-WDSOQIARSA-N Trp-Arg-Leu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(O)=O)=CNC2=C1 PXYJUECTGMGIDT-WDSOQIARSA-N 0.000 description 2
- PTAWAMWPRFTACW-SZMVWBNQSA-N Trp-Gln-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N PTAWAMWPRFTACW-SZMVWBNQSA-N 0.000 description 2
- RPVDDQYNBOVWLR-HOCLYGCPSA-N Trp-Gly-Leu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O RPVDDQYNBOVWLR-HOCLYGCPSA-N 0.000 description 2
- WBZOZLNLXVBCNW-LTHWPDAASA-N Trp-Thr-Ile Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)[C@@H](C)O)=CNC2=C1 WBZOZLNLXVBCNW-LTHWPDAASA-N 0.000 description 2
- VMXLNDRJXVAJFT-JYBASQMISA-N Trp-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N)O VMXLNDRJXVAJFT-JYBASQMISA-N 0.000 description 2
- XKTWZYNTLXITCY-QRTARXTBSA-N Trp-Val-Asn Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)=CNC2=C1 XKTWZYNTLXITCY-QRTARXTBSA-N 0.000 description 2
- VCXWRWYFJLXITF-AUTRQRHGSA-N Tyr-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VCXWRWYFJLXITF-AUTRQRHGSA-N 0.000 description 2
- JONPRIHUYSPIMA-UWJYBYFXSA-N Tyr-Ala-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JONPRIHUYSPIMA-UWJYBYFXSA-N 0.000 description 2
- XLMDWQNAOKLKCP-XDTLVQLUSA-N Tyr-Ala-Gln Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N XLMDWQNAOKLKCP-XDTLVQLUSA-N 0.000 description 2
- HTHCZRWCFXMENJ-KKUMJFAQSA-N Tyr-Arg-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O HTHCZRWCFXMENJ-KKUMJFAQSA-N 0.000 description 2
- ADBDQGBDNUTRDB-ULQDDVLXSA-N Tyr-Arg-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O ADBDQGBDNUTRDB-ULQDDVLXSA-N 0.000 description 2
- QYSBJAUCUKHSLU-JYJNAYRXSA-N Tyr-Arg-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O QYSBJAUCUKHSLU-JYJNAYRXSA-N 0.000 description 2
- PZXUIGWOEWWFQM-SRVKXCTJSA-N Tyr-Asn-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O PZXUIGWOEWWFQM-SRVKXCTJSA-N 0.000 description 2
- DANHCMVVXDXOHN-SRVKXCTJSA-N Tyr-Asp-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DANHCMVVXDXOHN-SRVKXCTJSA-N 0.000 description 2
- YGKVNUAKYPGORG-AVGNSLFASA-N Tyr-Asp-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O YGKVNUAKYPGORG-AVGNSLFASA-N 0.000 description 2
- TZXFLDNBYYGLKA-BZSNNMDCSA-N Tyr-Asp-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 TZXFLDNBYYGLKA-BZSNNMDCSA-N 0.000 description 2
- QHEGAOPHISYNDF-XDTLVQLUSA-N Tyr-Gln-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QHEGAOPHISYNDF-XDTLVQLUSA-N 0.000 description 2
- HZZKQZDUIKVFDZ-AVGNSLFASA-N Tyr-Gln-Ser Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N)O HZZKQZDUIKVFDZ-AVGNSLFASA-N 0.000 description 2
- KOVXHANYYYMBRF-IRIUXVKKSA-N Tyr-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O KOVXHANYYYMBRF-IRIUXVKKSA-N 0.000 description 2
- CTDPLKMBVALCGN-JSGCOSHPSA-N Tyr-Gly-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O CTDPLKMBVALCGN-JSGCOSHPSA-N 0.000 description 2
- FIRUOPRJKCBLST-KKUMJFAQSA-N Tyr-His-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O FIRUOPRJKCBLST-KKUMJFAQSA-N 0.000 description 2
- GFJXBLSZOFWHAW-JYJNAYRXSA-N Tyr-His-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O GFJXBLSZOFWHAW-JYJNAYRXSA-N 0.000 description 2
- GGXUDPQWAWRINY-XEGUGMAKSA-N Tyr-Ile-Gly Chemical compound OC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GGXUDPQWAWRINY-XEGUGMAKSA-N 0.000 description 2
- QARCDOCCDOLJSF-HJPIBITLSA-N Tyr-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QARCDOCCDOLJSF-HJPIBITLSA-N 0.000 description 2
- FDKDGFGTHGJKNV-FHWLQOOXSA-N Tyr-Phe-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N FDKDGFGTHGJKNV-FHWLQOOXSA-N 0.000 description 2
- SCZJKZLFSSPJDP-ACRUOGEOSA-N Tyr-Phe-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O SCZJKZLFSSPJDP-ACRUOGEOSA-N 0.000 description 2
- XJPXTYLVMUZGNW-IHRRRGAJSA-N Tyr-Pro-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O XJPXTYLVMUZGNW-IHRRRGAJSA-N 0.000 description 2
- NHOVZGFNTGMYMI-KKUMJFAQSA-N Tyr-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NHOVZGFNTGMYMI-KKUMJFAQSA-N 0.000 description 2
- GAKBTSMAPGLQFA-JNPHEJMOSA-N Tyr-Thr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 GAKBTSMAPGLQFA-JNPHEJMOSA-N 0.000 description 2
- DJSYPCWZPNHQQE-FHWLQOOXSA-N Tyr-Tyr-Gln Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C1=CC=C(O)C=C1 DJSYPCWZPNHQQE-FHWLQOOXSA-N 0.000 description 2
- AFWXOGHZEKARFH-ACRUOGEOSA-N Tyr-Tyr-His Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=C(O)C=C1 AFWXOGHZEKARFH-ACRUOGEOSA-N 0.000 description 2
- ABSXSJZNRAQDDI-KJEVXHAQSA-N Tyr-Val-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ABSXSJZNRAQDDI-KJEVXHAQSA-N 0.000 description 2
- DJIJBQYBDKGDIS-JYJNAYRXSA-N Tyr-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(C)C)C(O)=O DJIJBQYBDKGDIS-JYJNAYRXSA-N 0.000 description 2
- UEOOXDLMQZBPFR-ZKWXMUAHSA-N Val-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N UEOOXDLMQZBPFR-ZKWXMUAHSA-N 0.000 description 2
- YFOCMOVJBQDBCE-NRPADANISA-N Val-Ala-Glu Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N YFOCMOVJBQDBCE-NRPADANISA-N 0.000 description 2
- SLLKXDSRVAOREO-KZVJFYERSA-N Val-Ala-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)N)O SLLKXDSRVAOREO-KZVJFYERSA-N 0.000 description 2
- LABUITCFCAABSV-BPNCWPANSA-N Val-Ala-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LABUITCFCAABSV-BPNCWPANSA-N 0.000 description 2
- LNYOXPDEIZJDEI-NHCYSSNCSA-N Val-Asn-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N LNYOXPDEIZJDEI-NHCYSSNCSA-N 0.000 description 2
- ISERLACIZUGCDX-ZKWXMUAHSA-N Val-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N ISERLACIZUGCDX-ZKWXMUAHSA-N 0.000 description 2
- CGGVNFJRZJUVAE-BYULHYEWSA-N Val-Asp-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N CGGVNFJRZJUVAE-BYULHYEWSA-N 0.000 description 2
- QHDXUYOYTPWCSK-RCOVLWMOSA-N Val-Asp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N QHDXUYOYTPWCSK-RCOVLWMOSA-N 0.000 description 2
- JXGWQYWDUOWQHA-DZKIICNBSA-N Val-Gln-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N JXGWQYWDUOWQHA-DZKIICNBSA-N 0.000 description 2
- CVIXTAITYJQMPE-LAEOZQHASA-N Val-Glu-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CVIXTAITYJQMPE-LAEOZQHASA-N 0.000 description 2
- KZKMBGXCNLPYKD-YEPSODPASA-N Val-Gly-Thr Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O KZKMBGXCNLPYKD-YEPSODPASA-N 0.000 description 2
- KVRLNEILGGVBJX-IHRRRGAJSA-N Val-His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)CC1=CN=CN1 KVRLNEILGGVBJX-IHRRRGAJSA-N 0.000 description 2
- BZMIYHIJVVJPCK-QSFUFRPTSA-N Val-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N BZMIYHIJVVJPCK-QSFUFRPTSA-N 0.000 description 2
- DJQIUOKSNRBTSV-CYDGBPFRSA-N Val-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)C)N DJQIUOKSNRBTSV-CYDGBPFRSA-N 0.000 description 2
- DAVNYIUELQBTAP-XUXIUFHCSA-N Val-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N DAVNYIUELQBTAP-XUXIUFHCSA-N 0.000 description 2
- BTWMICVCQLKKNR-DCAQKATOSA-N Val-Leu-Ser Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C([O-])=O BTWMICVCQLKKNR-DCAQKATOSA-N 0.000 description 2
- XXWBHOWRARMUOC-NHCYSSNCSA-N Val-Lys-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)O)N XXWBHOWRARMUOC-NHCYSSNCSA-N 0.000 description 2
- IJGPOONOTBNTFS-GVXVVHGQSA-N Val-Lys-Glu Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O IJGPOONOTBNTFS-GVXVVHGQSA-N 0.000 description 2
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 description 2
- XPKCFQZDQGVJCX-RHYQMDGZSA-N Val-Lys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N)O XPKCFQZDQGVJCX-RHYQMDGZSA-N 0.000 description 2
- USLVEJAHTBLSIL-CYDGBPFRSA-N Val-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C USLVEJAHTBLSIL-CYDGBPFRSA-N 0.000 description 2
- NHXZRXLFOBFMDM-AVGNSLFASA-N Val-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C NHXZRXLFOBFMDM-AVGNSLFASA-N 0.000 description 2
- LTTQCQRTSHJPPL-ZKWXMUAHSA-N Val-Ser-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)N LTTQCQRTSHJPPL-ZKWXMUAHSA-N 0.000 description 2
- PGQUDQYHWICSAB-NAKRPEOUSA-N Val-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N PGQUDQYHWICSAB-NAKRPEOUSA-N 0.000 description 2
- GVNLOVJNNDZUHS-RHYQMDGZSA-N Val-Thr-Lys Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O GVNLOVJNNDZUHS-RHYQMDGZSA-N 0.000 description 2
- OEVFFOBAXHBXKM-HSHDSVGOSA-N Val-Trp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](C(C)C)N)O OEVFFOBAXHBXKM-HSHDSVGOSA-N 0.000 description 2
- JXCOEPXCBVCTRD-JYJNAYRXSA-N Val-Tyr-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N JXCOEPXCBVCTRD-JYJNAYRXSA-N 0.000 description 2
- NLNCNKIVJPEFBC-DLOVCJGASA-N Val-Val-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O NLNCNKIVJPEFBC-DLOVCJGASA-N 0.000 description 2
- AOILQMZPNLUXCM-AVGNSLFASA-N Val-Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN AOILQMZPNLUXCM-AVGNSLFASA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 108010041407 alanylaspartic acid Proteins 0.000 description 2
- 108010005233 alanylglutamic acid Proteins 0.000 description 2
- 108010044940 alanylglutamine Proteins 0.000 description 2
- 108010011559 alanylphenylalanine Proteins 0.000 description 2
- 108010070783 alanyltyrosine Proteins 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 108010057412 arginyl-glycyl-aspartyl-phenylalanine Proteins 0.000 description 2
- 108010062796 arginyllysine Proteins 0.000 description 2
- 108010077245 asparaginyl-proline Proteins 0.000 description 2
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 2
- 108010093581 aspartyl-proline Proteins 0.000 description 2
- 108010038633 aspartylglutamate Proteins 0.000 description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 238000012650 click reaction Methods 0.000 description 2
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 2
- 229940009976 deoxycholate Drugs 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 239000012538 diafiltration buffer Substances 0.000 description 2
- 108010054813 diprotin B Proteins 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 2
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 2
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 2
- 108010049041 glutamylalanine Proteins 0.000 description 2
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 2
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 2
- 108010081551 glycylphenylalanine Proteins 0.000 description 2
- 108010087823 glycyltyrosine Proteins 0.000 description 2
- 108010037850 glycylvaline Proteins 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 108010040030 histidinoalanine Proteins 0.000 description 2
- 108010085325 histidylproline Proteins 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 108010078274 isoleucylvaline Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N isourea group Chemical group NC(O)=N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 108010064235 lysylglycine Proteins 0.000 description 2
- 108010056582 methionylglutamic acid Proteins 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 201000007970 necrotizing fasciitis Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 238000009520 phase I clinical trial Methods 0.000 description 2
- 108010012581 phenylalanylglutamate Proteins 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108010004914 prolylarginine Proteins 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 108010048818 seryl-histidine Proteins 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- 108010020532 tyrosyl-proline Proteins 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 229940124856 vaccine component Drugs 0.000 description 2
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FVWWZESGQZCBFO-UHFFFAOYSA-N 1-(4-azidophenyl)propan-2-amine Chemical compound CC(N)CC1=CC=C(N=[N+]=[N-])C=C1 FVWWZESGQZCBFO-UHFFFAOYSA-N 0.000 description 1
- AIHDUTVBOYDXOW-UHFFFAOYSA-N 4-(dimethylamino)pyridin-1-ium-1-carbonitrile Chemical compound CN(C)C1=CC=[N+](C#N)C=C1 AIHDUTVBOYDXOW-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- LBJYAILUMSUTAM-ZLUOBGJFSA-N Ala-Asn-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O LBJYAILUMSUTAM-ZLUOBGJFSA-N 0.000 description 1
- AWNAEZICPNGAJK-FXQIFTODSA-N Ala-Met-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O AWNAEZICPNGAJK-FXQIFTODSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- HOBNTSHITVVNBN-ZPFDUUQYSA-N Asp-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N HOBNTSHITVVNBN-ZPFDUUQYSA-N 0.000 description 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- CAVMESABQIKFKT-IUCAKERBSA-N Glu-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)N CAVMESABQIKFKT-IUCAKERBSA-N 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- NKVZTQVGUNLLQW-JBDRJPRFSA-N Ile-Ala-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O)N NKVZTQVGUNLLQW-JBDRJPRFSA-N 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- NEEOBPIXKWSBRF-IUCAKERBSA-N Leu-Glu-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O NEEOBPIXKWSBRF-IUCAKERBSA-N 0.000 description 1
- 238000003231 Lowry assay Methods 0.000 description 1
- 238000009013 Lowry's assay Methods 0.000 description 1
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010034839 Pharyngitis streptococcal Diseases 0.000 description 1
- 241000255969 Pieris brassicae Species 0.000 description 1
- JMVQDLDPDBXAAX-YUMQZZPRSA-N Pro-Gly-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 JMVQDLDPDBXAAX-YUMQZZPRSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- VIIJCAQMJBHSJH-FXQIFTODSA-N Ser-Met-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O VIIJCAQMJBHSJH-FXQIFTODSA-N 0.000 description 1
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 241000147000 Shigella flexneri 2a Species 0.000 description 1
- 241001353153 Shigella flexneri 3a Species 0.000 description 1
- 241001353149 Shigella flexneri 6 Species 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 101000815632 Streptococcus suis (strain 05ZYH33) Rqc2 homolog RqcH Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- GFDUZZACIWNMPE-KZVJFYERSA-N Thr-Ala-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O GFDUZZACIWNMPE-KZVJFYERSA-N 0.000 description 1
- XZUBGOYOGDRYFC-XGEHTFHBSA-N Thr-Ser-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(O)=O XZUBGOYOGDRYFC-XGEHTFHBSA-N 0.000 description 1
- QGVBFDIREUUSHX-IFFSRLJSSA-N Thr-Val-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O QGVBFDIREUUSHX-IFFSRLJSSA-N 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- NYTKXWLZSNRILS-IFFSRLJSSA-N Val-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)N)O NYTKXWLZSNRILS-IFFSRLJSSA-N 0.000 description 1
- 101710123661 Venom allergen 5 Proteins 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000016150 acute pharyngitis Diseases 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000013378 biophysical characterization Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- ZPWOOKQUDFIEIX-UHFFFAOYSA-N cyclooctyne Chemical group C1CCCC#CCC1 ZPWOOKQUDFIEIX-UHFFFAOYSA-N 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002009 diols Chemical group 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 102000036072 fibronectin binding proteins Human genes 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000028557 immunoglobulin binding proteins Human genes 0.000 description 1
- 108091009323 immunoglobulin binding proteins Proteins 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000013365 molecular weight analysis method Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012475 sodium chloride buffer Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/2111—C5a peptidase (3.4.21.110)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
本發明提供純化適用於免疫原性組合物中之高分子量細菌多醣(例如細胞壁多醣)及其多肽-多醣結合物之方法。
Description
本發明概言之係關於細菌多醣、其純化、其多肽結合及包括該等多醣-多肽結合物之免疫原性組合物之領域。
細菌細胞壁及細胞膜與諸多聚合分子(包含醣結合物及多醣(PS))締合,該等聚合分子在細菌中發揮各種結構及功能作用。在革蘭氏陰性(gram-negative)細菌中,外膜主要包括脂多醣(LPS)。革蘭氏陽性細菌缺乏外膜,但具有含有特殊多醣之厚肽聚醣層。一些菌株之革蘭氏陰性及革蘭氏陽性細菌另外含有有助於毒性之結合肽聚醣之莢膜多醣。
誘導針對許多PS (包含諸如腦膜炎球菌、HiB及肺炎球菌等細菌之彼等)之免疫性可抵抗疾病,且已研發多種有效疫苗。然而,大規模疫苗製造同樣需要大規模且成本有效地供應不含其他細胞組分之純、均質多醣。純化多醣之一些傳統方法依賴於苛刻條件(例如濃氫氟酸),此會引起關於安全性之問題且限制生產放大。另外,許多純化方法會一定程度地降解靶多醣,從而降低產率或產生具有有限或較小免疫原性之低分子量多醣。因此,需要更安全、更高產且更有效之多醣產生方法。
A型鏈球菌(Group A Streptococcus,GAS)係每年在全世界引起700百萬例咽炎(「鏈球菌性咽喉炎」)之主要人類病原體,且嚴重侵襲性感染、敗血症、壞死性筋膜炎、中耳炎及中毒性休克症候群之病例日益增加。GAS亦造成感染後免疫介導之風濕性心臟病(RHD),該疾病係發展中國家中之主要死亡病因。當前大約有30百萬人受RHD影響,其中每年超過300,000人死亡(60% < 70歲)且損失11.5百萬失能調整後生命年。儘管全球高度需要,但並無針對GAS之安全且有效之商業疫苗。該病原體之特徵為接種疫苗帶來特殊挑戰,包含其不變之透明質酸(遍佈於結締組織中之一種免疫學惰性碳水化合物)莢膜。另外,免疫顯性表面錨定性GAS M蛋白高度多型(>200個
emm類型),且其二聚體捲曲螺旋結構之區域可在RHD中激起針對心臟組織之自體免疫反應。因此,需要可預防或治療GAS感染之免疫原性組合物。該等組合物可利用蛋白質-抗原結合物,且由此需要具有足夠免疫原性之結合物。
本文揭示多肽-多醣結合物,其包括:(a) GAS多肽抗原或非GAS載體多肽,其包括至少一個非天然胺基酸(nnAA);及(b)經純化細胞壁多醣或結合肽聚醣之莢膜多醣,其分子量為至少約10 kDa至至少約40 kDa。
本文闡述包括A型鏈球菌(GAS) C5a肽酶多肽抗原、GAS鏈球菌溶血素O (SLO)多肽抗原及多肽-多醣結合物之免疫原性組合物。多肽-多醣結合物可包括(i)釀膿鏈球菌黏附及分裂(Streptococcus pyogenes Adhesion and Division, SpyAD)結合多肽或其片段,其包括至少一個非天然胺基酸(nnAA),其中至少一個nnAA包括點擊化學反應性基團;及(ii) GAS多醣或其變體,其缺乏免疫顯性N-乙醯基葡萄糖胺(GlcNAc)側鏈。可藉由連接體衍生GAS多醣或其變體之約8 mol%至約20 mol%之多醣重複單元。多肽-多醣結合物之平均分子量可介於約185 kDa與約700 kDa之間或介於約190 kDa與約700 kDa之間。
本文亦揭示自細菌細胞純化細胞壁多醣或結合肽聚醣之莢膜多醣之製程,該製程包括:(a)在包括鹼及還原劑之溶液中水解細菌細胞以形成包括多醣之溶解物;及(b)將包括多醣之溶解物與溶壁酶一起培育以形成游離多醣溶液。
相關申請案之交叉參考
本申請案主張2021年2月17日提出申請之美國臨時申請案第63/150,516號及2021年12月10日提出申請之美國臨時申請案第63/288,387號之權益,該等臨時申請案中之每一者之揭示內容以全文引用方式併入本文中。
政府權益之聲明
本發明在美國政府支持下以CARB-X納稅穿透實體(CARB-X Through Entity)下之由衛生與公共服務部防備與響應助理部長辦公室(Health and Human Services Office of the Assistant Secretary for Preparedness and Response, HHS/ASPR)授予之許可號93.360 (子受方4500003905)來獲得。政府擁有本發明之某些權利。
以電子方式提交之文字檔案之說明
與本申請案有關之序列表係以文字形式代替紙印式來提供,且在此以引用方式併入說明書中。含有序列表之文字檔案之名稱為STRO_015_02WO_SeqList_ST25。文字檔案為363 kb,創建於2022年2月14日,且以電子方式經由EFS-Web提交。
本文闡述自細菌細胞純化高分子量多醣PS (在本文中稱為長多醣)之方法。該等PS之平均分子量高於使用業內已知方法分離者,且由此可用於產生具有增加之免疫原性及/或穩定性之疫苗、免疫原性組合物及諸如此類。該等免疫原性組合物闡述於本文中。除增加PS之大小外,本文所闡述之製程可使得產率高於傳統純化方法。因此,該等方法可更有效地產生經純化PS。
多醣之純化
本文所闡述之製程可用於自細菌細胞純化多醣。可(例如)使用業內已知之標準技術將細菌細胞自培養物分離為糰粒。在一些實施例中,本發明提供自細菌細胞純化細胞壁多醣或結合肽聚醣之莢膜多醣(例如包含純化細菌細胞之糰粒)之製程。
本文所用之「純化」係指自多醣去除或部分地去除存在於細菌細胞中之非多醣組分。純化可意指去除至少約85%之雜質及/或副產物。在一些實施例中,「經純化」多醣溶液或製劑含有小於約15%、約14%、約13%、約12%、約11%、約10%、約9%、約8%、約7%、約6%、約5%、約4%、約3%、約2%、約1%、約0.9%、約0.8%、約0.7%、約0.6%、約0.5%、約0.4%、約0.3%、約0.2%、約0.1%、約0.09%、約0.08%、約0.07%。約0.06%、約0.05%、約0.04%、約0.03%、約0.02%或約0.01%之雜質及/或副產物。
本文所用之「細胞壁多醣」係指發現於細菌細胞壁中之任何PS,其與發現於(例如)細菌莢膜中者不同。細胞壁多醣可經由肽聚醣結合至細胞。細胞壁多醣可來自克蘭氏陽性或革蘭氏陰性細菌細胞。一種實例性細胞壁多醣係A型鏈球菌(GAS) PS。
本文所用之「結合肽聚醣之莢膜多醣」係指細菌莢膜中經由肽聚醣結合至細胞且在本文所闡述製程之條件下抵抗降解的任何PS。該等多醣包含含有單醣(包含葡萄糖、鼠李糖、半乳糖、甘露糖、核糖、葡萄糖醛酸、半乳糖醛酸及2-乙醯胺基-4-胺基-2,4,6-三去氧半乳糖(AATGal))之一些組合之某些PS。結合肽聚醣之莢膜多醣可來自克蘭氏陽性或革蘭氏陰性細菌細胞。適於藉由所闡述方法純化之結合肽聚醣之莢膜多醣之特徵亦可在於具有極少O-乙醯化或極少磷酸二酯鍵。
通常,自本文所闡述之細菌細胞純化細胞壁多醣或結合肽聚醣之莢膜多醣之製程包括:在包括鹼及還原劑之溶液中水解細菌細胞;及將含多醣組合物與溶壁酶一起培育以形成游離多醣溶液。在一些實施例中,該製程包括(a)在包括鹼及還原劑之溶液中水解細菌細胞以形成包括多醣之溶解物;及(b)將包括多醣之溶解物與溶壁酶一起培育以形成游離多醣溶液。在一些實施例中,自細菌細胞產生經純化細胞壁多醣或結合肽聚醣之莢膜多醣之製程包括(a)將細菌細胞與溶壁酶一起培育以形成經裂解多醣溶液;及(b)將經裂解多醣溶液與鹼一起培育以形成游離多醣溶液。
在一些實施例中,本文所闡述之製程可適於純化缺乏O-乙醯基之多醣。純化製程可用於具有N-乙醯化葡萄糖、鼠李糖、甘露糖、核糖或半乳糖單體之PS。在本文所闡述之製程之一些實施例中,細菌細胞係假單胞菌(
Pseudomonas)細菌細胞、鏈球菌(
Streptococcus)細菌細胞、葡萄球菌(
Staphylococcus)細菌細胞、奈瑟菌(
Neisseria)細菌細胞、嗜血桿菌(
Haemophilus)細菌細胞、李斯特菌(
Listeria)細菌細胞、腸球菌(
Enterococcus)細菌細胞或梭菌(
Clostridium)細菌細胞。在某些實施例中,細菌細胞係選自由以下組成之群:銅綠假單胞菌(
Pseudomonas aeruginosa)、草綠色鏈球菌(
Streptococcus viridans)、變種鏈球菌(
Streptococcus mutans)及釀膿鏈球菌。
在某些實施例中,細菌細胞係釀膿鏈球菌,亦稱為A型鏈球菌(GAS)。GAS係克蘭氏陽性、β-溶血性鏈球菌。其在人類中引起多種疾病。該等疾病包含鏈球菌性咽喉炎(急性咽炎)、中耳炎及皮膚與軟組織感染(例如膿疱病及蜂窩組織炎)。該等疾病亦可包含稀有病例之侵襲性(嚴重)病況,例如壞死性筋膜炎(食肉病)及中毒性休克症候群(TSS)。若干毒性因子有助於GAS之發病,例如M蛋白、溶血素及細胞外酶。在某些實施例中,釀膿鏈球菌細菌細胞屬選自以下之血清型:M1、M2、M3、M4、M5、M6、M9、M11、M12、M13、M18、M22、M25、M28、M41、M43、M44、M62、M71、M72、M74、M75、M77、M80、M81、M83、M87、M89及M92、M94、M110或任一前述血清型之突變體。在本文所闡述之製程之一些實施例中,在純化期間有效去除M蛋白(例如M1),且同時維持經分離長多醣之良好產率。
在一些實施例中,可改造釀膿鏈球菌細菌細胞以產生缺乏免疫顯性N-乙醯基葡萄糖胺(GLcNAc)側鏈之多醣或其變體(例如參見國際PCT公開案第WO 2013/020090號、美國專利第10,780,155號、國際PCT公開案第WO 2021/167996號及Gao, N. J.等人,2020年12月29日. Infectious Microbes and Diseases, doi: 10.1097/IM9.0000000000000044)。
在一些實施例中,本文所闡述之製程可適於自細菌細胞純化結合肽聚醣之莢膜多醣。
在本發明製程中,使用鹼處理細菌細胞可用於自其他細胞組分(例如細胞壁等)釋放多醣。與利用酸處理之已知PS純化方法不同,如本文所闡述使用之鹼可避免水解天然多醣中所含之醣苷鍵。具體而言,自細菌細胞純化細胞壁多醣或結合肽聚醣之莢膜多醣之製程包括在包括鹼及還原劑之溶液中水解細菌細胞以形成包括多醣的溶解物。適用於所揭示製程之鹼之非限制性實例係鹼金屬氫氧化物,例如NaOH、KOH、LiOH;碳酸鹽,例如Na
2CO
3及K
2CO
3;有機胺,例如Et
3N及NH
3;及醇鹽,例如NaOMe、NaOEt及KO
tBu。在一些實施例中,鹼係NaOH、KOH或LiOH。在某些實施例中,鹼係NaOH。在某些實施例中,鹼係KOH。在一些實施例中,鹼係LiOH。
在一些實施例中,鹼濃度介於約2M至約8M之間。在某些實施例中,鹼濃度介於約2M與約6M之間。在某些實施例中,鹼濃度介於約2M與約4M之間。在某些實施例中,鹼濃度介於約4M與約8M之間。在某些實施例中,鹼濃度介於約4M與約6M之間。在某些實施例中,鹼濃度介於約6M與約8M之間。在本發明之一些實施例中,包括鹼及還原劑之溶液大於約pH 7。在某些實施例中,包括鹼及還原劑之溶液係約pH 8、約pH 9、約pH 10、約pH 11、約pH 12、約pH 13或約pH 14。
PS可在高pH下經由稱為「剝離反應」之過程發生降解,且可添加還原劑以防止此過程發生。可選擇任何適宜還原劑來抵抗剝離反應。在一些實施例中,還原劑係選自硼氫化鈉、氰基硼氫化鈉、三乙醯氧基硼氫化鈉、二硫蘇糖醇或β-巰基乙醇。在某些實施例中,還原劑係硼氫化鈉。還原劑之濃度可介於約1 mM與約500 mM之間。在一些實施例中,還原劑之濃度介於約1 mM與約500 mM之間。在某些實施例中,還原劑之濃度介於約1 mM與約400 mM、約1 mM與約300 mM、約1 mM與約200 mM、約1 mM與約100 mM、約1 mM與約50 mM、約1 mM與約10 mM、約10 mM與約100 mM、約100 mM與約400 mM、約100 mM與約300 mM、約100 mM與約200 mM、約200 mM與約400 mM、約200 mM與約300 mM及約300 mM與約400 mM之間。
當在包括鹼及還原劑之溶液中水解細菌細胞以形成包括多醣之溶解物時,可升高溫度以達成較高分子量PS及其較大產率。在一些實施例中,水解步驟進一步包括在約30℃與約100℃之間培育溶液。在某些實施例中,水解步驟進一步包括在以下溫度之間培育溶液:約30℃與約100℃;約30℃與約90℃;約30℃與約80℃;約30℃與約70℃;約30℃與約60℃;約30℃與約50℃;約30℃與約40℃;約40℃與約100℃;約40℃與約90℃;約40℃與約80℃;約40℃與約70℃;約40℃與約60℃;約40℃與約50℃;約50℃與約100℃;約50℃與約90℃;約50℃與約80℃;約50℃與約70℃;約50℃與約60℃;約60℃與約100℃;約60℃與約90℃;約60℃與約80℃;約60℃與約70℃;約70℃與約100℃;約70℃與約90℃;約70℃與約80℃;約80℃與約100℃;約80℃與約90℃;或約90℃與約100℃。
可將用以形成包括多醣之溶解物之包括鹼及還原劑之溶液培育足以完成反應的時間量。舉例而言,在一些實施例中,水解步驟進一步包括將溶液培育約0.5小時至約20小時。在某些實施例中,水解步驟進一步包括將溶液培育約0.5小時至約1小時、約1小時至約5小時、約5小時至約20小時、約5小時至約15小時、約5小時至約10小時、約10小時至約20小時、約10小時至約15小時或約15小時至約20小時。可(例如)藉由使用適當分析方法測定多醣產率來監測水解是否完成。
因在包括鹼及還原劑之溶液中水解細菌細胞以形成包括多醣之溶解物可形成必須去除之非PS副產物,故該製程可包括一或多個pH調節步驟以有助於去除彼等副產物。在一實施例中,一或多個pH調節步驟獨立地選自:(i)升高包括多醣之溶解物之pH,或(ii)降低包括多醣之溶解物之pH。
在一些實施例中,該製程包括將包括多醣之溶解物之pH降至介於約3與約7之間。在某些實施例中,該製程包括將包括多醣之溶解物之pH降至介於約3與約6、約3與約5、約3與約4、約4與約7、約4與約6、約4與約5、約5與約7或約5與約6之間。在一些實施例中,該製程包括將包括多醣之溶解物之pH降至約3、約3.5、約4、約4.5、約5、約5.5、約6、約6.5或約7。在一些實施例中,該製程包括:(i)將包括多醣之溶解物之pH降至介於約5.5與7.0之間;(ii)將包括多醣之溶解物之pH降至約3;及(iii)將包括多醣之溶解物之pH升至介於約5.5與7.0之間。在某些實施例中,該製程包括:(i)將包括多醣之溶解物之pH降至約6.5;(ii)將包括多醣之溶解物之pH降至約3;及(iii)將包括多醣之溶解物之pH升至約6.5。
在本文所揭示之製程中,可在一或多個pH調節步驟之後於室溫下培育包括多醣之溶解物。「室溫」定義為實驗室背景中之環境溫度,且通常介於約20℃與約25℃之間。在一些實施例中,在一或多個pH調節步驟之後於約4℃與約30℃之間培育包括多醣之溶解物。在某些實施例中,在一或多個pH調節步驟之後於以下溫度之間培育包括多醣之溶解物:約4℃與約30℃;約4℃與約25℃;約4℃與約20℃;約4℃與約15℃;約4℃與約10℃;約10℃與約30℃;約10℃與約25℃;約10℃與約20℃;約10℃與約15℃;約15℃與約30℃;約15℃與約25℃;約15℃與約20℃;約20℃與約30℃;約20℃與約25℃;或約25℃與約30℃。
去除在水解步驟期間形成之固體副產物可較為有利。因此,在一些實施例中,本文所揭示之製程可進一步包括自包括多醣之溶解物去除固體。在一些實施例中,自包括多醣之溶解物去除固體包括過濾、離心或其組合。在一些實施例中,過濾包括深度過濾、切向流過濾(TFF)、無菌過濾、膜過濾或前述各項之組合。在某些實施例中,藉由離心自包括多醣之溶解物去除固體。可以任何順序組合應用去除固體之各種方法。在一些實施例中,過濾包括深度過濾及後續TFF。
在本發明製程中,使用溶壁酶處理包括多醣之細菌細胞或溶解物可用於裂解肽聚醣內之醣苷鍵,從而自其胺基酸框架釋放PS。溶壁酶可(例如)裂解
N-乙醯基胞壁酸(NAM)與N-乙醯基葡萄糖胺(NAG)之間之鍵。具體而言,在水解之後,酶促裂解步驟可包括將包括多醣之溶解物與溶壁酶一起培育以形成游離多醣溶液。在一些實施例中,溶壁酶係變溶菌素(mutanolysin)、溶菌酶或噬菌體水解酶。為進一步有助於純化,在某些實施例中,將包括多醣之溶解物與溶壁酶一起培育以形成游離多醣溶液進一步包括與蛋白酶一起培育。在一些實施例中,蛋白酶係蛋白酶K。在某些實施例中,蛋白酶係蛋白酶K、胰蛋白酶、胰凝乳蛋白酶、內蛋白酶Asp-N、內蛋白酶Arg-C、內蛋白酶Glu-C、內蛋白酶Lys-C、胃蛋白酶、嗜熱菌蛋白酶、彈性蛋白酶、木瓜酶、枯草桿菌蛋白酶(substilisin)、梭菌蛋白酶(clostripain)、羧肽酶A、羧肽酶B、羧肽酶P、羧肽酶Y、細胞自溶酶C、醯基胺基酸釋放酶或焦麩胺酸鹽。
在本文所揭示之製程之一些實施例中,將包括多醣之溶解物與溶壁酶一起培育以形成游離多醣溶液進一步包括將包括多醣之溶解物與溶壁酶升溫至介於約30℃與約65℃之間。在一些實施例中,將包括多醣之溶解物與溶壁酶升溫至介於約30℃與約60℃、約30℃與約55℃、約30℃與約50℃、約30℃與約45℃、約30℃與約40℃、約30℃與約35℃、約40℃與約60℃、約40℃與約55℃、約40℃與約50℃、約40℃與約60℃、約40℃與約55℃、約40℃與約50℃、約45℃與約60℃、約45℃與約55℃、約45℃與約50℃、約50℃與約60℃或約55℃與約60℃之間。
在一些實施例中,將包括多醣之溶解物與蛋白酶升溫。在一些實施例中,將包括多醣之溶解物與蛋白酶升溫至介於約45℃與約55℃、約45℃與約50℃或約50℃與約55℃之間。
在包括PS之溶解物與溶壁酸或包括PS之溶解物與蛋白酶之情形下,可將溶解物升溫至少2小時。在一些實施例中,將溶解物升溫約6小時至約20小時、約6小時至約18小時、約6小時至約16小時、約6小時至約14小時、約6小時至約12小時、約6小時至約10小時、約6小時至約8小時、約8小時至約20小時、約8小時至約18小時、約8小時至約16小時、約8小時至約14小時、約8小時至約12小時、約8小時至約10小時、約10小時至約20小時、約10小時至約18小時、約10小時至約16小時、約10小時至約14小時、約10小時至約12小時、約12小時至約20小時、約12小時至約18小時、約12小時至約16小時、約12小時至約14小時、約14小時至約20小時、約14小時至約18小時、約14小時至約16小時、約16小時至約20小時、約16小時至約18小時、約118小時至約20小時。
為進一步有助於分離PS與副產物,進一步純化在一起培育包括多醣之溶解物與溶壁酶之步驟期間產生之游離多醣溶液。在一些實施例中,進一步純化游離多醣溶液以減小核酸、酶、宿主細胞蛋白(HCP)或前述各項之組合之濃度。在某些實施例中,藉由沈澱、陰離子交換層析、陽離子交換層析、疏水性相互作用層析、陶瓷羥基磷灰石型層析或其組合進一步純化游離多醣溶液。
在一些實施例中,藉由沈澱進一步純化游離多醣溶液。可藉由諸多化學或物理方式誘導此沈澱。在一些實施例中,進一步純化處理游離多醣溶液以減小核酸、酶、宿主細胞蛋白(HCP)或前述各項之組合之濃度。在一些實施例中,使用表面活性劑處理游離多醣溶液。在一些實施例中,表面活性劑係鯨蠟基三甲基溴化銨(CTAB)。在某些實施例中,游離多醣溶液中之CTAB濃度為約0.1%至約10%。在一些實施例中,游離多醣溶液中之CTAB濃度為約0.1%至約0.5%、約0.5%至約3%、約0.5%至約2%、約0.5%至約1%、約1%至約10%、約1%至約9%、約1%至約8%、約1%至約7%、約1%至約6%、約1%至約5%、約1%至約4%、約1%至約3%、約1%至約2%、約2%至約10%、約2%至約9%、約2%至約8%、約2%至約7%、約2%至約6%、約2%至約5%、約2%至約4%、約2%至約3%、約3%至約10%、約3%至約9%、約3%至約8%、約3%至約7%、約3%至約6%、約3%至約5%、約3%至約4%、約4%至約10%、約4%至約9%、約4%至約8%、約4%至約7%、約4%至約6%、約4%至約5%、約5%至約10%、約5%至約9%、約5%至約8%、約5%至約7%、約5%至約6%、約6%至約10%、約6%至約9%、約6%至約8%、約6%至約7%、約7%至約10%、約7%至約9%、約7%至約8%、約8%至約10%、約8%至約9%或約9%至約10%。
可利用碘化鉀(KI)或另一適宜鹽自溶液去除過量CTAB。在一些實施例中,使用KI處理游離多醣溶液。在一些實施例中,游離多醣溶液中之KI濃度介於約20 mM至約400 mM之間。在某些實施例中,KI濃度介於約20 mM與約300 mM、約20 mM與約200 mM、約20 mM與約100 mM、約20 mM與約50 mM、約50 mM與約300 mM、約50 mM與約200 mM、約50 mM與約100 mM、約100 mM與約300 mM、約100 mM與約200 mM或約200 mM與約300 mM之間。
可在任何時刻下藉由過濾、離心、層析或前述各項之組合進一步純化在自細菌細胞產生經純化細胞壁多醣或結合肽聚醣之莢膜多醣之製程期間產生的游離多醣溶液。在一些實施例中,使用過濾。在某些實施例中,過濾包括深度過濾、切向流過濾(TFF)、無菌過濾或前述各項之組合。在一些實施例中,層析包括疏水性相互作用層析(HIC)、陰離子交換層析(AEX)、陶瓷羥基磷灰石型層析或陽離子交換層析(CEX)。
多肽 - 多醣結合物
如先前所論述,藉由本文所闡述之方法產生之高分子量多醣適於形成用於疫苗及諸如此類之多肽-多醣結合物。
本發明之高分子量多醣亦可稱為「長多醣」。
因此,本文揭示一種多肽-多醣結合物,其包括:(a)多肽抗原(例如GAS多肽抗原)或非GAS載體多肽,其包括至少一個非天然胺基酸(nnAA);及(b)經純化細胞壁多醣或結合肽聚醣之莢膜多醣,其分子量為至少約10 kDa至至少約40 kDa。如本文更詳細地所闡述,nnAA包括點擊化學反應性基團以促進多肽抗原與PS之間之結合。
在一些實施例中,結合物中所使用之多醣係經純化細胞壁多醣或結合肽聚醣之莢膜多醣。
如先前所闡述,GAS係人類健康中引起諸多疾病之重要細菌。在一些實施例中,經純化細胞壁多醣係GAS多醣。一種GAS多醣A型碳水化合物(GAC)係由聚鼠李糖主鏈與免疫顯性N-乙醯基葡萄糖胺(GLcNAc)側鏈構成並存在於所有GAS血清型菌株之表面上(不論M類型如何),且已作為GAS候選疫苗進行檢驗。經親和純化之抗GAC抗體成功地調理了三種所測試GAS血清型(Salvadori等人,1995. J. Infect. Dis. 171:593–600.),且經GAC免疫化之小鼠可抵抗腹膜腔內及鼻內GAS攻擊(Sabharwal等人,2006. J. Infect. Dis. 193:129-135)。然而,抗GAC抗體與宿主心臟瓣膜蛋白(Goldstein等人,1967. Nature 213:44-47)及細胞骨架蛋白(例如肌動蛋白、角蛋白、肌球蛋白及波形蛋白)之間之免疫學交叉反應性會引發關於使用GAC作為GAS疫苗組分之重要潛在安全性問題。因此,在一些實施例中,經純化細胞壁多醣係缺乏免疫顯性GlcNAc側鏈之GAC變體(例如參見國際PCT公開案第WO 2013/020090號、美國專利第10,780,155號及Gao, N. J.等人,Infectious Microbes and Diseases, 2021, 3(2), 87-100)。
在一些實施例中,經純化細胞壁多醣或結合肽聚醣之莢膜多醣之平均分子量為約10 kDa至約45 kDa、約10 kDa至約40 kDa、約10 kDa至約35 kDa、約10 kDa至約30 kDa、約10 kDa至約25 kDa、約10 kDa至約20 kDa、約10 kDa至約15 kDa;15 kDa至約40 kDa、約15 kDa至約35 kDa、約15 kDa至約30 kDa、約15 kDa至約25 kDa、約15 kDa至約20 kDa;20 kDa至約40 kDa、約20 kDa至約35 kDa、約20 kDa至約30 kDa、約20 kDa至約25 kDa;25 kDa至約40 kDa、約25 kDa至約35 kDa、約25 kDa至約30 kDa、約30 kDa至約40 kDa、約30 kDa至約35 kDa或約35 kDa至約40 kDa。在一些實施例中,經純化細胞壁多醣或結合肽聚醣之莢膜多醣具有約10 kDa、約15 kDa、約20 kDa、約25 kDa、約30 kDa、約35 kDa、約40 kDa或約45 kDa之平均分子量。
在一些實施例中,使用點擊化學反應性基團修飾經純化細胞壁多醣或結合肽聚醣之莢膜多醣以有利於結合至結合蛋白。點擊化學反應性基團之實例可參見(例如)國際PCT公開案第WO 2018/126229號及國際PCT公開案第WO 2021/167996號,該等公開案中之每一者之全部內容以引用方式併入本文中。舉例而言,在一些實施例中,使用DBCO或DBCO-PEG (例如DBCO-PEG-NH
2)修飾經純化細胞壁多醣或結合肽聚醣之莢膜多醣。在一些實施例中,使用DBCO-(PEG)
4-NH
2修飾經純化細胞壁多醣或結合肽聚醣之莢膜多醣。
經純化細胞壁多醣或結合肽聚醣之莢膜多醣經點擊化學反應性基團或包括點擊化學反應性基團之連接體之修飾程度可藉由多少或百分之多少(例如mol%)之多醣重複單元(PSRU)已經修飾來定義。因此,在本文所闡述之經純化細胞壁多醣或結合肽聚醣之莢膜多醣之一些實施例中,介於約8 mol%與20 mol%之間之多醣重複單元由點擊化學反應性基團或包括點擊化學反應性基團之連接體衍生。在一些實施例中,介於約8 mol%與約20 mol%、約8 mol%與約19 mol%、約8 mol%與約18 mol%、約8 mol%與約17 mol%、約8 mol%與約16 mol%、約8 mol%與約15 mol%、約8 mol%與約14 mol%、8 mol%與約13 mol%、約8 mol%與約12 mol%、約8 mol%與約11 mol%、8 mol%與約10 mol%、約8 mol%與約9 mol%、約9 mol%與約20 mol%、約9 mol%與約19 mol%、約9 mol%與約18 mol%、約9 mol%與約17 mol%、約9 mol%與約16 mol%、約9 mol%與約15 mol%、約9 mol%與約14 mol%、9 mol%與約13 mol%、約9 mol%與約12 mol%、約9 mol%與約11 mol%、9 mol%與約10 mol%、約10 mol%與約20 mol%、約10 mol%與約19 mol%、約10 mol%與約18 mol%、約10 mol%與約17 mol%、約10 mol%與約16 mol%、約10 mol%與約15 mol%、約10 mol%與約14 mol%、10 mol%與約13 mol%、約10 mol%與約12 mol%、約10 mol%與約11 mol%、約11 mol%與約20 mol%、約11 mol%與約19 mol%、約11 mol%與約18 mol%、約11 mol%與約17 mol%、約11 mol%與約16 mol%、約11 mol%與約15 mol%、約11 mol%與約14 mol%、11 mol%與約13 mol%、約11 mol%與約12 mol%、約12 mol%與約20 mol%、約12 mol%與約19 mol%、約12 mol%與約18 mol%、約12 mol%與約17 mol%、約12 mol%與約16 mol%、約12 mol%與約15 mol%、約12 mol%與約14 mol%、12 mol%與約13 mol%、約13 mol%與約20 mol%、約13 mol%與約19 mol%、約13 mol%與約18 mol%、約13 mol%與約17 mol%、約13 mol%與約16 mol%、約13 mol%與約15 mol%、約13 mol%與約14 mol%、約14 mol%與約20 mol%、約14 mol%與約19 mol%、約14 mol%與約18 mol%、約14 mol%與約17 mol%、約14 mol%與約16 mol%、約14 mol%與約15 mol%、約15 mol%與約20 mol%、約15 mol%與約19 mol%、約15 mol%與約18 mol%、約15 mol%與約17 mol%、約15 mol%與約16 mol%、約16 mol%與約20 mol%、約16 mol%與約19 mol%、約16 mol%與約18 mol%、約16 mol%與約17 mol%、約17 mol%與約20 mol%、約17 mol%與約19 mol%、約17 mol%與約18 mol%、約18 mol%與約20 mol%、約18 mol%與約19 mol%或約19 mol%與約20 mol%之間之多醣PS重複單元由點擊化學反應性基團或包括點擊化學反應性基團之連接體衍生。在一些實施例中,多醣之多醣重複單元係GAS多醣之多醣重複單元或其變體。在本文所闡述之經純化細胞壁多醣或結合肽聚醣之莢膜多醣之一些實施例中,約8、9、10、11、12、13、14、15、16、17、18、19或20 mol%之多醣重複單元由點擊化學反應性基團或包括點擊化學反應性基團之連接體衍生。在一些實施例中,GAS多醣或其變體缺乏免疫顯性N-乙醯基葡萄糖胺(GlcNAc)側鏈。
一般而言,增加多醣之多醣重複單元中之連接體納入(mol%)可產生分子量增加之多肽-多醣結合物。如本文進一步所論述,使用具有較大連接體納入之多醣形成之多肽-多醣結合物可展現之免疫原性大於連接體納入莫耳百分比較低者。另外,連接體納入增加之多醣亦可在結合後產生較低量之游離多醣,如本文進一步所論述。
在提及本文所闡述之多肽-多醣結合物及免疫原性組合物時,「游離多醣」係指未結合至多肽之多醣、經連接體及/或點擊化學反應性基團衍生之多醣或多醣片段。舉例而言,在衍生多醣與多肽之間運行結合反應之後,游離多醣可存在於多肽-多醣結合物之混合物中。可(例如)藉由合成實例6中所闡述之方法來量測游離多醣濃度。
本文所闡述之結合物中所使用之多肽抗原可為GAS或非GAS多肽抗原。在一些實施例中,多肽抗原係包括至少一個非天然胺基酸(nnAA)之全長GAS多肽抗原或全長GAS多肽抗原之片段。在一些實施例中,多肽抗原係選自C5a肽酶(UniProt P15926)、鏈球菌溶血素O (SLO, UniProt P0C0I3)、鏈球菌免疫球蛋白結合蛋白35 (Sib35, UniProt (Q1XG74)及纖連蛋白結合蛋白F1 (Sfb1, UniProt Q48VN7)及黏附及分裂多肽(SpyAD, UniProt Q9A1H3)。
本文所闡述之結合物中所使用之非GAS載體多肽可基於包括至少一個非天然胺基酸之全長非GAS載體多肽或全長非GAS載體多肽之片段。在一些實施例中,非GAS載體多肽係選自精胺酸去亞胺酶(ADI, UniProt P0C0B3)、CRM197 (1272033-67-6)、鐵蛋白(UniProt P02792)及蛋白質D (UniProt R4R7Q5)。
在一些實施例中,多肽抗原或非GAS載體蛋白在野生型胺基酸序列中包括一或多個胺基酸突變。舉例而言,在一些實施例中,多肽抗原係SpyAD,其中SpyAD多肽包括一或多個胺基酸突變。在一些實施例中,多肽抗原係ADI,其中ADI多肽包括一或多個胺基酸突變。在一些實施例中,胺基酸突變係D277A (例如SEQ ID NO: 36)。
在一些實施例中,多肽抗原或非GAS載體蛋白包括至少一個非天然胺基酸(nnAA)。在一些實施例中,至少一個nnAA取代多肽抗原或非GAS載體多肽中之離胺酸、白胺酸、精胺酸或異白胺酸。在一些實施例中,一或多個nnAA包括點擊化學反應性基團。在本文中,「點擊化學反應性基團」係指能夠與第二點擊化學反應性基團發生點擊化學反應之部分(例如疊氮化物或炔烴)。在一些實施例中,一種點擊化學反應性基團與第二點擊化學反應性基團反應形成經取代三唑。此類點擊反應之實例可參見(例如)國際PCT公開案第WO 2018/126229號。用於生物醫學應用中之無金屬點擊反應之一般實例可參見(例如) Kim等人,
Chemical Science, 2019, 10, 7835-7851。包括點擊化學反應性基團之nnAA之實例包含2-胺基-3-(4-疊氮基苯基)丙酸(pAF)、2-胺基-4-疊氮基丁酸、2-疊氮基-3-苯基丙酸、2-胺基-3-疊氮基丙酸、2-胺基-3-(4-(疊氮基甲基)苯基)丙酸(pAMF)、2-胺基-3-(5-(疊氮基甲基)吡啶-2-基)丙酸、2-胺基-3-(4-(疊氮基甲基)吡啶-2-基)丙酸、2-胺基-3-(6-(疊氮基甲基)吡啶-3-基)丙酸及2-胺基-5-疊氮基戊酸。在一些實施例中,結合多肽包括一或多個nnAA,其中每一nnAA係pAMF。
本文所闡述之多肽-多醣結合物可藉由其分子量(例如平均分子量)來表徵,可藉由任何適當表徵方法(例如SEC-MALS)來定義分子量。多肽-多醣結合物可(例如)具有大於約185 kDa或大於190 kDa之分子量或平均分子量。在一些實施例中,多肽-多醣結合物可具有介於約185 kDa與約700 kDa、約185 kDa與約600 kDa、約185 kDa與約500 kDa、約185 kDa與約400 kDa、約185 kDa與約300 kDa及約185 kDa與約200 kDa之間之分子量或平均分子量。在一些實施例中,多肽-多醣結合物之分子量或平均分子量可介於以下各項之間:約185 kDa與約700 kDa、約185 kDa與約650 kDa、約185 kDa與約600 kDa、約185 kDa與約550 kDa、約185 kDa與約500 kDa、約185 kDa與約450 kDa、約185 kDa與約400 kDa、約185 kDa與約350 kDa、約185 kDa與約300 kDa、約185 kDa與約250 kDa、約185 kDa與約200 kDa、之間約190 kDa與約700 kDa、約190 kDa與約650 kDa、約190 kDa與約600 kDa、約190 kDa與約550 kDa、約190 kDa與約500 kDa、約190 kDa與約450 kDa、約190 kDa與約400 kDa、約190 kDa與約350 kDa、約190 kDa與約300 kDa、約190 kDa與約250 kDa、約190 kDa與約200 kDa、約200 kDa與約700 kDa、約200 kDa與約650 kDa、約200 kDa與約600 kDa、約200 kDa與約550 kDa、約200 kDa與約500 kDa、約200 kDa與約450 kDa、約200 kDa與約400 kDa、約200 kDa與約350 kDa、約200 kDa與約300 kDa、約200 kDa與約250 kDa、約250 kDa與約700 kDa、約250 kDa與約650 kDa、約250 kDa與約600 kDa、約250 kDa與約550 kDa、約250 kDa與約500 kDa、約250 kDa與約450 kDa、約250 kDa與約400 kDa、約250 kDa與約350 kDa、約250 kDa與約300 kDa、約300 kDa與約700 kDa、約300 kDa與約650 kDa、約300 kDa與約600 kDa、約300 kDa與約550 kDa、約300 kDa與約500 kDa、約300 kDa與約450 kDa、約300 kDa與約400 kDa、約300 kDa與約350 kDa、約350 kDa與約700 kDa、約350 kDa與約650 kDa、約350 kDa與約600 kDa、約350 kDa與約550 kDa、約350 kDa與約500 kDa、約350 kDa與約450 kDa、約350 kDa與約400 kDa、約400 kDa與約700 kDa、約400 kDa與約650 kDa、約400 kDa與約600 kDa、約400 kDa與約550 kDa、約400 kDa與約500 kDa、約400 kDa與約450 kDa、約450 kDa與約700 kDa、約450 kDa與約650 kDa、約450 kDa與約600 kDa、約450 kDa與約550 kDa、約450 kDa與約500 kDa、約500 kDa與約700 kDa、約500 kDa與約650 kDa、約500 kDa與約600 kDa、約500 kDa與約550 kDa、約550 kDa與約700 kDa、約550 kDa與約650 kDa、約550 kDa與約600 kDa、約600 kDa與約700 kDa、約600 kDa與約650 kDa或約650 kDa與約700 kDa。在一些實施例中,多肽-多醣結合物可具有約185、190、200、250、300、350、400、450、500、550、600、650或700 kDa之分子量或平均分子量。
在一些實施例中,本文所闡述之多肽-多醣結合物可藉由其分子量來表徵。在一些實施例中,本文所闡述之多肽-多醣結合物可藉由GAS多醣或其變體中由連接體衍生之多醣重複單元之mol%來表徵。在一些實施例中,本文所闡述之多肽-多醣結合物可藉由其分子量及藉由GAS多醣或其變體中由連接體衍生之多醣重複單元之mol%來表徵。
在一些實施例中,本文所闡述之多肽-多醣結合物包括:(a) GAS多肽抗原或非GAS載體多肽,其包括至少一個非天然胺基酸(nnAA),其中nnAA包括點擊化學反應性基團;及(b)經純化細胞壁多醣或結合肽聚醣之莢膜多醣,其分子量為至少約10 kDa至至少約40 kDa。
在一些實施例中,本文所闡述之多肽-多醣結合物包括:(a) GAS多肽抗原或非GAS載體多肽,其包括至少一個非天然胺基酸(nnAA),其中nnAA包括點擊化學反應性基團;及(b)經純化細胞壁多醣或結合肽聚醣之莢膜多醣,其分子量為至少約10 kDa至至少約40 kDa;其中GAS多醣或其變體之介於約10 mol%與約18 mol%之間之多醣重複單元由連接體衍生。
表1含有所選多肽抗原及非GAS載體蛋白(包含其天然、變體、截短及含nnAA-形式)之實例性序列。
表1A含有包含nnAA之所選多肽抗原之實例性序列。
表 1. 實例性多肽序列
表 1A. 實例性多肽序列
序列編號 | 名稱 / 說明 | 胺基酸序列 |
1 | C5a [90-1035片段] WT,具有前導序列 | MHHHHHHGSGENLYFQGKTADTPVTSKATIRDLNDPSQVKTLQEKAGKGAGTVVAVIDAGFDKNHEAWRLTDKTKARYQSKEDLEKAKKEHGITYGEWVNDKVAYYHDYSKDGKTAVDQEHGTHVSGILSGNAPSETKEPYRLEGAMPEAQLLLMRVEIVNGLADYARNYAQAIRDAVNLGAKVINMSFGNAALAYANLPDETKKAFDYAKSKGVSIVTSAGNDSSFGGKTRLPLADHPDYGVVGTPAAADSTLTVASYSPDKQLTETATVKTADKQDKEMPVLSTNRFEPNKAYDYAYANRGMKEDDFKDVKGKIALIERGDIDFKDKIANAKKAGAVGVLIYDNQDKGFPIELPNVDQMPAAFISRKDGLLLKDNPKKTITFNATPKVLPTASGTKLSRFSSWGLTADGNIKPDIAAPGQDILSSVANNKYAKLSGTSMSAPLVAGIMGLLQKQYETQYPDMTPSERLDLAKKVLMSSATALYDEDEKAYFSPRQQGAGAVDAKKASAATMYVTDKDNTSSKVHLNNVSDTFEVTVTVHNKSDKPQELYYQATVQTDKVDGKHFALAPKALYETSWQKITIPANSSKQVTVPIDASRFSKDLLAQMKNGYFLEGFVRFKQDPTKEELMSIPYIGFRGDFGNLSALEKPIYDSKDGSSYYHEANSDAKDQLDGDGLQFYALKNNFTALTTESNPWTIIKAVKEGVENIEDIESSEITETIFAGTFAKQDDDSHYYIHRHANGKPYAAISPNGDGNRDYVQFQGTFLRNAKNLVAEVLDKEGNVVWTSEVTEQVVKNYNNDLASTLGSTRFEKTRWDGKDKDGKVVANGTYTYRVRYTPISSGAKEQHTDFDVIVDNTTPEVATSATFSTEDRRLTLASKPKTSQPVYRERIAYTYMDEDLPTTEYISPNEDGTFTLPEEAETMEGATVPLKMSDFTYVVEDMAGNITYTPVTKLLEGHSNK |
2 | C5a [90-1035片段] WT,不具有前導序列 | KTADTPVTSKATIRDLNDPSQVKTLQEKAGKGAGTVVAVIDAGFDKNHEAWRLTDKTKARYQSKEDLEKAKKEHGITYGEWVNDKVAYYHDYSKDGKTAVDQEHGTHVSGILSGNAPSETKEPYRLEGAMPEAQLLLMRVEIVNGLADYARNYAQAIRDAVNLGAKVINMSFGNAALAYANLPDETKKAFDYAKSKGVSIVTSAGNDSSFGGKTRLPLADHPDYGVVGTPAAADSTLTVASYSPDKQLTETATVKTADKQDKEMPVLSTNRFEPNKAYDYAYANRGMKEDDFKDVKGKIALIERGDIDFKDKIANAKKAGAVGVLIYDNQDKGFPIELPNVDQMPAAFISRKDGLLLKDNPKKTITFNATPKVLPTASGTKLSRFSSWGLTADGNIKPDIAAPGQDILSSVANNKYAKLSGTSMSAPLVAGIMGLLQKQYETQYPDMTPSERLDLAKKVLMSSATALYDEDEKAYFSPRQQGAGAVDAKKASAATMYVTDKDNTSSKVHLNNVSDTFEVTVTVHNKSDKPQELYYQATVQTDKVDGKHFALAPKALYETSWQKITIPANSSKQVTVPIDASRFSKDLLAQMKNGYFLEGFVRFKQDPTKEELMSIPYIGFRGDFGNLSALEKPIYDSKDGSSYYHEANSDAKDQLDGDGLQFYALKNNFTALTTESNPWTIIKAVKEGVENIEDIESSEITETIFAGTFAKQDDDSHYYIHRHANGKPYAAISPNGDGNRDYVQFQGTFLRNAKNLVAEVLDKEGNVVWTSEVTEQVVKNYNNDLASTLGSTRFEKTRWDGKDKDGKVVANGTYTYRVRYTPISSGAKEQHTDFDVIVDNTTPEVATSATFSTEDRRLTLASKPKTSQPVYRERIAYTYMDEDLPTTEYISPNEDGTFTLPEEAETMEGATVPLKMSDFTYVVEDMAGNITYTPVTKLLEGHSNK |
3 | C5a [90-1035片段] D131A/S513A,具有前導序列 | MHHHHHHGSGENLYFQGKTADTPVTSKATIRDLNDPSQVKTLQEKAGKGAGTVVAVIAAGFDKNHEAWRLTDKTKARYQSKEDLEKAKKEHGITYGEWVNDKVAYYHDYSKDGKTAVDQEHGTHVSGILSGNAPSETKEPYRLEGAMPEAQLLLMRVEIVNGLADYARNYAQAIRDAVNLGAKVINMSFGNAALAYANLPDETKKAFDYAKSKGVSIVTSAGNDSSFGGKTRLPLADHPDYGVVGTPAAADSTLTVASYSPDKQLTETATVKTADKQDKEMPVLSTNRFEPNKAYDYAYANRGMKEDDFKDVKGKIALIERGDIDFKDKIANAKKAGAVGVLIYDNQDKGFPIELPNVDQMPAAFISRKDGLLLKDNPKKTITFNATPKVLPTASGTKLSRFSSWGLTADGNIKPDIAAPGQDILSSVANNKYAKLSGTAMSAPLVAGIMGLLQKQYETQYPDMTPSERLDLAKKVLMSSATALYDEDEKAYFSPRQQGAGAVDAKKASAATMYVTDKDNTSSKVHLNNVSDTFEVTVTVHNKSDKPQELYYQATVQTDKVDGKHFALAPKALYETSWQKITIPANSSKQVTVPIDASRFSKDLLAQMKNGYFLEGFVRFKQDPTKEELMSIPYIGFRGDFGNLSALEKPIYDSKDGSSYYHEANSDAKDQLDGDGLQFYALKNNFTALTTESNPWTIIKAVKEGVENIEDIESSEITETIFAGTFAKQDDDSHYYIHRHANGKPYAAISPNGDGNRDYVQFQGTFLRNAKNLVAEVLDKEGNVVWTSEVTEQVVKNYNNDLASTLGSTRFEKTRWDGKDKDGKVVANGTYTYRVRYTPISSGAKEQHTDFDVIVDNTTPEVATSATFSTEDRRLTLASKPKTSQPVYRERIAYTYMDEDLPTTEYISPNEDGTFTLPEEAETMEGATVPLKMSDFTYVVEDMAGNITYTPVTKLLEGHSNK |
4 | C5a [90-1035片段] D131A/S513A,不具有前導序列 | KTADTPVTSKATIRDLNDPSQVKTLQEKAGKGAGTVVAVIAAGFDKNHEAWRLTDKTKARYQSKEDLEKAKKEHGITYGEWVNDKVAYYHDYSKDGKTAVDQEHGTHVSGILSGNAPSETKEPYRLEGAMPEAQLLLMRVEIVNGLADYARNYAQAIRDAVNLGAKVINMSFGNAALAYANLPDETKKAFDYAKSKGVSIVTSAGNDSSFGGKTRLPLADHPDYGVVGTPAAADSTLTVASYSPDKQLTETATVKTADKQDKEMPVLSTNRFEPNKAYDYAYANRGMKEDDFKDVKGKIALIERGDIDFKDKIANAKKAGAVGVLIYDNQDKGFPIELPNVDQMPAAFISRKDGLLLKDNPKKTITFNATPKVLPTASGTKLSRFSSWGLTADGNIKPDIAAPGQDILSSVANNKYAKLSGTAMSAPLVAGIMGLLQKQYETQYPDMTPSERLDLAKKVLMSSATALYDEDEKAYFSPRQQGAGAVDAKKASAATMYVTDKDNTSSKVHLNNVSDTFEVTVTVHNKSDKPQELYYQATVQTDKVDGKHFALAPKALYETSWQKITIPANSSKQVTVPIDASRFSKDLLAQMKNGYFLEGFVRFKQDPTKEELMSIPYIGFRGDFGNLSALEKPIYDSKDGSSYYHEANSDAKDQLDGDGLQFYALKNNFTALTTESNPWTIIKAVKEGVENIEDIESSEITETIFAGTFAKQDDDSHYYIHRHANGKPYAAISPNGDGNRDYVQFQGTFLRNAKNLVAEVLDKEGNVVWTSEVTEQVVKNYNNDLASTLGSTRFEKTRWDGKDKDGKVVANGTYTYRVRYTPISSGAKEQHTDFDVIVDNTTPEVATSATFSTEDRRLTLASKPKTSQPVYRERIAYTYMDEDLPTTEYISPNEDGTFTLPEEAETMEGATVPLKMSDFTYVVEDMAGNITYTPVTKLLEGHSNK |
5 | SLO [79-571片段] WT,具有His標籤及TEV序列 | MHHHHHHGSGENLYFQGAPKEMPLESAEKEEKKSEDKKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQGAYVAQYEILWDEINYDDKGKEVITKRRWDNNWYSKTSPFSTVIPLGANSRNIRIMARECTGLAWEWWRKVIDERDVKLSKEINVNISGSTLSPYGSITYK |
6 | SLO [79-571片段] WT,不具有前導序列 | APKEMPLESAEKEEKKSEDKKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQGAYVAQYEILWDEINYDDKGKEVITKRRWDNNWYSKTSPFSTVIPLGANSRNIRIMARECTGLAWEWWRKVIDERDVKLSKEINVNISGSTLSPYGSITYK |
7 | SLO [79-571片段] W535A,具有前導序列 | MHHHHHHGSGENLYFQGAPKEMPLESAEKEEKKSEDKKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQGAYVAQYEILWDEINYDDKGKEVITKRRWDNNWYSKTSPFSTVIPLGANSRNIRIMARECTGLAAEWWRKVIDERDVKLSKEINVNISGSTLSPYGSITYK |
8 | SLO [79-571片段] W535A,不具有前導序列 | APKEMPLESAEKEEKKSEDKKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQGAYVAQYEILWDEINYDDKGKEVITKRRWDNNWYSKTSPFSTVIPLGANSRNIRIMARECTGLAAEWWRKVIDERDVKLSKEINVNISGSTLSPYGSITYK |
9 | SpyAD [33-849片段] WT,具有前導序列 | MHHHHHHGSGENLYFQGQVKADDRASGETKASNTHDDSLPKPETIQEAKATIDAVEKTLSQQKAELTELATALTKTTAEINHLKEQQDNEQKALTSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKTSEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELSRLKSSAPSTQDSIVGNNTMKAPQGYPLEELKKLEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPADRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYKKTHGNTRPSFVYGQPGVSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAINFLRVDKHNPNAPVYLGFSTSNVGSLNEHFVMFPESNIANHQRFNKTPIKAVGSTKDYAQRVGTVSDTIAAIKGKVSSLENRLSAIHQEADIMAAQAKVSQLQGKLASTLKQSDSLNLQVRQLNDTKGSLRTELLAAKAKQAQLEATRDQSLAKLASLKAALHQTEALAEQAAARVTALVAKKAHLQYLRDFKLNPNRLQVIRERIDNTKQDLAKTTSSLLNAQEALAALQAKQSSLEATIATTEHQLTLLKTLANEKEYRHLDEDIATVPDLQVAPPLTGVKPLSYSKIDTTPLVQEMVKETKQLLEASARLAAENTSLVAEALVGQTSEMVASNAIVSKITSSITQPSSKTSYGSGSSTTSNLISDVDESTQR |
10 | SpyAD [33-849片段] WT,不具有前導序列 | QVKADDRASGETKASNTHDDSLPKPETIQEAKATIDAVEKTLSQQKAELTELATALTKTTAEINHLKEQQDNEQKALTSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKTSEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELSRLKSSAPSTQDSIVGNNTMKAPQGYPLEELKKLEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPADRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYKKTHGNTRPSFVYGQPGVSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAINFLRVDKHNPNAPVYLGFSTSNVGSLNEHFVMFPESNIANHQRFNKTPIKAVGSTKDYAQRVGTVSDTIAAIKGKVSSLENRLSAIHQEADIMAAQAKVSQLQGKLASTLKQSDSLNLQVRQLNDTKGSLRTELLAAKAKQAQLEATRDQSLAKLASLKAALHQTEALAEQAAARVTALVAKKAHLQYLRDFKLNPNRLQVIRERIDNTKQDLAKTTSSLLNAQEALAALQAKQSSLEATIATTEHQLTLLKTLANEKEYRHLDEDIATVPDLQVAPPLTGVKPLSYSKIDTTPLVQEMVKETKQLLEASARLAAENTSLVAEALVGQTSEMVASNAIVSKITSSITQPSSKTSYGSGSSTTSNLISDVDESTQR |
11 | SpyAD [33-849片段] nnAA (例如pAMF)突變體,具有前導序列 X = nnAA (例如pAMF)位置K64/K287/K386/K657 -根據全長序列編號 | MHHHHHHGSGENLYFQGQVKADDRASGETKASNTHDDSLPKPETIQEA X ATIDAVEKTLSQQKAELTELATALTKTTAEINHLKEQQDNEQKALTSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKTSEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELSRLKSSAPSTQDSIVGNNTMKAPQGYPLEELK X LEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPADRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYK X THGNTRPSFVYGQPGVSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAINFLRVDKHNPNAPVYLGFSTSNVGSLNEHFVMFPESNIANHQRFNKTPIKAVGSTKDYAQRVGTVSDTIAAIKGKVSSLENRLSAIHQEADIMAAQAKVSQLQGKLASTLKQSDSLNLQVRQLNDTKGSLRTELLAAKAKQAQLEATRDQSLAKLASLKAALHQTEALAEQAAARVTALVAK X AHLQYLRDFKLNPNRLQVIRERIDNTKQDLAKTTSSLLNAQEALAALQAKQSSLEATIATTEHQLTLLKTLANEKEYRHLDEDIATVPDLQVAPPLTGVKPLSYSKIDTTPLVQEMVKETKQLLEASARLAAENTSLVAEALVGQTSEMVASNAIVSKITSSITQPSSKTSYGSGSSTTSNLISDVDESTQR |
12 | SpyAD [33-849片段] nnAA (例如pAMF)突變體,不具有前導序列 X = nnAA (例如pAMF) K64/K287/K386/K657 -根據全長序列編號 | QVKADDRASGETKASNTHDDSLPKPETIQEA X ATIDAVEKTLSQQKAELTELATALTKTTAEINHLKEQQDNEQKALTSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKTSEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELSRLKSSAPSTQDSIVGNNTMKAPQGYPLEELK X LEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPADRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYK X THGNTRPSFVYGQPGVSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAINFLRVDKHNPNAPVYLGFSTSNVGSLNEHFVMFPESNIANHQRFNKTPIKAVGSTKDYAQRVGTVSDTIAAIKGKVSSLENRLSAIHQEADIMAAQAKVSQLQGKLASTLKQSDSLNLQVRQLNDTKGSLRTELLAAKAKQAQLEATRDQSLAKLASLKAALHQTEALAEQAAARVTALVAK X AHLQYLRDFKLNPNRLQVIRERIDNTKQDLAKTTSSLLNAQEALAALQAKQSSLEATIATTEHQLTLLKTLANEKEYRHLDEDIATVPDLQVAPPLTGVKPLSYSKIDTTPLVQEMVKETKQLLEASARLAAENTSLVAEALVGQTSEMVASNAIVSKITSSITQPSSKTSYGSGSSTTSNLISDVDESTQR |
13 | ADI [全長] WT,具有前導序列 | MHHHHHHGSGENLYFQGTAQTPIHVYSEIG KLKKVLLHRPGKEIENLMPDYLERLLFDDIPFLEDAQKEHDAFAQALRDEGIEVLYLETLAAESLVTPEIREAFIDEYLSEANIRGRATKKAIRELLMAIEDNQELIEKTMAGVQKSELPEIPASEKGLTDLVESNYPFAIDPMPNLYFTRDPFATIGTGVSLNHMFSETRNRETLYG KYIFTHHPIYGGGKVPMVYDRNETTRIEGGDELVLSKDVLAVGISQRTDAASIEKLLVNIFKQNLGFKKVLAFEFANNRKFMHLDTVFTMVDYDKFTIHPEIEGDLRVYSVTYDNEELHIVEE KGDLAELLAANLGVEKVDLIRCGGDNLVAAGREQWNDGSNTLTIAPGVVVVYNRNTITNAILESKGLKLIKIHGSELVRGRGGPRCMSMPFEREDI |
14 | ADI [全長] WT,不具有前導序列 | TAQTPIHVYSEIG KLKKVLLHRPGKEIENLMPDYLERLLFDDIPFLEDAQKEHDAFAQALRDEGIEVLYLETLAAESLVTPEIREAFIDEYLSEANIRGRATKKAIRELLMAIEDNQELIEKTMAGVQKSELPEIPASEKGLTDLVESNYPFAIDPMPNLYFTRDPFATIGTGVSLNHMFSETRNRETLYG KYIFTHHPIYGGGKVPMVYDRNETTRIEGGDELVLSKDVLAVGISQRTDAASIEKLLVNIFKQNLGFKKVLAFEFANNRKFMHLDTVFTMVDYDKFTIHPEIEGDLRVYSVTYDNEELHIVEE KGDLAELLAANLGVEKVDLIRCGGDNLVAAGREQWNDGSNTLTIAPGVVVVYNRNTITNAILESKGLKLIKIHGSELVRGRGGPRCMSMPFEREDI |
15 | ADI [全長] D277A,具有前導序列 | MHHHHHHGSGENLYFQGTAQTPIHVYSEIG KLKKVLLHRPGKEIENLMPDYLERLLFDDIPFLEDAQKEHDAFAQALRDEGIEVLYLETLAAESLVTPEIREAFIDEYLSEANIRGRATKKAIRELLMAIEDNQELIEKTMAGVQKSELPEIPASEKGLTDLVESNYPFAIDPMPNLYFTRDPFATIGTGVSLNHMFSETRNRETLYG KYIFTHHPIYGGGKVPMVYDRNETTRIEGGDELVLSKDVLAVGISQRTDAASIEKLLVNIFKQNLGFKKVLAFEFANNRKFMHLATVFTMVDYDKFTIHPEIEGDLRVYSVTYDNEELHIVEE KGDLAELLAANLGVEKVDLIRCGGDNLVAAGREQWNDGSNTLTIAPGVVVVYNRNTITNAILESKGLKLIKIHGSELVRGRGGPRCMSMPFEREDI |
16 | ADI [全長] D277A,不具有前導序列 | TAQTPIHVYSEIG KLKKVLLHRPGKEIENLMPDYLERLLFDDIPFLEDAQKEHDAFAQALRDEGIEVLYLETLAAESLVTPEIREAFIDEYLSEANIRGRATKKAIRELLMAIEDNQELIEKTMAGVQKSELPEIPASEKGLTDLVESNYPFAIDPMPNLYFTRDPFATIGTGVSLNHMFSETRNRETLYG KYIFTHHPIYGGGKVPMVYDRNETTRIEGGDELVLSKDVLAVGISQRTDAASIEKLLVNIFKQNLGFKKVLAFEFANNRKFMHLATVFTMVDYDKFTIHPEIEGDLRVYSVTYDNEELHIVEE KGDLAELLAANLGVEKVDLIRCGGDNLVAAGREQWNDGSNTLTIAPGVVVVYNRNTITNAILESKGLKLIKIHGSELVRGRGGPRCMSMPFEREDI |
17 | ADI [全長] nnAA (例如pAMF),具有前導序列 X = nnAA (例如pAMF)位置- K15、K193、K316 | MHHHHHHGSGENLYFQGTAQTPIHVYSEIG XLKKVLLHRPGKEIENLMPDYLERLLFDDIPFLEDAQKEHDAFAQALRDEGIEVLYLETLAAESLVTPEIREAFIDEYLSEANIRGRATKKAIRELLMAIEDNQELIEKTMAGVQKSELPEIPASEKGLTDLVESNYPFAIDPMPNLYFTRDPFATIGTGVSLNHMFSETRNRETLYG XYIFTHHPIYGGGKVPMVYDRNETTRIEGGDELVLSKDVLAVGISQRTDAASIEKLLVNIFKQNLGFKKVLAFEFANNRKFMHLDTVFTMVDYDKFTIHPEIEGDLRVYSVTYDNEELHIVEE XGDLAELLAANLGVEKVDLIRCGGDNLVAAGREQWNDGSNTLTIAPGVVVVYNRNTITNAILESKGLKLIKIHGSELVRGRGGPRCMSMPFEREDI |
18 | ADI [全長] nnAA (例如pAMF)突變體,不具有前導序列 X = nnAA (例如pAMF)位置- K15、K193、K316 | TAQTPIHVYSEIG XLKKVLLHRPGKEIENLMPDYLERLLFDDIPFLEDAQKEHDAFAQALRDEGIEVLYLETLAAESLVTPEIREAFIDEYLSEANIRGRATKKAIRELLMAIEDNQELIEKTMAGVQKSELPEIPASEKGLTDLVESNYPFAIDPMPNLYFTRDPFATIGTGVSLNHMFSETRNRETLYG XYIFTHHPIYGGGKVPMVYDRNETTRIEGGDELVLSKDVLAVGISQRTDAASIEKLLVNIFKQNLGFKKVLAFEFANNRKFMHLDTVFTMVDYDKFTIHPEIEGDLRVYSVTYDNEELHIVEE XGDLAELLAANLGVEKVDLIRCGGDNLVAAGREQWNDGSNTLTIAPGVVVVYNRNTITNAILESKGLKLIKIHGSELVRGRGGPRCMSMPFEREDI |
19 | ADI (mut5) [全長] D277A nnAA (例如pAMF),具有前導序列 X = nnAA (例如pAMF)位置- K15、K193、K316 | MHHHHHHGSGENLYFQGTAQTPIHVYSEIG XLKKVLLHRPGKEIENLMPDYLERLLFDDIPFLEDAQKEHDAFAQALRDEGIEVLYLETLAAESLVTPEIREAFIDEYLSEANIRGRATKKAIRELLMAIEDNQELIEKTMAGVQKSELPEIPASEKGLTDLVESNYPFAIDPMPNLYFTRDPFATIGTGVSLNHMFSETRNRETLYG XYIFTHHPIYGGGKVPMVYDRNETTRIEGGDELVLSKDVLAVGISQRTDAASIEKLLVNIFKQNLGFKKVLAFEFANNRKFMHLATVFTMVDYDKFTIHPEIEGDLRVYSVTYDNEELHIVEE XGDLAELLAANLGVEKVDLIRCGGDNLVAAGREQWNDGSNTLTIAPGVVVVYNRNTITNAILESKGLKLIKIHGSELVRGRGGPRCMSMPFEREDI |
20 | ADI (mut5) [全長] D277A nnAA (例如pAMF),不具有前導序列 X = nnAA (例如pAMF)位置- K15、K193、K316 | TAQTPIHVYSEIG XLKKVLLHRPGKEIENLMPDYLERLLFDDIPFLEDAQKEHDAFAQALRDEGIEVLYLETLAAESLVTPEIREAFIDEYLSEANIRGRATKKAIRELLMAIEDNQELIEKTMAGVQKSELPEIPASEKGLTDLVESNYPFAIDPMPNLYFTRDPFATIGTGVSLNHMFSETRNRETLYG XYIFTHHPIYGGGKVPMVYDRNETTRIEGGDELVLSKDVLAVGISQRTDAASIEKLLVNIFKQNLGFKKVLAFEFANNRKFMHLATVFTMVDYDKFTIHPEIEGDLRVYSVTYDNEELHIVEE XGDLAELLAANLGVEKVDLIRCGGDNLVAAGREQWNDGSNTLTIAPGVVVVYNRNTITNAILESKGLKLIKIHGSELVRGRGGPRCMSMPFEREDI |
21 | hFL [全長] WT,具有前導序列 | MHHHHHHGSGSSQIRQNYSTDVEAAVNSLVNLYLQASYTYLSLGFYFDRDDVALEGVSHFFRELAEEKREGYERLLKMQNQRGGRALFQDIKKPAEDEWGKTPDAMKAAMALEKKLNQALLDLHALGSARTDPHLCDFLETHFLDEEVKLIKKMGDHLTNLHRLGGPEAGLGEYLFERLTLKHD |
22 | hFL [全長] WT,不具有前導序列 | SSQIRQNYSTDVEAAVNSLVNLYLQASYTYLSLGFYFDRDDVALEGVSHFFRELAEEKREGYERLLKMQNQRGGRALFQDIKKPAEDEWGKTPDAMKAAMALEKKLNQALLDLHALGSARTDPHLCDFLETHFLDEEVKLIKKMGDHLTNLHRLGGPEAGLGEYLFERLTLKHD |
23 | hFL [全長] nnAA (例如pAMF),具有前導序列 X = nnAA (例如pAMF)位置- I5 | MHHHHHHGSGSSQ X RQNYSTDVEAAVNSLVNLYLQASYTYLSLGFYFDRDDVALEGVSHFFRELAEEKREGYERLLKMQNQRGGRALFQDIKKPAEDEWGKTPDAMKAAMALEKKLNQALLDLHALGSARTDPHLCDFLETHFLDEEVKLIKKMGDHLTNLHRLGGPEAGLGEYLFERLTLKHD |
24 | hFL [全長] nnAA (例如pAMF),不具有前導序列 X = nnAA (例如pAMF)位置- I5 | SSQ X RQNYSTDVEAAVNSLVNLYLQASYTYLSLGFYFDRDDVALEGVSHFFRELAEEKREGYERLLKMQNQRGGRALFQDIKKPAEDEWGKTPDAMKAAMALEKKLNQALLDLHALGSARTDPHLCDFLETHFLDEEVKLIKKMGDHLTNLHRLGGPEAGLGEYLFERLTLKHD |
25 | eCRM-pAMF6突變體 | MGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQ X GIQKPKSGTQGNYDDDWKEFYSTDNKYDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVGTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMYEYMAQACAGNRVRNSVGSSLSCINLDWDVIRD X TKTKIESLKEHGPIKNKMSESPNKTVSEEKAXQYLEEFHQTALEHPELSEL XTVTGTNPVFAGANYAAWAVNVAQVIDSETADNLEKTTAALSILPGIGSVMGIADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGELVDIGFAAYNFVESIINLFQVVHNSYNRPAYSPGH X TQPFLHDGYAVSWNTVEDSIIRTGFQGESGHDIKITAENTPLPIAGVLLPTIPGKLDVNKSKTHISVNGRKIRMRCRAIDGDVTFCRPKSPVYVGNGVHANLHVAFHRSSSEKIHSNEISSDSIGVLGYQKTVDHTKVNS X LSLFFEIKS |
26 | ADI (mut2) [全長] D277A nnAA (例如pAMF),具有前導序列 X = nnAA (例如pAMF)位置- K123、K247、K316 | MHHHHHHGSGENLYFQGTAQTPIHVYSEIGKLKKVLLHRPGKEIENLMPDYLERLLFDDIPFLEDAQKEHDAFAQALRDEGIEVLYLETLAAESLVTPEIREAFIDEYLSEANIRGRATKKAIRELLMAIEDNQELIE XTMAGVQKSELPEIPASEKGLTDLVESNYPFAIDPMPNLYFTRDPFATIGTGVSLNHMFSETRNRETLYGKYIFTHHPIYGGGKVPMVYDRNETTRIEGGDELVLSKDVLAVGISQRTDAASIE XLLVNIFKQNLGFKKVLAFEFANNRKFMHLATVFTMVDYDKFTIHPEIEGDLRVYSVTYDNEELHIVEE XGDLAELLAANLGVEKVDLIRCGGDNLVAAGREQWNDGSNTLTIAPGVVVVYNRNTITNAILESKGLKLIKIHGSELVRGRGGPRCMSMPFEREDI |
27 | ADI (mut2) [全長] D277A nnAA (例如pAMF),不具有前導序列,且具有來自裂解之G懸突 X = nnAA (例如pAMF)位置- K123、K247、K316 | GTAQTPIHVYSEIGKLKKVLLHRPGKEIENLMPDYLERLLFDDIPFLEDAQKEHDAFAQALRDEGIEVLYLETLAAESLVTPEIREAFIDEYLSEANIRGRATKKAIRELLMAIEDNQELIE XTMAGVQKSELPEIPASEKGLTDLVESNYPFAIDPMPNLYFTRDPFATIGTGVSLNHMFSETRNRETLYGKYIFTHHPIYGGGKVPMVYDRNETTRIEGGDELVLSKDVLAVGISQRTDAASIE XLLVNIFKQNLGFKKVLAFEFANNRKFMHLATVFTMVDYDKFTIHPEIEGDLRVYSVTYDNEELHIVEE XGDLAELLAANLGVEKVDLIRCGGDNLVAAGREQWNDGSNTLTIAPGVVVVYNRNTITNAILESKGLKLIKIHGSELVRGRGGPRCMSMPFEREDI |
28 | 具有前導序列之Sfb1重複區 | MHHHHHHGSGVETEDTKEPGVLMGGQSESVEFTKDTQTGMSGQTTPQVETEDTKEPGVLMGGQSESVEFTKDTQTGMSGQTASQVETEDTKEPGVLMGGQSESVEFTKDTQTGMSGQTTPQVETEDTKEPGVLMGGQSESVEFTKDTQTGMSGFSET |
29 | C5a [90-1035片段] WT,不具有前導序列且具有來自裂解之G懸突 | GKTADTPVTSKATIRDLNDPSQVKTLQEKAGKGAGTVVAVIDAGFDKNHEAWRLTDKTKARYQSKEDLEKAKKEHGITYGEWVNDKVAYYHDYSKDGKTAVDQEHGTHVSGILSGNAPSETKEPYRLEGAMPEAQLLLMRVEIVNGLADYARNYAQAIRDAVNLGAKVINMSFGNAALAYANLPDETKKAFDYAKSKGVSIVTSAGNDSSFGGKTRLPLADHPDYGVVGTPAAADSTLTVASYSPDKQLTETATVKTADKQDKEMPVLSTNRFEPNKAYDYAYANRGMKEDDFKDVKGKIALIERGDIDFKDKIANAKKAGAVGVLIYDNQDKGFPIELPNVDQMPAAFISRKDGLLLKDNPKKTITFNATPKVLPTASGTKLSRFSSWGLTADGNIKPDIAAPGQDILSSVANNKYAKLSGTSMSAPLVAGIMGLLQKQYETQYPDMTPSERLDLAKKVLMSSATALYDEDEKAYFSPRQQGAGAVDAKKASAATMYVTDKDNTSSKVHLNNVSDTFEVTVTVHNKSDKPQELYYQATVQTDKVDGKHFALAPKALYETSWQKITIPANSSKQVTVPIDASRFSKDLLAQMKNGYFLEGFVRFKQDPTKEELMSIPYIGFRGDFGNLSALEKPIYDSKDGSSYYHEANSDAKDQLDGDGLQFYALKNNFTALTTESNPWTIIKAVKEGVENIEDIESSEITETIFAGTFAKQDDDSHYYIHRHANGKPYAAISPNGDGNRDYVQFQGTFLRNAKNLVAEVLDKEGNVVWTSEVTEQVVKNYNNDLASTLGSTRFEKTRWDGKDKDGKVVANGTYTYRVRYTPISSGAKEQHTDFDVIVDNTTPEVATSATFSTEDRRLTLASKPKTSQPVYRERIAYTYMDEDLPTTEYISPNEDGTFTLPEEAETMEGATVPLKMSDFTYVVEDMAGNITYTPVTKLLEGHSNK |
30 | C5a [90-1035片段] D131A/S513A,不具有前導序列且具有來自裂解之G懸突 | GKTADTPVTSKATIRDLNDPSQVKTLQEKAGKGAGTVVAVIAAGFDKNHEAWRLTDKTKARYQSKEDLEKAKKEHGITYGEWVNDKVAYYHDYSKDGKTAVDQEHGTHVSGILSGNAPSETKEPYRLEGAMPEAQLLLMRVEIVNGLADYARNYAQAIRDAVNLGAKVINMSFGNAALAYANLPDETKKAFDYAKSKGVSIVTSAGNDSSFGGKTRLPLADHPDYGVVGTPAAADSTLTVASYSPDKQLTETATVKTADKQDKEMPVLSTNRFEPNKAYDYAYANRGMKEDDFKDVKGKIALIERGDIDFKDKIANAKKAGAVGVLIYDNQDKGFPIELPNVDQMPAAFISRKDGLLLKDNPKKTITFNATPKVLPTASGTKLSRFSSWGLTADGNIKPDIAAPGQDILSSVANNKYAKLSGTAMSAPLVAGIMGLLQKQYETQYPDMTPSERLDLAKKVLMSSATALYDEDEKAYFSPRQQGAGAVDAKKASAATMYVTDKDNTSSKVHLNNVSDTFEVTVTVHNKSDKPQELYYQATVQTDKVDGKHFALAPKALYETSWQKITIPANSSKQVTVPIDASRFSKDLLAQMKNGYFLEGFVRFKQDPTKEELMSIPYIGFRGDFGNLSALEKPIYDSKDGSSYYHEANSDAKDQLDGDGLQFYALKNNFTALTTESNPWTIIKAVKEGVENIEDIESSEITETIFAGTFAKQDDDSHYYIHRHANGKPYAAISPNGDGNRDYVQFQGTFLRNAKNLVAEVLDKEGNVVWTSEVTEQVVKNYNNDLASTLGSTRFEKTRWDGKDKDGKVVANGTYTYRVRYTPISSGAKEQHTDFDVIVDNTTPEVATSATFSTEDRRLTLASKPKTSQPVYRERIAYTYMDEDLPTTEYISPNEDGTFTLPEEAETMEGATVPLKMSDFTYVVEDMAGNITYTPVTKLLEGHSNK |
31 | SLO [79-571片段] WT,不具有前導序列且具有來自裂解之G懸突 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQGAYVAQYEILWDEINYDDKGKEVITKRRWDNNWYSKTSPFSTVIPLGANSRNIRIMARECTGLAWEWWRKVIDERDVKLSKEINVNISGSTLSPYGSITYK |
32 | SLO [79-571片段] W535A,不具有前導序列且具有來自裂解之G懸突 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQGAYVAQYEILWDEINYDDKGKEVITKRRWDNNWYSKTSPFSTVIPLGANSRNIRIMARECTGLAAEWWRKVIDERDVKLSKEINVNISGSTLSPYGSITYK |
33 | SpyAD [33-849片段] WT,不具有前導序列且具有來自裂解之G懸突 | GQVKADDRASGETKASNTHDDSLPKPETIQEAKATIDAVEKTLSQQKAELTELATALTKTTAEINHLKEQQDNEQKALTSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKTSEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELSRLKSSAPSTQDSIVGNNTMKAPQGYPLEELKKLEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPADRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYKKTHGNTRPSFVYGQPGVSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAINFLRVDKHNPNAPVYLGFSTSNVGSLNEHFVMFPESNIANHQRFNKTPIKAVGSTKDYAQRVGTVSDTIAAIKGKVSSLENRLSAIHQEADIMAAQAKVSQLQGKLASTLKQSDSLNLQVRQLNDTKGSLRTELLAAKAKQAQLEATRDQSLAKLASLKAALHQTEALAEQAAARVTALVAKKAHLQYLRDFKLNPNRLQVIRERIDNTKQDLAKTTSSLLNAQEALAALQAKQSSLEATIATTEHQLTLLKTLANEKEYRHLDEDIATVPDLQVAPPLTGVKPLSYSKIDTTPLVQEMVKETKQLLEASARLAAENTSLVAEALVGQTSEMVASNAIVSKITSSITQPSSKTSYGSGSSTTSNLISDVDESTQR |
34 | SpyAD [33-849片段] nnAA (例如pAMF),不具有前導序列且具有來自裂解之G懸突 X = nnAA (例如pAMF)位置K64/K287/K386/K657 -編號 | GQVKADDRASGETKASNTHDDSLPKPETIQEA X ATIDAVEKTLSQQKAELTELATALTKTTAEINHLKEQQDNEQKALTSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKTSEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELSRLKSSAPSTQDSIVGNNTMKAPQGYPLEELK X LEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPADRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYK X THGNTRPSFVYGQPGVSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAINFLRVDKHNPNAPVYLGFSTSNVGSLNEHFVMFPESNIANHQRFNKTPIKAVGSTKDYAQRVGTVSDTIAAIKGKVSSLENRLSAIHQEADIMAAQAKVSQLQGKLASTLKQSDSLNLQVRQLNDTKGSLRTELLAAKAKQAQLEATRDQSLAKLASLKAALHQTEALAEQAAARVTALVAK X AHLQYLRDFKLNPNRLQVIRERIDNTKQDLAKTTSSLLNAQEALAALQAKQSSLEATIATTEHQLTLLKTLANEKEYRHLDEDIATVPDLQVAPPLTGVKPLSYSKIDTTPLVQEMVKETKQLLEASARLAAENTSLVAEALVGQTSEMVASNAIVSKITSSITQPSSKTSYGSGSSTTSNLISDVDESTQR |
35 | ADI [全長] WT,不具有前導序列且具有來自裂解之G懸突 | GTAQTPIHVYSEIG KLKKVLLHRPGKEIENLMPDYLERLLFDDIPFLEDAQKEHDAFAQALRDEGIEVLYLETLAAESLVTPEIREAFIDEYLSEANIRGRATKKAIRELLMAIEDNQELIEKTMAGVQKSELPEIPASEKGLTDLVESNYPFAIDPMPNLYFTRDPFATIGTGVSLNHMFSETRNRETLYG KYIFTHHPIYGGGKVPMVYDRNETTRIEGGDELVLSKDVLAVGISQRTDAASIEKLLVNIFKQNLGFKKVLAFEFANNRKFMHLDTVFTMVDYDKFTIHPEIEGDLRVYSVTYDNEELHIVEE KGDLAELLAANLGVEKVDLIRCGGDNLVAAGREQWNDGSNTLTIAPGVVVVYNRNTITNAILESKGLKLIKIHGSELVRGRGGPRCMSMPFEREDI |
36 | ADI [全長] D277A,不具有前導序列且具有來自裂解之G懸突 | GTAQTPIHVYSEIG KLKKVLLHRPGKEIENLMPDYLERLLFDDIPFLEDAQKEHDAFAQALRDEGIEVLYLETLAAESLVTPEIREAFIDEYLSEANIRGRATKKAIRELLMAIEDNQELIEKTMAGVQKSELPEIPASEKGLTDLVESNYPFAIDPMPNLYFTRDPFATIGTGVSLNHMFSETRNRETLYG KYIFTHHPIYGGGKVPMVYDRNETTRIEGGDELVLSKDVLAVGISQRTDAASIEKLLVNIFKQNLGFKKVLAFEFANNRKFMHLATVFTMVDYDKFTIHPEIEGDLRVYSVTYDNEELHIVEE KGDLAELLAANLGVEKVDLIRCGGDNLVAAGREQWNDGSNTLTIAPGVVVVYNRNTITNAILESKGLKLIKIHGSELVRGRGGPRCMSMPFEREDI |
37 | ADI [全長] nnAA (例如pAMF),不具有前導序列且具有來自裂解之G懸突 X = nnAA (例如pAMF)位置- K15、K193、K316 | GTAQTPIHVYSEIG XLKKVLLHRPGKEIENLMPDYLERLLFDDIPFLEDAQKEHDAFAQALRDEGIEVLYLETLAAESLVTPEIREAFIDEYLSEANIRGRATKKAIRELLMAIEDNQELIEKTMAGVQKSELPEIPASEKGLTDLVESNYPFAIDPMPNLYFTRDPFATIGTGVSLNHMFSETRNRETLYG XYIFTHHPIYGGGKVPMVYDRNETTRIEGGDELVLSKDVLAVGISQRTDAASIEKLLVNIFKQNLGFKKVLAFEFANNRKFMHLDTVFTMVDYDKFTIHPEIEGDLRVYSVTYDNEELHIVEE XGDLAELLAANLGVEKVDLIRCGGDNLVAAGREQWNDGSNTLTIAPGVVVVYNRNTITNAILESKGLKLIKIHGSELVRGRGGPRCMSMPFEREDI |
38 | ADI (mut5) [全長] D277A nnAA (例如pAMF),不具有前導序列且具有來自裂解之G懸突 X = nnAA (例如pAMF)位置- K15、K193、K316 | GTAQTPIHVYSEIG XLKKVLLHRPGKEIENLMPDYLERLLFDDIPFLEDAQKEHDAFAQALRDEGIEVLYLETLAAESLVTPEIREAFIDEYLSEANIRGRATKKAIRELLMAIEDNQELIEKTMAGVQKSELPEIPASEKGLTDLVESNYPFAIDPMPNLYFTRDPFATIGTGVSLNHMFSETRNRETLYG XYIFTHHPIYGGGKVPMVYDRNETTRIEGGDELVLSKDVLAVGISQRTDAASIEKLLVNIFKQNLGFKKVLAFEFANNRKFMHLATVFTMVDYDKFTIHPEIEGDLRVYSVTYDNEELHIVEE XGDLAELLAANLGVEKVDLIRCGGDNLVAAGREQWNDGSNTLTIAPGVVVVYNRNTITNAILESKGLKLIKIHGSELVRGRGGPRCMSMPFEREDI |
39 | hFL [全長] WT,具有前導序列 | MHHHHHHGSGSSQIRQNYSTDVEAAVNSLVNLYLQASYTYLSLGFYFDRDDVALEGVSHFFRELAEEKREGYERLLKMQNQRGGRALFQDIKKPAEDEWGKTPDAMKAAMALEKKLNQALLDLHALGSARTDPHLCDFLETHFLDEEVKLIKKMGDHLTNLHRLGGPEAGLGEYLFERLTLKHD |
40 | hFL [全長] WT,不具有前導序列 | SSQIRQNYSTDVEAAVNSLVNLYLQASYTYLSLGFYFDRDDVALEGVSHFFRELAEEKREGYERLLKMQNQRGGRALFQDIKKPAEDEWGKTPDAMKAAMALEKKLNQALLDLHALGSARTDPHLCDFLETHFLDEEVKLIKKMGDHLTNLHRLGGPEAGLGEYLFERLTLKHD |
41 | hFL [全長] nnAA (例如pAMF),具有前導序列 X = nnAA (例如pAMF)位置- I5 | MHHHHHHGSGSSQ X RQNYSTDVEAAVNSLVNLYLQASYTYLSLGFYFDRDDVALEGVSHFFRELAEEKREGYERLLKMQNQRGGRALFQDIKKPAEDEWGKTPDAMKAAMALEKKLNQALLDLHALGSARTDPHLCDFLETHFLDEEVKLIKKMGDHLTNLHRLGGPEAGLGEYLFERLTLKHD |
42 | hFL [全長] nnAA (例如pAMF),不具有前導序列 X = nnAA (例如pAMF)位置- I5 | SSQ X RQNYSTDVEAAVNSLVNLYLQASYTYLSLGFYFDRDDVALEGVSHFFRELAEEKREGYERLLKMQNQRGGRALFQDIKKPAEDEWGKTPDAMKAAMALEKKLNQALLDLHALGSARTDPHLCDFLETHFLDEEVKLIKKMGDHLTNLHRLGGPEAGLGEYLFERLTLKHD |
43 | eCRM-pAMF6突變體 | GADDVVDSSKSFVMENFSSYHGTKPGYVDSIQ X GIQKPKSGTQGNYDDDWKEFYSTDNKYDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVGTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMYEYMAQACAGNRVRNSVGSSLSCINLDWDVIRD X TKTKIESLKEHGPIKNKMSESPNKTVSEEKAXQYLEEFHQTALEHPELSEL XTVTGTNPVFAGANYAAWAVNVAQVIDSETADNLEKTTAALSILPGIGSVMGIADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGELVDIGFAAYNFVESIINLFQVVHNSYNRPAYSPGH X TQPFLHDGYAVSWNTVEDSIIRTGFQGESGHDIKITAENTPLPIAGVLLPTIPGKLDVNKSKTHISVNGRKIRMRCRAIDGDVTFCRPKSPVYVGNGVHANLHVAFHRSSSEKIHSNEISSDSIGVLGYQKTVDHTKVNS X LSLFFEIKS |
44 | SLO(ΔC11) W535A,不具有前導序列且具有來自裂解之G懸突 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQGAYVAQYEILWDEINYDDKGKEVITKRRWDNNWYSKTSPFSTVIPLGANSRNIRIMARECTGLAAEWWRKVIDERDVKLSKEINVNISGS |
45 | SLO(ΔC21)片段,具有W535A,不具有前導序列且具有來自裂解之G懸突 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQGAYVAQYEILWDEINYDDKGKEVITKRRWDNNWYSKTSPFSTVIPLGANSRNIRIMARECTGLAAEWWRKVIDERDVKLS |
46 | SLO(ΔC31)片段,具有W535A,不具有前導序列且具有來自裂解之G懸突 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQGAYVAQYEILWDEINYDDKGKEVITKRRWDNNWYSKTSPFSTVIPLGANSRNIRIMARECTGLAAEWWRK |
47 | SLO(ΔC11)之SLO(ΔC41)片段,不具有前導序列且具有來自裂解之G懸突 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQGAYVAQYEILWDEINYDDKGKEVITKRRWDNNWYSKTSPFSTVIPLGANSRNIRIMAREC |
48 | SLO(ΔC11)之SLO(ΔC51)片段,不具有前導序列且具有來自裂解之G懸突 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQGAYVAQYEILWDEINYDDKGKEVITKRRWDNNWYSKTSPFSTVIPLGANS |
49 | SLO(ΔC11)之SLO(ΔC61)片段,不具有前導序列且具有來自裂解之G懸突 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQGAYVAQYEILWDEINYDDKGKEVITKRRWDNNWYSKTSPF |
50 | SLO(ΔC11)之SLO(ΔC71)片段,不具有前導序列且具有來自裂解之G懸突 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQGAYVAQYEILWDEINYDDKGKEVITKRRWD |
51 | SLO(ΔC11)之SLO(ΔC81)片段,不具有前導序列且具有來自裂解之G懸突 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQGAYVAQYEILWDEINYDDKG |
52 | SLO(ΔC11)之SLO(ΔC91)片段,不具有前導序列且具有來自裂解之G懸突 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQGAYVAQYEIL |
53 | SLO(ΔC11)之SLO(ΔC101)片段,不具有前導序列且具有來自裂解之G懸突 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQ |
54 | SLO(ΔC11)之SLO(ΔC101)片段,不具有前導序列且具有來自裂解之G懸突 X = nnAA (例如pAMF)或天然胺基酸(例如:K98、K112、R151、K189、K272、K323、K357、K375、K407、K464;或K或R。) | GAPKEMPLESAEKEEKKSED XKKSEEDHTEEIND XIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIE XKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTEN XPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNS XILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTF XELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSS XSNDVEAAFSAALKGTDV XTNGKYSDILENSSFTAVVLGGDAAEHNKVVT XDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSG XINLSHQ |
55 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 1 -不具有前導序列且具有來自裂解之G懸突(420995) X = nnAA (例如pAMF)位置- K98、R151 、K272、K357 | GAPKEMPLESAEKEEKKSED XKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIE XKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNS XILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSS XSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQ |
56 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 2 -不具有前導序列且具有來自裂解之G懸突(420996) X = nnAA (例如pAMF)位置- K112、K189、K323、K375 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEIND XIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTEN XPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTF XELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDV XTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQ |
57 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 3 -不具有前導序列且具有來自裂解之G懸突(420997) X = nnAA (例如pAMF)位置- R151、K272、K357、K407 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIE XKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNS XILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSS XSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVT XDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQ |
58 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 4 -不具有前導序列且具有來自裂解之G懸突(420998) X = nnAA (例如pAMF)位置- R151、K272、K375、K464 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIE XKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNS XILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDV XTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSG XINLSHQ |
59 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 5 -不具有前導序列且具有來自裂解之G懸突(420999) X = nnAA (例如pAMF)位置- K112、K272、K357、K464 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEIND XIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNS XILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSS XSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSG XINLSHQ |
60 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 6 -不具有前導序列且具有來自裂解之G懸突(421000) X = nnAA (例如pAMF)位置- K98、K189、K357 | GAPKEMPLESAEKEEKKSED XKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTEN XPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSS XSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQ |
61 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 7 -不具有前導序列且具有來自裂解之G懸突(421001) X = nnAA (例如pAMF)位置-K112、K189、K323 | GAPKEMPLESAEKEEKKSED XKKSEEDHTEEIND XIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTEN XPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTF XELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQ |
62 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 8 -不具有前導序列且具有來自裂解之G懸突(421002) X = nnAA (例如pAMF)位置- K98、R151、K272 | GAPKEMPLESAEKEEKKSED XKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIE XKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNS XILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQ |
63 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 9 -不具有前導序列且具有來自裂解之G懸突(421003) X = nnAA (例如pAMF)位置-K112、K272、K375 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEIND XIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNS XILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDV XTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQ |
64 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 10 -不具有前導序列且具有來自裂解之G懸突(421004) X = nnAA (例如pAMF)位置-K112、K323、K407 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEIND XIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTF XELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVT XDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQ |
65 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 10 -不具有前導序列且具有來自裂解之G懸突(426507) X = nnAA (例如pAMF)位置- K98、R151、K272、K357、K407 | GAPKEMPLESAEKEEKKSED XKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIE XKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNS XILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSS XSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVT XDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQ |
66 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 10 -不具有前導序列且具有來自裂解之G懸突(426508) X = nnAA (例如pAMF)位置- K112、K189、K323、K375、K464 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEIND XIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTEN XPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTF XELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDV XTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSG XINLSHQ |
67 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 10 -不具有前導序列且具有來自裂解之G懸突(426509) X = nnAA (例如pAMF)位置- K112、R151、K272、K357、K407 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEIND XIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIE XKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNS XILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSS XSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVT XDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQ |
68 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 10 -不具有前導序列且具有來自裂解之G懸突(426510) X = nnAA (例如pAMF)位置- K98、R151、K272、K357、K407、K464 | GAPKEMPLESAEKEEKKSED XKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIE XKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNS XILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSS XSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVT XDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSG XINLSHQ |
69 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 10 -不具有前導序列且具有來自裂解之G懸突(426511) X = nnAA (例如pAMF)位置- K112、R151、K189、K323、K375、K464 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEIND XIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIE XKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTEN XPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTF XELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDV XTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSG XINLSHQ |
70 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 10 -不具有前導序列且具有來自裂解之G懸突(426512) X = nnAA (例如pAMF)位置- K98、K112、K189、K323、K375、K464 | GAPKEMPLESAEKEEKKSED XKKSEEDHTEEIND XIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTEN XPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTF XELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDV XTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSG XINLSHQ |
71 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 10 -不具有前導序列且具有來自裂解之G懸突(426513) X = nnAA (例如pAMF)位置- K112、R151、K189、K272、K357、K407、K464 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEIND XIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIE XKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTEN XPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNS XILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSS XSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVT XDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSG XINLSHQ |
72 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 10 -不具有前導序列且具有來自裂解之G懸突(426514) X = nnAA (例如pAMF)位置- K98、R151、K189、K323、K375、K407、K464 | GAPKEMPLESAEKEEKKSED XKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIE XKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTEN XPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTF XELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDV XTNGKYSDILENSSFTAVVLGGDAAEHNKVVT XDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSG XINLSHQ |
73 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 10 -不具有前導序列且具有來自裂解之G懸突(426515) X = nnAA (例如pAMF)位置- K112、K189、K272、K357、K375、K407、K464 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEIND XIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTEN XPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNS XILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSS XSNDVEAAFSAALKGTDV XTNGKYSDILENSSFTAVVLGGDAAEHNKVVT XDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSG XINLSHQ |
74 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 10 -不具有前導序列且具有來自裂解之G懸突(426516) X = nnAA (例如pAMF)位置- K98、K112、R151、K189、K272、K323、K357、K375 | GAPKEMPLESAEKEEKKSED XKKSEEDHTEEIND XIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIE XKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTEN XPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNS XILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTF XELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSS XSNDVEAAFSAALKGTDV XTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQ |
75 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 10 -不具有前導序列且具有來自裂解之G懸突(426510) X = nnAA (例如pAMF)位置- K98、R151、K189、K272、K323、K357、K407、K464 | GAPKEMPLESAEKEEKKSED XKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIE XKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTEN XPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNS XILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTF XELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSS XSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVT XDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSG XINLSHQ |
76 | SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF) 10 -不具有前導序列且具有來自裂解之G懸突(426515) X = nnAA (例如pAMF)位置- K112、K189、K272、K323、K357、K375、K407、K464 | GAPKEMPLESAEKEEKKSEDKKKSEEDHTEEIND XIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTEN XPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNS XILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTF XELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSS XSNDVEAAFSAALKGTDV XTNGKYSDILENSSFTAVVLGGDAAEHNKVVT XDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSG XINLSHQ |
序列編號 | 名稱 / 說明 | 胺基酸序列 |
77 | SpyAD [33-714片段] nnAA (例如pAMF)突變體,不具有前導序列 SEQ ID NO: 34之片段 X = nnAA (例如pAMF) K64/K287/K386/K657 -根據全長序列編號 | GQVKADDRASGETKASNTHDDSLPKPETIQEAXATIDAVEKTLSQQKAELTELATALTKTTAEINHLKEQQDNEQKALTSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKTSEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELSRLKSSAPSTQDSIVGNNTMKAPQGYPLEELKXLEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPADRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYKXTHGNTRPSFVYGQPGVSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAINFLRVDKHNPNAPVYLGFSTSNVGSLNEHFVMFPESNIANHQRFNKTPIKAVGSTKDYAQRVGTVSDTIAAIKGKVSSLENRLSAIHQEADIMAAQAKVSQLQGKLASTLKQSDSLNLQVRQLNDTKGSLRTELLAAKAKQAQLEATRDQSLAKLASLKAALHQTEALAEQAAARVTALVAKXAHLQYLRDFKLNPNRLQVIRERIDNTKQDLAKTTSSLLNAQEALAALQAKQSSLEAT |
78 | SpyAD [33-699片段] nnAA (例如pAMF)突變體,不具有前導序列 SEQ ID NO: 34之片段 X = nnAA (例如pAMF) K64/K287/K386/K657 -根據全長序列編號 | GQVKADDRASGETKASNTHDDSLPKPETIQEAXATIDAVEKTLSQQKAELTELATALTKTTAEINHLKEQQDNEQKALTSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKTSEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELSRLKSSAPSTQDSIVGNNTMKAPQGYPLEELKXLEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPADRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYKXTHGNTRPSFVYGQPGVSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAINFLRVDKHNPNAPVYLGFSTSNVGSLNEHFVMFPESNIANHQRFNKTPIKAVGSTKDYAQRVGTVSDTIAAIKGKVSSLENRLSAIHQEADIMAAQAKVSQLQGKLASTLKQSDSLNLQVRQLNDTKGSLRTELLAAKAKQAQLEATRDQSLAKLASLKAALHQTEALAEQAAARVTALVAKXAHLQYLRDFKLNPNRLQVIRERIDNTKQDLAKTTSSLLNAQE |
79 | SpyAD [33-684片段] nnAA (例如pAMF)突變體,不具有前導序列 SEQ ID NO: 34之片段 X = nnAA (例如pAMF) K64/K287/K386/K657 -根據全長序列編號 | GQVKADDRASGETKASNTHDDSLPKPETIQEA XATIDAVEKTLSQQKAELTELATALTKTTAEINHLKEQQDNEQKALTSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKTSEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELSRLKSSAPSTQDSIVGNNTMKAPQGYPLEELK XLEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPADRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYK XTHGNTRPSFVYGQPGVSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAINFLRVDKHNPNAPVYLGFSTSNVGSLNEHFVMFPESNIANHQRFNKTPIKAVGSTKDYAQRVGTVSDTIAAIKGKVSSLENRLSAIHQEADIMAAQAKVSQLQGKLASTLKQSDSLNLQVRQLNDTKGSLRTELLAAKAKQAQLEATRDQSLAKLASLKAALHQTEALAEQAAARVTALVAK XAHLQYLRDFKLNPNRLQVIRERIDNTK |
80 | SpyAD [33-849片段] nnAA (例如pAMF)突變體,具有長前導序列 X = nnAA (例如pAMF)位置K64/K287/K386/K657 -根據全長序列編號 | MHHHHHHHHHHHHGSGENLYFQGQVKADDRASGETKASNTHDDSLPKPETIQEA XATIDAVEKTLSQQKAELTELATALTKTTAEINHLKEQQDNEQKALTSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKTSEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELSRLKSSAPSTQDSIVGNNTMKAPQGYPLEELK XLEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPADRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYK XTHGNTRPSFVYGQPGVSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAINFLRVDKHNPNAPVYLGFSTSNVGSLNEHFVMFPESNIANHQRFNKTPIKAVGSTKDYAQRVGTVSDTIAAIKGKVSSLENRLSAIHQEADIMAAQAKVSQLQGKLASTLKQSDSLNLQVRQLNDTKGSLRTELLAAKAKQAQLEATRDQSLAKLASLKAALHQTEALAEQAAARVTALVAK XAHLQYLRDFKLNPNRLQVIRERIDNTKQDLAKTTSSLLNAQEALAALQAKQSSLEATIATTEHQLTLLKTLANEKEYRHLDEDIATVPDLQVAPPLTGVKPLSYSKIDTTPLVQEMVKETKQLLEASARLAAENTSLVAEALVGQTSEMVASNAIVSKITSSITQPSSKTSYGSGSSTTSNLISDVDESTQR |
81 | SpyAD [33-594片段] nnAA (例如pAMF)突變體,具有長前導序列 SEQ ID NO: 34之片段 X = nnAA (例如pAMF)位置K64/K287/K386-根據全長序列編號 | QVKADDRASGETKASNTHDDSLPKPETIQEA XATIDAVEKTLSQQKAELTELATALTKTTAEINHLKEQQDNEQKALTSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKTSEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELSRLKSSAPSTQDSIVGNNTMKAPQGYPLEELK XLEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPADRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYK XTHGNTRPSFVYGQPGVSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAINFLRVDKHNPNAPVYLGFSTSNVGSLNEHFVMFPESNIANHQRFNKTPIKAVGSTKDYAQRVGTVSDTIAAIKGKVSSLENRLSAIHQEADIMAAQAKVSQLQGKLASTLKQSDSLNLQV |
82 | SpyAD [33-657片段] nnAA (例如pAMF)突變體,具有長前導序列 SEQ ID NO: 34之片段 X = nnAA (例如pAMF)位置K64/K287/K386/K657 -根據全長序列編號 | QVKADDRASGETKASNTHDDSLPKPETIQEA XATIDAVEKTLSQQKAELTELATALTKTTAEINHLKEQQDNEQKALTSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKTSEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELSRLKSSAPSTQDSIVGNNTMKAPQGYPLEELK XLEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPADRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYK XTHGNTRPSFVYGQPGVSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAINFLRVDKHNPNAPVYLGFSTSNVGSLNEHFVMFPESNIANHQRFNKTPIKAVGSTKDYAQRVGTVSDTIAAIKGKVSSLENRLSAIHQEADIMAAQAKVSQLQGKLASTLKQSDSLNLQVRQLNDTKGSLRTELLAAKAKQAQLEATRDQSLAKLASLKAALHQTEALAEQAAARVTALVAK X |
83 | SpyAD [33-667片段] nnAA (例如pAMF)突變體,具有長前導序列 SEQ ID NO: 34之片段 X = nnAA (例如pAMF)位置K64/K287/K386/K657 -根據全長序列編號 | QVKADDRASGETKASNTHDDSLPKPETIQEA XATIDAVEKTLSQQKAELTELATALTKTTAEINHLKEQQDNEQKALTSAQEIYTNTLASSEETLLAQGAEHQRELTATETELHNAQADQHSKETALSEQKASISAETTRAQDLVEQVKTSEQNIAKLNAMISNPDAITKAAQTANDNTKALSSELEKAKADLENQKAKVKKQLTEELAAQKAALAEKEAELSRLKSSAPSTQDSIVGNNTMKAPQGYPLEELK XLEASGYIGSASYNNYYKEHADQIIAKASPGNQLNQYQDIPADRNRFVDPDNLTPEVQNELAQFAAHMINSVRRQLGLPPVTVTAGSQEFARLLSTSYK XTHGNTRPSFVYGQPGVSGHYGVGPHDKTIIEDSAGASGLIRNDDNMYENIGAFNDVHTVNGIKRGIYDSIKYMLFTDHLHGNTYGHAINFLRVDKHNPNAPVYLGFSTSNVGSLNEHFVMFPESNIANHQRFNKTPIKAVGSTKDYAQRVGTVSDTIAAIKGKVSSLENRLSAIHQEADIMAAQAKVSQLQGKLASTLKQSDSLNLQVRQLNDTKGSLRTELLAAKAKQAQLEATRDQSLAKLASLKAALHQTEALAEQAAARVTALVAK XAHLQYLRDFK |
在一些實施例中,多肽抗原係SLO。在一些實施例中,多肽抗原係SLO(ΔC101)且在選自SEQ ID NO: 53之K98、K112、R151、K189、K272、K323、K357、K375、K407及K464之位置處包括三個或四個nnAA取代。在一些實施例中,多肽抗原係SLO(ΔC101)且包括在以下位置處經取代之nnAA或由其組成:位置K98、R151、K272及K357;位置K112、K189、K323及K375;位置R151、K272、K357及K407;位置R151、K272、K375及K464;位置K112、K272、K357及K464;位置K98、K189及K357;位置K112、K189及K323;位置K98、R151及K272;位置K112、K272及K375;或位置K112、K323及K407。在一些實施例中,三個或四個nnAA各自係pAMF。在一些實施例中,多肽抗原係SLO多肽且包括與SEQ ID NO: 55、56、57、58、59、60、61、62、63或64中之任一者至少95%、96%、97%、98%或99%一致之胺基酸序列。在一些實施例中,結合多肽係SLO多肽且包括SEQ ID NO: 55、56、57、58、59、60、61、62、63或64中之任一者之胺基酸序列或由其組成。
在一些實施例中,多肽抗原係SLO多肽。在一些實施例中,多肽抗原係SLO(ΔC101)且在選自SEQ ID NO: 53之K98、K112、R151、K189、K272、K323、K357、K375、K407及K464之位置處包括5、6、7或8個nnAA取代。在一些實施例中,多肽抗原係SLO(ΔC101)且包括在以下位置處經取代之nnAA或由其組成:位置K98、R151、K272、K357及K407;位置K112、K189、K323、K375及K464;位置K112、R151、K272、K357及K407;位置K98、R151、K272、K357、K407及K464;位置K112、R151、K189、K323、K375及K464;位置K98、K112、K189、K323、K375及K464;位置K112、R151、K189、K272、K357、K407及K464;位置K98、R151、K189、K323、K375、K407及K464;位置K112、K189、K272、K357、K375、K407及K464;位置K98、K112、R151、K189、K272、K323、K357及K375;位置K98、R151、K189、K272、K323、K357、K407及K464;或位置K112、K189、K272、K323、K357、K375、K407及K464。在一些實施例中,5、6、7或8個nnAA各自係pAMF。在一些實施例中,多肽抗原係SLO多肽且包括與SEQ ID NO: 65、66、67、68、69、70、71、72、73、74、75或76中之任一者至少95%、96%、97%、98%或99%一致之胺基酸序列。在一些實施例中,多肽抗原係SLO多肽且包括SEQ ID NO: 65、66、67、68、69、70、71、72、73、74、75或76中之任一者之胺基酸序列或由其組成。
在一些實施例中,多肽抗原係SpyAD且在SEQ ID NO: 9之位置K64、K287、K396及K657處包括4個nnAA取代。在一些實施例中,多肽抗原係SpyAD且在SEQ ID NO: 33之位置K64、K287、K396及K657處包括4個nnAA取代。在一些實施例中,4個nnAA各自係pAMF。在一些實施例中,多肽抗原係SpyAD且包括與SEQ ID NO: 11或SEQ ID NO: 12至少95%、96%、97%、98%或99%一致之胺基酸序列。在一些實施例中,4個nnAA各自係pAMF。在一些實施例中,多肽抗原係SpyAD且包括與SEQ ID NO: 34至少95%、96%、97%、98%或99%一致之胺基酸序列。在一些實施例中,多肽抗原係SpyAD且包括SEQ ID NO: 11或SEQ ID NO: 12之胺基酸序列或由其組成。在一些實施例中,多肽抗原係SpyAD且包括SEQ ID NO: 34之胺基酸序列或由其組成。
在一些實施例中,多肽抗原係SpyAD且包括與SEQ ID NO: 11、SEQ ID NO: 12或SEQ ID NO: 80至少95%、96%、97%、98%或99%一致之胺基酸序列。在一些實施例中,多肽抗原係SpyAD且包括SEQ ID NO: 11、SEQ ID NO: 12或SEQ ID NO: 80之胺基酸序列或由其組成。
在一些實施例中,多肽抗原係SpyAD且包括與SEQ ID NO: 77、SEQ ID NO: 78、SEQ ID NO: 79、SEQ ID NO: 81、SEQ ID NO: 82或SEQ ID NO: 83至少95%、96%、97%、98%或99%一致之胺基酸序列。在一些實施例中,多肽抗原係SpyAD且包括SEQ ID NO: 77、SEQ ID NO: 78或SEQ ID NO: 79、SEQ ID NO: 81、SEQ ID NO: 82或SEQ ID NO: 83或由其組成。
在一些實施例中,非GAS載體多肽包括eCRM197或由其組成。在某些實施例中,eCRM197具有SEQ ID NO: 25之序列。
在一些實施例中,GAS多肽抗原或非GAS載體多肽包括表1中所列示多肽之胺基酸序列或由其組成。在一些實施例中,GAS多肽抗原或非GAS載體多肽包括與SEQ ID NO: 1-76中之任一者至少95%、96%、97%、98%或99%一致之胺基酸序列。
在一些實施例中,GAS多肽抗原或非GAS載體多肽包括表1或1A中所列示多肽之胺基酸序列或由其組成。在一些實施例中,GAS多肽抗原或非GAS載體多肽包括與SEQ ID NO: 1-80中之任一者至少95%、96%、97%、98%或99%一致之胺基酸序列。
在一些實施例中,GAS多肽抗原或非GAS載體多肽包括表1中所列示多肽之胺基酸序列或由其組成。在一些實施例中,GAS多肽抗原或非GAS載體多肽包括與SEQ ID NO: 1-76中之任一者至少95%、96%、97%、98%或99%一致之胺基酸序列。
在一些實施例中,GAS多肽抗原或非GAS載體多肽包括表1A中所列示多肽之胺基酸序列或由其組成。在一些實施例中,GAS多肽抗原或非GAS載體多肽包括與SEQ ID NO: 77-80中之任一者至少95%、96%、97%、98%或99%一致之胺基酸序列。
免疫原性組合物
如先前所論述,藉由本文所闡述方法產生之長多醣及使用長多醣製備之多醣-多肽結合物適用於免疫原性組合物(例如用於治療或預防病況之疫苗)中。舉例而言,在一些實施例中,免疫原性組合物可在個體中誘導針對GAS細菌之保護性免疫反應。在一些實施例中,本文提供本文所闡述之免疫原性組合物之用途,其用以製造用於在個體中誘導針對GAS細菌之保護性免疫反應之藥劑。
在本文中,術語「個體」係指哺乳動物。在一些實施例中,個體係小鼠、大鼠、狗、天竺鼠、綿羊、非人類靈長類動物或人類。在一些實施例中,個體係人類。在一些實施例中,人類個體為18歲或更年長。在一些實施例中,人類個體小於18歲。
在一些實施例中,人類個體介於6個月齡與17歲之間。在一些實施例中,人類個體介於6個月齡與9歲之間、介於6個月齡與8歲之間、介於6個月齡與7歲之間、介於6個月齡與6歲之間、介於6個月齡與5歲之間、介於6個月齡與4歲之間、介於6個月齡與3歲之間、介於6個月齡與2歲之間或介於6個月齡與1歲之間。在一些實施例中,人類個體介於5歲與17歲之間、介於7歲與17歲之間、介於9歲與17歲之間、介於11歲與17歲之間、介於13歲與17歲之間或介於15歲與17歲之間。在一些實施例中,人類個體為6個月齡、1歲、2歲、3歲、4歲、5歲、6歲、7歲、8歲、9歲、10歲、11歲、12歲、13歲、14歲、15歲、16歲、17歲或18歲。
在本文中,術語「保護性免疫反應」涵蓋在個體中誘發抗GAS抗體反應。可藉由業內已知方式來測定在投與本文所闡述之免疫原性組合物之後所生成之效價,例如藉由衍生自免疫化個體之血清試樣之ELISA分析。在一些實施例中,本文所闡述之免疫原性組合物在所治療個體中誘發抗體反應,其中所生成抗體結合至多種(亦即兩種或更多種) GAS血清型。在一些實施例中,本文所闡述之免疫原性組合物在所治療個體中誘發抗體反應,其中所生成抗體結合至2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28、29、30、31、32、33、34、35或更多種GAS血清型。在一些實施例中,本文所闡述之免疫原性組合物不誘發針對人類蛋白質或組織之抗體反應。
在一些實施例中,本文所闡述之免疫原性組合物在所治療個體中誘發抗體反應,其中所生成抗體結合至至少一種選自M1、M2、M3、M4、M5、M6、M9、M11、M12、M13、M18、M22、M25、M28、M62、M71、M72、M74、M75、M77、M80、M81、M83、M87、M89及M92之GAS血清型。在一些實施例中,本文所闡述之免疫原性組合物在所治療個體中誘發抗體反應,其中所生成抗體結合至兩種或更多種選自M1、M2、M3、M4、M5、M6、M9、M11、M12、M13、M18、M22、M25、M28、M62、M71、M72、M74、M75、M77、M80、M81、M83、M87、M89及M92之GAS血清型。
在一些實施例中,本文所闡述之免疫原性組合物在所治療個體中誘發抗體反應,其中所生成抗體結合至至少一種選自M1、M2、M3、M4、M6、M11、M12、M22、M28、M75及M89之GAS血清型。在一些實施例中,本文所闡述之免疫原性組合物在所治療個體中誘發抗體反應,其中所生成抗體結合至兩種或更多種選自M1、M2、M3、M4、M6、M11、M12、M22、M28、M75及M89之GAS血清型。
在一些實施例中,本文所闡述之免疫原性組合物在所治療個體中誘發抗體反應,其中所生成抗體結合至至少一種選自M1、M3、M5、M9、M12、M18、M22、M25、M28、M71、M72及M74之GAS血清型。在一些實施例中,本文所闡述之免疫原性組合物在所治療個體中誘發抗體反應,其中所生成抗體結合至兩種或更多種選自M1、M3、M5、M9、M12、M18、M22、M25、M28、M71、M72及M74之GAS血清型。
在一些實施例中,本文所闡述之免疫原性組合物在所治療個體中誘發抗體反應,其中所生成抗體結合至至少一種選自M1、M4、M6、M11、M12、M22、M44、M75、M77、M77及M81之GAS血清型。在一些實施例中,本文所闡述之免疫原性組合物在所治療個體中誘發抗體反應,其中所生成抗體結合至兩種或更多種選自M1、M4、M6、M11、M12、M22、M44、M75、M77、M77及M81之GAS血清型。
在一些實施例中,本文所闡述之免疫原性組合物在所治療個體中誘發抗體反應,其中所生成抗體結合至至少一種選自M1、M2、M3、M4、M6、M9、M12、M18、M22、M75、M77、M89及M92之GAS血清型。在一些實施例中,本文所闡述之免疫原性組合物在所治療個體中誘發抗體反應,其中所生成抗體結合至兩種或更多種選自M1、M2、M3、M4、M6、M9、M12、M18、M22、M75、M77、M89及M92之GAS血清型。
在一些實施例中,本文所闡述之免疫原性組合物在所治療個體中誘發抗體反應,其中所生成抗體結合至至少一種選自M1、M2、M3、M4、M5、M6、M9、M11、M12、M13、M28、M62及M89之GAS血清型。在一些實施例中,本文所闡述之免疫原性組合物在所治療個體中誘發抗體反應,其中所生成抗體結合至兩種或更多種選自M1、M2、M3、M4、M5、M6、M9、M11、M12、M13、M28、M62及M89之GAS血清型。
在一些實施例中,本文所闡述之免疫原性組合物在所治療個體中誘發抗體反應,其中所生成抗體結合至至少一種選自M1、M2、M3、M4、M6、M12、M22、M28、M49、M53、M68、M77、M80、M83、M87、M89及M92之GAS血清型。在一些實施例中,本文所闡述之免疫原性組合物在所治療個體中誘發抗體反應,其中所生成抗體結合至兩種或更多種選自M1、M2、M3、M4、M6、M12、M22、M28、M49、M53、M68、M77、M80、M83、M87、M89及M92之GAS血清型。
在一些實施例中,本文所闡述之免疫原性組合物在所治療個體中誘發關於結合至一或多種志賀桿菌(
Shigella)血清型之抗體反應。在一些實施例中,本文所闡述之免疫原性組合物在所治療個體中誘發關於結合至一或多種GAS血清型且亦結合至一或多種志賀桿菌血清型之抗體反應。在一些實施例中,志賀桿菌血清型包括含有聚鼠李糖主鏈之多醣。包括該等多醣之實例性志賀桿菌血清型包括福氏志賀桿菌(
S. flexneri),例如福氏志賀桿菌2A及3A以及福氏志賀桿菌
6。
該等免疫原性組合物通常可包括(a) A型鏈球菌(GAS) C5a肽酶多肽抗原;(b) GAS鏈球菌溶血素O (SLO)多肽抗原;及(c)多肽-多醣結合物。
在一些實施例中,A型鏈球菌(GAS) C5a肽酶多肽抗原可為全長、天然C5a肽酶多肽或其片段。在一些實施例中,C5a肽酶多肽抗原或其片段包括SEQ ID NO: 1、SEQ ID NO: 2、SEQ ID NO: 3、SEQ ID NO: 4、SEQ ID NO: 29或SEQ ID NO: 30之胺基酸序列或由其組成。在一些實施例中,C5a肽酶多肽抗原或其片段包括SEQ ID NO: 29或SEQ ID NO: 30之胺基酸序列或由其組成。在一些實施例中,C5a肽酶多肽抗原包括SEQ ID NO: 30之胺基酸序列或由其組成。在一些實施例中,C5a肽酶多肽抗原或其片段包括與SEQ ID NO: 1、SEQ ID NO: 2、SEQ ID NO: 3、SEQ ID NO: 4、SEQ ID NO: 29或SEQ ID NO: 30至少95%、96%、97%、98%或99%一致之胺基酸序列或由其組成。在一些實施例中,C5a肽酶多肽抗原或其片段包括與SEQ ID NO: 29或SEQ ID NO: 30至少95%、96%、97%、98%或99%一致之胺基酸序列。在一些實施例中,C5a肽酶多肽抗原或其片段具有SEQ ID NO: 1、SEQ ID NO: 2、SEQ ID NO: 3、SEQ ID NO: 4、SEQ ID NO: 29或SEQ ID NO: 30之胺基酸序列。在一些實施例中,C5a肽酶多肽抗原或其片段具有SEQ ID NO: 29或SEQ ID NO: 30之胺基酸序列。
同樣,本文所闡述之免疫原性組合物可包括GAS鏈球菌溶血素O (SLO)多肽抗原或其片段。在一些實施例中,SLO多肽抗原或其片段包括SEQ ID NO: 5、SEQ ID NO: 6、SEQ ID NO: 7、SEQ ID NO: 8、SEQ ID NO: 31、SEQ ID NO: 32、SEQ ID NO: 44、SEQ ID NO: 45、SEQ ID NO: 46、SEQ ID NO: 47、SEQ ID NO: 48、SEQ ID NO: 49、SEQ ID NO: 50、SEQ ID NO: 51、SEQ ID NO: 52或SEQ ID NO: 53之胺基酸序列或由其組成。在某些實施例中,SLO多肽抗原或其片段包括SEQ ID NO: 31、SEQ ID NO: 32、SEQ ID NO: 44、SEQ ID NO: 45、SEQ ID NO: 46、SEQ ID NO: 47、SEQ ID NO: 48、SEQ ID NO: 49、SEQ ID NO: 50、SEQ ID NO: 51、SEQ ID NO: 52或SEQ ID NO: 53之胺基酸序列或由其組成。在某些實施例中,SLO抗原包括SEQ ID NO: 53之胺基酸序列或由其組成。在本文所闡述之一些實施例中,SLO抗原或其片段包括與SEQ ID NO: 5、SEQ ID NO: 6、SEQ ID NO: 7、SEQ ID NO: 8、SEQ ID NO: 31、SEQ ID NO: 32、SEQ ID NO: 44、SEQ ID NO: 45、SEQ ID NO: 46、SEQ ID NO: 47、SEQ ID NO: 48、SEQ ID NO: 49、SEQ ID NO: 50、SEQ ID NO: 51、SEQ ID NO: 52或SEQ ID NO: 53至少95%、96%、97%、98%或99%一致之胺基酸序列或由其組成。在本文所闡述之一些實施例中,SLO抗原或其片段包括與SEQ ID NO: 31、SEQ ID NO: 32、SEQ ID NO: 44、SEQ ID NO: 45、SEQ ID NO: 46、SEQ ID NO: 47、SEQ ID NO: 48、SEQ ID NO: 49、SEQ ID NO: 50、SEQ ID NO: 51、SEQ ID NO: 52或SEQ ID NO: 53至少95%、96%、97%、98%或99%一致之胺基酸序列或由其組成。在本文所闡述之一些實施例中,SLO抗原或其片段包括與SEQ ID NO: 53至少95%、96%、97%、98%或99%一致之胺基酸序列或由其組成。在一些實施例中,SLO抗原或其片段具有SEQ ID NO: 5、SEQ ID NO: 6、SEQ ID NO: 7、SEQ ID NO: 8、SEQ ID NO: 31、SEQ ID NO: 32、SEQ ID NO: 44、SEQ ID NO: 45、SEQ ID NO: 46、SEQ ID NO: 47、SEQ ID NO: 48、SEQ ID NO: 49、SEQ ID NO: 50、SEQ ID NO: 51、SEQ ID NO: 52或SEQ ID NO: 53之胺基酸序列。在一些實施例中,SLO抗原或其片段具有SEQ ID NO: 31、SEQ ID NO: 32、SEQ ID NO: 44、SEQ ID NO: 45、SEQ ID NO: 46、SEQ ID NO: 47、SEQ ID NO: 48、SEQ ID NO: 49、SEQ ID NO: 50、SEQ ID NO: 51、SEQ ID NO: 52或SEQ ID NO: 53之胺基酸序列。在一些實施例中,SLO抗原或其片段具有SEQ ID NO: 53之胺基酸序列。
本文所闡述之免疫原性組合物可包括多肽-多醣結合物。在一些實施例中,多肽-多醣結合物包括:(i)釀膿鏈球菌黏附及分裂(SpyAD)結合多肽或其片段,其包括至少一個非天然胺基酸(nnAA),其中至少一個nnAA包括點擊化學反應性基團;及(ii) GAS多醣或其變體,其缺乏免疫顯性N-乙醯基葡萄糖胺(GlcNAc)側鏈。
如上文所論述,免疫原性組合物之SpyAD結合多肽或其片段包括至少一個包括點擊化學反應性基團之nnAA,從而使得其能夠結合至GAS多醣或其變體。在一些實施例中,至少一個nnAA可選自2-胺基-3-(4-疊氮基苯基)丙酸(pAF)、2-胺基-4-疊氮基丁酸、2-疊氮基-3-苯基丙酸、2-胺基-3-疊氮基丙酸、2-胺基-3-(4-(疊氮基甲基)苯基)丙酸(pAMF)、2-胺基-3-(5-(疊氮基甲基)吡啶-2-基)丙酸、2-胺基-3-(4-(疊氮基甲基)吡啶-2-基)丙酸、2-胺基-3-(6-(疊氮基甲基)吡啶-3-基)丙酸及2-胺基-5-疊氮基戊酸。在一些實施例中,至少一個nnAA係pAMF。
SpyAD結合多肽可為天然或全長SpyAD結合多肽或其片段。在一些實施例中,SpyAD結合多肽或其片段包括與SEQ ID NO: 33至少95%、96%、97%、98%或99%一致之胺基酸序列或由其組成。在一些實施例中,SpyAD結合多肽包括或由其組成作為SEQ ID NO: 33之片段之胺基酸序列。在一些實施例中,SpyAD結合多肽具有作為SEQ ID NO: 33之片段之胺基酸序列。
在一些實施例中,SpyAD結合多肽或其片段在SEQ ID NO: 33之位置K64、K287、K386及K657處包括pAMF取代(注意:本文之編號係基於全長天然序列)。因此,在一些實施例中,SpyAD結合多肽或其片段包括SEQ ID NO: 34、SEQ ID NO: 77、SEQ ID NO: 78、SEQ ID NO: 79、SEQ ID NO: 81、SEQ ID NO: 82或SEQ ID NO: 83之胺基酸序列或由其組成。在一些實施例中,SpyAD結合多肽或其片段包括與SEQ ID NO: 34、SEQ ID NO: 77、SEQ ID NO: 78、SEQ ID NO: 79、SEQ ID NO: 81、SEQ ID NO: 82或SEQ ID NO: 83至少95%、96%、97%、98%或99%一致之胺基酸序列或由其組成。在一些實施例中,SpyAD結合多肽或其片段包括與SEQ ID NO: 34至少95%、96%、97%、98%或99%一致之胺基酸序列或由其組成。在某些實施例中,SpyAD結合多肽或其片段具有SEQ ID NO: 34、SEQ ID NO: 77、SEQ ID NO: 78、SEQ ID NO: 79、SEQ ID NO: 81、SEQ ID NO: 82或SEQ ID NO: 83之胺基酸序列。在某些實施例中,SpyAD結合多肽或其片段具有SEQ ID NO: 34之胺基酸序列。
在本文所闡述之免疫原性組合物之一些實施例中,C5a肽酶多肽抗原或其片段包括與SEQ ID NO: 30至少95%一致之胺基酸序列;SLO多肽抗原或其片段包括與SEQ ID NO: 53至少95%一致之胺基酸序列;且SpyAD結合多肽或其片段包括與SEQ ID NO: 34至少95%一致之胺基酸序列。在某些實施例中,C5a肽酶多肽抗原或其片段包括SEQ ID NO: 30之胺基酸序列;SLO多肽抗原或其片段包括SEQ ID NO: 53之胺基酸序列;且SpyAD結合多肽或其片段包括SEQ ID NO: 34之胺基酸序列。在一些實施例中,C5a肽酶多肽抗原或其片段具有SEQ ID NO: 30之胺基酸序列;SLO多肽抗原或其片段具有SEQ ID NO: 53之胺基酸序列;且SpyAD結合多肽或其片段具有SEQ ID NO: 34之胺基酸序列。
在本文所闡述之任一免疫原性組合物之一些實施例中,多肽-多醣結合物之GAS多醣或其變體中介於約8 mol%與20 mol%之間之多醣重複單元由點擊化學反應性基團或包括點擊化學反應性基團之連接體衍生。在一些實施例中,介於約8 mol%與約20 mol%、約8 mol%與約19 mol%、約8 mol%與約18 mol%、約8 mol%與約17 mol%、約8 mol%與約16 mol%、約8 mol%與約15 mol%、約8 mol%與約14 mol%、8 mol%與約13 mol%、約8 mol%與約12 mol%、約8 mol%與約11 mol%、8 mol%與約10 mol%、約8 mol%與約9 mol%、約9 mol%與約20 mol%、約9 mol%與約19 mol%、約9 mol%與約18 mol%、約9 mol%與約17 mol%、約9 mol%與約16 mol%、約9 mol%與約15 mol%、約9 mol%與約14 mol%、9 mol%與約13 mol%、約9 mol%與約12 mol%、約9 mol%與約11 mol%、9 mol%與約10 mol%、約10 mol%與約20 mol%、約10 mol%與約19 mol%、約10 mol%與約18 mol%、約10 mol%與約17 mol%、約10 mol%與約16 mol%、約10 mol%與約15 mol%、約10 mol%與約14 mol%、10 mol%與約13 mol%、約10 mol%與約12 mol%、約10 mol%與約11 mol%、約11 mol%與約20 mol%、約11 mol%與約19 mol%、約11 mol%與約18 mol%、約11 mol%與約17 mol%、約11 mol%與約16 mol%、約11 mol%與約15 mol%、約11 mol%與約14 mol%、11 mol%與約13 mol%、約11 mol%與約12 mol%、約12 mol%與約20 mol%、約12 mol%與約19 mol%、約12 mol%與約18 mol%、約12 mol%與約17 mol%、約12 mol%與約16 mol%、約12 mol%與約15 mol%、約12 mol%與約14 mol%、12 mol%與約13 mol%、約13 mol%與約20 mol%、約13 mol%與約19 mol%、約13 mol%與約18 mol%、約13 mol%與約17 mol%、約13 mol%與約16 mol%、約13 mol%與約15 mol%、約13 mol%與約14 mol%、約14 mol%與約20 mol%、約14 mol%與約19 mol%、約14 mol%與約18 mol%、約14 mol%與約17 mol%、約14 mol%與約16 mol%、約14 mol%與約15 mol%、約15 mol%與約20 mol%、約15 mol%與約19 mol%、約15 mol%與約18 mol%、約15 mol%與約17 mol%、約15 mol%與約16 mol%、約16 mol%與約20 mol%、約16 mol%與約19 mol%、約16 mol%與約18 mol%、約16 mol%與約17 mol%、約17 mol%與約20 mol%、約17 mol%與約19 mol%、約17 mol%與約18 mol%、約18 mol%與約20 mol%、約18 mol%與約19 mol%或約19 mol%與約20 mol%之間之多醣PS重複單元由點擊化學反應性基團或包括點擊化學反應性基團之連接體衍生。在一些實施例中,多醣之多醣重複單元係GAS多醣之多醣重複單元或其變體。在本文所闡述之免疫原性組合物之一些實施例中,多肽-多醣結合物之GAS多醣或其變體中約8、9、10、11、12、13、14、15、16、17、18、19或20 mol%之多醣重複單元由點擊化學反應性基團或包括點擊化學反應性基團之連接體衍生。在一些實施例中,多肽-多醣結合物之GAS多醣或其變體缺乏免疫顯性N-乙醯基葡萄糖胺(GlcNAc)側鏈。
在本發明之免疫原性組合物之一些實施例中,連接體在與nnAA之點擊化學反應性基團反應之前包括式I結構:
(式I)
其中,X係多醣之至少一個多醣重複單元且n為至少1。在一些實施例中,多醣係GAS多醣或其變體。在一些實施例中,n為至少1、至少2、至少3、至少4或至少5。在一些實施例中,n為1、2、3、4或5。在此處或其他處將X闡述為附接至GAS多醣或其變體之多醣重複單元之情形下,此可係指化學附接至或經由多醣重複單元內之任何適宜官能基進行附接(例如與可源自鄰位二醇之氧化之醛經由還原胺化進行反應)。在一些實施例中,式I之X及-NH-係異脲部分之一部分。
在一些實施例中,SpyAD結合多肽連接至式II之GAS多醣或其變體:
(式II)
其中,R
1係H、甲醯基或SpyAD結合多肽或其片段之至少一個胺基酸;R
2係OH或SpyAD結合多肽或其片段之至少一個胺基酸;W係CH或N;y係至少1;n係至少1;且X係GAS多醣或其變體之至少一個多醣重複單元。在一些實施例中,R
1及R
2皆係SpyAD結合多肽或其片段之胺基酸。在一些實施例中,y係至少1、至少2或至少3。在某些實施例中,y為1、2或3。在一些實施例中,兩個W皆係CH。在一些實施例中,兩個W皆係N。在一些實施例中,一個W係N且一個W係CH。在一些實施例中,n係至少1、至少2、至少3、至少4或至少5。在某些實施例中,n為1、2、3、4或5。在一些實施例中,式I之X及-NH-係異脲部分之一部分。
在本文所闡述之免疫原性組合物之一些實施例中,GAS多醣或其變體具有至少約10 kDa至至少約40 kDa之分子量。在某些實施例中,經純化細胞壁多醣或結合肽聚醣之莢膜多醣之平均分子量為約10 kDa至約40 kDa、約10 kDa至約35 kDa、約10 kDa至約30 kDa、約10 kDa至約25 kDa、約10 kDa至約20 kDa、約10 kDa至約15 kDa、15 kDa至約40 kDa、約15 kDa至約35 kDa、約15 kDa至約30 kDa、約15 kDa至約25 kDa、約15 kDa至約20 kDa、20 kDa至約40 kDa、約20 kDa至約35 kDa、約20 kDa至約30 kDa、約20 kDa至約25 kDa、25 kDa至約40 kDa、約25 kDa至約35 kDa、約25 kDa至約30 kDa、約30 kDa至約40 kDa、約30 kDa至約35 kDa或約35 kDa至約40 kDa。在一些實施例中,經純化細胞壁多醣或結合肽聚醣之莢膜多醣具有約10 kDa、約15 kDa、約20 kDa、約25 kDa、約30 kDa、約35 kDa或約40 kDa之平均分子量。在一些實施例中,GAS多醣或其變體缺乏免疫顯性N-乙醯基葡萄糖胺(GlcNAc)側鏈。
除具有較長多醣外,本文所闡述之免疫原性組合物之多肽-多醣結合物亦可具有增加之平均分子量。在本文所闡述之任一多肽-多醣結合物之一些實施例中,平均分子量大於約185 kDa或190 kDa。在一些實施例中,平均分子量介於約185 kDa與約700 kDa、約185 kDa與約600 kDa、約185 kDa與約500 kDa、約185 kDa與約400 kDa、約185 kDa與約300 kDa及約185 kDa與約200 kDa之間。在一些實施例中,多肽-多醣結合物之分子量或平均分子量可介於以下各項之間:約185 kDa與約700 kDa、約185 kDa與約650 kDa、約185 kDa與約600 kDa、約185 kDa與約550 kDa、約185 kDa與約500 kDa、約185 kDa與約450 kDa、約185 kDa與約400 kDa、約185 kDa與約350 kDa、約185 kDa與約300 kDa、約185 kDa與約250 kDa、約185 kDa與約200 kDa、約200 kDa與約700 kDa、約200 kDa與約650 kDa、約200 kDa與約600 kDa、約200 kDa與約550 kDa、約200 kDa與約500 kDa、約200 kDa與約450 kDa、約200 kDa與約400 kDa、約200 kDa與約350 kDa、約200 kDa與約300 kDa、約200 kDa與約250 kDa、約250 kDa與約700 kDa、約250 kDa與約650 kDa、約250 kDa與約600 kDa、約250 kDa與約550 kDa、約250 kDa與約500 kDa、約250 kDa與約450 kDa、約250 kDa與約400 kDa、約250 kDa與約350 kDa、約250 kDa與約300 kDa、約300 kDa與約700 kDa、約300 kDa與約650 kDa、約300 kDa與約600 kDa、約300 kDa與約550 kDa、約300 kDa與約500 kDa、約300 kDa與約450 kDa、約300 kDa與約400 kDa、約300 kDa與約350 kDa、約350 kDa與約700 kDa、約350 kDa與約650 kDa、約350 kDa與約600 kDa、約350 kDa與約550 kDa、約350 kDa與約500 kDa、約350 kDa與約450 kDa、約350 kDa與約400 kDa、約400 kDa與約700 kDa、約400 kDa與約650 kDa、約400 kDa與約600 kDa、約400 kDa與約550 kDa、約400 kDa與約500 kDa、約400 kDa與約450 kDa、約450 kDa與約700 kDa、約450 kDa與約650 kDa、約450 kDa與約600 kDa、約450 kDa與約550 kDa、約450 kDa與約500 kDa、約500 kDa與約700 kDa、約500 kDa與約650 kDa、約500 kDa與約600 kDa、約500 kDa與約550 kDa、約550 kDa與約700 kDa、約550 kDa與約650 kDa、約550 kDa與約600 kDa、約600 kDa與約700 kDa、約600 kDa與約650 kDa或約650 kDa與約700 kDa。在一些實施例中,多肽-多醣結合物可具有約185、200、250、300、350、400、450、500、550、600、650或700 kDa之分子量或平均分子量。在一些實施例中,多肽-多醣結合物之GAS多醣或其變體缺乏免疫顯性N-乙醯基葡萄糖胺(GlcNAc)側鏈。
使用本文所闡述之長多醣可產生包括減小量之游離GAS多醣或其變體之免疫原性組合物。舉例而言,免疫原性組合物可進一步包括小於約60%、55%、50%、45%、40%、35%、30%、25%、20%、15%、10%或5%之游離GAS多醣或其變體。在一些實施例中,免疫原性組合物進一步包括約60%、55%、50%、45%、40%、35%、30%、25%、20%、15%、10%或5%之游離GAS多醣或其變體。
本文所闡述之免疫原性組合物可適於在個體中誘導針對A型鏈球菌(GAS)細菌之保護性免疫反應,該應用包括投與本文所闡述之任一免疫原性組合物。在一些實施例中,免疫原性組合物可在個體中誘導針對A型鏈球菌(GAS)細菌之抗體反應且並不在個體中誘導針對人類組織之抗體反應。在一些實施例中,本發明提供本文所闡述之免疫原性組合物之用途,其用以製造用於在個體中誘導針對GAS細菌之保護性免疫反應之藥劑。亦提供本文所闡述之任一免疫原性組合物之用途,其用於在個體中誘導針對GAS細菌之保護性免疫反應。在一些實施例中,個體為18歲或更年長。在一些實施例中,個體小於18歲。在一些實施例中,個體介於5歲與17歲之間、介於6個月與9歲之間或介於5歲與9歲之間。
在一些實施例中,本文所闡述之免疫原性組合物包括:(i)釀膿鏈球菌黏附及分裂(SpyAD)結合多肽或其片段,其包括至少一個非天然胺基酸(nnAA),其中至少一個nnAA包括點擊化學反應性基團;及(ii) GAS多醣或其變體,其缺乏免疫顯性N-乙醯基葡萄糖胺(GlcNAc)側鏈。在一些實施例中,GAS多醣或其變體之介於約8 mol%與約20 mol%之間之多醣重複單元由連接體衍生。另外,在一些實施例中,多肽-多醣結合物之平均分子量介於約185 kDa與約700 kDa之間。在一些實施例中,多肽-多醣結合物之平均分子量大於約185 kDa。在一些實施例中,多肽-多醣結合物之平均分子量大於約190 kDa。
在一些實施例中,免疫原性組合物可包括:(a)包括SEQ ID NO: 30之胺基酸序列或由其組成之A型鏈球菌(GAS) C5a肽酶多肽抗原或其片段;(b)包括SEQ ID NO: 53之胺基酸序列或由其組成之GAS鏈球菌溶血素O (SLO)多肽抗原或其片段;及(c)多肽-多醣結合物,其包括:(i)包括SEQ ID NO: 34之胺基酸序列或由其組成之釀膿鏈球菌黏附及分裂(SpyAD)結合多肽或其片段;及(ii) GAS多醣或其變體,其缺乏免疫顯性N-乙醯基葡萄糖胺(GlcNAc)側鏈。在一些實施例中,GAS多醣或其變體之介於約8 mol%與約20 mol%之間之多醣重複單元由連接體衍生。在一些實施例中,多肽-多醣結合物之平均分子量介於約185 kDa與約700 kDa之間。在一些實施例中,多肽-多醣結合物之平均分子量介於約200 kDa與約700 kDa之間。在某些實施例中,平均分子量介於約300 kDa與約600 kDa之間。在某些實施例中,平均分子量介於約400 kDa與約500 kDa之間。在一些實施例中,GAS多醣或其變體具有至少約10 kDa至至少約40 kDa之分子量。在一些實施例中,SpyAD結合多肽係SEQ ID NO: 34之胺基酸序列之片段,且包括SEQ ID NO: 77、SEQ ID NO: 78、SEQ ID NO: 79、SEQ ID NO: 81、SEQ ID NO: 82或SEQ ID NO: 83之胺基酸序列或由其組成。
在一些實施例中,本文所闡述之免疫原性組合物包括(a) A型鏈球菌(GAS) C5a肽酶多肽抗原;(b) GAS鏈球菌溶血素O (SLO)多肽抗原;及(c)多肽-多醣結合物,其包括:(i)釀膿鏈球菌黏附及分裂(SpyAD)結合多肽或其片段,其包括至少一個非天然胺基酸(nnAA),其中至少一個nnAA包括點擊化學反應性基團;及(ii) GAS多醣或其變體,其缺乏免疫顯性N-乙醯基葡萄糖胺(GlcNAc)側鏈;其中多肽-多醣結合物之平均分子量介於約185 kDa與約700 kDa之間。
在一些實施例中,免疫原性組合物包括(a) A型鏈球菌(GAS) C5a肽酶多肽抗原;(b) GAS鏈球菌溶血素O (SLO)多肽抗原;及(c)多肽-多醣結合物,其包括:(i)釀膿鏈球菌黏附及分裂(SpyAD)結合多肽或其片段,其包括至少一個非天然胺基酸(nnAA),其中至少一個nnAA包括點擊化學反應性基團;及(ii) GAS多醣或其變體,其缺乏免疫顯性N-乙醯基葡萄糖胺(GlcNAc)側鏈;其中GAS多醣或其變體之介於約8 mol%與約20 mol%之間之多醣重複單元由連接體衍生。
在一些實施例中,本文所闡述之免疫原性組合物包括(a) A型鏈球菌(GAS) C5a肽酶多肽抗原;(b) GAS鏈球菌溶血素O (SLO)多肽抗原;及(c)多肽-多醣結合物,其包括:(i)釀膿鏈球菌黏附及分裂(SpyAD)結合多肽或其片段,其包括至少一個非天然胺基酸(nnAA),其中至少一個nnAA包括點擊化學反應性基團;及(ii) GAS多醣或其變體,其缺乏免疫顯性N-乙醯基葡萄糖胺(GlcNAc)側鏈;其中GAS多醣或其變體之介於約8 mol%與約20 mol%之間之多醣重複單元由連接體衍生;且其中多肽-多醣結合物之平均分子量介於約185 kDa與約700 kDa之間。
列舉實施例
實施例I-1.一種自細菌細胞純化細胞壁多醣或結合肽聚醣之莢膜多醣之方法,該方法包括:
(a)在包括鹼及還原劑之溶液中水解該細菌細胞以形成包括多醣之溶解物;及
(b)將該包括多醣之溶解物與溶壁酶一起培育以形成游離多醣溶液。
實施例I-2.如實施例I-1之方法,其中該細菌細胞係假單胞菌細菌細胞、鏈球菌細菌細胞、葡萄球菌細菌細胞、奈瑟菌細菌細胞、嗜血桿菌細菌細胞、李斯特菌細菌細胞、腸球菌細菌細胞或梭菌細菌細胞。
實施例I-3.如實施例I-1或I-2之方法,其中該細菌細胞係選自銅綠假單胞菌、草綠色鏈球菌、變種鏈球菌或釀膿鏈球菌等。
實施例I-4.如實施例I-3之方法,其中該釀膿鏈球菌細菌細胞屬選自M1、M2、M3、M4、M5、M6、M9、M11、M12、M13、M18、M22、M25、M28、M62、M71、M72、M74、M75、M77、M80、M81、M83、M87、M89或M92之血清型。
實施例I-5.如實施例I-3之方法,其中該釀膿鏈球菌細菌細胞產生缺乏免疫顯性N-乙醯基葡萄糖胺(GlcNAc)側鏈之多醣或其變體。
實施例I-6.如實施例I-1之方法,其用於自細菌細胞純化結合肽聚醣之莢膜多醣。
實施例I-7.如實施例I-1至I-6中任一項之方法,其中步驟(a)之該鹼係NaOH、KOH或LiOH。
實施例I-8.如實施例I-1至I-7中任一項之方法,其中步驟(a)之該鹼係NaOH。
實施例I-9.如實施例I-1至I-8中任一項之方法,其中鹼濃度介於約2M至約8M之間。
實施例I-10.如實施例I-1至I-9中任一項之方法,其中該包括鹼及還原劑之溶液為約pH 14。
實施例I-11.如實施例I-1至I-10中任一項之方法,其中該還原劑係硼氫化鈉、氰基硼氫化鈉、三乙醯氧基硼氫化鈉、二硫蘇糖醇或β-巰基乙醇。
實施例I-12.如實施例I-1至I-11中任一項之方法,其中該還原劑係硼氫化鈉。
實施例I-13.如實施例I-1至I-12中任一項之方法,其中該還原劑之濃度介於約1 mM與500 mM之間。
實施例I-14.如實施例I-1至I-13中任一項之方法,其中步驟(a)進一步包括在約30℃與約100℃之間培育該溶液。
實施例I-15.如實施例I-1至I-14中任一項之方法,其中步驟(a)進一步包括將該溶液培育約0.5小時至約20小時。
實施例I-16.如實施例I-1至I-15中任一項之方法,其中步驟(a)進一步包括一或多個pH調節步驟。
實施例I-17.如實施例I-16之方法,其中該一或多個pH調節步驟獨立地選自:
(i)升高該包括多醣之溶解物之pH,或
(ii)降低該包括多醣之溶解物之pH。
實施例I-18.如實施例I-17之方法,其包括將該包括多醣之溶解物之pH降至介於約3與7.0之間。
實施例I-19.如實施例I-17或I-18之方法,其包括將該包括多醣之溶解物之pH降至約6.5。
實施例I-20.如實施例I-17或I-18之方法,其包括將該包括多醣之溶解物之pH降至介於約3與約4之間。
實施例I-21.如實施例I-16或I-17之方法,其包括
(i)將該包括多醣之溶解物之pH降至介於約5.5與7.0之間;
(ii)將該包括多醣之溶解物之pH降至約3;及
(iii)將該包括多醣之溶解物之pH升至介於約5.5與7.0之間。
實施例I-22.如實施例I-16至I-21中任一項之方法,其中在該一或多個pH調節步驟之後於約室溫(r.t.)下培育該包括多醣之溶解物。
實施例I-23.如實施例I-17至I-20中任一項之方法,其中在該一或多個pH調節步驟之後於約4℃與約30℃之間培育該包括多醣之溶解物。
實施例I-24.如實施例I-1至I-23中任一項之方法,其進一步包括自該包括多醣之溶解物去除固體。
實施例I-25.如實施例I-24之方法,其中自該包括多醣之溶解物去除固體包括過濾、離心或其組合。
實施例I-26.如實施例I-25之方法,其中該過濾包括深度過濾、切向流過濾(TFF)、無菌過濾或前述各項之組合。
實施例I-27.如實施例I-25或I-26之方法,其中該過濾包括深度過濾及後續TFF。
實施例I-28.如實施例I-24或I-25之方法,其中藉由離心自該包括多醣之溶解物去除固體。
實施例I-29.如實施例I-1至I-28中任一項之方法,其中步驟(b)之該溶壁酶係變溶菌素、溶菌酶或噬菌體水解酶。
實施例I-30.如實施例I-1至I-29中任一項之方法,其中步驟(b)進一步包括與蛋白酶一起培育。
實施例I-31.如實施例I-30之方法,其中該蛋白酶係蛋白酶K、胰蛋白酶、胰凝乳蛋白酶、內蛋白酶Asp-N、內蛋白酶Arg-C、內蛋白酶Glu-C、內蛋白酶Lys-C、胃蛋白酶、嗜熱菌蛋白酶、彈性蛋白酶、木瓜酶、枯草桿菌蛋白酶、梭菌蛋白酶、羧肽酶A、羧肽酶B、羧肽酶P、羧肽酶Y、細胞自溶酶C、醯基胺基酸釋放酶或焦麩胺酸鹽。
實施例I-32.如實施例I-1至I-31中任一項之方法,其中步驟(b)進一步包括將該包括多醣之溶解物與該溶壁酶升溫至介於約30℃與約65℃之間。
實施例I-33.如實施例I-30至I-32中任一項之方法,其中將該包括多醣之溶解物與該蛋白酶升溫至介於約45℃與55℃之間。
實施例I-34.如實施例I-32或I-33之方法,其中將該溶解物升溫約6小時至約20小時。
實施例I-35.如實施例I-1至I-34中任一項之方法,其中進一步純化步驟(b)之該游離多醣溶液以減小核酸、酶、宿主細胞蛋白(HCP)或前述各項之組合之濃度。
實施例I-36.如實施例I-1至I-35中任一項之方法,其中藉由沈澱進一步純化步驟(b)之該游離多醣溶液。
實施例I-37.如實施例I-1至I-36中任一項之方法,其中使用鯨蠟基三甲基溴化銨(CTAB)處理步驟(b)之該游離多醣溶液。
實施例I-38.如實施例I-37之方法,其中該游離多醣溶液中之CTAB濃度為約0.1%至約10%。
實施例I-39.如實施例I-37或38之方法,該CTAB濃度介於約0.5%與約3%之間。
實施例I-40.如實施例I-37至I-39中任一項之方法,其中使用碘化鉀(KI)處理步驟(b)之該游離多醣溶液。
實施例I-41.如實施例I-32之方法,其中該游離多醣溶液中之KI濃度介於約20 mM至約400 mM之間。
實施例I-42.如實施例I-1至I-41中任一項之方法,其中藉由過濾、離心、層析或前述各項之組合進一步純化該游離多醣溶液。
實施例I-43.如實施例I-42之方法,其中該過濾包括深度過濾、切向流過濾(TFF)、無菌過濾或前述各項之組合。
實施例I-44.如實施例I-42之方法,其中該層析包括疏水性相互作用層析(HIC)、陰離子交換層析(AEX)、陶瓷羥基磷灰石型層析或陽離子交換層析(CEX)。
實施例I-45.一種多肽-多醣結合物,其包括:
(a) GAS多肽抗原或非GAS載體多肽,其包括至少一個非天然胺基酸(nnAA);及
(b)經純化細胞壁多醣或結合肽聚醣之莢膜多醣,其分子量為至少約10 kDa至至少約40 kDa。
實施例I-46.如實施例I-45之多肽-多醣結合物,其中該經純化細胞壁多醣缺乏免疫顯性N-乙醯基葡萄糖胺(GlcNAc)側鏈。
實施例I-47.如實施例I-45至I-46之多肽-多醣結合物,其中該多肽抗原係全長GAS多肽抗原或全長GAS多肽抗原之片段。
實施例I-48.如實施例I-45至I-47中任一項之多肽-多醣結合物,其中該至少一個nnAA取代該多肽抗原或該非GAS載體多肽中之離胺酸、白胺酸、異白胺酸或精胺酸。
實施例I-49.如實施例I-45至I-48中任一項之多肽-多醣結合物,其中該nnAA包括點擊化學反應性基團。
實施例I-50.如實施例I-45至I-49中任一項之多肽-多醣結合物,其中該nnAA係選自2-胺基-3-(4-疊氮基苯基)丙酸(pAF)、2-胺基-4-疊氮基丁酸、2-疊氮基-3-苯基丙酸、2-胺基-3-疊氮基丙酸、2-胺基-3-(4-(疊氮基甲基)苯基)丙酸(pAMF)、2-胺基-3-(5-(疊氮基甲基)吡啶-2-基)丙酸、2-胺基-3-(4-(疊氮基甲基)吡啶-2-基)丙酸、2-胺基-3-(6-(疊氮基甲基)吡啶-3-基)丙酸及2-胺基-5-疊氮基戊酸。
實施例I-51.如實施例I-45至I-50中任一項之多肽-多醣結合物,其中該nnAA係pAMF。
實施例I-52.如實施例I-45至I-51中任一項之多肽-多醣結合物,其中該多肽抗原係選自C5a肽酶、鏈球菌溶血素O (SLO)、SpyAD、Sib35及Sfb1。
實施例I-53.如實施例I-45至I-52中任一項之多肽-多醣結合物,其中該多肽抗原係SLO。
實施例I-54.如實施例I-53之多肽-多醣結合物,其中該SLO多肽抗原包括與SEQ ID NO: 31、SEQ ID NO: 32或SEQ ID NO: 53至少95%一致之胺基酸序列。
實施例I-55.如實施例I-53之多肽-多醣結合物,其中該SLO多肽抗原與SEQ ID NO: 31、SEQ ID NO: 32或SEQ ID NO: 53至少95%一致。
實施例I-56.如實施例I-53至I-55中任一項之多肽-多醣結合物,其中該SLO多肽在選自K98、K112、R151、K189、K272、K323、K357、K375、K407或K464之位置處包括3或4個pAMF取代。
實施例I-57.如實施例I-53至I-56中任一項之多肽-多醣結合物,其中該SLO多肽包括SEQ ID NO: 55、SEQ ID NO: 56、SEQ ID NO: 57、SEQ ID NO: 58、SEQ ID NO: 59、SEQ ID NO: 60、SEQ ID NO: 61、SEQ ID NO: 62、SEQ ID NO: 63或SEQ ID NO: 64之胺基酸序列。
實施例I-58.如實施例I-53至I-56中任一項之多肽-多醣結合物,其中該SLO多肽具有SEQ ID NO: 55、SEQ ID NO: 56、SEQ ID NO: 57、SEQ ID NO: 58、SEQ ID NO: 59、SEQ ID NO: 60、SEQ ID NO: 61、SEQ ID NO: 62、SEQ ID NO: 63或SEQ ID NO: 64之胺基酸序列。
實施例I-59.如實施例I-53至I-55中任一項之多肽-多醣結合物,其中該SLO多肽在選自K98、K112、R151、K189、K272、K323、K357、K375、K407或K464之位置處包括5、6、7或8個pAMF取代。
實施例I-60.如實施例I-53至I-55或59中任一項之多肽-多醣結合物,其中該SLO多肽包括SEQ ID NO: 65、SEQ ID NO: 66、SEQ ID NO: 67、SEQ ID NO: 68、SEQ ID NO: 69、SEQ ID NO: 70、SEQ ID NO: 71、SEQ ID NO: 72、SEQ ID NO: 73、SEQ ID NO: 74、SEQ ID NO: 75或SEQ ID NO: 76之胺基酸序列。
實施例I-61.如實施例I-53至I-55或59至60中任一項之多肽-多醣結合物,其中該SLO多肽具有SEQ ID NO: 65、SEQ ID NO: 66、SEQ ID NO: 67、SEQ ID NO: 68、SEQ ID NO: 69、SEQ ID NO: 70、SEQ ID NO: 71、SEQ ID NO: 72、SEQ ID NO: 73、SEQ ID NO: 74、SEQ ID NO: 75或SEQ ID NO: 76之胺基酸序列。
實施例I-62.如實施例I-45至I-52中任一項之多肽-多醣結合物,其中該多肽抗原係SpyAD多肽。
實施例I-63.如實施例I-62之多肽-多醣結合物,其中該SpyAD多肽包括與SEQ ID NO: 33至少95%一致之胺基酸序列。
實施例I-64.如實施例I-62之多肽-多醣結合物,其中該SpyAD多肽與SEQ ID NO: 33至少95%一致。
實施例I-65.如實施例I-62至I-64中任一項之多肽-多醣結合物,其中該SpyAD多肽在SEQ ID NO: 33之位置K64、K287、K386及K657處包括pAMF取代。
實施例I-66.如實施例I-62至I-65中任一項之多肽-多醣結合物,其中該SpyAD多肽包括SEQ ID NO: 34之胺基酸序列。
實施例I-67.如實施例I-62至I-65中任一項之多肽-多醣結合物,其中該SpyAD多肽具有SEQ ID NO: 34之胺基酸序列。
實施例I-68.如實施例I-45至I-45或48至51中任一項之多肽-多醣結合物,其中該非GAS載體多肽係選自ADI、鐵蛋白、蛋白質D及eCRM197。
實施例I-69.如實施例I-68之多肽-多醣結合物,其中該非GAS載體多肽係eCRM197。
實施例I-70.如實施例I-69之多肽-多醣結合物,其中該eCRM197具有SEQ ID NO: 25之序列。
實施例I-71.如實施例I-45至I-50中任一項之多肽-多醣結合物,其中該GAS多肽抗原或非GAS載體多肽包括表1中所列示多肽之胺基酸序列或由其組成。
實施例II-1.一種多肽-多醣結合物,其包括:
(a) GAS多肽抗原或非GAS載體多肽,其包括至少一個非天然胺基酸(nnAA),其中該nnAA包括點擊化學反應性基團;及
(b)經純化細胞壁多醣或結合肽聚醣之莢膜多醣,其分子量為至少約10 kDa至至少約40 kDa。
實施例II-2.如實施例II-1之多肽-多醣結合物,其中該經純化細胞壁多醣缺乏免疫顯性N-乙醯基葡萄糖胺(GlcNAc)側鏈。
實施例II-3.如實施例II-1至II-2之多肽-多醣結合物,其中該GAS多肽抗原係全長GAS多肽抗原或全長GAS多肽抗原之片段。
實施例II-4.如實施例II-1至II-3中任一項之多肽-多醣結合物,其中該細胞壁多醣係GAS多醣或其變體。
實施例II-5.如實施例II-4之多肽-多醣結合物,其中該GAS多醣或其變體之介於約8 mol%與約20 mol%之間之多醣重複單元由連接體衍生。
實施例II-6.如實施例II-4至II-5之多肽-多醣結合物,其中該GAS多醣或其變體之介於約10 mol%與約20 mol%之間之多醣重複單元由連接體衍生。
實施例II-7.如實施例II-4至II-6之多肽-多醣結合物,其中該GAS多醣或其變體之介於約10 mol%與約18 mol%之間之多醣重複單元由連接體衍生。
實施例II-8.如實施例II-1至II-6中任一項之多肽-多醣結合物,其中平均分子量介於約185 kDa與約700 kDa之間。
實施例II-9.如實施例II-1至II-7中任一項之多肽-多醣結合物,其中平均分子量介於約200 kDa與約700 kDa之間。
實施例II-10.如實施例II-1至II-9中任一項之多肽-多醣結合物,其中該多肽-多醣結合物之該平均分子量介於約300 kDa與約600 kDa之間。
實施例II-11.如實施例II-1至II-10中任一項之多肽-多醣結合物,其中該多肽-多醣結合物之該平均分子量介於約400 kDa與約500 kDa之間。
實施例II-12.如實施例II-1至II-11中任一項之多肽-多醣結合物,其中該至少一個nnAA取代該GAS多肽抗原或該非GAS載體多肽中之離胺酸、白胺酸、異白胺酸或精胺酸。
實施例II-13.如實施例II-1至II-12中任一項之多肽-多醣結合物,其中該至少一個nnAA係選自2-胺基-3-(4-疊氮基苯基)丙酸(pAF)、2-胺基-4-疊氮基丁酸、2-疊氮基-3-苯基丙酸、2-胺基-3-疊氮基丙酸、2-胺基-3-(4-(疊氮基甲基)苯基)丙酸(pAMF)、2-胺基-3-(5-(疊氮基甲基)吡啶-2-基)丙酸、2-胺基-3-(4-(疊氮基甲基)吡啶-2-基)丙酸、2-胺基-3-(6-(疊氮基甲基)吡啶-3-基)丙酸及2-胺基-5-疊氮基戊酸。
實施例II-14.如實施例II-1至II-13中任一項之多肽-多醣結合物,其中該至少一個nnAA係pAMF。
實施例II-15.如實施例II-1至II-14中任一項之多肽-多醣結合物,其中該GAS多肽抗原係選自C5a肽酶、鏈球菌溶血素O (SLO)、SpyAD、Sib35及Sfb1。
實施例II-15a. 如實施例II-1至II-15中任一項之多肽-多醣結合物,其中該GAS多肽抗原係SLO。
實施例II-15b. 如實施例II-15a之多肽-多醣結合物,其中該SLO多肽抗原包括與SEQ ID NO: 31、SEQ ID NO: 32或SEQ ID NO: 53至少95%一致之胺基酸序列。
實施例II-15c. 如實施例II-15b之多肽-多醣結合物,其中該SLO多肽抗原與SEQ ID NO: 31、SEQ ID NO: 32或SEQ ID NO: 53至少95%一致。
實施例II-15d. 如實施例II-15a至II-15c中任一項之多肽-多醣結合物,其中該SLO多肽在選自K98、K112、R151、K189、K272、K323、K357、K375、K407或K464之位置處包括3或4個pAMF取代。
實施例II-15e.如實施例II-15a至15d中任一項之多肽-多醣結合物,其中該SLO多肽包括SEQ ID NO: 55、SEQ ID NO: 56、SEQ ID NO: 57、SEQ ID NO: 58、SEQ ID NO: 59、SEQ ID NO: 60、SEQ ID NO: 61、SEQ ID NO: 62、SEQ ID NO: 63或SEQ ID NO: 64之胺基酸序列。
實施例II-15f.如實施例II-15a至II-15d中任一項之多肽-多醣結合物,其中該SLO多肽具有SEQ ID NO: 55、SEQ ID NO: 56、SEQ ID NO: 57、SEQ ID NO: 58、SEQ ID NO: 59、SEQ ID NO: 60、SEQ ID NO: 61、SEQ ID NO: 62、SEQ ID NO: 63或SEQ ID NO: 64之胺基酸序列。
實施例II-15g.如實施例II-15a至II-15c中任一項之多肽-多醣結合物,其中該SLO多肽在選自K98、K112、R151、K189、K272、K323、K357、K375、K407或K464之位置處包括5、6、7或8個pAMF取代。
實施例II-15h.如實施例II-15a至II-15c或II-22中任一項之多肽-多醣結合物,其中該SLO多肽包括SEQ ID NO: 65、SEQ ID NO: 66、SEQ ID NO: 67、SEQ ID NO: 68、SEQ ID NO: 69、SEQ ID NO: 70、SEQ ID NO: 71、SEQ ID NO: 72、SEQ ID NO: 73、SEQ ID NO: 74、SEQ ID NO: 75或SEQ ID NO: 76之胺基酸序列。
實施例II-15i.如實施例II-15a至II-15c或II-15g至II-15f中任一項之多肽-多醣結合物,其中該SLO多肽具有SEQ ID NO: 65、SEQ ID NO: 66、SEQ ID NO: 67、SEQ ID NO: 68、SEQ ID NO: 69、SEQ ID NO: 70、SEQ ID NO: 71、SEQ ID NO: 72、SEQ ID NO: 73、SEQ ID NO: 74、SEQ ID NO: 75或SEQ ID NO: 76之胺基酸序列。
實施例II-16.如實施例II-1至II-15或II-15a至II-15i中任一項之多肽-多醣結合物,其中該GAS多肽抗原係SpyAD多肽或其片段。
實施例II-17.如實施例II-16之多肽-多醣結合物,其中該SpyAD多肽包括與SEQ ID NO: 33至少95%一致之胺基酸序列。
實施例II-18.如實施例II-16之多肽-多醣結合物,其中該SpyAD多肽與SEQ ID NO: 33至少95%一致。
實施例II-19.如實施例II-16至II-18中任一項之多肽-多醣結合物,其中該SpyAD多肽在SEQ ID NO: 33之位置K64、K287、K386及K657處包括pAMF取代。
實施例II-20.如實施例II-16至II-19中任一項之多肽-多醣結合物,其中該SpyAD多肽包括SEQ ID NO: 34之胺基酸序列。
實施例II-21.如實施例II-16至II-19中任一項之多肽-多醣結合物,其中該SpyAD多肽具有SEQ ID NO: 34之胺基酸序列。
實施例II-22.如實施例II-16至II-19中任一項之多肽-多醣結合物,其中該SpyAD多肽包括SEQ ID NO: 77、SEQ ID NO: 78、SEQ ID NO: 79、SEQ ID NO: 81、SEQ ID NO: 82或SEQ ID NO: 83之胺基酸序列。
實施例II-23.如實施例II-16至II-19中任一項之多肽-多醣結合物,其中該SpyAD多肽具有SEQ ID NO: 77、SEQ ID NO: 78、SEQ ID NO: 79、SEQ ID NO: 81、SEQ ID NO: 82或SEQ ID NO: 83之胺基酸序列。
實施例II-24.如實施例II-1至II-2或II-4至II-14中任一項之多肽-多醣結合物,其中該非GAS載體多肽係選自ADI、鐵蛋白、蛋白質D及eCRM197。
實施例II-25.如實施例II-24之多肽-多醣結合物,其中該非GAS載體多肽係eCRM197。
實施例II-26.如實施例II-25之多肽-多醣結合物,其中該eCRM197具有SEQ ID NO: 25之序列。
實施例II-27.如實施例II-1至II-13中任一項之多肽-多醣結合物,其中該GAS多肽抗原或非GAS載體多肽包括表1中所列示多肽之胺基酸序列或由其組成。
實施例II-28.如實施例II-1至II-13中任一項之多肽-多醣結合物,其中該GAS多肽抗原或非GAS載體多肽包括表1A中所列示多肽之胺基酸序列或由其組成。
實施例II-29.一種免疫原性組合物,其包括:
(a) A型鏈球菌(GAS) C5a肽酶多肽抗原;
(b) GAS鏈球菌溶血素O (SLO)多肽抗原;及
(c)多肽-多醣結合物,其包括
釀膿鏈球菌黏附及分裂(SpyAD)結合多肽或其片段,其包括至少一個非天然胺基酸(nnAA),其中該至少一個nnAA包括點擊化學反應性基團,及
GAS多醣或其變體,其缺乏免疫顯性N-乙醯基葡萄糖胺(GlcNAc)側鏈;
其中該GAS多醣或其變體之介於約8 mol%與約20 mol%之間之多醣重複單元由連接體衍生;且
其中該多肽-多醣結合物之平均分子量介於約185 kDa與約700 kDa之間。
實施例II-30.如實施例II-29之免疫原性組合物,其中該C5a肽酶多肽抗原包括SEQ ID NO: 29或SEQ ID NO: 30之胺基酸序列。
實施例II-31.如實施例II-29或II-30之免疫原性組合物,其中該C5a肽酶多肽抗原包括與SEQ ID NO: 29或SEQ ID NO: 30至少95%一致之胺基酸序列。
實施例II-32.如實施例II-29至II-31中任一項之免疫原性組合物,其中該C5a肽酶多肽抗原具有SEQ ID NO: 29或SEQ ID NO: 30之胺基酸序列。
實施例II-33.如實施例II-29至II-32中任一項之免疫原性組合物,其中該SLO多肽抗原包括SEQ ID NO: 31、SEQ ID NO: 32、SEQ ID NO: 44、SEQ ID NO: 45、SEQ ID NO: 46、SEQ ID NO: 47、SEQ ID NO: 48、SEQ ID NO: 49、SEQ ID NO: 50、SEQ ID NO: 51、SEQ ID NO: 52或SEQ ID NO: 53之胺基酸序列。
實施例II-34.如實施例II-29至II-33之免疫原性組合物,其中該SLO抗原包括與SEQ ID NO: 31、SEQ ID NO: 32、SEQ ID NO: 44、SEQ ID NO: 45、SEQ ID NO: 46、SEQ ID NO: 47、SEQ ID NO: 48、SEQ ID NO: 49、SEQ ID NO: 50、SEQ ID NO: 51、SEQ ID NO: 52或SEQ ID NO: 53至少95%一致之胺基酸序列。
實施例II-35.如實施例II-29至II-34中任一項之免疫原性組合物,其中該SLO多肽抗原具有SEQ ID NO: 31、SEQ ID NO: 32、SEQ ID NO: 44、SEQ ID NO: 45、SEQ ID NO: 46、SEQ ID NO: 47、SEQ ID NO: 48、SEQ ID NO: 49、SEQ ID NO: 50、SEQ ID NO: 51、SEQ ID NO: 52或SEQ ID NO: 53之胺基酸序列。
實施例II-36.如實施例II-29至II-35中任一項之免疫原性組合物,其中該至少一個nnAA係選自2-胺基-3-(4-疊氮基苯基)丙酸(pAF)、2-胺基-4-疊氮基丁酸、2-疊氮基-3-苯基丙酸、2-胺基-3-疊氮基丙酸、2-胺基-3-(4-(疊氮基甲基)苯基)丙酸(pAMF)、2-胺基-3-(5-(疊氮基甲基)吡啶-2-基)丙酸、2-胺基-3-(4-(疊氮基甲基)吡啶-2-基)丙酸、2-胺基-3-(6-(疊氮基甲基)吡啶-3-基)丙酸及2-胺基-5-疊氮基戊酸。
實施例II-37.如實施例II-29至II-36中任一項之免疫原性組合物,其中該至少一個nnAA係pAMF。
實施例II-38.如實施例II-29至II-37中任一項之免疫原性組合物,其中該SpyAD結合多肽或其片段包括與SEQ ID NO: 33至少95%一致之胺基酸序列。
實施例II-39.如實施例II-29至II-38中任一項之免疫原性組合物,其中該SpyAD結合多肽包括作為SEQ ID NO: 33之片段之胺基酸序列。
實施例II-40.如實施例II-29至II-38中任一項之免疫原性組合物,其中該SpyAD結合多肽具有作為SEQ ID NO: 33之片段之胺基酸序列。
實施例II-41.如實施例II-29至II-40中任一項之免疫原性組合物,其中該SpyAD結合多肽在SEQ ID NO: 33之位置K64、K287、K386及K657處包括pAMF取代。
實施例II-42.如實施例II-29至II-41中任一項之免疫原性組合物,其中該SpyAD結合多肽包括SEQ ID NO: 34、SEQ ID NO: 77、SEQ ID NO: 78、SEQ ID NO: 79、SEQ ID NO: 81、SEQ ID NO: 82或SEQ ID NO: 83之胺基酸序列。
實施例II-43.如實施例II-29至II-42中任一項之免疫原性組合物,其中該SpyAD結合多肽包括與SEQ ID NO: 34、SEQ ID NO: 77、SEQ ID NO: 78、SEQ ID NO: 79、SEQ ID NO: 81、SEQ ID NO: 82或SEQ ID NO: 83至少95%一致之胺基酸序列。
實施例II-44.如實施例II-29至II-43中任一項之免疫原性組合物,其中該SpyAD結合多肽具有SEQ ID NO: 34、SEQ ID NO: 77、SEQ ID NO: 78、SEQ ID NO: 79、SEQ ID NO: 81、SEQ ID NO: 82或SEQ ID NO: 83之胺基酸序列。
實施例II-45.如實施例II-29至II-44中任一項之免疫原性組合物,其中該C5a肽酶多肽抗原包括與SEQ ID NO: 30至少95%一致之胺基酸序列;該SLO多肽抗原包括與SEQ ID NO: 53至少95%一致之胺基酸序列;且該SpyAD結合多肽包括與SEQ ID NO: 34至少95%一致之胺基酸序列。
實施例II-46.如實施例II-29至II-45中任一項之免疫原性組合物,其中該C5a肽酶多肽抗原包括SEQ ID NO: 30之胺基酸序列;該SLO多肽抗原包括SEQ ID NO: 53之胺基酸序列;且該SpyAD結合多肽包括SEQ ID NO: 34之胺基酸序列。
實施例II-47.如實施例II-29至II-46中任一項之免疫原性組合物,其中該C5a肽酶多肽抗原具有SEQ ID NO: 30之胺基酸序列;該SLO多肽抗原具有SEQ ID NO: 53之胺基酸序列;且該SpyAD結合多肽具有SEQ ID NO: 34之胺基酸序列。
實施例II-48.如實施例II-29至II-47中任一項之免疫原性組合物,其中該GAS多醣或其變體之介於約15 mol%與約20 mol%之間之多醣重複單元由連接體衍生。
實施例II-49.如實施例II-29至II-48中任一項之免疫原性組合物,其中該連接體在與該nnAA之該點擊化學反應性基團反應之前包括式I結構:
(式I)
其中,X係GAS多醣或其片段之至少一個多醣重複單元;且n係至少1。
實施例II-50.如實施例II-29至II-49中任一項之免疫原性組合物,其中該SpyAD結合多肽或其片段連接至式II之GAS多醣:
(式II)
其中,
R
1係H、甲醯基或該SpyAD結合多肽之至少一個胺基酸;
R
2係OH或SpyAD結合多肽之至少一個胺基酸;
W係CH或N;
y係至少1;
n係至少1;且
X係GAS多醣或其變體之至少一個多醣重複單元。
實施例II-51.如實施例II-29至II-50中任一項之免疫原性組合物,其中該GAS多醣或其變體具有至少約10 kDa至至少約40 kDa之分子量。
實施例II-52.如實施例II-29至II-51中任一項之免疫原性組合物,其中該多肽-多醣結合物之平均分子量介於約185 kDa與約700 kDa之間。
實施例II-53.如實施例II-29至II-52中任一項之免疫原性組合物,其中該多肽-多醣結合物之平均分子量介於約200 kDa與約700 kDa之間。
實施例II-54.如實施例II-29至II-53中任一項之免疫原性組合物,其中該多肽-多醣結合物之平均分子量介於約300 kDa與約700 kDa之間。
實施例II-55.如實施例II-29至II-54中任一項之免疫原性組合物,其中該多肽-多醣結合物之平均分子量介於約300 kDa與約600 kDa之間。
實施例II-56.如實施例II-29至II-55中任一項之免疫原性組合物,其進一步包括小於約60%之游離GAS多醣或其變體。
實施例II-57.如實施例II-29至II-56中任一項之免疫原性組合物,其進一步包括小於約50%之游離GAS多醣或其變體。
實施例II-58.如實施例II-29至II-57中任一項之免疫原性組合物,其進一步包括小於約25%之游離GAS多醣或其變體。
實施例II-59.如實施例II-29至II-58中任一項之免疫原性組合物,其進一步包括小於約15%之游離GAS多醣或其變體。
實施例II-60.如實施例II-29至II-59中任一項之免疫原性組合物,其進一步包括小於約10%之游離GAS多醣或其變體。
實施例II-61.一種在個體中誘導針對A型鏈球菌(GAS)細菌之保護性免疫反應之方法,其包括向該個體投與如實施例II-29至II-60中任一項之免疫原性組合物。
實施例II-62.如實施例II-61之方法,其中該免疫原性組合物在該個體中誘導針對該A型鏈球菌(GAS)細菌之抗體反應且並不在該個體中誘導針對人類組織之抗體反應。
實施例II-63.一種如實施例II-29至II-60中任一項之免疫原性組合物之用途,其用以製造用於在個體中誘導針對GAS細菌之保護性免疫反應之藥劑。
實施例II-64.一種如實施例II-29至II-60中任一項之免疫原性組合物之用途,其用於在個體中誘導針對GAS細菌之保護性免疫反應。
實施例II-65.一種自細菌細胞純化細胞壁多醣或結合肽聚醣之莢膜多醣之方法,該方法包括:
(a)在包括鹼及還原劑之溶液中水解該細菌細胞以形成包括多醣之溶解物;及
(b)將該包括多醣之溶解物與溶壁酶一起培育以形成游離多醣溶液。
實施例II-66.如實施例II-65之方法,其中該細菌細胞係假單胞菌細菌細胞、鏈球菌細菌細胞、葡萄球菌細菌細胞、奈瑟菌細菌細胞、嗜血桿菌細菌細胞、李斯特菌細菌細胞、腸球菌細菌細胞或梭菌細菌細胞。
實施例II-67.如實施例II-65或II-66之方法,其中該細菌細胞係選自銅綠假單胞菌、草綠色鏈球菌、變種鏈球菌及釀膿鏈球菌。
實施例II-68.如實施例II-67之方法,其中該釀膿鏈球菌細菌細胞屬選自M1、M2、M3、M4、M5、M6、M9、M11、M12、M13、M18、M22、M25、M28、M62、M71、M72、M74、M75、M77、M80、M81、M83、M87、M89或M92之血清型。
實施例II-69.如實施例II-68之方法,其中該釀膿鏈球菌細菌細胞產生缺乏免疫顯性N-乙醯基葡萄糖胺(GlcNAc)側鏈之多醣或其變體。
實施例II-70.如實施例II-65之方法,其用於自細菌細胞純化結合肽聚醣之莢膜多醣。
實施例II-71.如實施例II-65至II-70中任一項之方法,其中步驟(a)之該鹼係NaOH、KOH或LiOH。
實施例II-72.如實施例II-65至II-71中任一項之方法,其中步驟(a)之該鹼係NaOH。
實施例II-73.如實施例II-65至II-72中任一項之方法,其中鹼濃度介於約2M至約8M之間。
實施例II-74.如實施例II-65至II-73中任一項之方法,其中該包括鹼及還原劑之溶液為約pH 14。
實施例II-75.如實施例II-65至II-72中任一項之方法,其中該還原劑係硼氫化鈉、氰基硼氫化鈉、三乙醯氧基硼氫化鈉、二硫蘇糖醇或β-巰基乙醇。
實施例II-76.如實施例II-65至II-73中任一項之方法,其中該還原劑係硼氫化鈉。
實施例II-77.如實施例II-65至II-76中任一項之方法,其中該還原劑之濃度介於約1 mM與500 mM之間。
實施例II-78.如實施例II-65至II-75中任一項之方法,其中步驟(a)進一步包括在約30℃與約100℃之間培育該溶液。
實施例II-79.如實施例II-65至II-78中任一項之方法,其中步驟(a)進一步包括將該溶液培育約0.5小時至約20小時。
實施例II-80.如實施例II-65至II-79中任一項之方法,其中步驟(a)進一步包括一或多個pH調節步驟。
實施例II-81.如實施例II-80之方法,其中該一或多個pH調節步驟獨立地選自:
(i)升高該包括多醣之溶解物之pH,或
(ii)降低該包括多醣之溶解物之pH。
實施例II-82.如實施例II-81之方法,其包括將該包括多醣之溶解物之pH降至介於約3與7.0之間。
實施例II-83.如實施例II-81或II-82之方法,其包括將該包括多醣之溶解物之pH降至約6.5。
實施例II-84.如實施例II-81或II-82之方法,其包括將該包括多醣之溶解物之pH降至介於約3與約4之間。
實施例II-85.如實施例II-80或II-81之方法,其包括
(i)將該包括多醣之溶解物之pH降至介於約5.5與7.0之間;
(ii)將該包括多醣之溶解物之pH降至約3;及
(iii)將該包括多醣之溶解物之pH升至介於約5.5與7.0之間。
實施例II-86.如實施例II-80至II-85中任一項之方法,其中在該一或多個pH調節步驟之後於約室溫(r.t.)下培育該包括多醣之溶解物。
實施例II-87.如實施例II-81至II-84中任一項之方法,其中在該一或多個pH調節步驟之後於約4℃與約30℃之間培育該包括多醣之溶解物。
實施例II-88.如實施例II-65至II-87中任一項之方法,其進一步包括自該包括多醣之溶解物去除固體。
實施例II-89.如實施例II-88之方法,其中自該包括多醣之溶解物去除固體包括過濾、離心或其組合。
實施例II-90.如實施例II-89之方法,其中該過濾包括深度過濾、切向流過濾(TFF)、無菌過濾或前述各項之組合。
實施例II-91.如實施例II-89或II-90之方法,其中該過濾包括深度過濾及後續TFF。
實施例II-92.如實施例II-88或II-89之方法,其中藉由離心自該包括多醣之溶解物去除固體。
實施例II-93.如實施例II-65至II-92中任一項之方法,其中步驟(b)之該溶壁酶係變溶菌素、溶菌酶或噬菌體水解酶。
實施例II-94.如實施例II-65至II-93中任一項之方法,其中步驟(b)進一步包括與蛋白酶一起培育。
實施例II-95.如實施例II-94之方法,其中該蛋白酶係蛋白酶K、胰蛋白酶、胰凝乳蛋白酶、內蛋白酶Asp-N、內蛋白酶Arg-C、內蛋白酶Glu-C、內蛋白酶Lys-C、胃蛋白酶、嗜熱菌蛋白酶、彈性蛋白酶、木瓜酶、枯草桿菌蛋白酶、梭菌蛋白酶、羧肽酶A、羧肽酶B、羧肽酶P、羧肽酶Y、細胞自溶酶C、醯基胺基酸釋放酶或焦麩胺酸鹽。
實施例II-96.如實施例II-65至II-95中任一項之方法,其中步驟(b)進一步包括將該包括多醣之溶解物與該溶壁酶升溫至介於約30℃與約65℃之間。
實施例II-97.如實施例II-94至II-96中任一項之方法,其中將該包括多醣之溶解物與該蛋白酶升溫至介於約45℃與55℃之間。
實施例II-98.如實施例II-96或II-97之方法,其中將該溶解物升溫約6小時至約20小時。
實施例II-99.如實施例II-65至II-98中任一項之方法,其中進一步純化步驟(b)之該游離多醣溶液以減小核酸、酶、宿主細胞蛋白(HCP)或前述各項之組合之濃度。
實施例II-100.如實施例II-65至II-99中任一項之方法,其中藉由沈澱進一步純化步驟(b)之該游離多醣溶液。
實施例II-101.如實施例II-65至II-100中任一項之方法,其中使用鯨蠟基三甲基溴化銨(CTAB)處理步驟(b)之該游離多醣溶液。
實施例II-102.如實施例II-101之方法,其中該游離多醣溶液中之CTAB濃度為約0.1%至約10%。
實施例II-103.如實施例II-101或II-102之方法,CTAB之濃度介於約0.5%與約3%之間。
實施例II-104.如實施例II-101至II-103中任一項之方法,其中使用碘化鉀(KI)處理步驟(b)之該游離多醣溶液。
實施例II-105.如實施例II-104之方法,其中該游離多醣溶液中之KI濃度介於約20 mM至約400 mM之間。
實施例II-106.如實施例II-65至II-105中任一項之方法,其中藉由過濾、離心、層析或前述各項之組合進一步純化該游離多醣溶液。
實施例II-107.如實施例II-106之方法,其中該過濾包括深度過濾、切向流過濾(TFF)、無菌過濾或前述各項之組合。
實施例II-108.如實施例II-106之方法,其中該層析包括疏水性相互作用層析(HIC)、陰離子交換層析(AEX)、陶瓷羥基磷灰石型層析或陽離子交換層析(CEX)。
實施例II-109.一種免疫原性組合物,其包括:
(a)包括SEQ ID NO: 30之胺基酸序列或由其組成之A型鏈球菌(GAS) C5a肽酶多肽抗原或其片段;
(b)包括SEQ ID NO: 53之胺基酸序列或由其組成之GAS鏈球菌溶血素O (SLO)多肽抗原或其片段;及
(c)多肽-多醣結合物,其包括
包括SEQ ID NO: 34之胺基酸序列或由其組成之釀膿鏈球菌黏附及分裂(SpyAD)結合多肽或其片段,及
GAS多醣或其變體,其缺乏免疫顯性N-乙醯基葡萄糖胺(GlcNAc)側鏈;
其中該GAS多醣或其變體之介於約8 mol%與約20 mol%之間之多醣重複單元由連接體衍生。
實施例II-110.如實施例II-109之免疫原性組合物,其中該多肽-多醣結合物之平均分子量介於約185 kDa與約700 kDa之間。
實施例II-111.如實施例II-109或II-110之免疫原性組合物,其中該多肽-多醣結合物之平均分子量介於約200 kDa與約700 kDa之間。
實施例II-112.如實施例II-109至II-111中任一項之免疫原性組合物,其中該多肽-多醣結合物之平均分子量介於約300 kDa與約700 kDa之間。
實施例II-113.如實施例II-109至II-112中任一項之多肽-多醣結合物,其中該多肽-多醣結合物之該平均分子量介於約300 kDa與約600 kDa之間。
實施例II-114.如實施例II-109至II-113中任一項之多肽-多醣結合物,其中該GAS多醣或其變體具有至少約10 kDa至至少約40 kDa之分子量。
實施例II-115.如實施例II-109至II-114中任一項之多肽-多醣結合物,其中該SpyAD結合多肽係SEQ ID NO: 34之胺基酸序列之片段,且包括SEQ ID NO: 77、SEQ ID NO: 78、SEQ ID NO: 79、SEQ ID NO: 81、SEQ ID NO: 82或SEQ ID NO: 83之胺基酸序列或由其組成。
實例
合成實例 1 : 高分子量 ( 長 ) 多醣之純化
實施實驗以自GAS細菌培養物提取及純化GAS多醣。圖1展示本文所闡述之試樣純化之簡化流程圖。
鹼水解 :將所製備GAS細胞糰粒再懸浮於50 mM NaCl溶液中。使用血清學移液管,添加50mL NaCl並渦旋直至再懸浮。添加10N氫氧化鈉及1M硼氫化鈉直至達到4N NaOH及25mM NaBH
4之最終濃度。將經再懸浮糰粒分配至各離心瓶中,其中最終靶體積為160mL/1L發酵體積。在分配溶液時,使用恆定渦旋以確保均質性。將瓶置於65℃預加熱培育器中之振盪器上並保持2小時。在培育之後,將水解溶液在25℃下以14,000 x g離心30 min以粒化任何細胞碎屑,應確保在離心之前使水解試樣冷卻至室溫。在停止離心後立即收集上清液以不干擾糰粒,且將上清液中和至pH 6.5 ± 0.3。在中和時,將瓶置於4℃冰浴上,使用37% HCl調節pH,且視需要使用1M NaOH進一步調節。然後將試樣在4℃下培育過夜。
過濾 :在培育之後,形成白色沈澱物。將溶液在10,000xg下離心30 min。形成含有宿主細胞蛋白(HCP)之大塊白色糰粒。收集澄清上清液。使用37% HCl將pH調節至3.0,且將溶液在室溫下培育1小時。使用Clarisolve過濾器µPod -40MS過濾試樣。舉例而言:在23mL/min之幫浦流速下,使水流經過濾器直至啟動,且然後打開閥門並使用120mL體積沖洗,並使用120 mL體積之15mM NaCl平衡。使提取物以23mL/min之相同幫浦流速通過過濾器,且收集來自過濾器之澄清滲透液。使用60mL 15mM NaCl洗滌過濾器,且沖洗出管及過濾器內容物。棄除濾液。將試樣pH再調節至6.5 ± 0.3。然後實施切向流過濾(TFF-10k)以去除鹽,濃縮(超濾),然後緩衝液交換(滲濾)於10mM NaCl中。
變溶菌素處理:藉由添加1M MgCl
2直至達到1mM MgCl
2之最終濃度且添加200 mM磷酸鈉(10×)直至達到20mM磷酸鈉(pH 6.8)之最終濃度來製備用於變溶菌素處理之溶液。添加變溶菌素溶液(5000 IU/mL)直至達到120 IU/mL。將試樣在37℃及振盪下培育過夜。
蛋白酶-K 處理:然後藉由添加蛋白酶-K溶液直至最終濃度為40 IU/mL (45u/mg蛋白酶-K)來使用蛋白酶-K處理試樣。將混合物在50℃下培育過夜且同時輕輕混合。
沈澱及過濾:為使試樣中之酶、核酸及HCP沈澱,添加於20mM磷酸鈉緩衝液(pH 6.8)中之CTAB,在30℃下振盪1小時。將以下所有所用溶液預熱:PS試樣、5% CTAB儲備溶液及200mM磷酸鈉(pH 6.8)。在加熱的同時混合(磁力攪拌棒) PS溶液,且經加熱攪拌板配備有內部溫度計以始終監測溶液中之溫度。將200mM磷酸鈉(pH 6.8)溶液添加至PS溶液中直至達到20mM磷酸鈉之最終濃度。將5% CTAB添加至PS溶液中直至達到1% CTAB濃度。將溶液混合1小時。使用40MS過濾器,對沈澱溶液實施深度過濾。舉例而言,使用200mL MilliQ H20以23mL/min之幫浦流速沖洗系統,且一旦水開始自排放口流出,則立即關閉排放口,從而迫使溶液自出口流出(底料)。然後使用75mL 20mM磷酸鈉(pH 6.8)及15mM NaCl之溶液沖洗系統。在23mL/min下過濾試樣,並使用60mL 20mM磷酸鈉(pH 6.8)及15mM NaCl溶液以20 mL/min沖洗。收集滲透液直至洗脫出氣泡為止。棄除濾液。
將PS溶液及274 mM KI升溫至30℃。將足量274mM KI添加至混合PS溶液中直至達成27.4mM KI之最終濃度。將混合物在30℃及混合下培育1小時。將溶液在培育後於30℃、10,000xg下離心30分鐘。收集上清液且棄除糰粒,注意糰粒易於破碎。然後經由0.45µm過濾器真空過濾上清液。
首先藉由TFF-10k濃縮試樣,隨後使用9DV之350mM NaCl滲濾且最後使用2 DV之MilliQ水滲濾。舉例而言,TFF系統體積為約35mL,其中幫浦流速設定於200mL/min,且使用9 DV (50mL)之緩衝液在TMP: 7-8 psi下實施滲濾。
然後藉由疏水性相互作用層析使用經3M氯化鈉及50mM磷酸鈉(pH 6.8)預平衡之HiPrep™ Butyl Fast Flow 16/10來純化多醣溶液。將氯化鈉及磷酸鹽緩衝液添加至多醣溶液中直至達到3M氯化鈉及50mM磷酸鉀(pH 6.8)。使多醣溶液通過HIC樹脂且以流經模式進行操作。使用相同平衡緩衝液洗滌樹脂且收集流經液及洗滌液以供進一步處理。
實施最終TFF (10kDa/ 3kDa)以藉由針對9DV之15mM NaCl或WFI進行滲濾來去除PS試樣中之高NaCl內容物。然後對經純化PS溶液實施0.22 um過濾。
圖2A、圖2B及圖2C展示藉由合成實例1所產生源自表現缺乏GlcNAc之PS之GAS細菌菌株之經純化多醣的NMR分析(參見PCT/US2012/049604)。NMR證實存在聚鼠李糖且不存在GlcNAc。對於試樣製備而言,將經純化多醣溶液凍乾並交換至D
2O中,其中添加TSP作為內部標準品。在50℃下於400 MHz儀器上獲得質子NMR光譜,其中信號係40次掃描之平均值。應用0.2 Hz之譜線加寬。該純化方案亦能夠產生不含M蛋白之經純化多醣,如藉由圖3之西方墨點所證實。圖4A及4B展示概述替代實例性多醣純化方法之流程圖。
合成實例 2 : 用於衍生高分子量多醣之一般方案
可使用DBCO-PEG連接體對經純化多醣(例如藉由實例1之方法所產生者)實施官能化。
通常,向多醣水溶液(在添加所有試劑之後之最終濃度為5.5 mM)中添加硼酸鹽緩衝液(1M, pH 8.5),其中硼酸鹽在最終體積中之最終濃度為100 mM。然後添加水以填充任何額外反應體積。在劇烈攪拌下添加2.5當量(相對於多醣重複單元)之四氟硼酸1-氰基-4-二甲基胺基吡啶鎓(CDAP;來自於乙腈中之100 mg/mL溶液)。將CDAP儲存於-20℃下且溶液必須在即將使用之前製備。在添加CDAP之後5分鐘(此時刻較為關鍵-長於5 min任何時間會導致減少DBCO-PEG-胺納入),添加0.5莫耳當量之二苯并環辛炔-胺連接體(來自DMSO儲備溶液,最終DMSO濃度為5% v/v)。將DBCO-PEG4-胺連接體儲存於-20℃下且必須在即將使用之前製備。在進一步反應一小時之後,以1:10 (按體積)添加甘胺酸(2M, pH 8.35)以得到200 mM甘胺酸之最終濃度,從而淬滅任何未反應氰酸酯。在淬滅1 h之後,然後經由Zeba旋轉管柱純化所衍生多醣。將2-3 mL溶液添加至每一10 mL Zeba管柱中。以Bound/Free DBCO HPLC方法分析經純化多醣以測定殘餘DBCO-PEG4-胺連接體及DMAP是否藉由管柱純化完全去除。可視需要進一步純化材料。使用蒽酮分析量測多醣濃度,且使用309 nm下之吸光度量測二苯并環辛炔濃度。組合該兩個值以估計經二苯并環辛炔官能基衍生之多醣之百分比。用於CDAP反應之DBCO百分比應介於5-10%之間。
GAS 多醣之DBCO-PEG4 衍生 :在劇烈攪拌下,向GAS多醣於100 mM硼酸鹽緩衝液(pH 8.5)中之6 mM溶液中添加三當量(相對於多醣重複單元)四氟硼酸1-氰基-4-二甲基胺基吡啶鎓(CDAP;來自於乙腈中之100 mg/mL溶液)以促進反應性羥基處之氰基化。在添加CDAP之後5分鐘,添加2莫耳當量之於DMSO中之二苯并環辛炔-胺連接體儲備液,其中最終DMSO濃度為5% (v/v)。在DBCO衍生之後,將200 mM甘胺酸添加至反應液中以淬滅未反應氰酸酯。經由zeba旋轉去鹽管柱純化DBCO源多醣且藉由反相評價所回收材料之純度。在309 nm下監測吸光度時HPLC中之單峰證實,過量DBCO連接體及其他反應副產物已完全去除。最後,使用蒽酮分析(參見下文)量測多醣濃度且使用309 nm下之吸光度量測二苯并環辛炔濃度。組合該兩個值以估計經二苯并環辛炔官能基衍生之多醣之百分比。對於結合而言,GAS多醣之DBCO衍生%保持於5-10%之間。
總多醣濃度之蒽酮分析 :在冷硫酸中製備蒽酮試劑(Sigma-Aldrich, CAS#90-44-8)之2 mg/ml儲備液,同時在水中製備包括2x鼠李糖之多醣重複單元(PSRU)之1 mM儲備液並作為標準品。一式三份在孔中平鋪(96孔板) 100 µl PSRU儲備液(連續稀釋成參考標準品)或未知試樣(以1:3稀釋),隨後添加200 µl /孔之蒽酮試劑儲備液。充分混合所有反應液並使用板蓋密封以供在95℃下培育10 min。將板短暫置於冰上以冷卻至環境溫度,然後使用UV/VIS讀板儀在620 nm下量測吸光度。為測定未知試樣之濃度,使用PSRU標準濃度及吸光度來生成最小平方擬合回歸。
合成實例 3 : 經 pAMF 修飾之結合多肽之表現及純化
實施實驗以表現及純化來自無細胞蛋白質合成提取物之經pAMF修飾之結合多肽。
在無細胞蛋白質合成(CFPS)反應中使用衍生自改造以產生用於在琥珀色終止密碼子處插入nnAA之正交tRNA之大腸桿菌(
E. coli)之提取物(XtractCF
+)來表現含有nnAA (例如pAMF)的多肽。用於選殖、表現及純化該等經修飾結合多肽之試樣方案可參見(例如) Kapoor等人,
Biochemistry, 2018, 57(5), 516-519。
合成實例 4 : 用於使高分子量多醣與多肽抗原或非 GAS 載體多肽結合以形成多肽 - 多醣結合物之一般方案
通常,藉由使DBCO基團之環辛炔部分與納入多肽抗原或非GAS載體多肽中之nnAA側鏈之疊氮化物部分進行反應來使多肽抗原或非GAS載體多肽結合至實例2的經純化DBCO源多醣。DBCO與疊氮化物基團之間之結合反應之試樣方案可參見(例如) Zimmerman等人,
Bioconjugate Chemistry, 2014, 25(2), 351-361及Kapoor等人,
Biochemistry, 2018, 57(5), 516-519。
pAMF 源GAS 多醣與SpyAD 之結合 :將SpyAD[4pAMF] (SEQ ID NO: 34)與DBCO源GAS多醣以1:1比率[各0.5 mg/ml]混合以促進經由點擊化學之結合。在結合後,抵靠50 kDa截止膜透析反應混合物以去除過量之未反應游離多醣。藉由SEC (多角度光散射) MALS分析所回收結合物且使用蒽酮分析來估計濃度。圖5係概述使用DBCO-(PEG)
4-NH
2衍生GAS多醣且隨後結合至pAMF源SpyAD之反應圖。圖6展示SpyAD[4pAMF] (SEQ ID NO: 34)多肽-多醣結合物在結合反應3.5小時之後及在透析後之SEC MALS分析。在3.5小時之後,觀察到大於1 MDa之結合物。在透析後,所分離結合物之大小分佈在大約186 kDa處展示峰。圖7展示使用相同SpyAD多肽作為本發明實例之多肽-多醣結合物之SEC-MALS分析,但其中利用基於氫氟酸之PS純化(試樣方案可參見(例如) van Sorge, N.M.等人,2014,
Cell Host Microbe.15(6): 729-740)。使用藉由舊方法純化之PS測得之峰分子量為153 kDa,與之相比,本發明所闡述之經純化多醣之峰分子量為約186 kDa。
使用Agilent HPLC 1100除氣器、溫度受控性自動採樣儀(4℃)、管柱室(25℃)及UV-VIS二極體陣列檢測器(Agilent, Santa Clara, CA)以及DAWN-HELEOS多角度雷射光散射檢測器及Optilab T-rEX差示折射干涉儀(Wyatt Technology, Santa Barbara, CA)來實施SEC MALS-UV-RI,該差示折射干涉儀耦合至三個串聯TOSOH管柱:TSKgel Guard PWXL,6.0 mm ID × 4.0 cm長,12 µm顆粒;TOSOH TSKgel 6000 PWXL,7.8 mm ID × 30 cm長,13 µm顆粒;及TSKgel 3000 PWXL,7.8 mm ID × 30 cm長,7µm顆粒。以0.5 mL/min流速使用由含有5% (v/v)乙腈之0.2 µm過濾性1x PBS組成之移動相且注射50-100 µg試樣以供分析。使用Agilent Open Lab軟體來控制HPLC,且使用Wyatt Astra 7軟體進行數據收集及分子量分析。
合成實例 5 : 表現具有 3 、 4 、 5 、 6 、 7 或 8 個 nnAA 之經截短 SLO( Δ C101) 多肽 , 純化 , 並結合
舉例而言,根據上述方法(例如參見合成實例3)來表現含有nnAA之經截短SLO(ΔC101)變體。變體含有3、4、5、6、7或8個對應於SEQ ID NO: 55、SEQ ID NO: 56、SEQ ID NO: 57、SEQ ID NO: 58、SEQ ID NO: 59、SEQ ID NO: 60、SEQ ID NO: 61、SEQ ID NO: 62、SEQ ID NO: 63、SEQ ID NO: 65、SEQ ID NO: 66、SEQ ID NO: 67、SEQ ID NO: 68、SEQ ID NO: 69、SEQ ID NO: 70、SEQ ID NO: 71、SEQ ID NO: 72、SEQ ID NO: 73、SEQ ID NO: 74、SEQ ID NO: 75及SEQ ID NO: 76之pAMF殘基。圖8A展示22種SLO(ΔC101)變體(var1-var22)及其pAMF納入位點之示意圖。圖8B展示該22種pAMF變體(3pAMF-8pAMF)之表現含量(以總蛋白質濃度及可溶性蛋白質濃度表示)。圖8C展示表現之相應凝膠(SEQ ID NO: 65-76對應於var11-var22)。8D展示揭示pAMF在經純化變體之子組中成功納入之凝膠,如藉由DBCO-TAMRA標記所證實(var1、5、6、10、11、12、14及15)。簡言之,對於純化而言,收穫CFPS物,旋轉並過濾,然後以0.75 ml/min加載於預平衡hisTRAP excel 1 ml管柱上並在單一步驟中使用於6 ml最終體積中之250 mM咪唑進行洗脫。使用SDS-PAGE安全藍染色分析5 µl之每一步驟部分。此後,將洗脫液稀釋3倍並加載於CaptoQ管柱上以供最終純化,且使用安全藍染色及DBCO TAMRA標記進行分析。濃縮FT部分並以200 µl等分試樣形式儲存於-80℃下。SEC-MALS分析提供經純化變體之子組之分子質量估計(圖8E)。此分析展示,5-pAMF (var11)及6-pAMF (var14)變體在溶液中展示高階寡聚態。
SLO( ΔC101) 多肽與5 、6 、7 或8 個nnAA 之結合 :使用上述方法(含有於合成實例4中)使含有5、6、7或8個nnAA之多肽結合至GAS多醣。以此方式,使SEQ ID NO: 65、SEQ ID NO: 66、SEQ ID NO: 68及SEQ ID NO: 69之含有pAM之SLO (ΔC101)變體結合至長DBCO源GAC (合成實例l)。藉由SDS page分析結合反應,如圖9A中所展示。每一變體之第一泳道展示結合前之蛋白質。藉由SEC-MALS測定最終結合物大小,其結果展示於圖10中。
使用3-及5-pAMF SLO變體作為載體蛋白所生成之結合物之生物物理表徵及免疫原性評價。為使用經純化SLO(ΔC101)變體來生成結合物,使用含有3 pAMF (var1及var5)及4 pAMF (var6及var10)之SLO(ΔC101)變體與定義膜錨定GAS碳水化合物(GAC
PR)之物質之富DBCO源聚鼠李糖核心(亦即GAC
PR-DBCO)進行無銅點擊化學反應。將每一蛋白質與DBCO-GAC
PR在室溫及恆定攪拌下混合4h。此後,收穫反應液且使用緩衝液透析結合物以去除過量游離PS。接下來,對經純化結合物實施SEC-MALS分析,該分析估得,使用含有3個pAMF之SLO(ΔC101)變體生成之結合物之平均莫耳質量為97或116kDa (圖9B),且使用含有4個pAMF之SLO(ΔC101)變體生成之結合物之平均莫耳質量為68或74 kDa (圖9C)。最後,經純化結合物之SDS-PAGE分析及後續SafeBlue
TM染色證實了該等結果,且證實載體蛋白已完全消耗以在點擊化學反應後生成每一結合物(圖9B-9C)。
合成實例 6 : 多醣重複單元中之連接體納入之最佳化
如上文所闡述,可藉由連接體(例如DBCO-PEG)衍生經純化多醣(例如GAS多醣,例如藉由實例1之方法產生者)。可以若干相關方式(例如DBCO-PEG4-胺之納入%,如藉由mol連接體/mol PSRU所量測;由連接體衍生之PSRU之mol%)來定義由DBCO-PEG4-胺衍生之GAS多醣之多醣重複單元(PSRU)之mol%。
向含有缺乏免疫顯性N-乙醯基葡萄糖胺側鏈之A型碳水化合物(GAC)多醣、硼酸鈉(pH 8.8)及二甲基亞碸之水溶液中添加於乙腈中之四氟硼酸1-氰基-4-二甲基胺基吡啶鎓(CDAP,相對於GAC多醣重複單元為0.5-4莫耳當量)。在5分鐘之後,添加DBCO-PEG4-胺(0.5-2莫耳當量)於二甲基亞碸中之溶液。反應組分之最終濃度如下:GAC, 4 mg/mL;硼酸鈉,0.1 M;二甲基亞碸,10% v/v。在1小時之後,添加甘胺酸直至最終濃度為0.2 M。在2小時之後,藉由凝膠過濾層析或藉由切向流過濾使用鹽水溶液及水作為滲濾緩衝液來純化反應混合物。分析活化GAC (亦稱為APS、活化多醣)之多醣濃度及DBCO-PEG4-胺納入%。
藉由改變反應條件,使用上述方案製備納入6-15% DBCO-PEG4-胺(相對於PSRU之mol%)之GAS多醣。表2展示產生所述納入%之實例。
表 2 : 試樣 PS 活化條件及官能化結果
合成實例 7 : 長多醣及 SpyAD 之最佳化結合條件
APS 批號 | CDAP 莫耳當量 | DBCO 莫耳當量 | 所納入 DBCO-PEG4- 胺 % (mol DBCO / mol PSRU) |
A | 1 | 1 | 6 |
B | 2 | 1 | 11 |
C | 3 | 1 | 15 |
D | 1 | 1 | 6 |
E | 2 | 1 | 12 |
F | 1.4 | 1 | 7 |
本文所闡述之長多醣之結合效率取決於連接體納入mol% (例如參見合成實例6)以及多肽之反應濃度及活化多醣相對於多肽的量。
試樣結合方案 :向含有活化多醣(參見合成實例6)及磷酸鹽緩衝鹽水之水溶液中添加SpyAD-4pAMF (SEQ ID NO: 34)。反應組分之最終濃度如下:具有DBCO連接體之活化PS,0.075-1.35 mg/mL;SpyAD-4pAMF, 0.5-3.7 mg/mL。在16-20小時之後,添加疊氮化鈉(相對於多醣重複單元為4當量)。在2小時之後,藉由透析或切向流過濾使用磷酸鹽緩衝鹽水作為滲濾緩衝液來純化反應混合物。經由0.22微米級過濾器(Pall KM2EKVS)過濾結合物且然後分析多醣濃度、蛋白質濃度、游離醣百分比及分子量。所產生結合物之實例展示於表3中。
表 3 : 試樣 PS 活化條件及官能化結果
結合物批號 | 活化 PS 中之所納入 DBCO-PEG4- 胺 % | SpyAD 濃度 (mg/mL) | 輸入 APS:SpyAD 質量比 | 結合物 Mw (kDa) | 游離醣 (FS) % | 經純化結合物中之輸出比 (PS:SpyAD) | 針對 FS% 調節之輸出比 |
CNJ-A | 6% | 0.5 | 1 | 144 | 30% | 0.28 | 0.19 |
CNJ-B | 6% | 0.5 | 0.5 | 166 | 25% | 0.22 | 0.17 |
CNJ-C | 6% | 0.5 | 0.15 | 157 | 7% | 0.12 | 0.11 |
CNJ-D | 6% | 1 | 0.3 | 182 | 13% | 0.17 | 0.15 |
CNJ-E | 11% | 0.5 | 1 | 145 | 35% | 0.31 | 0.20 |
CNJ-F | 11% | 0.5 | 0.5 | 156 | 14% | 0.18 | 0.16 |
CNJ-G | 11% | 0.5 | 0.3 | 175 | 5% | 0.17 | 0.16 |
CNJ-H | 11% | 0.5 | 0.15 | 176 | 8% | 0.14 | 0.13 |
CNJ-I | 11% | 1 | 0.3 | 205 | 11% | 0.16 | 0.14 |
CNJ-J | 15% | 0.5 | 1 | 179 | 24% | 0.26 | 0.20 |
CNJ-K | 15% | 0.5 | 0.5 | 177 | 16% | 0.18 | 0.15 |
CNJ-L | 15% | 0.5 | 0.3 | 263 | 0% | 0.22 | 0.22 |
CNJ-M | 15% | 0.5 | 0.15 | 214 | 21% | 0.12 | 0.09 |
CNJ-N | 15% | 1 | 0.3 | 213 | 13% | 0.22 | 0.19 |
CNJ-O | 11% | 2.76 | 0.3 | 247 | 49% | 0.21 | 0.11 |
CNJ-P | 11% | 2.76 | 0.15 | 374 | 14% | 0.14 | 0.12 |
CNJ-Q | 11% | 2.76 | 0.15 | 381 | 14% | 0.12 | 0.10 |
CNJ-R | 11% | 2.76 | 0.075 | 319 | 14% | 0.09 | 0.08 |
CNJ-S | 15% | 2.76 | 0.3 | 273 | 36% | 0.18 | 0.11 |
CNJ-T | 15% | 2.76 | 0.15 | 412 | 6% | 0.13 | 0.12 |
CNJ-U | 15% | 2.76 | 0.15 | 372 | 8% | 0.14 | 0.13 |
CNJ-V | 15% | 2.76 | 0.075 | 445 | 14% | 0.09 | 0.08 |
CNJ-W | 11% | 2.76 | 0.15 | 342 | 14% | 0.11 | 0.10 |
CNJ-X | 6% | 3.7 | 0.15 | 246 | 24% | 0.10 | 0.08 |
CNJ-Y | 11% | 3.7 | 0.15 | 429 | 14% | 0.10 | 0.09 |
CNJ-Z | 15% | 3.7 | 0.15 | 476 | 15% | 0.12 | 0.10 |
CNJ-AA | 15% | 3.7 | 0.1 | 556 | 13% | 0.10 | 0.09 |
CNJ-AB | 6% | 1.8 | 0.75 | 201 | 52% | 0.42 | 0.20 |
CNJ-AC | 11% | 1.8 | 0.75 | 221 | 52% | 0.34 | 0.17 |
CNJ-AD | 15% | 1.8 | 0.75 | 244 | 60% | 0.39 | 0.16 |
CNJ-AE | 6% | 0.5 | 0.5 | 172 | 51% | 0.26 | 0.13 |
CNJ-AF | 6% | 0.5 | 0.5 | 171 | 15% | 0.19 | 0.16 |
CNJ-AG | 15% | 3.7 | 0.14 | 469 | 8% | 0.13 | 0.12 |
CNJ-AH | 7% | 0.5 | 0.5 | 184 | 35% | 0.23 | 0.15 |
CNJ-AI | 12% | 2.5 | 0.15 | 318 | 10% | 0.10 | 0.09 |
如下文之生物實例中進一步所論述,在使用本發明之長多醣製得之結合物中,較高分子量SpyAD-GAC結合物(例如藉由合成實例7中之方法製得者)針對SpyAD及GAC所誘發之效價強於低分子量結合物。若干因素對於高分子量結合物之產生較為重要。首先,納入活化多醣中之DBCO-PEG4-胺之百分比(例如合成實例4)會影響結合物大小。在6-15%之範圍內,較高DBCO納入程度(mol%)通常產生較大結合物。其次,較高GAC:SpyAD質量比通常產生較小結合物,而較低比率則產生未結合SpyAD多肽。0.10-0.15之質量比通常會限制未結合SpyAD及活化多醣之量,且產生較大結合物。最後,在既定GAC:SpyAD比率下,較高濃度之兩種反應物通常產生較大結合物。
活化多醣中之所納入DBCO-PEG4-胺百分比報告為莫耳比率(總DBCO-PEG4-胺)*(結合DBCO-PEG4-胺%)/(PSRU濃度)。如下所述來獲得彼等值:對於總DBCO-PEG4-胺而言,在307 nm下量測APS試樣之吸光度。藉由使用針對DBCO-PEG4-胺測得之消光係數來測定試樣中之總DBCO-PEG4-胺濃度。藉由HPLC分析來量測結合DBCO-PEG4-胺百分比。將試樣注於Sepax Zenix-C SEC-300管柱上並使用含有50 mM氯化鉀、15% v/v乙腈及0.1% v/v三氟乙酸之移動相洗脫。將結合DBCO-PEG4-胺百分比測定為310 nm下之(APS) / (APS +游離DBCO-PEG4-胺)之峰面積比。
如先前所闡述使用蒽酮分析來量測多醣濃度。遵循製造商方案使用皮爾斯改良勞裡分析套組(Pierce Modified Lowry assay kit)來分析試樣之蛋白質濃度。為量測游離醣,製備去氧膽酸鈉溶液(1% w/v於水中)且使用HCl將pH調節至6.8。向結合物溶液中添加0.1體積去氧膽酸鹽儲備溶液及0.05體積HCl (1 M)。旋轉試樣並回收上清液,且將此程序再重複一次。藉由蒽酮分析(如先前所闡述)量測上清液之多醣含量,且將結合物之游離醣含量測定為去氧膽酸鹽上清液之多醣濃度與結合物之多醣濃度之比率。如先前所闡述藉由SEC-MALS來測定結合物分子量。
舉例而言,藉由改變上述參數來產生SpyAD結合物CNJ-AE、CNJ-AF及CNJ-AG。值得注意地,結合物CNJ-AG具有大約469 kDa之平均分子量(藉由SEC-MALS測得),與之相比,CNJ-AE及CNJ-AF之平均分子量為170 kDa (參見圖13)。此可歸因於活化多醣中之較高DBCO納入程度(15%對6%)、反應混合物中之較高SpyAD多肽濃度及活化多醣與多肽之較低輸入質量比。另外,CNJ-AG係使用較低量之游離多醣所產生,此簡化了純化程序且使得用於本文所闡述之免疫原性組合物中之活性醫藥成分較為一致。此亦意味著,產生更為有效、成本更低且節約試劑。
合成實例 8 : SpyAD 片段之表現
根據合成實例3之方法來表現SEQ ID NO: 34之SpyAD多肽片段(SEQ ID NO: 77、SEQ ID NO: 78、SEQ ID NO: 79及SEQ ID NP: 81)。使用編碼2x6-his標籤前導序列(例如SEQ ID NO: 80之序列)之多肽之構築體來表現具有對應於在純化並裂解前導標籤後之序列之SEQ ID NO: 77、78、79及81的每一片段。
與天然或全長SpyAD序列相比,SpyAD片段可用於改良表現、純化及/或免疫原性。為監測期望多肽片段之產生,將
14C-白胺酸(GE Life Sciences, Piscataway, NJ)添加至CFPS反應中以合成SEQ ID NO: 77、78、79及81,並納入轉譯多肽中。在23℃及振盪下10小時之後,藉由在4,500 rpm下旋轉10分鐘來回收上清液。藉由
14C計數來估計總蛋白及可溶性蛋白之表現效價。將總共4 µl上清液加載至4-12% SDS-PAGE非還原凝膠上。在80℃下將蛋白質凝膠去水2小時之後,藉由自動射線攝影術使用Storm 820磷光成像儀來分析天然SpyAD (SEQ ID NO: 33)、SpyAD(4pAMF) (SEQ ID NO: 34)及片段(SEQ ID NO: 77、78、79及81)之表現模式。
圖14展示天然SpyAD、SpyAD(4pAMF)及4種片段之表現之自動射線攝影術結果以及每一試樣中之總蛋白及可溶性蛋白的表現效價。值得注意地,天然SpyAD及SpyAD(4pAMF)表現混合物具有6個介於50 kDa與75 kDa之間之污染片段帶,而SEQ ID NO: 77-79及81之SpyAD片段則在相同區域內展示較少帶。CFPS反應中之改良蛋白質表現含量產生較高回收率。此簡化了多肽之純化程序且產生繼續用於結合至衍生多醣之較清潔材料。
生物實例 1 : 使用多醣或多醣結合物之小鼠主動免疫化
在藉由真皮下及腹膜腔內注射進行攻擊之前對小鼠實施主動免疫。
表 4 : 試樣免疫化實驗時間線 - 真皮下及腹膜腔內攻擊
真皮下攻擊 - 步驟 | 腹膜腔內攻擊 - 步驟 |
第1天:第1免疫化 | 第1天:第1免疫化 |
第14天:第2免疫化 | 第14天:第2免疫化 |
第28天:第3免疫化 | 第28天:第3免疫化 |
第42天:感染攻擊 | 第41天:將小鼠剃毛 |
第49天:終止實驗 | 第42天:感染攻擊 |
第45天:使小鼠安樂死並收集病灶 |
第1 、第2 及第3 免疫化- 真皮下及腹膜腔內攻擊 :藉由組合50 µL明礬(鋁膠)與10 µg抗原或5 µg結合物並充分混合以使抗原吸附於明礬上來製備抗原/佐劑混合物。將每一抗原/佐劑混合物抽取至配備有26 ½號針之1 mL注射器中。使用吸入之異氟醚將每一小鼠麻醉並將100 µL所製備疫苗注射至後腿肌肉中。
攻擊用小鼠之準備- 真皮下攻擊:使用異氟醚將小鼠麻醉。使用電動剃刀將小鼠之後背剃毛,注意不要劃傷皮膚。將脫毛膏施加至經剃毛後背上且靜置幾分鐘,然後使用紙巾將其充分擦拭乾淨。將小鼠拍乾並使其自異氟醚處理恢復。
攻擊用材料之製備- 真皮下及腹膜腔內攻擊:使GAS培養物生長至對數生長中期。使用無菌磷酸鹽緩衝鹽水調節細胞濃度,連續稀釋細菌並平鋪於瓊脂上以證實細菌劑量。對於真皮下攻擊而言,靶向CFU/10 µL/小鼠為1×10
6,且將細菌抽取至配備有26 ½號針之500 µL漢密爾頓注射器(Hamilton syringe)中。對於腹膜腔內攻擊而言,在第35天,靶向CFU/100 µL/小鼠為1×10
7,且將細菌抽取至配備有26 ½號針之1 mL注射器中。使用吸入之異氟醚將小鼠麻醉且然後將200 µL M1 89155細菌注射至腹膜腔中。使小鼠在正常空氣中自麻醉狀態恢復。在1週過程中追蹤小鼠存活,並每天檢查多次。
真皮下攻擊及病灶收集:對於真皮下攻擊而言,在第35天,使用吸入之異氟醚將小鼠麻醉且然後使用漢密爾頓注射器之重複分配器將10 µL GAS細菌注射至經剃毛後背中。在3天過程中,每天藉由對位於尺子旁邊之經異氟醚麻醉之小鼠拍照來追蹤病灶大小。在第3天收集病灶之前,針對每一皮膚病灶準備含有1.0 mm二氧化矽珠粒及1 mL PBS之無菌2 mL螺口管。記錄每一管之重量。在第3天,當病灶完全發展時,使用CO
2及頸椎脫位術對小鼠實施安樂死。使用清潔手術儀器,切下每一皮膚病灶並置於預稱重管中。記錄管重以供組織質量計算。將該等管置於MagnaLyser珠粒攪拌器中,且將該等管在6000 rpm下攪拌60 s。然後將該等管置於冰上以冷卻60 s,隨後重複攪拌循環。連續稀釋試樣,且將溶解物置於瓊脂上以量化細菌負荷。
實施兩個平行實驗,其中在整個實驗中對一組動物采血以測試接種疫苗後之抗原特異性抗體效價。在另一組中,在實驗過程期間並不對小鼠采血。最後以類似方式攻擊兩組動物以實施病灶大小及CFU/mg分析。
生物實例 2 : 在鼠類模型中評價多肽抗原或非 GAS 載體多肽及其多肽 - 多醣結合物之免疫原性
在鼠類模型中藉由如上文在生物實例1中所闡述之方法來評價合成實例2及3之多肽抗原或非GAS載體多肽及其多醣結合物。在第0、7及14天對小鼠實施免疫,隨後在第21天處死後進行終末采血。
使用5 µg之每一多醣結合物對小鼠實施免疫。在終末采血之後量測針對多肽及多醣之抗體效價。可使用根據實例1之方法產生之長多醣作為該等免疫原性實驗之ELISA分析中的包被抗原。圖11A展示在使用5 µg之經pAMF取代之SLO(ΔC101)-var1、SLO(ΔC101)-var5、SLO(ΔC101)-var6及SLO(ΔC101)-var10 (對應於SEQ ID NO: 55、59、60及64)之每一多醣結合物對小鼠實施免疫之後的ELISA。該等多肽-多醣結合物使用短多醣,但圖11A之第一繪圖展示在終末采血之後量測之抗體效價,其中ELISA利用長多醣(藉由實例1之方法產生)作為包被抗原。圖11A之第二繪圖展示利用多肽包被抗原之ELISA中之抗體效價。
使用不同小組之小鼠重複上述實驗,且在分析單獨蛋白質或結合物組之抗血清時記錄針對SLO之抗體效價(>10
6),如圖11B中所展示。此實驗證實,仔細選擇用於位點選擇性結合之pAMF納入殘基可不破壞作為載體蛋白之SLO上之關鍵免疫原性表位。最後,亦記錄針對GAC
PR之穩定抗體反應(>10
6)
(圖11B)。總而言之,此結果展示,CFPS提供了用於表現及純化含有nnAA之病原體特異性蛋白質抗原之有效平臺,其可成功地用於生成免疫原性結合物。
生物實例 3 : 多醣及多肽 - 多醣結合物之穩定性
實施實驗以量測實例1之多醣及其結合物之穩定性。將多醣或多肽-多醣結合物在-20℃、5℃及25℃下保持至少6個月。在6、12及24個月時獲取試樣,且分析每一試樣之pH及分子量以測定穩定性。
生物實例 4 : M1 GAS 攻擊中之 SLO 變體結合物與 SLO 變體及 eCRM197- 多醣結合物共投與之對比
使用模擬品、SLO(ΔC101)var1-GAC
PR結合物或組合疫苗[SLO(ΔC101)var1 + eCRM-GAC
PR]對小鼠(N=10/組)實施免疫。自5週齡開始,每14天一次對野生型雌性CD-1小鼠(查理士河(Charles River))實施免疫,總共3個劑量。每一小鼠之每一劑量之所提供肌內免疫化由100 µl總體積組成,該總體積包含50 µl Alhydrogel 2%氫氧化鋁佐劑(Invivogen)且根據製造商說明書製得。在最終免疫化之後14天,藉由i.p.注射使小鼠感染1×10
7個CFU M1 89155 GAS並追蹤存活情況。使用時序Mantel-Cox測試計算卡普蘭-邁耶存活曲線(Kaplan-Meier survival curve)之統計學。如圖12中所展示,與組合疫苗組不同,僅使用SLO(ΔC101)var1-GAC
PR之免疫化提供顯著高於模擬組之保護(
p=0.012)。此結果展示,與使用非相關載體蛋白生成結合物之習用方法不同,GAC
PR與CFPS生成之GAS特異性蛋白質抗原之位點特異性結合提供較佳活體內保護。
生物實例 5 : 在 NZW 兔中使用免疫原性組合物評估 SpyAD-PS 結合物之免疫原性
製備含有不同量SpyAD-PS結合物與等量多肽抗原C5a (SEQ ID NO: 30)及SLO (SEQ ID NO: 50)之組合之測試物品(展示於表5中)。測試結合物CNJ-AE、NJ-AF及CNJ-AG (參見合成實例6及7)。
表 4 : 試樣免疫化實驗時間線 - 真皮下及腹膜腔內攻擊
測試物品 | 組 | 抗原數 |
0.062 μg結合物(CNJ-AE)及每一蛋白質抗原 | 1 | 3 |
0.25 μg結合物(CNJ-AE)及每一蛋白質抗原 | 2 | 3 |
1.0 μg結合物(CNJ-AE)及每一蛋白質抗原 | 3 | 3 |
4.0 μg結合物(CNJ-AE)及每一蛋白質抗原 | 4 | 3 |
0.062 μg結合物(CNJ-AG)及每一蛋白質抗原 | 5 | 3 |
0.25 μg結合物(CNJ-AG)及每一蛋白質抗原 | 6 | 3 |
1.0 μg結合物(CNJ-AG)及每一蛋白質抗原 | 7 | 3 |
4.0 μg結合物(CNJ-AG)及每一蛋白質抗原 | 8 | 3 |
0.25 μg結合物(CNJ-AF)及每一蛋白質抗原 | 9 | 3 |
在含有5 mM琥珀酸鈉(pH 5.8)、150 mM氯化鈉及0.02%聚山梨醇酯80之緩衝液中調配所有測試物品。31.2 μg磷酸鋁存在於每一劑量中。以0.25 mL/劑量(雙側,0.125 mL/肢體)將結合物經肌內投用至雌性新西蘭白兔(New Zealand white rabbit)中。在第0、21及42天投與劑量,且在第-1、14、35及56天收集血液。每組投用10隻兔。藉由ELISA使用SLO、C5A、SpyAD、SpyAD-GAC及eCRM-GAC作為包被抗原來量測針對每一抗原之效價。
對於每一ELISA實驗而言,使用無菌過濾之PBS (總共100 μL,pH 7.4 ± 0.2)稀釋含有所關注抗原之包被溶液,且以0.5 μg/mL添加至每一孔中。將板在密封容器中於2℃至8℃下保持16至24小時。然後使用板洗滌緩衝液(350 μL/孔)將板洗滌3次,然後藉由添200 μL PBS + 3%牛血清白蛋白(BSA)來封閉板並在室溫下培育60至65分鐘。在使用板洗滌緩衝液將板洗滌3次之後,自1:10濃度開始製備來自測試物品治療動物之血清試樣(50 μL)之5倍連續稀釋液並添加至指定孔中。亦將對照(試樣稀釋劑:1X PBS + 3% BSA;商業正常血清[Jackson ImmunoResearch]陰性對照;及藉由3-或5倍稀釋連續稀釋之陽性對照)添加至指定孔中。一式兩份加載測試物品血清試樣且單一性加載對照(較佳地加載於一個板上),並在35℃至39℃下培育60至65分鐘。使用板洗滌緩衝液將板洗滌6次,添加結合之驢抗兔IgG (H+L)過氧化物酶,並將板在室溫下培育60至65分鐘且然後再洗滌6次。添加ABTS受質且將板在室溫下培育30分鐘。在415 nm及570 nm下讀取板。
展示於圖15、16、17、18及19 (分別使用C5a、SLO、SpyAD、SpyAD-GAC及eCRM-GAC包被抗原)中之每一ELISA之結果展示,高分子量SpyAD-GAC結合物(CNJ-AG)針對SpyAD及GAC所誘發之效價強於低分子量結合物(CNJ-AE及CNJ-AF)。在一些情形下,在等效劑量下,高分子量結合物在第35天所誘發之效價係低分子量結合物(CNJ-AE)之3-30倍(例如0.062 µg及0.25 µg,組6對組2)。
在不同緩衝液中量測結合物之穩定性以評價質量回收、結合物分子量及顆粒形成在儲存於25℃下時或在經受多個冷凍/解凍循環時之變化。4種此類緩衝液係(i) 20 mM磷酸鉀(pH 7.4)、10%山梨醇;(ii) 20 mM磷酸鉀(pH 7.4)、10%山梨醇、10 mM氯化鈉;(iii) 20 mM磷酸鉀(pH 7.4)、10%山梨醇、10 mM氯化鈉、0.02%聚山梨醇酯80;及(iv) 20 mM參(羥甲基)胺基甲烷(pH 8.0)、10%山梨醇、50 mM氯化鈉。
亦如上所述使用具有不同分子量之結合物、以一或兩個劑量且在經受加速穩定性(例如高於可用於所製造疫苗產品之溫度的溫度)條件或冷凍/解凍循環之前及之後來實施活體內免疫原性研究。舉例而言,結合物低於250 kDa,介於250 kDa與400 kDa之間,及/或高於400 kDa。該等實驗進一步評價結合條件對產率及免疫原性之效應,評價如何使本文所闡述之結合物經受游離/解凍循環可產生免疫原性變化,且在一或多個劑量值下評價該兩個變量。
生物實例 6 : 人類 I 期及 IIA 期臨床試驗設計
初始I期臨床研究係在18-29歲健康成人(N=96)中進行之隨機化、安慰劑對照、遞增劑量之研究(表3)。此初始臨床研究之目標係安全性、劑量反應及免疫原性(IgG抗體)。因此年齡範圍內之許多個體具有預存在之GAS暴露及免疫性,故全面評估基線免疫性以瞭解預存在免疫性對疫苗反應之影響。評估對於每一疫苗組分之IgG反應及針對不同組中不同M血清型之同時GAS分離物之OPK抗體效價。
表 5 : I 期臨床試驗組
I 期臨床試驗設計 | ||||
組 | N | 治療 | 劑量 | 時間表 |
1A | 24 | GAS疫苗 | 低 | 第0、28天 |
1B | 8 | 安慰劑 | 第0、28天 | |
2A | 24 | GAS疫苗 | 中等 | 第0、28天 |
2B | 8 | 安慰劑 | 第0、28天 | |
3A | 24 | GAS疫苗 | 高 | 第0、28天 |
3B | 8 | 安慰劑 | 第0、28天 |
2A期臨床研究係隨機化、安慰劑對照、多中心之研究,其用以在10至17歲個體、隨後5至9歲兒童之連續小組(N=96)中評估疫苗(表4)。此研究之目標係評估安全性、免疫原性(血清之IgG抗體反應及調理吞噬殺死活性)及初步效能(GAS咽炎發生率)。監測每一患者12個月以測定治療組中之鏈球菌咽炎發生率。
表 6 : IIA 期臨床試驗組
IIA 期臨床試驗設計 | ||||
N | 年齡 ( 歲 ) | 治療 | 劑量 | 時間表 |
36 | 10-17 | GAS疫苗 | 由PI決定 | 第0、28天 |
12 | 10-17 | 安慰劑 | 第0、28天 | |
36 | 5-9 | GAS疫苗 | 中等 | 第0、28天 |
12 | 5-9 | 安慰劑 | 第0、28天 |
圖1展示概述一實例性多醣純化方法之流程圖。
圖2A、圖2B及圖2C展示源自表現缺乏GlcNAc之PS之GAS細菌菌株之經純化多醣的NMR分析。
圖3展示證實在如實例1中所闡述純化時自多醣去除M蛋白之西方墨點。
圖4A及4B展示概述替代實例性多醣純化方法之流程圖。
圖5展示概述使用DBCO-(PEG)
4-NH
2衍生GAS且隨後結合至pAMF源SpyAD之反應圖。
圖6展示在3.5小時結合反應後及在透析後如實例1中所闡述製得之SpyAD[4pAMF]多肽-多醣結合物之SEC MALS分析。
圖7展示SpyAD[4pAMF]多肽-多醣結合物之SEC-MALS分析,其中使用基於氫氟酸之PS純化方法(峰1:2070.5 kDa;峰2:135,200 Da)。
圖8A展示22種SLO(ΔC101)變體(var1-var22)及其pAMF納入位點之示意圖。
圖8B及圖8C展示22種具有3-8個pAMF之SLO變體之表現含量及含有5-8個pAMF之經純化變體的相應凝膠。
圖8D展示經安全藍(Safe Blue)染色及經DBCO-TAMRA標記之凝膠,該等凝膠展示經純化變體之子組(var1、5、6、10、11、12、14及15)中之成功pAMF納入。
圖8E展示提供經純化變體之子組(var1、5、6、10、11、12、14及15)之估計分子質量之SEC-MALS分析。
圖9A展示具有長GAC之5-及6-pAMF變體SLO結合物之SDS-PAGE分析。圖9B展示經純化結合物之SEC-MALS分析,該分析展示使用含有3個pAMF之SLO(ΔC101)變體生成之結合物之平均莫耳質量為97或116kDa (插圖莫耳質量-GAC
PR: 6.2 kDa及GAC
PR-DBCO: 6.8 kDa),圖9C展示經純化結合物之SEC-MALS分析,該分析展示使用含有4個pAMF之SLO(ΔC101)變體生成之結合物之平均莫耳質量為68或74 kDa。
圖10展示具有長GAC多醣之5-及6-pAMF變體SLO結合物之SEC-MALS數據。
圖11A展示在使用利用所選SLO(ΔC101)變體製得之結合物及使用長GAC多醣作為ELISA中之包被抗原實施免疫後小鼠之抗體效價。
圖11B展示在使用利用所選SLO(ΔC101)變體製得之結合物及使用長GAC多醣作為ELISA中之包被抗原實施免疫後另一小組小鼠之抗體效價。
圖12展示在使用GAS血清型M1攻擊後使用模擬品、SLO(ΔC101)var1-GAC結合物或組合疫苗[SLO(ΔC101)var1 + eCRM-GACPR]之活體內小鼠免疫化研究之結果。
圖13展示比較結合物CNJ-AE、CNJ-AF及CNJ-AG與天然SpyAD之凝膠,該凝膠展示,用於產生CNJ-AG之條件產生較高分子量結合物。
圖14展示自動射線攝影術實驗之結果(展示估計表現效價之凝膠及繪圖),該等結果證實,SpyAD片段(例如SEQ ID NO: 77、78、79及81)在表現期間產生較少不期望片段,從而使得更易於純化且更佳地結合至活化多醣。
圖15、圖16、圖17、圖18、圖19展示免疫化研究之結果(經由ELISA測得之抗體效價),該等免疫化研究比較具有不同分子量且使用不同結合條件產生之SpyAD-GAC結合物。
<![CDATA[<110> 美商VAXCYTE公司(Vaxcyte, Inc.)]]> <![CDATA[<120> 多醣及其多肽結合物之純化方法]]> <![CDATA[<130> STRO-015/02WO 331540-2122]]> <![CDATA[<150> US 63/288,387]]> <![CDATA[<151> 2021-12-10]]> <![CDATA[<150> US 63/150,516]]> <![CDATA[<151> 2021-02-17]]> <![CDATA[<160> 83 ]]> <![CDATA[<170> PatentIn version 3.5]]> <![CDATA[<210> 1]]> <![CDATA[<211> 962]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> C5a [90-1035片段] - WT,具有前導序列]]> <![CDATA[<400> 1]]> Met His His His His His His Gly Ser Gly Glu Asn Leu Tyr Phe Gln 1 5 10 15 Gly Lys Thr Ala Asp Thr Pro Val Thr Ser Lys Ala Thr Ile Arg Asp 20 25 30 Leu Asn Asp Pro Ser Gln Val Lys Thr Leu Gln Glu Lys Ala Gly Lys 35 40 45 Gly Ala Gly Thr Val Val Ala Val Ile Asp Ala Gly Phe Asp Lys Asn 50 55 60 His Glu Ala Trp Arg Leu Thr Asp Lys Thr Lys Ala Arg Tyr Gln Ser 65 70 75 80 Lys Glu Asp Leu Glu Lys Ala Lys Lys Glu His Gly Ile Thr Tyr Gly 85 90 95 Glu Trp Val Asn Asp Lys Val Ala Tyr Tyr His Asp Tyr Ser Lys Asp 100 105 110 Gly Lys Thr Ala Val Asp Gln Glu His Gly Thr His Val Ser Gly Ile 115 120 125 Leu Ser Gly Asn Ala Pro Ser Glu Thr Lys Glu Pro Tyr Arg Leu Glu 130 135 140 Gly Ala Met Pro Glu Ala Gln Leu Leu Leu Met Arg Val Glu Ile Val 145 150 155 160 Asn Gly Leu Ala Asp Tyr Ala Arg Asn Tyr Ala Gln Ala Ile Arg Asp 165 170 175 Ala Val Asn Leu Gly Ala Lys Val Ile Asn Met Ser Phe Gly Asn Ala 180 185 190 Ala Leu Ala Tyr Ala Asn Leu Pro Asp Glu Thr Lys Lys Ala Phe Asp 195 200 205 Tyr Ala Lys Ser Lys Gly Val Ser Ile Val Thr Ser Ala Gly Asn Asp 210 215 220 Ser Ser Phe Gly Gly Lys Thr Arg Leu Pro Leu Ala Asp His Pro Asp 225 230 235 240 Tyr Gly Val Val Gly Thr Pro Ala Ala Ala Asp Ser Thr Leu Thr Val 245 250 255 Ala Ser Tyr Ser Pro Asp Lys Gln Leu Thr Glu Thr Ala Thr Val Lys 260 265 270 Thr Ala Asp Lys Gln Asp Lys Glu Met Pro Val Leu Ser Thr Asn Arg 275 280 285 Phe Glu Pro Asn Lys Ala Tyr Asp Tyr Ala Tyr Ala Asn Arg Gly Met 290 295 300 Lys Glu Asp Asp Phe Lys Asp Val Lys Gly Lys Ile Ala Leu Ile Glu 305 310 315 320 Arg Gly Asp Ile Asp Phe Lys Asp Lys Ile Ala Asn Ala Lys Lys Ala 325 330 335 Gly Ala Val Gly Val Leu Ile Tyr Asp Asn Gln Asp Lys Gly Phe Pro 340 345 350 Ile Glu Leu Pro Asn Val Asp Gln Met Pro Ala Ala Phe Ile Ser Arg 355 360 365 Lys Asp Gly Leu Leu Leu Lys Asp Asn Pro Lys Lys Thr Ile Thr Phe 370 375 380 Asn Ala Thr Pro Lys Val Leu Pro Thr Ala Ser Gly Thr Lys Leu Ser 385 390 395 400 Arg Phe Ser Ser Trp Gly Leu Thr Ala Asp Gly Asn Ile Lys Pro Asp 405 410 415 Ile Ala Ala Pro Gly Gln Asp Ile Leu Ser Ser Val Ala Asn Asn Lys 420 425 430 Tyr Ala Lys Leu Ser Gly Thr Ser Met Ser Ala Pro Leu Val Ala Gly 435 440 445 Ile Met Gly Leu Leu Gln Lys Gln Tyr Glu Thr Gln Tyr Pro Asp Met 450 455 460 Thr Pro Ser Glu Arg Leu Asp Leu Ala Lys Lys Val Leu Met Ser Ser 465 470 475 480 Ala Thr Ala Leu Tyr Asp Glu Asp Glu Lys Ala Tyr Phe Ser Pro Arg 485 490 495 Gln Gln Gly Ala Gly Ala Val Asp Ala Lys Lys Ala Ser Ala Ala Thr 500 505 510 Met Tyr Val Thr Asp Lys Asp Asn Thr Ser Ser Lys Val His Leu Asn 515 520 525 Asn Val Ser Asp Thr Phe Glu Val Thr Val Thr Val His Asn Lys Ser 530 535 540 Asp Lys Pro Gln Glu Leu Tyr Tyr Gln Ala Thr Val Gln Thr Asp Lys 545 550 555 560 Val Asp Gly Lys His Phe Ala Leu Ala Pro Lys Ala Leu Tyr Glu Thr 565 570 575 Ser Trp Gln Lys Ile Thr Ile Pro Ala Asn Ser Ser Lys Gln Val Thr 580 585 590 Val Pro Ile Asp Ala Ser Arg Phe Ser Lys Asp Leu Leu Ala Gln Met 595 600 605 Lys Asn Gly Tyr Phe Leu Glu Gly Phe Val Arg Phe Lys Gln Asp Pro 610 615 620 Thr Lys Glu Glu Leu Met Ser Ile Pro Tyr Ile Gly Phe Arg Gly Asp 625 630 635 640 Phe Gly Asn Leu Ser Ala Leu Glu Lys Pro Ile Tyr Asp Ser Lys Asp 645 650 655 Gly Ser Ser Tyr Tyr His Glu Ala Asn Ser Asp Ala Lys Asp Gln Leu 660 665 670 Asp Gly Asp Gly Leu Gln Phe Tyr Ala Leu Lys Asn Asn Phe Thr Ala 675 680 685 Leu Thr Thr Glu Ser Asn Pro Trp Thr Ile Ile Lys Ala Val Lys Glu 690 695 700 Gly Val Glu Asn Ile Glu Asp Ile Glu Ser Ser Glu Ile Thr Glu Thr 705 710 715 720 Ile Phe Ala Gly Thr Phe Ala Lys Gln Asp Asp Asp Ser His Tyr Tyr 725 730 735 Ile His Arg His Ala Asn Gly Lys Pro Tyr Ala Ala Ile Ser Pro Asn 740 745 750 Gly Asp Gly Asn Arg Asp Tyr Val Gln Phe Gln Gly Thr Phe Leu Arg 755 760 765 Asn Ala Lys Asn Leu Val Ala Glu Val Leu Asp Lys Glu Gly Asn Val 770 775 780 Val Trp Thr Ser Glu Val Thr Glu Gln Val Val Lys Asn Tyr Asn Asn 785 790 795 800 Asp Leu Ala Ser Thr Leu Gly Ser Thr Arg Phe Glu Lys Thr Arg Trp 805 810 815 Asp Gly Lys Asp Lys Asp Gly Lys Val Val Ala Asn Gly Thr Tyr Thr 820 825 830 Tyr Arg Val Arg Tyr Thr Pro Ile Ser Ser Gly Ala Lys Glu Gln His 835 840 845 Thr Asp Phe Asp Val Ile Val Asp Asn Thr Thr Pro Glu Val Ala Thr 850 855 860 Ser Ala Thr Phe Ser Thr Glu Asp Arg Arg Leu Thr Leu Ala Ser Lys 865 870 875 880 Pro Lys Thr Ser Gln Pro Val Tyr Arg Glu Arg Ile Ala Tyr Thr Tyr 885 890 895 Met Asp Glu Asp Leu Pro Thr Thr Glu Tyr Ile Ser Pro Asn Glu Asp 900 905 910 Gly Thr Phe Thr Leu Pro Glu Glu Ala Glu Thr Met Glu Gly Ala Thr 915 920 925 Val Pro Leu Lys Met Ser Asp Phe Thr Tyr Val Val Glu Asp Met Ala 930 935 940 Gly Asn Ile Thr Tyr Thr Pro Val Thr Lys Leu Leu Glu Gly His Ser 945 950 955 960 Asn Lys <![CDATA[<210> 2]]> <![CDATA[<211> 945]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 釀膿鏈球菌]]> <![CDATA[<400> 2]]> Lys Thr Ala Asp Thr Pro Val Thr Ser Lys Ala Thr Ile Arg Asp Leu 1 5 10 15 Asn Asp Pro Ser Gln Val Lys Thr Leu Gln Glu Lys Ala Gly Lys Gly 20 25 30 Ala Gly Thr Val Val Ala Val Ile Asp Ala Gly Phe Asp Lys Asn His 35 40 45 Glu Ala Trp Arg Leu Thr Asp Lys Thr Lys Ala Arg Tyr Gln Ser Lys 50 55 60 Glu Asp Leu Glu Lys Ala Lys Lys Glu His Gly Ile Thr Tyr Gly Glu 65 70 75 80 Trp Val Asn Asp Lys Val Ala Tyr Tyr His Asp Tyr Ser Lys Asp Gly 85 90 95 Lys Thr Ala Val Asp Gln Glu His Gly Thr His Val Ser Gly Ile Leu 100 105 110 Ser Gly Asn Ala Pro Ser Glu Thr Lys Glu Pro Tyr Arg Leu Glu Gly 115 120 125 Ala Met Pro Glu Ala Gln Leu Leu Leu Met Arg Val Glu Ile Val Asn 130 135 140 Gly Leu Ala Asp Tyr Ala Arg Asn Tyr Ala Gln Ala Ile Arg Asp Ala 145 150 155 160 Val Asn Leu Gly Ala Lys Val Ile Asn Met Ser Phe Gly Asn Ala Ala 165 170 175 Leu Ala Tyr Ala Asn Leu Pro Asp Glu Thr Lys Lys Ala Phe Asp Tyr 180 185 190 Ala Lys Ser Lys Gly Val Ser Ile Val Thr Ser Ala Gly Asn Asp Ser 195 200 205 Ser Phe Gly Gly Lys Thr Arg Leu Pro Leu Ala Asp His Pro Asp Tyr 210 215 220 Gly Val Val Gly Thr Pro Ala Ala Ala Asp Ser Thr Leu Thr Val Ala 225 230 235 240 Ser Tyr Ser Pro Asp Lys Gln Leu Thr Glu Thr Ala Thr Val Lys Thr 245 250 255 Ala Asp Lys Gln Asp Lys Glu Met Pro Val Leu Ser Thr Asn Arg Phe 260 265 270 Glu Pro Asn Lys Ala Tyr Asp Tyr Ala Tyr Ala Asn Arg Gly Met Lys 275 280 285 Glu Asp Asp Phe Lys Asp Val Lys Gly Lys Ile Ala Leu Ile Glu Arg 290 295 300 Gly Asp Ile Asp Phe Lys Asp Lys Ile Ala Asn Ala Lys Lys Ala Gly 305 310 315 320 Ala Val Gly Val Leu Ile Tyr Asp Asn Gln Asp Lys Gly Phe Pro Ile 325 330 335 Glu Leu Pro Asn Val Asp Gln Met Pro Ala Ala Phe Ile Ser Arg Lys 340 345 350 Asp Gly Leu Leu Leu Lys Asp Asn Pro Lys Lys Thr Ile Thr Phe Asn 355 360 365 Ala Thr Pro Lys Val Leu Pro Thr Ala Ser Gly Thr Lys Leu Ser Arg 370 375 380 Phe Ser Ser Trp Gly Leu Thr Ala Asp Gly Asn Ile Lys Pro Asp Ile 385 390 395 400 Ala Ala Pro Gly Gln Asp Ile Leu Ser Ser Val Ala Asn Asn Lys Tyr 405 410 415 Ala Lys Leu Ser Gly Thr Ser Met Ser Ala Pro Leu Val Ala Gly Ile 420 425 430 Met Gly Leu Leu Gln Lys Gln Tyr Glu Thr Gln Tyr Pro Asp Met Thr 435 440 445 Pro Ser Glu Arg Leu Asp Leu Ala Lys Lys Val Leu Met Ser Ser Ala 450 455 460 Thr Ala Leu Tyr Asp Glu Asp Glu Lys Ala Tyr Phe Ser Pro Arg Gln 465 470 475 480 Gln Gly Ala Gly Ala Val Asp Ala Lys Lys Ala Ser Ala Ala Thr Met 485 490 495 Tyr Val Thr Asp Lys Asp Asn Thr Ser Ser Lys Val His Leu Asn Asn 500 505 510 Val Ser Asp Thr Phe Glu Val Thr Val Thr Val His Asn Lys Ser Asp 515 520 525 Lys Pro Gln Glu Leu Tyr Tyr Gln Ala Thr Val Gln Thr Asp Lys Val 530 535 540 Asp Gly Lys His Phe Ala Leu Ala Pro Lys Ala Leu Tyr Glu Thr Ser 545 550 555 560 Trp Gln Lys Ile Thr Ile Pro Ala Asn Ser Ser Lys Gln Val Thr Val 565 570 575 Pro Ile Asp Ala Ser Arg Phe Ser Lys Asp Leu Leu Ala Gln Met Lys 580 585 590 Asn Gly Tyr Phe Leu Glu Gly Phe Val Arg Phe Lys Gln Asp Pro Thr 595 600 605 Lys Glu Glu Leu Met Ser Ile Pro Tyr Ile Gly Phe Arg Gly Asp Phe 610 615 620 Gly Asn Leu Ser Ala Leu Glu Lys Pro Ile Tyr Asp Ser Lys Asp Gly 625 630 635 640 Ser Ser Tyr Tyr His Glu Ala Asn Ser Asp Ala Lys Asp Gln Leu Asp 645 650 655 Gly Asp Gly Leu Gln Phe Tyr Ala Leu Lys Asn Asn Phe Thr Ala Leu 660 665 670 Thr Thr Glu Ser Asn Pro Trp Thr Ile Ile Lys Ala Val Lys Glu Gly 675 680 685 Val Glu Asn Ile Glu Asp Ile Glu Ser Ser Glu Ile Thr Glu Thr Ile 690 695 700 Phe Ala Gly Thr Phe Ala Lys Gln Asp Asp Asp Ser His Tyr Tyr Ile 705 710 715 720 His Arg His Ala Asn Gly Lys Pro Tyr Ala Ala Ile Ser Pro Asn Gly 725 730 735 Asp Gly Asn Arg Asp Tyr Val Gln Phe Gln Gly Thr Phe Leu Arg Asn 740 745 750 Ala Lys Asn Leu Val Ala Glu Val Leu Asp Lys Glu Gly Asn Val Val 755 760 765 Trp Thr Ser Glu Val Thr Glu Gln Val Val Lys Asn Tyr Asn Asn Asp 770 775 780 Leu Ala Ser Thr Leu Gly Ser Thr Arg Phe Glu Lys Thr Arg Trp Asp 785 790 795 800 Gly Lys Asp Lys Asp Gly Lys Val Val Ala Asn Gly Thr Tyr Thr Tyr 805 810 815 Arg Val Arg Tyr Thr Pro Ile Ser Ser Gly Ala Lys Glu Gln His Thr 820 825 830 Asp Phe Asp Val Ile Val Asp Asn Thr Thr Pro Glu Val Ala Thr Ser 835 840 845 Ala Thr Phe Ser Thr Glu Asp Arg Arg Leu Thr Leu Ala Ser Lys Pro 850 855 860 Lys Thr Ser Gln Pro Val Tyr Arg Glu Arg Ile Ala Tyr Thr Tyr Met 865 870 875 880 Asp Glu Asp Leu Pro Thr Thr Glu Tyr Ile Ser Pro Asn Glu Asp Gly 885 890 895 Thr Phe Thr Leu Pro Glu Glu Ala Glu Thr Met Glu Gly Ala Thr Val 900 905 910 Pro Leu Lys Met Ser Asp Phe Thr Tyr Val Val Glu Asp Met Ala Gly 915 920 925 Asn Ile Thr Tyr Thr Pro Val Thr Lys Leu Leu Glu Gly His Ser Asn 930 935 940 Lys 945 <![CDATA[<210> 3]]> <![CDATA[<211> 962]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> C5a [90-1035片段] D131A/S513A突變體,具有前導序列]]> <![CDATA[<400> 3]]> Met His His His His His His Gly Ser Gly Glu Asn Leu Tyr Phe Gln 1 5 10 15 Gly Lys Thr Ala Asp Thr Pro Val Thr Ser Lys Ala Thr Ile Arg Asp 20 25 30 Leu Asn Asp Pro Ser Gln Val Lys Thr Leu Gln Glu Lys Ala Gly Lys 35 40 45 Gly Ala Gly Thr Val Val Ala Val Ile Ala Ala Gly Phe Asp Lys Asn 50 55 60 His Glu Ala Trp Arg Leu Thr Asp Lys Thr Lys Ala Arg Tyr Gln Ser 65 70 75 80 Lys Glu Asp Leu Glu Lys Ala Lys Lys Glu His Gly Ile Thr Tyr Gly 85 90 95 Glu Trp Val Asn Asp Lys Val Ala Tyr Tyr His Asp Tyr Ser Lys Asp 100 105 110 Gly Lys Thr Ala Val Asp Gln Glu His Gly Thr His Val Ser Gly Ile 115 120 125 Leu Ser Gly Asn Ala Pro Ser Glu Thr Lys Glu Pro Tyr Arg Leu Glu 130 135 140 Gly Ala Met Pro Glu Ala Gln Leu Leu Leu Met Arg Val Glu Ile Val 145 150 155 160 Asn Gly Leu Ala Asp Tyr Ala Arg Asn Tyr Ala Gln Ala Ile Arg Asp 165 170 175 Ala Val Asn Leu Gly Ala Lys Val Ile Asn Met Ser Phe Gly Asn Ala 180 185 190 Ala Leu Ala Tyr Ala Asn Leu Pro Asp Glu Thr Lys Lys Ala Phe Asp 195 200 205 Tyr Ala Lys Ser Lys Gly Val Ser Ile Val Thr Ser Ala Gly Asn Asp 210 215 220 Ser Ser Phe Gly Gly Lys Thr Arg Leu Pro Leu Ala Asp His Pro Asp 225 230 235 240 Tyr Gly Val Val Gly Thr Pro Ala Ala Ala Asp Ser Thr Leu Thr Val 245 250 255 Ala Ser Tyr Ser Pro Asp Lys Gln Leu Thr Glu Thr Ala Thr Val Lys 260 265 270 Thr Ala Asp Lys Gln Asp Lys Glu Met Pro Val Leu Ser Thr Asn Arg 275 280 285 Phe Glu Pro Asn Lys Ala Tyr Asp Tyr Ala Tyr Ala Asn Arg Gly Met 290 295 300 Lys Glu Asp Asp Phe Lys Asp Val Lys Gly Lys Ile Ala Leu Ile Glu 305 310 315 320 Arg Gly Asp Ile Asp Phe Lys Asp Lys Ile Ala Asn Ala Lys Lys Ala 325 330 335 Gly Ala Val Gly Val Leu Ile Tyr Asp Asn Gln Asp Lys Gly Phe Pro 340 345 350 Ile Glu Leu Pro Asn Val Asp Gln Met Pro Ala Ala Phe Ile Ser Arg 355 360 365 Lys Asp Gly Leu Leu Leu Lys Asp Asn Pro Lys Lys Thr Ile Thr Phe 370 375 380 Asn Ala Thr Pro Lys Val Leu Pro Thr Ala Ser Gly Thr Lys Leu Ser 385 390 395 400 Arg Phe Ser Ser Trp Gly Leu Thr Ala Asp Gly Asn Ile Lys Pro Asp 405 410 415 Ile Ala Ala Pro Gly Gln Asp Ile Leu Ser Ser Val Ala Asn Asn Lys 420 425 430 Tyr Ala Lys Leu Ser Gly Thr Ala Met Ser Ala Pro Leu Val Ala Gly 435 440 445 Ile Met Gly Leu Leu Gln Lys Gln Tyr Glu Thr Gln Tyr Pro Asp Met 450 455 460 Thr Pro Ser Glu Arg Leu Asp Leu Ala Lys Lys Val Leu Met Ser Ser 465 470 475 480 Ala Thr Ala Leu Tyr Asp Glu Asp Glu Lys Ala Tyr Phe Ser Pro Arg 485 490 495 Gln Gln Gly Ala Gly Ala Val Asp Ala Lys Lys Ala Ser Ala Ala Thr 500 505 510 Met Tyr Val Thr Asp Lys Asp Asn Thr Ser Ser Lys Val His Leu Asn 515 520 525 Asn Val Ser Asp Thr Phe Glu Val Thr Val Thr Val His Asn Lys Ser 530 535 540 Asp Lys Pro Gln Glu Leu Tyr Tyr Gln Ala Thr Val Gln Thr Asp Lys 545 550 555 560 Val Asp Gly Lys His Phe Ala Leu Ala Pro Lys Ala Leu Tyr Glu Thr 565 570 575 Ser Trp Gln Lys Ile Thr Ile Pro Ala Asn Ser Ser Lys Gln Val Thr 580 585 590 Val Pro Ile Asp Ala Ser Arg Phe Ser Lys Asp Leu Leu Ala Gln Met 595 600 605 Lys Asn Gly Tyr Phe Leu Glu Gly Phe Val Arg Phe Lys Gln Asp Pro 610 615 620 Thr Lys Glu Glu Leu Met Ser Ile Pro Tyr Ile Gly Phe Arg Gly Asp 625 630 635 640 Phe Gly Asn Leu Ser Ala Leu Glu Lys Pro Ile Tyr Asp Ser Lys Asp 645 650 655 Gly Ser Ser Tyr Tyr His Glu Ala Asn Ser Asp Ala Lys Asp Gln Leu 660 665 670 Asp Gly Asp Gly Leu Gln Phe Tyr Ala Leu Lys Asn Asn Phe Thr Ala 675 680 685 Leu Thr Thr Glu Ser Asn Pro Trp Thr Ile Ile Lys Ala Val Lys Glu 690 695 700 Gly Val Glu Asn Ile Glu Asp Ile Glu Ser Ser Glu Ile Thr Glu Thr 705 710 715 720 Ile Phe Ala Gly Thr Phe Ala Lys Gln Asp Asp Asp Ser His Tyr Tyr 725 730 735 Ile His Arg His Ala Asn Gly Lys Pro Tyr Ala Ala Ile Ser Pro Asn 740 745 750 Gly Asp Gly Asn Arg Asp Tyr Val Gln Phe Gln Gly Thr Phe Leu Arg 755 760 765 Asn Ala Lys Asn Leu Val Ala Glu Val Leu Asp Lys Glu Gly Asn Val 770 775 780 Val Trp Thr Ser Glu Val Thr Glu Gln Val Val Lys Asn Tyr Asn Asn 785 790 795 800 Asp Leu Ala Ser Thr Leu Gly Ser Thr Arg Phe Glu Lys Thr Arg Trp 805 810 815 Asp Gly Lys Asp Lys Asp Gly Lys Val Val Ala Asn Gly Thr Tyr Thr 820 825 830 Tyr Arg Val Arg Tyr Thr Pro Ile Ser Ser Gly Ala Lys Glu Gln His 835 840 845 Thr Asp Phe Asp Val Ile Val Asp Asn Thr Thr Pro Glu Val Ala Thr 850 855 860 Ser Ala Thr Phe Ser Thr Glu Asp Arg Arg Leu Thr Leu Ala Ser Lys 865 870 875 880 Pro Lys Thr Ser Gln Pro Val Tyr Arg Glu Arg Ile Ala Tyr Thr Tyr 885 890 895 Met Asp Glu Asp Leu Pro Thr Thr Glu Tyr Ile Ser Pro Asn Glu Asp 900 905 910 Gly Thr Phe Thr Leu Pro Glu Glu Ala Glu Thr Met Glu Gly Ala Thr 915 920 925 Val Pro Leu Lys Met Ser Asp Phe Thr Tyr Val Val Glu Asp Met Ala 930 935 940 Gly Asn Ile Thr Tyr Thr Pro Val Thr Lys Leu Leu Glu Gly His Ser 945 950 955 960 Asn Lys <![CDATA[<210> 4]]> <![CDATA[<211> 945]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> C5a [90-1035片段] D131A/S513A突變體,不具有前導序列]]> <![CDATA[<400> 4]]> Lys Thr Ala Asp Thr Pro Val Thr Ser Lys Ala Thr Ile Arg Asp Leu 1 5 10 15 Asn Asp Pro Ser Gln Val Lys Thr Leu Gln Glu Lys Ala Gly Lys Gly 20 25 30 Ala Gly Thr Val Val Ala Val Ile Ala Ala Gly Phe Asp Lys Asn His 35 40 45 Glu Ala Trp Arg Leu Thr Asp Lys Thr Lys Ala Arg Tyr Gln Ser Lys 50 55 60 Glu Asp Leu Glu Lys Ala Lys Lys Glu His Gly Ile Thr Tyr Gly Glu 65 70 75 80 Trp Val Asn Asp Lys Val Ala Tyr Tyr His Asp Tyr Ser Lys Asp Gly 85 90 95 Lys Thr Ala Val Asp Gln Glu His Gly Thr His Val Ser Gly Ile Leu 100 105 110 Ser Gly Asn Ala Pro Ser Glu Thr Lys Glu Pro Tyr Arg Leu Glu Gly 115 120 125 Ala Met Pro Glu Ala Gln Leu Leu Leu Met Arg Val Glu Ile Val Asn 130 135 140 Gly Leu Ala Asp Tyr Ala Arg Asn Tyr Ala Gln Ala Ile Arg Asp Ala 145 150 155 160 Val Asn Leu Gly Ala Lys Val Ile Asn Met Ser Phe Gly Asn Ala Ala 165 170 175 Leu Ala Tyr Ala Asn Leu Pro Asp Glu Thr Lys Lys Ala Phe Asp Tyr 180 185 190 Ala Lys Ser Lys Gly Val Ser Ile Val Thr Ser Ala Gly Asn Asp Ser 195 200 205 Ser Phe Gly Gly Lys Thr Arg Leu Pro Leu Ala Asp His Pro Asp Tyr 210 215 220 Gly Val Val Gly Thr Pro Ala Ala Ala Asp Ser Thr Leu Thr Val Ala 225 230 235 240 Ser Tyr Ser Pro Asp Lys Gln Leu Thr Glu Thr Ala Thr Val Lys Thr 245 250 255 Ala Asp Lys Gln Asp Lys Glu Met Pro Val Leu Ser Thr Asn Arg Phe 260 265 270 Glu Pro Asn Lys Ala Tyr Asp Tyr Ala Tyr Ala Asn Arg Gly Met Lys 275 280 285 Glu Asp Asp Phe Lys Asp Val Lys Gly Lys Ile Ala Leu Ile Glu Arg 290 295 300 Gly Asp Ile Asp Phe Lys Asp Lys Ile Ala Asn Ala Lys Lys Ala Gly 305 310 315 320 Ala Val Gly Val Leu Ile Tyr Asp Asn Gln Asp Lys Gly Phe Pro Ile 325 330 335 Glu Leu Pro Asn Val Asp Gln Met Pro Ala Ala Phe Ile Ser Arg Lys 340 345 350 Asp Gly Leu Leu Leu Lys Asp Asn Pro Lys Lys Thr Ile Thr Phe Asn 355 360 365 Ala Thr Pro Lys Val Leu Pro Thr Ala Ser Gly Thr Lys Leu Ser Arg 370 375 380 Phe Ser Ser Trp Gly Leu Thr Ala Asp Gly Asn Ile Lys Pro Asp Ile 385 390 395 400 Ala Ala Pro Gly Gln Asp Ile Leu Ser Ser Val Ala Asn Asn Lys Tyr 405 410 415 Ala Lys Leu Ser Gly Thr Ala Met Ser Ala Pro Leu Val Ala Gly Ile 420 425 430 Met Gly Leu Leu Gln Lys Gln Tyr Glu Thr Gln Tyr Pro Asp Met Thr 435 440 445 Pro Ser Glu Arg Leu Asp Leu Ala Lys Lys Val Leu Met Ser Ser Ala 450 455 460 Thr Ala Leu Tyr Asp Glu Asp Glu Lys Ala Tyr Phe Ser Pro Arg Gln 465 470 475 480 Gln Gly Ala Gly Ala Val Asp Ala Lys Lys Ala Ser Ala Ala Thr Met 485 490 495 Tyr Val Thr Asp Lys Asp Asn Thr Ser Ser Lys Val His Leu Asn Asn 500 505 510 Val Ser Asp Thr Phe Glu Val Thr Val Thr Val His Asn Lys Ser Asp 515 520 525 Lys Pro Gln Glu Leu Tyr Tyr Gln Ala Thr Val Gln Thr Asp Lys Val 530 535 540 Asp Gly Lys His Phe Ala Leu Ala Pro Lys Ala Leu Tyr Glu Thr Ser 545 550 555 560 Trp Gln Lys Ile Thr Ile Pro Ala Asn Ser Ser Lys Gln Val Thr Val 565 570 575 Pro Ile Asp Ala Ser Arg Phe Ser Lys Asp Leu Leu Ala Gln Met Lys 580 585 590 Asn Gly Tyr Phe Leu Glu Gly Phe Val Arg Phe Lys Gln Asp Pro Thr 595 600 605 Lys Glu Glu Leu Met Ser Ile Pro Tyr Ile Gly Phe Arg Gly Asp Phe 610 615 620 Gly Asn Leu Ser Ala Leu Glu Lys Pro Ile Tyr Asp Ser Lys Asp Gly 625 630 635 640 Ser Ser Tyr Tyr His Glu Ala Asn Ser Asp Ala Lys Asp Gln Leu Asp 645 650 655 Gly Asp Gly Leu Gln Phe Tyr Ala Leu Lys Asn Asn Phe Thr Ala Leu 660 665 670 Thr Thr Glu Ser Asn Pro Trp Thr Ile Ile Lys Ala Val Lys Glu Gly 675 680 685 Val Glu Asn Ile Glu Asp Ile Glu Ser Ser Glu Ile Thr Glu Thr Ile 690 695 700 Phe Ala Gly Thr Phe Ala Lys Gln Asp Asp Asp Ser His Tyr Tyr Ile 705 710 715 720 His Arg His Ala Asn Gly Lys Pro Tyr Ala Ala Ile Ser Pro Asn Gly 725 730 735 Asp Gly Asn Arg Asp Tyr Val Gln Phe Gln Gly Thr Phe Leu Arg Asn 740 745 750 Ala Lys Asn Leu Val Ala Glu Val Leu Asp Lys Glu Gly Asn Val Val 755 760 765 Trp Thr Ser Glu Val Thr Glu Gln Val Val Lys Asn Tyr Asn Asn Asp 770 775 780 Leu Ala Ser Thr Leu Gly Ser Thr Arg Phe Glu Lys Thr Arg Trp Asp 785 790 795 800 Gly Lys Asp Lys Asp Gly Lys Val Val Ala Asn Gly Thr Tyr Thr Tyr 805 810 815 Arg Val Arg Tyr Thr Pro Ile Ser Ser Gly Ala Lys Glu Gln His Thr 820 825 830 Asp Phe Asp Val Ile Val Asp Asn Thr Thr Pro Glu Val Ala Thr Ser 835 840 845 Ala Thr Phe Ser Thr Glu Asp Arg Arg Leu Thr Leu Ala Ser Lys Pro 850 855 860 Lys Thr Ser Gln Pro Val Tyr Arg Glu Arg Ile Ala Tyr Thr Tyr Met 865 870 875 880 Asp Glu Asp Leu Pro Thr Thr Glu Tyr Ile Ser Pro Asn Glu Asp Gly 885 890 895 Thr Phe Thr Leu Pro Glu Glu Ala Glu Thr Met Glu Gly Ala Thr Val 900 905 910 Pro Leu Lys Met Ser Asp Phe Thr Tyr Val Val Glu Asp Met Ala Gly 915 920 925 Asn Ile Thr Tyr Thr Pro Val Thr Lys Leu Leu Glu Gly His Ser Asn 930 935 940 Lys 945 <![CDATA[<210> 5]]> <![CDATA[<211> 510]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO [79-571]片段,具有前導序列]]> <![CDATA[<400> 5]]> Met His His His His His His Gly Ser Gly Glu Asn Leu Tyr Phe Gln 1 5 10 15 Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 20 25 30 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 35 40 45 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 50 55 60 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 65 70 75 80 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 85 90 95 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 100 105 110 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 115 120 125 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 130 135 140 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 145 150 155 160 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 165 170 175 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 180 185 190 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 195 200 205 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 210 215 220 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 225 230 235 240 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 245 250 255 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 260 265 270 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 275 280 285 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 290 295 300 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 305 310 315 320 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 325 330 335 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 340 345 350 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 355 360 365 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 370 375 380 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 385 390 395 400 Ser Gly Lys Ile Asn Leu Ser His Gln Gly Ala Tyr Val Ala Gln Tyr 405 410 415 Glu Ile Leu Trp Asp Glu Ile Asn Tyr Asp Asp Lys Gly Lys Glu Val 420 425 430 Ile Thr Lys Arg Arg Trp Asp Asn Asn Trp Tyr Ser Lys Thr Ser Pro 435 440 445 Phe Ser Thr Val Ile Pro Leu Gly Ala Asn Ser Arg Asn Ile Arg Ile 450 455 460 Met Ala Arg Glu Cys Thr Gly Leu Ala Trp Glu Trp Trp Arg Lys Val 465 470 475 480 Ile Asp Glu Arg Asp Val Lys Leu Ser Lys Glu Ile Asn Val Asn Ile 485 490 495 Ser Gly Ser Thr Leu Ser Pro Tyr Gly Ser Ile Thr Tyr Lys 500 505 510 <![CDATA[<210> 6]]> <![CDATA[<211> 493]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 釀膿鏈球菌]]> <![CDATA[<400> 6]]> Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys Lys 1 5 10 15 Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile Asn 20 25 30 Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala Lys 35 40 45 Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys Lys 50 55 60 Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn Thr 65 70 75 80 Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr Tyr 85 90 95 Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys Pro 100 105 110 Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp Leu 115 120 125 Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr Tyr 130 135 140 Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His Asp 145 150 155 160 Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr Glu 165 170 175 Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val Asn 180 185 190 Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile Ser 195 200 205 Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe Tyr 210 215 220 Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp Lys 225 230 235 240 Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu Ala 245 250 255 Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe Val 260 265 270 Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe Ser 275 280 285 Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser Asp 290 295 300 Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp Ala 305 310 315 320 Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg Asn 325 330 335 Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr Pro 340 345 350 Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly Val 355 360 365 Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr Ser 370 375 380 Gly Lys Ile Asn Leu Ser His Gln Gly Ala Tyr Val Ala Gln Tyr Glu 385 390 395 400 Ile Leu Trp Asp Glu Ile Asn Tyr Asp Asp Lys Gly Lys Glu Val Ile 405 410 415 Thr Lys Arg Arg Trp Asp Asn Asn Trp Tyr Ser Lys Thr Ser Pro Phe 420 425 430 Ser Thr Val Ile Pro Leu Gly Ala Asn Ser Arg Asn Ile Arg Ile Met 435 440 445 Ala Arg Glu Cys Thr Gly Leu Ala Trp Glu Trp Trp Arg Lys Val Ile 450 455 460 Asp Glu Arg Asp Val Lys Leu Ser Lys Glu Ile Asn Val Asn Ile Ser 465 470 475 480 Gly Ser Thr Leu Ser Pro Tyr Gly Ser Ile Thr Tyr Lys 485 490 <![CDATA[<210> 7]]> <![CDATA[<211> 510]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO [79-571片段] - W535突變體,具有前導序列]]> <![CDATA[<400> 7]]> Met His His His His His His Gly Ser Gly Glu Asn Leu Tyr Phe Gln 1 5 10 15 Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 20 25 30 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 35 40 45 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 50 55 60 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 65 70 75 80 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 85 90 95 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 100 105 110 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 115 120 125 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 130 135 140 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 145 150 155 160 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 165 170 175 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 180 185 190 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 195 200 205 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 210 215 220 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 225 230 235 240 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 245 250 255 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 260 265 270 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 275 280 285 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 290 295 300 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 305 310 315 320 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 325 330 335 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 340 345 350 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 355 360 365 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 370 375 380 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 385 390 395 400 Ser Gly Lys Ile Asn Leu Ser His Gln Gly Ala Tyr Val Ala Gln Tyr 405 410 415 Glu Ile Leu Trp Asp Glu Ile Asn Tyr Asp Asp Lys Gly Lys Glu Val 420 425 430 Ile Thr Lys Arg Arg Trp Asp Asn Asn Trp Tyr Ser Lys Thr Ser Pro 435 440 445 Phe Ser Thr Val Ile Pro Leu Gly Ala Asn Ser Arg Asn Ile Arg Ile 450 455 460 Met Ala Arg Glu Cys Thr Gly Leu Ala Ala Glu Trp Trp Arg Lys Val 465 470 475 480 Ile Asp Glu Arg Asp Val Lys Leu Ser Lys Glu Ile Asn Val Asn Ile 485 490 495 Ser Gly Ser Thr Leu Ser Pro Tyr Gly Ser Ile Thr Tyr Lys 500 505 510 <![CDATA[<210> 8]]> <![CDATA[<211> 493]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO [79-571片段] - W535突變體,不具有前導序列]]> <![CDATA[<400> 8]]> Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys Lys 1 5 10 15 Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile Asn 20 25 30 Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala Lys 35 40 45 Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys Lys 50 55 60 Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn Thr 65 70 75 80 Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr Tyr 85 90 95 Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys Pro 100 105 110 Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp Leu 115 120 125 Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr Tyr 130 135 140 Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His Asp 145 150 155 160 Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr Glu 165 170 175 Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val Asn 180 185 190 Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile Ser 195 200 205 Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe Tyr 210 215 220 Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp Lys 225 230 235 240 Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu Ala 245 250 255 Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe Val 260 265 270 Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe Ser 275 280 285 Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser Asp 290 295 300 Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp Ala 305 310 315 320 Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg Asn 325 330 335 Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr Pro 340 345 350 Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly Val 355 360 365 Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr Ser 370 375 380 Gly Lys Ile Asn Leu Ser His Gln Gly Ala Tyr Val Ala Gln Tyr Glu 385 390 395 400 Ile Leu Trp Asp Glu Ile Asn Tyr Asp Asp Lys Gly Lys Glu Val Ile 405 410 415 Thr Lys Arg Arg Trp Asp Asn Asn Trp Tyr Ser Lys Thr Ser Pro Phe 420 425 430 Ser Thr Val Ile Pro Leu Gly Ala Asn Ser Arg Asn Ile Arg Ile Met 435 440 445 Ala Arg Glu Cys Thr Gly Leu Ala Ala Glu Trp Trp Arg Lys Val Ile 450 455 460 Asp Glu Arg Asp Val Lys Leu Ser Lys Glu Ile Asn Val Asn Ile Ser 465 470 475 480 Gly Ser Thr Leu Ser Pro Tyr Gly Ser Ile Thr Tyr Lys 485 490 <![CDATA[<210> 9]]> <![CDATA[<211> 834]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SpyAD [33-849片段] WT,具有前導序列]]> <![CDATA[<400> 9]]> Met His His His His His His Gly Ser Gly Glu Asn Leu Tyr Phe Gln 1 5 10 15 Gly Gln Val Lys Ala Asp Asp Arg Ala Ser Gly Glu Thr Lys Ala Ser 20 25 30 Asn Thr His Asp Asp Ser Leu Pro Lys Pro Glu Thr Ile Gln Glu Ala 35 40 45 Lys Ala Thr Ile Asp Ala Val Glu Lys Thr Leu Ser Gln Gln Lys Ala 50 55 60 Glu Leu Thr Glu Leu Ala Thr Ala Leu Thr Lys Thr Thr Ala Glu Ile 65 70 75 80 Asn His Leu Lys Glu Gln Gln Asp Asn Glu Gln Lys Ala Leu Thr Ser 85 90 95 Ala Gln Glu Ile Tyr Thr Asn Thr Leu Ala Ser Ser Glu Glu Thr Leu 100 105 110 Leu Ala Gln Gly Ala Glu His Gln Arg Glu Leu Thr Ala Thr Glu Thr 115 120 125 Glu Leu His Asn Ala Gln Ala Asp Gln His Ser Lys Glu Thr Ala Leu 130 135 140 Ser Glu Gln Lys Ala Ser Ile Ser Ala Glu Thr Thr Arg Ala Gln Asp 145 150 155 160 Leu Val Glu Gln Val Lys Thr Ser Glu Gln Asn Ile Ala Lys Leu Asn 165 170 175 Ala Met Ile Ser Asn Pro Asp Ala Ile Thr Lys Ala Ala Gln Thr Ala 180 185 190 Asn Asp Asn Thr Lys Ala Leu Ser Ser Glu Leu Glu Lys Ala Lys Ala 195 200 205 Asp Leu Glu Asn Gln Lys Ala Lys Val Lys Lys Gln Leu Thr Glu Glu 210 215 220 Leu Ala Ala Gln Lys Ala Ala Leu Ala Glu Lys Glu Ala Glu Leu Ser 225 230 235 240 Arg Leu Lys Ser Ser Ala Pro Ser Thr Gln Asp Ser Ile Val Gly Asn 245 250 255 Asn Thr Met Lys Ala Pro Gln Gly Tyr Pro Leu Glu Glu Leu Lys Lys 260 265 270 Leu Glu Ala Ser Gly Tyr Ile Gly Ser Ala Ser Tyr Asn Asn Tyr Tyr 275 280 285 Lys Glu His Ala Asp Gln Ile Ile Ala Lys Ala Ser Pro Gly Asn Gln 290 295 300 Leu Asn Gln Tyr Gln Asp Ile Pro Ala Asp Arg Asn Arg Phe Val Asp 305 310 315 320 Pro Asp Asn Leu Thr Pro Glu Val Gln Asn Glu Leu Ala Gln Phe Ala 325 330 335 Ala His Met Ile Asn Ser Val Arg Arg Gln Leu Gly Leu Pro Pro Val 340 345 350 Thr Val Thr Ala Gly Ser Gln Glu Phe Ala Arg Leu Leu Ser Thr Ser 355 360 365 Tyr Lys Lys Thr His Gly Asn Thr Arg Pro Ser Phe Val Tyr Gly Gln 370 375 380 Pro Gly Val Ser Gly His Tyr Gly Val Gly Pro His Asp Lys Thr Ile 385 390 395 400 Ile Glu Asp Ser Ala Gly Ala Ser Gly Leu Ile Arg Asn Asp Asp Asn 405 410 415 Met Tyr Glu Asn Ile Gly Ala Phe Asn Asp Val His Thr Val Asn Gly 420 425 430 Ile Lys Arg Gly Ile Tyr Asp Ser Ile Lys Tyr Met Leu Phe Thr Asp 435 440 445 His Leu His Gly Asn Thr Tyr Gly His Ala Ile Asn Phe Leu Arg Val 450 455 460 Asp Lys His Asn Pro Asn Ala Pro Val Tyr Leu Gly Phe Ser Thr Ser 465 470 475 480 Asn Val Gly Ser Leu Asn Glu His Phe Val Met Phe Pro Glu Ser Asn 485 490 495 Ile Ala Asn His Gln Arg Phe Asn Lys Thr Pro Ile Lys Ala Val Gly 500 505 510 Ser Thr Lys Asp Tyr Ala Gln Arg Val Gly Thr Val Ser Asp Thr Ile 515 520 525 Ala Ala Ile Lys Gly Lys Val Ser Ser Leu Glu Asn Arg Leu Ser Ala 530 535 540 Ile His Gln Glu Ala Asp Ile Met Ala Ala Gln Ala Lys Val Ser Gln 545 550 555 560 Leu Gln Gly Lys Leu Ala Ser Thr Leu Lys Gln Ser Asp Ser Leu Asn 565 570 575 Leu Gln Val Arg Gln Leu Asn Asp Thr Lys Gly Ser Leu Arg Thr Glu 580 585 590 Leu Leu Ala Ala Lys Ala Lys Gln Ala Gln Leu Glu Ala Thr Arg Asp 595 600 605 Gln Ser Leu Ala Lys Leu Ala Ser Leu Lys Ala Ala Leu His Gln Thr 610 615 620 Glu Ala Leu Ala Glu Gln Ala Ala Ala Arg Val Thr Ala Leu Val Ala 625 630 635 640 Lys Lys Ala His Leu Gln Tyr Leu Arg Asp Phe Lys Leu Asn Pro Asn 645 650 655 Arg Leu Gln Val Ile Arg Glu Arg Ile Asp Asn Thr Lys Gln Asp Leu 660 665 670 Ala Lys Thr Thr Ser Ser Leu Leu Asn Ala Gln Glu Ala Leu Ala Ala 675 680 685 Leu Gln Ala Lys Gln Ser Ser Leu Glu Ala Thr Ile Ala Thr Thr Glu 690 695 700 His Gln Leu Thr Leu Leu Lys Thr Leu Ala Asn Glu Lys Glu Tyr Arg 705 710 715 720 His Leu Asp Glu Asp Ile Ala Thr Val Pro Asp Leu Gln Val Ala Pro 725 730 735 Pro Leu Thr Gly Val Lys Pro Leu Ser Tyr Ser Lys Ile Asp Thr Thr 740 745 750 Pro Leu Val Gln Glu Met Val Lys Glu Thr Lys Gln Leu Leu Glu Ala 755 760 765 Ser Ala Arg Leu Ala Ala Glu Asn Thr Ser Leu Val Ala Glu Ala Leu 770 775 780 Val Gly Gln Thr Ser Glu Met Val Ala Ser Asn Ala Ile Val Ser Lys 785 790 795 800 Ile Thr Ser Ser Ile Thr Gln Pro Ser Ser Lys Thr Ser Tyr Gly Ser 805 810 815 Gly Ser Ser Thr Thr Ser Asn Leu Ile Ser Asp Val Asp Glu Ser Thr 820 825 830 Gln Arg <![CDATA[<210> 10]]> <![CDATA[<211> 817]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 釀膿鏈球菌]]> <![CDATA[<400> 10]]> Gln Val Lys Ala Asp Asp Arg Ala Ser Gly Glu Thr Lys Ala Ser Asn 1 5 10 15 Thr His Asp Asp Ser Leu Pro Lys Pro Glu Thr Ile Gln Glu Ala Lys 20 25 30 Ala Thr Ile Asp Ala Val Glu Lys Thr Leu Ser Gln Gln Lys Ala Glu 35 40 45 Leu Thr Glu Leu Ala Thr Ala Leu Thr Lys Thr Thr Ala Glu Ile Asn 50 55 60 His Leu Lys Glu Gln Gln Asp Asn Glu Gln Lys Ala Leu Thr Ser Ala 65 70 75 80 Gln Glu Ile Tyr Thr Asn Thr Leu Ala Ser Ser Glu Glu Thr Leu Leu 85 90 95 Ala Gln Gly Ala Glu His Gln Arg Glu Leu Thr Ala Thr Glu Thr Glu 100 105 110 Leu His Asn Ala Gln Ala Asp Gln His Ser Lys Glu Thr Ala Leu Ser 115 120 125 Glu Gln Lys Ala Ser Ile Ser Ala Glu Thr Thr Arg Ala Gln Asp Leu 130 135 140 Val Glu Gln Val Lys Thr Ser Glu Gln Asn Ile Ala Lys Leu Asn Ala 145 150 155 160 Met Ile Ser Asn Pro Asp Ala Ile Thr Lys Ala Ala Gln Thr Ala Asn 165 170 175 Asp Asn Thr Lys Ala Leu Ser Ser Glu Leu Glu Lys Ala Lys Ala Asp 180 185 190 Leu Glu Asn Gln Lys Ala Lys Val Lys Lys Gln Leu Thr Glu Glu Leu 195 200 205 Ala Ala Gln Lys Ala Ala Leu Ala Glu Lys Glu Ala Glu Leu Ser Arg 210 215 220 Leu Lys Ser Ser Ala Pro Ser Thr Gln Asp Ser Ile Val Gly Asn Asn 225 230 235 240 Thr Met Lys Ala Pro Gln Gly Tyr Pro Leu Glu Glu Leu Lys Lys Leu 245 250 255 Glu Ala Ser Gly Tyr Ile Gly Ser Ala Ser Tyr Asn Asn Tyr Tyr Lys 260 265 270 Glu His Ala Asp Gln Ile Ile Ala Lys Ala Ser Pro Gly Asn Gln Leu 275 280 285 Asn Gln Tyr Gln Asp Ile Pro Ala Asp Arg Asn Arg Phe Val Asp Pro 290 295 300 Asp Asn Leu Thr Pro Glu Val Gln Asn Glu Leu Ala Gln Phe Ala Ala 305 310 315 320 His Met Ile Asn Ser Val Arg Arg Gln Leu Gly Leu Pro Pro Val Thr 325 330 335 Val Thr Ala Gly Ser Gln Glu Phe Ala Arg Leu Leu Ser Thr Ser Tyr 340 345 350 Lys Lys Thr His Gly Asn Thr Arg Pro Ser Phe Val Tyr Gly Gln Pro 355 360 365 Gly Val Ser Gly His Tyr Gly Val Gly Pro His Asp Lys Thr Ile Ile 370 375 380 Glu Asp Ser Ala Gly Ala Ser Gly Leu Ile Arg Asn Asp Asp Asn Met 385 390 395 400 Tyr Glu Asn Ile Gly Ala Phe Asn Asp Val His Thr Val Asn Gly Ile 405 410 415 Lys Arg Gly Ile Tyr Asp Ser Ile Lys Tyr Met Leu Phe Thr Asp His 420 425 430 Leu His Gly Asn Thr Tyr Gly His Ala Ile Asn Phe Leu Arg Val Asp 435 440 445 Lys His Asn Pro Asn Ala Pro Val Tyr Leu Gly Phe Ser Thr Ser Asn 450 455 460 Val Gly Ser Leu Asn Glu His Phe Val Met Phe Pro Glu Ser Asn Ile 465 470 475 480 Ala Asn His Gln Arg Phe Asn Lys Thr Pro Ile Lys Ala Val Gly Ser 485 490 495 Thr Lys Asp Tyr Ala Gln Arg Val Gly Thr Val Ser Asp Thr Ile Ala 500 505 510 Ala Ile Lys Gly Lys Val Ser Ser Leu Glu Asn Arg Leu Ser Ala Ile 515 520 525 His Gln Glu Ala Asp Ile Met Ala Ala Gln Ala Lys Val Ser Gln Leu 530 535 540 Gln Gly Lys Leu Ala Ser Thr Leu Lys Gln Ser Asp Ser Leu Asn Leu 545 550 555 560 Gln Val Arg Gln Leu Asn Asp Thr Lys Gly Ser Leu Arg Thr Glu Leu 565 570 575 Leu Ala Ala Lys Ala Lys Gln Ala Gln Leu Glu Ala Thr Arg Asp Gln 580 585 590 Ser Leu Ala Lys Leu Ala Ser Leu Lys Ala Ala Leu His Gln Thr Glu 595 600 605 Ala Leu Ala Glu Gln Ala Ala Ala Arg Val Thr Ala Leu Val Ala Lys 610 615 620 Lys Ala His Leu Gln Tyr Leu Arg Asp Phe Lys Leu Asn Pro Asn Arg 625 630 635 640 Leu Gln Val Ile Arg Glu Arg Ile Asp Asn Thr Lys Gln Asp Leu Ala 645 650 655 Lys Thr Thr Ser Ser Leu Leu Asn Ala Gln Glu Ala Leu Ala Ala Leu 660 665 670 Gln Ala Lys Gln Ser Ser Leu Glu Ala Thr Ile Ala Thr Thr Glu His 675 680 685 Gln Leu Thr Leu Leu Lys Thr Leu Ala Asn Glu Lys Glu Tyr Arg His 690 695 700 Leu Asp Glu Asp Ile Ala Thr Val Pro Asp Leu Gln Val Ala Pro Pro 705 710 715 720 Leu Thr Gly Val Lys Pro Leu Ser Tyr Ser Lys Ile Asp Thr Thr Pro 725 730 735 Leu Val Gln Glu Met Val Lys Glu Thr Lys Gln Leu Leu Glu Ala Ser 740 745 750 Ala Arg Leu Ala Ala Glu Asn Thr Ser Leu Val Ala Glu Ala Leu Val 755 760 765 Gly Gln Thr Ser Glu Met Val Ala Ser Asn Ala Ile Val Ser Lys Ile 770 775 780 Thr Ser Ser Ile Thr Gln Pro Ser Ser Lys Thr Ser Tyr Gly Ser Gly 785 790 795 800 Ser Ser Thr Thr Ser Asn Leu Ile Ser Asp Val Asp Glu Ser Thr Gln 805 810 815 Arg <![CDATA[<210> 11]]> <![CDATA[<211> 834]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SpyAD [33-849片段] nnAA (例如pAMF) K64/K287/K386/K657突變體,具有前導序列]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (49)..(49)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (272)..(272)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (371)..(371)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (642)..(642)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 11]]> Met His His His His His His Gly Ser Gly Glu Asn Leu Tyr Phe Gln 1 5 10 15 Gly Gln Val Lys Ala Asp Asp Arg Ala Ser Gly Glu Thr Lys Ala Ser 20 25 30 Asn Thr His Asp Asp Ser Leu Pro Lys Pro Glu Thr Ile Gln Glu Ala 35 40 45 Xaa Ala Thr Ile Asp Ala Val Glu Lys Thr Leu Ser Gln Gln Lys Ala 50 55 60 Glu Leu Thr Glu Leu Ala Thr Ala Leu Thr Lys Thr Thr Ala Glu Ile 65 70 75 80 Asn His Leu Lys Glu Gln Gln Asp Asn Glu Gln Lys Ala Leu Thr Ser 85 90 95 Ala Gln Glu Ile Tyr Thr Asn Thr Leu Ala Ser Ser Glu Glu Thr Leu 100 105 110 Leu Ala Gln Gly Ala Glu His Gln Arg Glu Leu Thr Ala Thr Glu Thr 115 120 125 Glu Leu His Asn Ala Gln Ala Asp Gln His Ser Lys Glu Thr Ala Leu 130 135 140 Ser Glu Gln Lys Ala Ser Ile Ser Ala Glu Thr Thr Arg Ala Gln Asp 145 150 155 160 Leu Val Glu Gln Val Lys Thr Ser Glu Gln Asn Ile Ala Lys Leu Asn 165 170 175 Ala Met Ile Ser Asn Pro Asp Ala Ile Thr Lys Ala Ala Gln Thr Ala 180 185 190 Asn Asp Asn Thr Lys Ala Leu Ser Ser Glu Leu Glu Lys Ala Lys Ala 195 200 205 Asp Leu Glu Asn Gln Lys Ala Lys Val Lys Lys Gln Leu Thr Glu Glu 210 215 220 Leu Ala Ala Gln Lys Ala Ala Leu Ala Glu Lys Glu Ala Glu Leu Ser 225 230 235 240 Arg Leu Lys Ser Ser Ala Pro Ser Thr Gln Asp Ser Ile Val Gly Asn 245 250 255 Asn Thr Met Lys Ala Pro Gln Gly Tyr Pro Leu Glu Glu Leu Lys Xaa 260 265 270 Leu Glu Ala Ser Gly Tyr Ile Gly Ser Ala Ser Tyr Asn Asn Tyr Tyr 275 280 285 Lys Glu His Ala Asp Gln Ile Ile Ala Lys Ala Ser Pro Gly Asn Gln 290 295 300 Leu Asn Gln Tyr Gln Asp Ile Pro Ala Asp Arg Asn Arg Phe Val Asp 305 310 315 320 Pro Asp Asn Leu Thr Pro Glu Val Gln Asn Glu Leu Ala Gln Phe Ala 325 330 335 Ala His Met Ile Asn Ser Val Arg Arg Gln Leu Gly Leu Pro Pro Val 340 345 350 Thr Val Thr Ala Gly Ser Gln Glu Phe Ala Arg Leu Leu Ser Thr Ser 355 360 365 Tyr Lys Xaa Thr His Gly Asn Thr Arg Pro Ser Phe Val Tyr Gly Gln 370 375 380 Pro Gly Val Ser Gly His Tyr Gly Val Gly Pro His Asp Lys Thr Ile 385 390 395 400 Ile Glu Asp Ser Ala Gly Ala Ser Gly Leu Ile Arg Asn Asp Asp Asn 405 410 415 Met Tyr Glu Asn Ile Gly Ala Phe Asn Asp Val His Thr Val Asn Gly 420 425 430 Ile Lys Arg Gly Ile Tyr Asp Ser Ile Lys Tyr Met Leu Phe Thr Asp 435 440 445 His Leu His Gly Asn Thr Tyr Gly His Ala Ile Asn Phe Leu Arg Val 450 455 460 Asp Lys His Asn Pro Asn Ala Pro Val Tyr Leu Gly Phe Ser Thr Ser 465 470 475 480 Asn Val Gly Ser Leu Asn Glu His Phe Val Met Phe Pro Glu Ser Asn 485 490 495 Ile Ala Asn His Gln Arg Phe Asn Lys Thr Pro Ile Lys Ala Val Gly 500 505 510 Ser Thr Lys Asp Tyr Ala Gln Arg Val Gly Thr Val Ser Asp Thr Ile 515 520 525 Ala Ala Ile Lys Gly Lys Val Ser Ser Leu Glu Asn Arg Leu Ser Ala 530 535 540 Ile His Gln Glu Ala Asp Ile Met Ala Ala Gln Ala Lys Val Ser Gln 545 550 555 560 Leu Gln Gly Lys Leu Ala Ser Thr Leu Lys Gln Ser Asp Ser Leu Asn 565 570 575 Leu Gln Val Arg Gln Leu Asn Asp Thr Lys Gly Ser Leu Arg Thr Glu 580 585 590 Leu Leu Ala Ala Lys Ala Lys Gln Ala Gln Leu Glu Ala Thr Arg Asp 595 600 605 Gln Ser Leu Ala Lys Leu Ala Ser Leu Lys Ala Ala Leu His Gln Thr 610 615 620 Glu Ala Leu Ala Glu Gln Ala Ala Ala Arg Val Thr Ala Leu Val Ala 625 630 635 640 Lys Xaa Ala His Leu Gln Tyr Leu Arg Asp Phe Lys Leu Asn Pro Asn 645 650 655 Arg Leu Gln Val Ile Arg Glu Arg Ile Asp Asn Thr Lys Gln Asp Leu 660 665 670 Ala Lys Thr Thr Ser Ser Leu Leu Asn Ala Gln Glu Ala Leu Ala Ala 675 680 685 Leu Gln Ala Lys Gln Ser Ser Leu Glu Ala Thr Ile Ala Thr Thr Glu 690 695 700 His Gln Leu Thr Leu Leu Lys Thr Leu Ala Asn Glu Lys Glu Tyr Arg 705 710 715 720 His Leu Asp Glu Asp Ile Ala Thr Val Pro Asp Leu Gln Val Ala Pro 725 730 735 Pro Leu Thr Gly Val Lys Pro Leu Ser Tyr Ser Lys Ile Asp Thr Thr 740 745 750 Pro Leu Val Gln Glu Met Val Lys Glu Thr Lys Gln Leu Leu Glu Ala 755 760 765 Ser Ala Arg Leu Ala Ala Glu Asn Thr Ser Leu Val Ala Glu Ala Leu 770 775 780 Val Gly Gln Thr Ser Glu Met Val Ala Ser Asn Ala Ile Val Ser Lys 785 790 795 800 Ile Thr Ser Ser Ile Thr Gln Pro Ser Ser Lys Thr Ser Tyr Gly Ser 805 810 815 Gly Ser Ser Thr Thr Ser Asn Leu Ile Ser Asp Val Asp Glu Ser Thr 820 825 830 Gln Arg <![CDATA[<210> 12]]> <![CDATA[<211> 817]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SpyAD [33-849片段] nnAA (例如pAMF) K64/K287/K386/K657突變體,不具有前導序列]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (31)..(31)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> misc_feature]]> <![CDATA[<222> (32)..(32)]]> <![CDATA[<223> Xaa可為任何天然胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (255)..(255)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (354)..(354)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (625)..(625)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 12]]> Gln Val Lys Ala Asp Asp Arg Ala Ser Gly Glu Thr Lys Ala Ser Asn 1 5 10 15 Thr His Asp Asp Ser Leu Pro Lys Pro Glu Thr Ile Gln Glu Ala Xaa 20 25 30 Ala Thr Ile Asp Ala Val Glu Lys Thr Leu Ser Gln Gln Lys Ala Glu 35 40 45 Leu Thr Glu Leu Ala Thr Ala Leu Thr Lys Thr Thr Ala Glu Ile Asn 50 55 60 His Leu Lys Glu Gln Gln Asp Asn Glu Gln Lys Ala Leu Thr Ser Ala 65 70 75 80 Gln Glu Ile Tyr Thr Asn Thr Leu Ala Ser Ser Glu Glu Thr Leu Leu 85 90 95 Ala Gln Gly Ala Glu His Gln Arg Glu Leu Thr Ala Thr Glu Thr Glu 100 105 110 Leu His Asn Ala Gln Ala Asp Gln His Ser Lys Glu Thr Ala Leu Ser 115 120 125 Glu Gln Lys Ala Ser Ile Ser Ala Glu Thr Thr Arg Ala Gln Asp Leu 130 135 140 Val Glu Gln Val Lys Thr Ser Glu Gln Asn Ile Ala Lys Leu Asn Ala 145 150 155 160 Met Ile Ser Asn Pro Asp Ala Ile Thr Lys Ala Ala Gln Thr Ala Asn 165 170 175 Asp Asn Thr Lys Ala Leu Ser Ser Glu Leu Glu Lys Ala Lys Ala Asp 180 185 190 Leu Glu Asn Gln Lys Ala Lys Val Lys Lys Gln Leu Thr Glu Glu Leu 195 200 205 Ala Ala Gln Lys Ala Ala Leu Ala Glu Lys Glu Ala Glu Leu Ser Arg 210 215 220 Leu Lys Ser Ser Ala Pro Ser Thr Gln Asp Ser Ile Val Gly Asn Asn 225 230 235 240 Thr Met Lys Ala Pro Gln Gly Tyr Pro Leu Glu Glu Leu Lys Xaa Leu 245 250 255 Glu Ala Ser Gly Tyr Ile Gly Ser Ala Ser Tyr Asn Asn Tyr Tyr Lys 260 265 270 Glu His Ala Asp Gln Ile Ile Ala Lys Ala Ser Pro Gly Asn Gln Leu 275 280 285 Asn Gln Tyr Gln Asp Ile Pro Ala Asp Arg Asn Arg Phe Val Asp Pro 290 295 300 Asp Asn Leu Thr Pro Glu Val Gln Asn Glu Leu Ala Gln Phe Ala Ala 305 310 315 320 His Met Ile Asn Ser Val Arg Arg Gln Leu Gly Leu Pro Pro Val Thr 325 330 335 Val Thr Ala Gly Ser Gln Glu Phe Ala Arg Leu Leu Ser Thr Ser Tyr 340 345 350 Lys Xaa Thr His Gly Asn Thr Arg Pro Ser Phe Val Tyr Gly Gln Pro 355 360 365 Gly Val Ser Gly His Tyr Gly Val Gly Pro His Asp Lys Thr Ile Ile 370 375 380 Glu Asp Ser Ala Gly Ala Ser Gly Leu Ile Arg Asn Asp Asp Asn Met 385 390 395 400 Tyr Glu Asn Ile Gly Ala Phe Asn Asp Val His Thr Val Asn Gly Ile 405 410 415 Lys Arg Gly Ile Tyr Asp Ser Ile Lys Tyr Met Leu Phe Thr Asp His 420 425 430 Leu His Gly Asn Thr Tyr Gly His Ala Ile Asn Phe Leu Arg Val Asp 435 440 445 Lys His Asn Pro Asn Ala Pro Val Tyr Leu Gly Phe Ser Thr Ser Asn 450 455 460 Val Gly Ser Leu Asn Glu His Phe Val Met Phe Pro Glu Ser Asn Ile 465 470 475 480 Ala Asn His Gln Arg Phe Asn Lys Thr Pro Ile Lys Ala Val Gly Ser 485 490 495 Thr Lys Asp Tyr Ala Gln Arg Val Gly Thr Val Ser Asp Thr Ile Ala 500 505 510 Ala Ile Lys Gly Lys Val Ser Ser Leu Glu Asn Arg Leu Ser Ala Ile 515 520 525 His Gln Glu Ala Asp Ile Met Ala Ala Gln Ala Lys Val Ser Gln Leu 530 535 540 Gln Gly Lys Leu Ala Ser Thr Leu Lys Gln Ser Asp Ser Leu Asn Leu 545 550 555 560 Gln Val Arg Gln Leu Asn Asp Thr Lys Gly Ser Leu Arg Thr Glu Leu 565 570 575 Leu Ala Ala Lys Ala Lys Gln Ala Gln Leu Glu Ala Thr Arg Asp Gln 580 585 590 Ser Leu Ala Lys Leu Ala Ser Leu Lys Ala Ala Leu His Gln Thr Glu 595 600 605 Ala Leu Ala Glu Gln Ala Ala Ala Arg Val Thr Ala Leu Val Ala Lys 610 615 620 Xaa Ala His Leu Gln Tyr Leu Arg Asp Phe Lys Leu Asn Pro Asn Arg 625 630 635 640 Leu Gln Val Ile Arg Glu Arg Ile Asp Asn Thr Lys Gln Asp Leu Ala 645 650 655 Lys Thr Thr Ser Ser Leu Leu Asn Ala Gln Glu Ala Leu Ala Ala Leu 660 665 670 Gln Ala Lys Gln Ser Ser Leu Glu Ala Thr Ile Ala Thr Thr Glu His 675 680 685 Gln Leu Thr Leu Leu Lys Thr Leu Ala Asn Glu Lys Glu Tyr Arg His 690 695 700 Leu Asp Glu Asp Ile Ala Thr Val Pro Asp Leu Gln Val Ala Pro Pro 705 710 715 720 Leu Thr Gly Val Lys Pro Leu Ser Tyr Ser Lys Ile Asp Thr Thr Pro 725 730 735 Leu Val Gln Glu Met Val Lys Glu Thr Lys Gln Leu Leu Glu Ala Ser 740 745 750 Ala Arg Leu Ala Ala Glu Asn Thr Ser Leu Val Ala Glu Ala Leu Val 755 760 765 Gly Gln Thr Ser Glu Met Val Ala Ser Asn Ala Ile Val Ser Lys Ile 770 775 780 Thr Ser Ser Ile Thr Gln Pro Ser Ser Lys Thr Ser Tyr Gly Ser Gly 785 790 795 800 Ser Ser Thr Thr Ser Asn Leu Ile Ser Asp Val Asp Glu Ser Thr Gln 805 810 815 Arg <![CDATA[<210> 13]]> <![CDATA[<211> 427]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> ADI [全長] WT,具有前導序列]]> <![CDATA[<400> 13]]> Met His His His His His His Gly Ser Gly Glu Asn Leu Tyr Phe Gln 1 5 10 15 Gly Thr Ala Gln Thr Pro Ile His Val Tyr Ser Glu Ile Gly Lys Leu 20 25 30 Lys Lys Val Leu Leu His Arg Pro Gly Lys Glu Ile Glu Asn Leu Met 35 40 45 Pro Asp Tyr Leu Glu Arg Leu Leu Phe Asp Asp Ile Pro Phe Leu Glu 50 55 60 Asp Ala Gln Lys Glu His Asp Ala Phe Ala Gln Ala Leu Arg Asp Glu 65 70 75 80 Gly Ile Glu Val Leu Tyr Leu Glu Thr Leu Ala Ala Glu Ser Leu Val 85 90 95 Thr Pro Glu Ile Arg Glu Ala Phe Ile Asp Glu Tyr Leu Ser Glu Ala 100 105 110 Asn Ile Arg Gly Arg Ala Thr Lys Lys Ala Ile Arg Glu Leu Leu Met 115 120 125 Ala Ile Glu Asp Asn Gln Glu Leu Ile Glu Lys Thr Met Ala Gly Val 130 135 140 Gln Lys Ser Glu Leu Pro Glu Ile Pro Ala Ser Glu Lys Gly Leu Thr 145 150 155 160 Asp Leu Val Glu Ser Asn Tyr Pro Phe Ala Ile Asp Pro Met Pro Asn 165 170 175 Leu Tyr Phe Thr Arg Asp Pro Phe Ala Thr Ile Gly Thr Gly Val Ser 180 185 190 Leu Asn His Met Phe Ser Glu Thr Arg Asn Arg Glu Thr Leu Tyr Gly 195 200 205 Lys Tyr Ile Phe Thr His His Pro Ile Tyr Gly Gly Gly Lys Val Pro 210 215 220 Met Val Tyr Asp Arg Asn Glu Thr Thr Arg Ile Glu Gly Gly Asp Glu 225 230 235 240 Leu Val Leu Ser Lys Asp Val Leu Ala Val Gly Ile Ser Gln Arg Thr 245 250 255 Asp Ala Ala Ser Ile Glu Lys Leu Leu Val Asn Ile Phe Lys Gln Asn 260 265 270 Leu Gly Phe Lys Lys Val Leu Ala Phe Glu Phe Ala Asn Asn Arg Lys 275 280 285 Phe Met His Leu Asp Thr Val Phe Thr Met Val Asp Tyr Asp Lys Phe 290 295 300 Thr Ile His Pro Glu Ile Glu Gly Asp Leu Arg Val Tyr Ser Val Thr 305 310 315 320 Tyr Asp Asn Glu Glu Leu His Ile Val Glu Glu Lys Gly Asp Leu Ala 325 330 335 Glu Leu Leu Ala Ala Asn Leu Gly Val Glu Lys Val Asp Leu Ile Arg 340 345 350 Cys Gly Gly Asp Asn Leu Val Ala Ala Gly Arg Glu Gln Trp Asn Asp 355 360 365 Gly Ser Asn Thr Leu Thr Ile Ala Pro Gly Val Val Val Val Tyr Asn 370 375 380 Arg Asn Thr Ile Thr Asn Ala Ile Leu Glu Ser Lys Gly Leu Lys Leu 385 390 395 400 Ile Lys Ile His Gly Ser Glu Leu Val Arg Gly Arg Gly Gly Pro Arg 405 410 415 Cys Met Ser Met Pro Phe Glu Arg Glu Asp Ile 420 425 <![CDATA[<210> 14]]> <![CDATA[<211> 410]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 釀膿鏈球菌]]> <![CDATA[<400> 14]]> Thr Ala Gln Thr Pro Ile His Val Tyr Ser Glu Ile Gly Lys Leu Lys 1 5 10 15 Lys Val Leu Leu His Arg Pro Gly Lys Glu Ile Glu Asn Leu Met Pro 20 25 30 Asp Tyr Leu Glu Arg Leu Leu Phe Asp Asp Ile Pro Phe Leu Glu Asp 35 40 45 Ala Gln Lys Glu His Asp Ala Phe Ala Gln Ala Leu Arg Asp Glu Gly 50 55 60 Ile Glu Val Leu Tyr Leu Glu Thr Leu Ala Ala Glu Ser Leu Val Thr 65 70 75 80 Pro Glu Ile Arg Glu Ala Phe Ile Asp Glu Tyr Leu Ser Glu Ala Asn 85 90 95 Ile Arg Gly Arg Ala Thr Lys Lys Ala Ile Arg Glu Leu Leu Met Ala 100 105 110 Ile Glu Asp Asn Gln Glu Leu Ile Glu Lys Thr Met Ala Gly Val Gln 115 120 125 Lys Ser Glu Leu Pro Glu Ile Pro Ala Ser Glu Lys Gly Leu Thr Asp 130 135 140 Leu Val Glu Ser Asn Tyr Pro Phe Ala Ile Asp Pro Met Pro Asn Leu 145 150 155 160 Tyr Phe Thr Arg Asp Pro Phe Ala Thr Ile Gly Thr Gly Val Ser Leu 165 170 175 Asn His Met Phe Ser Glu Thr Arg Asn Arg Glu Thr Leu Tyr Gly Lys 180 185 190 Tyr Ile Phe Thr His His Pro Ile Tyr Gly Gly Gly Lys Val Pro Met 195 200 205 Val Tyr Asp Arg Asn Glu Thr Thr Arg Ile Glu Gly Gly Asp Glu Leu 210 215 220 Val Leu Ser Lys Asp Val Leu Ala Val Gly Ile Ser Gln Arg Thr Asp 225 230 235 240 Ala Ala Ser Ile Glu Lys Leu Leu Val Asn Ile Phe Lys Gln Asn Leu 245 250 255 Gly Phe Lys Lys Val Leu Ala Phe Glu Phe Ala Asn Asn Arg Lys Phe 260 265 270 Met His Leu Asp Thr Val Phe Thr Met Val Asp Tyr Asp Lys Phe Thr 275 280 285 Ile His Pro Glu Ile Glu Gly Asp Leu Arg Val Tyr Ser Val Thr Tyr 290 295 300 Asp Asn Glu Glu Leu His Ile Val Glu Glu Lys Gly Asp Leu Ala Glu 305 310 315 320 Leu Leu Ala Ala Asn Leu Gly Val Glu Lys Val Asp Leu Ile Arg Cys 325 330 335 Gly Gly Asp Asn Leu Val Ala Ala Gly Arg Glu Gln Trp Asn Asp Gly 340 345 350 Ser Asn Thr Leu Thr Ile Ala Pro Gly Val Val Val Val Tyr Asn Arg 355 360 365 Asn Thr Ile Thr Asn Ala Ile Leu Glu Ser Lys Gly Leu Lys Leu Ile 370 375 380 Lys Ile His Gly Ser Glu Leu Val Arg Gly Arg Gly Gly Pro Arg Cys 385 390 395 400 Met Ser Met Pro Phe Glu Arg Glu Asp Ile 405 410 <![CDATA[<210> 15]]> <![CDATA[<211> 427]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> ADI [全長] D277A突變體,具有前導序列]]> <![CDATA[<400> 15]]> Met His His His His His His Gly Ser Gly Glu Asn Leu Tyr Phe Gln 1 5 10 15 Gly Thr Ala Gln Thr Pro Ile His Val Tyr Ser Glu Ile Gly Lys Leu 20 25 30 Lys Lys Val Leu Leu His Arg Pro Gly Lys Glu Ile Glu Asn Leu Met 35 40 45 Pro Asp Tyr Leu Glu Arg Leu Leu Phe Asp Asp Ile Pro Phe Leu Glu 50 55 60 Asp Ala Gln Lys Glu His Asp Ala Phe Ala Gln Ala Leu Arg Asp Glu 65 70 75 80 Gly Ile Glu Val Leu Tyr Leu Glu Thr Leu Ala Ala Glu Ser Leu Val 85 90 95 Thr Pro Glu Ile Arg Glu Ala Phe Ile Asp Glu Tyr Leu Ser Glu Ala 100 105 110 Asn Ile Arg Gly Arg Ala Thr Lys Lys Ala Ile Arg Glu Leu Leu Met 115 120 125 Ala Ile Glu Asp Asn Gln Glu Leu Ile Glu Lys Thr Met Ala Gly Val 130 135 140 Gln Lys Ser Glu Leu Pro Glu Ile Pro Ala Ser Glu Lys Gly Leu Thr 145 150 155 160 Asp Leu Val Glu Ser Asn Tyr Pro Phe Ala Ile Asp Pro Met Pro Asn 165 170 175 Leu Tyr Phe Thr Arg Asp Pro Phe Ala Thr Ile Gly Thr Gly Val Ser 180 185 190 Leu Asn His Met Phe Ser Glu Thr Arg Asn Arg Glu Thr Leu Tyr Gly 195 200 205 Lys Tyr Ile Phe Thr His His Pro Ile Tyr Gly Gly Gly Lys Val Pro 210 215 220 Met Val Tyr Asp Arg Asn Glu Thr Thr Arg Ile Glu Gly Gly Asp Glu 225 230 235 240 Leu Val Leu Ser Lys Asp Val Leu Ala Val Gly Ile Ser Gln Arg Thr 245 250 255 Asp Ala Ala Ser Ile Glu Lys Leu Leu Val Asn Ile Phe Lys Gln Asn 260 265 270 Leu Gly Phe Lys Lys Val Leu Ala Phe Glu Phe Ala Asn Asn Arg Lys 275 280 285 Phe Met His Leu Ala Thr Val Phe Thr Met Val Asp Tyr Asp Lys Phe 290 295 300 Thr Ile His Pro Glu Ile Glu Gly Asp Leu Arg Val Tyr Ser Val Thr 305 310 315 320 Tyr Asp Asn Glu Glu Leu His Ile Val Glu Glu Lys Gly Asp Leu Ala 325 330 335 Glu Leu Leu Ala Ala Asn Leu Gly Val Glu Lys Val Asp Leu Ile Arg 340 345 350 Cys Gly Gly Asp Asn Leu Val Ala Ala Gly Arg Glu Gln Trp Asn Asp 355 360 365 Gly Ser Asn Thr Leu Thr Ile Ala Pro Gly Val Val Val Val Tyr Asn 370 375 380 Arg Asn Thr Ile Thr Asn Ala Ile Leu Glu Ser Lys Gly Leu Lys Leu 385 390 395 400 Ile Lys Ile His Gly Ser Glu Leu Val Arg Gly Arg Gly Gly Pro Arg 405 410 415 Cys Met Ser Met Pro Phe Glu Arg Glu Asp Ile 420 425 <![CDATA[<210> 16]]> <![CDATA[<211> 410]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> ADI [全長] D277A突變體,不具有前導序列]]> <![CDATA[<400> 16]]> Thr Ala Gln Thr Pro Ile His Val Tyr Ser Glu Ile Gly Lys Leu Lys 1 5 10 15 Lys Val Leu Leu His Arg Pro Gly Lys Glu Ile Glu Asn Leu Met Pro 20 25 30 Asp Tyr Leu Glu Arg Leu Leu Phe Asp Asp Ile Pro Phe Leu Glu Asp 35 40 45 Ala Gln Lys Glu His Asp Ala Phe Ala Gln Ala Leu Arg Asp Glu Gly 50 55 60 Ile Glu Val Leu Tyr Leu Glu Thr Leu Ala Ala Glu Ser Leu Val Thr 65 70 75 80 Pro Glu Ile Arg Glu Ala Phe Ile Asp Glu Tyr Leu Ser Glu Ala Asn 85 90 95 Ile Arg Gly Arg Ala Thr Lys Lys Ala Ile Arg Glu Leu Leu Met Ala 100 105 110 Ile Glu Asp Asn Gln Glu Leu Ile Glu Lys Thr Met Ala Gly Val Gln 115 120 125 Lys Ser Glu Leu Pro Glu Ile Pro Ala Ser Glu Lys Gly Leu Thr Asp 130 135 140 Leu Val Glu Ser Asn Tyr Pro Phe Ala Ile Asp Pro Met Pro Asn Leu 145 150 155 160 Tyr Phe Thr Arg Asp Pro Phe Ala Thr Ile Gly Thr Gly Val Ser Leu 165 170 175 Asn His Met Phe Ser Glu Thr Arg Asn Arg Glu Thr Leu Tyr Gly Lys 180 185 190 Tyr Ile Phe Thr His His Pro Ile Tyr Gly Gly Gly Lys Val Pro Met 195 200 205 Val Tyr Asp Arg Asn Glu Thr Thr Arg Ile Glu Gly Gly Asp Glu Leu 210 215 220 Val Leu Ser Lys Asp Val Leu Ala Val Gly Ile Ser Gln Arg Thr Asp 225 230 235 240 Ala Ala Ser Ile Glu Lys Leu Leu Val Asn Ile Phe Lys Gln Asn Leu 245 250 255 Gly Phe Lys Lys Val Leu Ala Phe Glu Phe Ala Asn Asn Arg Lys Phe 260 265 270 Met His Leu Ala Thr Val Phe Thr Met Val Asp Tyr Asp Lys Phe Thr 275 280 285 Ile His Pro Glu Ile Glu Gly Asp Leu Arg Val Tyr Ser Val Thr Tyr 290 295 300 Asp Asn Glu Glu Leu His Ile Val Glu Glu Lys Gly Asp Leu Ala Glu 305 310 315 320 Leu Leu Ala Ala Asn Leu Gly Val Glu Lys Val Asp Leu Ile Arg Cys 325 330 335 Gly Gly Asp Asn Leu Val Ala Ala Gly Arg Glu Gln Trp Asn Asp Gly 340 345 350 Ser Asn Thr Leu Thr Ile Ala Pro Gly Val Val Val Val Tyr Asn Arg 355 360 365 Asn Thr Ile Thr Asn Ala Ile Leu Glu Ser Lys Gly Leu Lys Leu Ile 370 375 380 Lys Ile His Gly Ser Glu Leu Val Arg Gly Arg Gly Gly Pro Arg Cys 385 390 395 400 Met Ser Met Pro Phe Glu Arg Glu Asp Ile 405 410 <![CDATA[<210> 17]]> <![CDATA[<211> 427]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> ADI [全長] WT nnAA (例如pAMF) K15/K193/K316,具有前導序列]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (31)..(31)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (209)..(209)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (332)..(332)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 17]]> Met His His His His His His Gly Ser Gly Glu Asn Leu Tyr Phe Gln 1 5 10 15 Gly Thr Ala Gln Thr Pro Ile His Val Tyr Ser Glu Ile Gly Xaa Leu 20 25 30 Lys Lys Val Leu Leu His Arg Pro Gly Lys Glu Ile Glu Asn Leu Met 35 40 45 Pro Asp Tyr Leu Glu Arg Leu Leu Phe Asp Asp Ile Pro Phe Leu Glu 50 55 60 Asp Ala Gln Lys Glu His Asp Ala Phe Ala Gln Ala Leu Arg Asp Glu 65 70 75 80 Gly Ile Glu Val Leu Tyr Leu Glu Thr Leu Ala Ala Glu Ser Leu Val 85 90 95 Thr Pro Glu Ile Arg Glu Ala Phe Ile Asp Glu Tyr Leu Ser Glu Ala 100 105 110 Asn Ile Arg Gly Arg Ala Thr Lys Lys Ala Ile Arg Glu Leu Leu Met 115 120 125 Ala Ile Glu Asp Asn Gln Glu Leu Ile Glu Lys Thr Met Ala Gly Val 130 135 140 Gln Lys Ser Glu Leu Pro Glu Ile Pro Ala Ser Glu Lys Gly Leu Thr 145 150 155 160 Asp Leu Val Glu Ser Asn Tyr Pro Phe Ala Ile Asp Pro Met Pro Asn 165 170 175 Leu Tyr Phe Thr Arg Asp Pro Phe Ala Thr Ile Gly Thr Gly Val Ser 180 185 190 Leu Asn His Met Phe Ser Glu Thr Arg Asn Arg Glu Thr Leu Tyr Gly 195 200 205 Xaa Tyr Ile Phe Thr His His Pro Ile Tyr Gly Gly Gly Lys Val Pro 210 215 220 Met Val Tyr Asp Arg Asn Glu Thr Thr Arg Ile Glu Gly Gly Asp Glu 225 230 235 240 Leu Val Leu Ser Lys Asp Val Leu Ala Val Gly Ile Ser Gln Arg Thr 245 250 255 Asp Ala Ala Ser Ile Glu Lys Leu Leu Val Asn Ile Phe Lys Gln Asn 260 265 270 Leu Gly Phe Lys Lys Val Leu Ala Phe Glu Phe Ala Asn Asn Arg Lys 275 280 285 Phe Met His Leu Asp Thr Val Phe Thr Met Val Asp Tyr Asp Lys Phe 290 295 300 Thr Ile His Pro Glu Ile Glu Gly Asp Leu Arg Val Tyr Ser Val Thr 305 310 315 320 Tyr Asp Asn Glu Glu Leu His Ile Val Glu Glu Xaa Gly Asp Leu Ala 325 330 335 Glu Leu Leu Ala Ala Asn Leu Gly Val Glu Lys Val Asp Leu Ile Arg 340 345 350 Cys Gly Gly Asp Asn Leu Val Ala Ala Gly Arg Glu Gln Trp Asn Asp 355 360 365 Gly Ser Asn Thr Leu Thr Ile Ala Pro Gly Val Val Val Val Tyr Asn 370 375 380 Arg Asn Thr Ile Thr Asn Ala Ile Leu Glu Ser Lys Gly Leu Lys Leu 385 390 395 400 Ile Lys Ile His Gly Ser Glu Leu Val Arg Gly Arg Gly Gly Pro Arg 405 410 415 Cys Met Ser Met Pro Phe Glu Arg Glu Asp Ile 420 425 <![CDATA[<210> 18]]> <![CDATA[<211> 410]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> ADI [全長] WT nnAA (例如pAMF) K15/K193/K316,不具有前導序列]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (14)..(14)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (192)..(192)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (315)..(315)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 18]]> Thr Ala Gln Thr Pro Ile His Val Tyr Ser Glu Ile Gly Xaa Leu Lys 1 5 10 15 Lys Val Leu Leu His Arg Pro Gly Lys Glu Ile Glu Asn Leu Met Pro 20 25 30 Asp Tyr Leu Glu Arg Leu Leu Phe Asp Asp Ile Pro Phe Leu Glu Asp 35 40 45 Ala Gln Lys Glu His Asp Ala Phe Ala Gln Ala Leu Arg Asp Glu Gly 50 55 60 Ile Glu Val Leu Tyr Leu Glu Thr Leu Ala Ala Glu Ser Leu Val Thr 65 70 75 80 Pro Glu Ile Arg Glu Ala Phe Ile Asp Glu Tyr Leu Ser Glu Ala Asn 85 90 95 Ile Arg Gly Arg Ala Thr Lys Lys Ala Ile Arg Glu Leu Leu Met Ala 100 105 110 Ile Glu Asp Asn Gln Glu Leu Ile Glu Lys Thr Met Ala Gly Val Gln 115 120 125 Lys Ser Glu Leu Pro Glu Ile Pro Ala Ser Glu Lys Gly Leu Thr Asp 130 135 140 Leu Val Glu Ser Asn Tyr Pro Phe Ala Ile Asp Pro Met Pro Asn Leu 145 150 155 160 Tyr Phe Thr Arg Asp Pro Phe Ala Thr Ile Gly Thr Gly Val Ser Leu 165 170 175 Asn His Met Phe Ser Glu Thr Arg Asn Arg Glu Thr Leu Tyr Gly Xaa 180 185 190 Tyr Ile Phe Thr His His Pro Ile Tyr Gly Gly Gly Lys Val Pro Met 195 200 205 Val Tyr Asp Arg Asn Glu Thr Thr Arg Ile Glu Gly Gly Asp Glu Leu 210 215 220 Val Leu Ser Lys Asp Val Leu Ala Val Gly Ile Ser Gln Arg Thr Asp 225 230 235 240 Ala Ala Ser Ile Glu Lys Leu Leu Val Asn Ile Phe Lys Gln Asn Leu 245 250 255 Gly Phe Lys Lys Val Leu Ala Phe Glu Phe Ala Asn Asn Arg Lys Phe 260 265 270 Met His Leu Asp Thr Val Phe Thr Met Val Asp Tyr Asp Lys Phe Thr 275 280 285 Ile His Pro Glu Ile Glu Gly Asp Leu Arg Val Tyr Ser Val Thr Tyr 290 295 300 Asp Asn Glu Glu Leu His Ile Val Glu Glu Xaa Gly Asp Leu Ala Glu 305 310 315 320 Leu Leu Ala Ala Asn Leu Gly Val Glu Lys Val Asp Leu Ile Arg Cys 325 330 335 Gly Gly Asp Asn Leu Val Ala Ala Gly Arg Glu Gln Trp Asn Asp Gly 340 345 350 Ser Asn Thr Leu Thr Ile Ala Pro Gly Val Val Val Val Tyr Asn Arg 355 360 365 Asn Thr Ile Thr Asn Ala Ile Leu Glu Ser Lys Gly Leu Lys Leu Ile 370 375 380 Lys Ile His Gly Ser Glu Leu Val Arg Gly Arg Gly Gly Pro Arg Cys 385 390 395 400 Met Ser Met Pro Phe Glu Arg Glu Asp Ile 405 410 <![CDATA[<210> 19]]> <![CDATA[<211> 427]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> ADI [全長] D277A nnAA (例如pAMF) K15/K193/K316,具有前導序列]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (31)..(31)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (209)..(209)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (332)..(332)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 19]]> Met His His His His His His Gly Ser Gly Glu Asn Leu Tyr Phe Gln 1 5 10 15 Gly Thr Ala Gln Thr Pro Ile His Val Tyr Ser Glu Ile Gly Xaa Leu 20 25 30 Lys Lys Val Leu Leu His Arg Pro Gly Lys Glu Ile Glu Asn Leu Met 35 40 45 Pro Asp Tyr Leu Glu Arg Leu Leu Phe Asp Asp Ile Pro Phe Leu Glu 50 55 60 Asp Ala Gln Lys Glu His Asp Ala Phe Ala Gln Ala Leu Arg Asp Glu 65 70 75 80 Gly Ile Glu Val Leu Tyr Leu Glu Thr Leu Ala Ala Glu Ser Leu Val 85 90 95 Thr Pro Glu Ile Arg Glu Ala Phe Ile Asp Glu Tyr Leu Ser Glu Ala 100 105 110 Asn Ile Arg Gly Arg Ala Thr Lys Lys Ala Ile Arg Glu Leu Leu Met 115 120 125 Ala Ile Glu Asp Asn Gln Glu Leu Ile Glu Lys Thr Met Ala Gly Val 130 135 140 Gln Lys Ser Glu Leu Pro Glu Ile Pro Ala Ser Glu Lys Gly Leu Thr 145 150 155 160 Asp Leu Val Glu Ser Asn Tyr Pro Phe Ala Ile Asp Pro Met Pro Asn 165 170 175 Leu Tyr Phe Thr Arg Asp Pro Phe Ala Thr Ile Gly Thr Gly Val Ser 180 185 190 Leu Asn His Met Phe Ser Glu Thr Arg Asn Arg Glu Thr Leu Tyr Gly 195 200 205 Xaa Tyr Ile Phe Thr His His Pro Ile Tyr Gly Gly Gly Lys Val Pro 210 215 220 Met Val Tyr Asp Arg Asn Glu Thr Thr Arg Ile Glu Gly Gly Asp Glu 225 230 235 240 Leu Val Leu Ser Lys Asp Val Leu Ala Val Gly Ile Ser Gln Arg Thr 245 250 255 Asp Ala Ala Ser Ile Glu Lys Leu Leu Val Asn Ile Phe Lys Gln Asn 260 265 270 Leu Gly Phe Lys Lys Val Leu Ala Phe Glu Phe Ala Asn Asn Arg Lys 275 280 285 Phe Met His Leu Ala Thr Val Phe Thr Met Val Asp Tyr Asp Lys Phe 290 295 300 Thr Ile His Pro Glu Ile Glu Gly Asp Leu Arg Val Tyr Ser Val Thr 305 310 315 320 Tyr Asp Asn Glu Glu Leu His Ile Val Glu Glu Xaa Gly Asp Leu Ala 325 330 335 Glu Leu Leu Ala Ala Asn Leu Gly Val Glu Lys Val Asp Leu Ile Arg 340 345 350 Cys Gly Gly Asp Asn Leu Val Ala Ala Gly Arg Glu Gln Trp Asn Asp 355 360 365 Gly Ser Asn Thr Leu Thr Ile Ala Pro Gly Val Val Val Val Tyr Asn 370 375 380 Arg Asn Thr Ile Thr Asn Ala Ile Leu Glu Ser Lys Gly Leu Lys Leu 385 390 395 400 Ile Lys Ile His Gly Ser Glu Leu Val Arg Gly Arg Gly Gly Pro Arg 405 410 415 Cys Met Ser Met Pro Phe Glu Arg Glu Asp Ile 420 425 <![CDATA[<210> 20]]> <![CDATA[<211> 410]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> ADI [全長] D277A nnAA (例如pAMF) K15/K193/K316,不具有前導序列]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (14)..(14)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (192)..(192)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (315)..(315)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 20]]> Thr Ala Gln Thr Pro Ile His Val Tyr Ser Glu Ile Gly Xaa Leu Lys 1 5 10 15 Lys Val Leu Leu His Arg Pro Gly Lys Glu Ile Glu Asn Leu Met Pro 20 25 30 Asp Tyr Leu Glu Arg Leu Leu Phe Asp Asp Ile Pro Phe Leu Glu Asp 35 40 45 Ala Gln Lys Glu His Asp Ala Phe Ala Gln Ala Leu Arg Asp Glu Gly 50 55 60 Ile Glu Val Leu Tyr Leu Glu Thr Leu Ala Ala Glu Ser Leu Val Thr 65 70 75 80 Pro Glu Ile Arg Glu Ala Phe Ile Asp Glu Tyr Leu Ser Glu Ala Asn 85 90 95 Ile Arg Gly Arg Ala Thr Lys Lys Ala Ile Arg Glu Leu Leu Met Ala 100 105 110 Ile Glu Asp Asn Gln Glu Leu Ile Glu Lys Thr Met Ala Gly Val Gln 115 120 125 Lys Ser Glu Leu Pro Glu Ile Pro Ala Ser Glu Lys Gly Leu Thr Asp 130 135 140 Leu Val Glu Ser Asn Tyr Pro Phe Ala Ile Asp Pro Met Pro Asn Leu 145 150 155 160 Tyr Phe Thr Arg Asp Pro Phe Ala Thr Ile Gly Thr Gly Val Ser Leu 165 170 175 Asn His Met Phe Ser Glu Thr Arg Asn Arg Glu Thr Leu Tyr Gly Xaa 180 185 190 Tyr Ile Phe Thr His His Pro Ile Tyr Gly Gly Gly Lys Val Pro Met 195 200 205 Val Tyr Asp Arg Asn Glu Thr Thr Arg Ile Glu Gly Gly Asp Glu Leu 210 215 220 Val Leu Ser Lys Asp Val Leu Ala Val Gly Ile Ser Gln Arg Thr Asp 225 230 235 240 Ala Ala Ser Ile Glu Lys Leu Leu Val Asn Ile Phe Lys Gln Asn Leu 245 250 255 Gly Phe Lys Lys Val Leu Ala Phe Glu Phe Ala Asn Asn Arg Lys Phe 260 265 270 Met His Leu Ala Thr Val Phe Thr Met Val Asp Tyr Asp Lys Phe Thr 275 280 285 Ile His Pro Glu Ile Glu Gly Asp Leu Arg Val Tyr Ser Val Thr Tyr 290 295 300 Asp Asn Glu Glu Leu His Ile Val Glu Glu Xaa Gly Asp Leu Ala Glu 305 310 315 320 Leu Leu Ala Ala Asn Leu Gly Val Glu Lys Val Asp Leu Ile Arg Cys 325 330 335 Gly Gly Asp Asn Leu Val Ala Ala Gly Arg Glu Gln Trp Asn Asp Gly 340 345 350 Ser Asn Thr Leu Thr Ile Ala Pro Gly Val Val Val Val Tyr Asn Arg 355 360 365 Asn Thr Ile Thr Asn Ala Ile Leu Glu Ser Lys Gly Leu Lys Leu Ile 370 375 380 Lys Ile His Gly Ser Glu Leu Val Arg Gly Arg Gly Gly Pro Arg Cys 385 390 395 400 Met Ser Met Pro Phe Glu Arg Glu Asp Ile 405 410 <![CDATA[<210> 21]]> <![CDATA[<211> 184]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人類鐵蛋白[全長] WT,具有前導序列]]> <![CDATA[<400> 21]]> Met His His His His His His Gly Ser Gly Ser Ser Gln Ile Arg Gln 1 5 10 15 Asn Tyr Ser Thr Asp Val Glu Ala Ala Val Asn Ser Leu Val Asn Leu 20 25 30 Tyr Leu Gln Ala Ser Tyr Thr Tyr Leu Ser Leu Gly Phe Tyr Phe Asp 35 40 45 Arg Asp Asp Val Ala Leu Glu Gly Val Ser His Phe Phe Arg Glu Leu 50 55 60 Ala Glu Glu Lys Arg Glu Gly Tyr Glu Arg Leu Leu Lys Met Gln Asn 65 70 75 80 Gln Arg Gly Gly Arg Ala Leu Phe Gln Asp Ile Lys Lys Pro Ala Glu 85 90 95 Asp Glu Trp Gly Lys Thr Pro Asp Ala Met Lys Ala Ala Met Ala Leu 100 105 110 Glu Lys Lys Leu Asn Gln Ala Leu Leu Asp Leu His Ala Leu Gly Ser 115 120 125 Ala Arg Thr Asp Pro His Leu Cys Asp Phe Leu Glu Thr His Phe Leu 130 135 140 Asp Glu Glu Val Lys Leu Ile Lys Lys Met Gly Asp His Leu Thr Asn 145 150 155 160 Leu His Arg Leu Gly Gly Pro Glu Ala Gly Leu Gly Glu Tyr Leu Phe 165 170 175 Glu Arg Leu Thr Leu Lys His Asp 180 <![CDATA[<210> 22]]> <![CDATA[<211> 174]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 22]]> Ser Ser Gln Ile Arg Gln Asn Tyr Ser Thr Asp Val Glu Ala Ala Val 1 5 10 15 Asn Ser Leu Val Asn Leu Tyr Leu Gln Ala Ser Tyr Thr Tyr Leu Ser 20 25 30 Leu Gly Phe Tyr Phe Asp Arg Asp Asp Val Ala Leu Glu Gly Val Ser 35 40 45 His Phe Phe Arg Glu Leu Ala Glu Glu Lys Arg Glu Gly Tyr Glu Arg 50 55 60 Leu Leu Lys Met Gln Asn Gln Arg Gly Gly Arg Ala Leu Phe Gln Asp 65 70 75 80 Ile Lys Lys Pro Ala Glu Asp Glu Trp Gly Lys Thr Pro Asp Ala Met 85 90 95 Lys Ala Ala Met Ala Leu Glu Lys Lys Leu Asn Gln Ala Leu Leu Asp 100 105 110 Leu His Ala Leu Gly Ser Ala Arg Thr Asp Pro His Leu Cys Asp Phe 115 120 125 Leu Glu Thr His Phe Leu Asp Glu Glu Val Lys Leu Ile Lys Lys Met 130 135 140 Gly Asp His Leu Thr Asn Leu His Arg Leu Gly Gly Pro Glu Ala Gly 145 150 155 160 Leu Gly Glu Tyr Leu Phe Glu Arg Leu Thr Leu Lys His Asp 165 170 <![CDATA[<210> 23]]> <![CDATA[<211> 184]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人類鐵蛋白[全長] nnAA (例如pAMF)突變體I5,具有前導序列]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (14)..(14)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 23]]> Met His His His His His His Gly Ser Gly Ser Ser Gln Xaa Arg Gln 1 5 10 15 Asn Tyr Ser Thr Asp Val Glu Ala Ala Val Asn Ser Leu Val Asn Leu 20 25 30 Tyr Leu Gln Ala Ser Tyr Thr Tyr Leu Ser Leu Gly Phe Tyr Phe Asp 35 40 45 Arg Asp Asp Val Ala Leu Glu Gly Val Ser His Phe Phe Arg Glu Leu 50 55 60 Ala Glu Glu Lys Arg Glu Gly Tyr Glu Arg Leu Leu Lys Met Gln Asn 65 70 75 80 Gln Arg Gly Gly Arg Ala Leu Phe Gln Asp Ile Lys Lys Pro Ala Glu 85 90 95 Asp Glu Trp Gly Lys Thr Pro Asp Ala Met Lys Ala Ala Met Ala Leu 100 105 110 Glu Lys Lys Leu Asn Gln Ala Leu Leu Asp Leu His Ala Leu Gly Ser 115 120 125 Ala Arg Thr Asp Pro His Leu Cys Asp Phe Leu Glu Thr His Phe Leu 130 135 140 Asp Glu Glu Val Lys Leu Ile Lys Lys Met Gly Asp His Leu Thr Asn 145 150 155 160 Leu His Arg Leu Gly Gly Pro Glu Ala Gly Leu Gly Glu Tyr Leu Phe 165 170 175 Glu Arg Leu Thr Leu Lys His Asp 180 <![CDATA[<210> 24]]> <![CDATA[<211> 174]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人類鐵蛋白[全長] nnAA (例如pAMF)突變體I5,不具有前導序列]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (4)..(4)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 24]]> Ser Ser Gln Xaa Arg Gln Asn Tyr Ser Thr Asp Val Glu Ala Ala Val 1 5 10 15 Asn Ser Leu Val Asn Leu Tyr Leu Gln Ala Ser Tyr Thr Tyr Leu Ser 20 25 30 Leu Gly Phe Tyr Phe Asp Arg Asp Asp Val Ala Leu Glu Gly Val Ser 35 40 45 His Phe Phe Arg Glu Leu Ala Glu Glu Lys Arg Glu Gly Tyr Glu Arg 50 55 60 Leu Leu Lys Met Gln Asn Gln Arg Gly Gly Arg Ala Leu Phe Gln Asp 65 70 75 80 Ile Lys Lys Pro Ala Glu Asp Glu Trp Gly Lys Thr Pro Asp Ala Met 85 90 95 Lys Ala Ala Met Ala Leu Glu Lys Lys Leu Asn Gln Ala Leu Leu Asp 100 105 110 Leu His Ala Leu Gly Ser Ala Arg Thr Asp Pro His Leu Cys Asp Phe 115 120 125 Leu Glu Thr His Phe Leu Asp Glu Glu Val Lys Leu Ile Lys Lys Met 130 135 140 Gly Asp His Leu Thr Asn Leu His Arg Leu Gly Gly Pro Glu Ala Gly 145 150 155 160 Leu Gly Glu Tyr Leu Phe Glu Arg Leu Thr Leu Lys His Asp 165 170 <![CDATA[<210> 25]]> <![CDATA[<211> 536]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> eCRM - nnAA (例如pAMF)突變體]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (34)..(34)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (213)..(213)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (245)..(245)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (265)..(265)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (386)..(386)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (527)..(527)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 25]]> Met Gly Ala Asp Asp Val Val Asp Ser Ser Lys Ser Phe Val Met Glu 1 5 10 15 Asn Phe Ser Ser Tyr His Gly Thr Lys Pro Gly Tyr Val Asp Ser Ile 20 25 30 Gln Xaa Gly Ile Gln Lys Pro Lys Ser Gly Thr Gln Gly Asn Tyr Asp 35 40 45 Asp Asp Trp Lys Glu Phe Tyr Ser Thr Asp Asn Lys Tyr Asp Ala Ala 50 55 60 Gly Tyr Ser Val Asp Asn Glu Asn Pro Leu Ser Gly Lys Ala Gly Gly 65 70 75 80 Val Val Lys Val Thr Tyr Pro Gly Leu Thr Lys Val Leu Ala Leu Lys 85 90 95 Val Asp Asn Ala Glu Thr Ile Lys Lys Glu Leu Gly Leu Ser Leu Thr 100 105 110 Glu Pro Leu Met Glu Gln Val Gly Thr Glu Glu Phe Ile Lys Arg Phe 115 120 125 Gly Asp Gly Ala Ser Arg Val Val Leu Ser Leu Pro Phe Ala Glu Gly 130 135 140 Ser Ser Ser Val Glu Tyr Ile Asn Asn Trp Glu Gln Ala Lys Ala Leu 145 150 155 160 Ser Val Glu Leu Glu Ile Asn Phe Glu Thr Arg Gly Lys Arg Gly Gln 165 170 175 Asp Ala Met Tyr Glu Tyr Met Ala Gln Ala Cys Ala Gly Asn Arg Val 180 185 190 Arg Asn Ser Val Gly Ser Ser Leu Ser Cys Ile Asn Leu Asp Trp Asp 195 200 205 Val Ile Arg Asp Xaa Thr Lys Thr Lys Ile Glu Ser Leu Lys Glu His 210 215 220 Gly Pro Ile Lys Asn Lys Met Ser Glu Ser Pro Asn Lys Thr Val Ser 225 230 235 240 Glu Glu Lys Ala Xaa Gln Tyr Leu Glu Glu Phe His Gln Thr Ala Leu 245 250 255 Glu His Pro Glu Leu Ser Glu Leu Xaa Thr Val Thr Gly Thr Asn Pro 260 265 270 Val Phe Ala Gly Ala Asn Tyr Ala Ala Trp Ala Val Asn Val Ala Gln 275 280 285 Val Ile Asp Ser Glu Thr Ala Asp Asn Leu Glu Lys Thr Thr Ala Ala 290 295 300 Leu Ser Ile Leu Pro Gly Ile Gly Ser Val Met Gly Ile Ala Asp Gly 305 310 315 320 Ala Val His His Asn Thr Glu Glu Ile Val Ala Gln Ser Ile Ala Leu 325 330 335 Ser Ser Leu Met Val Ala Gln Ala Ile Pro Leu Val Gly Glu Leu Val 340 345 350 Asp Ile Gly Phe Ala Ala Tyr Asn Phe Val Glu Ser Ile Ile Asn Leu 355 360 365 Phe Gln Val Val His Asn Ser Tyr Asn Arg Pro Ala Tyr Ser Pro Gly 370 375 380 His Xaa Thr Gln Pro Phe Leu His Asp Gly Tyr Ala Val Ser Trp Asn 385 390 395 400 Thr Val Glu Asp Ser Ile Ile Arg Thr Gly Phe Gln Gly Glu Ser Gly 405 410 415 His Asp Ile Lys Ile Thr Ala Glu Asn Thr Pro Leu Pro Ile Ala Gly 420 425 430 Val Leu Leu Pro Thr Ile Pro Gly Lys Leu Asp Val Asn Lys Ser Lys 435 440 445 Thr His Ile Ser Val Asn Gly Arg Lys Ile Arg Met Arg Cys Arg Ala 450 455 460 Ile Asp Gly Asp Val Thr Phe Cys Arg Pro Lys Ser Pro Val Tyr Val 465 470 475 480 Gly Asn Gly Val His Ala Asn Leu His Val Ala Phe His Arg Ser Ser 485 490 495 Ser Glu Lys Ile His Ser Asn Glu Ile Ser Ser Asp Ser Ile Gly Val 500 505 510 Leu Gly Tyr Gln Lys Thr Val Asp His Thr Lys Val Asn Ser Xaa Leu 515 520 525 Ser Leu Phe Phe Glu Ile Lys Ser 530 535 <![CDATA[<210> 26]]> <![CDATA[<211> 427]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> ADI (mut2) [全長] D277A nnAA (例如pAMF)突變體,具有前導序列]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (139)..(139)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (263)..(263)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (332)..(332)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 26]]> Met His His His His His His Gly Ser Gly Glu Asn Leu Tyr Phe Gln 1 5 10 15 Gly Thr Ala Gln Thr Pro Ile His Val Tyr Ser Glu Ile Gly Lys Leu 20 25 30 Lys Lys Val Leu Leu His Arg Pro Gly Lys Glu Ile Glu Asn Leu Met 35 40 45 Pro Asp Tyr Leu Glu Arg Leu Leu Phe Asp Asp Ile Pro Phe Leu Glu 50 55 60 Asp Ala Gln Lys Glu His Asp Ala Phe Ala Gln Ala Leu Arg Asp Glu 65 70 75 80 Gly Ile Glu Val Leu Tyr Leu Glu Thr Leu Ala Ala Glu Ser Leu Val 85 90 95 Thr Pro Glu Ile Arg Glu Ala Phe Ile Asp Glu Tyr Leu Ser Glu Ala 100 105 110 Asn Ile Arg Gly Arg Ala Thr Lys Lys Ala Ile Arg Glu Leu Leu Met 115 120 125 Ala Ile Glu Asp Asn Gln Glu Leu Ile Glu Xaa Thr Met Ala Gly Val 130 135 140 Gln Lys Ser Glu Leu Pro Glu Ile Pro Ala Ser Glu Lys Gly Leu Thr 145 150 155 160 Asp Leu Val Glu Ser Asn Tyr Pro Phe Ala Ile Asp Pro Met Pro Asn 165 170 175 Leu Tyr Phe Thr Arg Asp Pro Phe Ala Thr Ile Gly Thr Gly Val Ser 180 185 190 Leu Asn His Met Phe Ser Glu Thr Arg Asn Arg Glu Thr Leu Tyr Gly 195 200 205 Lys Tyr Ile Phe Thr His His Pro Ile Tyr Gly Gly Gly Lys Val Pro 210 215 220 Met Val Tyr Asp Arg Asn Glu Thr Thr Arg Ile Glu Gly Gly Asp Glu 225 230 235 240 Leu Val Leu Ser Lys Asp Val Leu Ala Val Gly Ile Ser Gln Arg Thr 245 250 255 Asp Ala Ala Ser Ile Glu Xaa Leu Leu Val Asn Ile Phe Lys Gln Asn 260 265 270 Leu Gly Phe Lys Lys Val Leu Ala Phe Glu Phe Ala Asn Asn Arg Lys 275 280 285 Phe Met His Leu Ala Thr Val Phe Thr Met Val Asp Tyr Asp Lys Phe 290 295 300 Thr Ile His Pro Glu Ile Glu Gly Asp Leu Arg Val Tyr Ser Val Thr 305 310 315 320 Tyr Asp Asn Glu Glu Leu His Ile Val Glu Glu Xaa Gly Asp Leu Ala 325 330 335 Glu Leu Leu Ala Ala Asn Leu Gly Val Glu Lys Val Asp Leu Ile Arg 340 345 350 Cys Gly Gly Asp Asn Leu Val Ala Ala Gly Arg Glu Gln Trp Asn Asp 355 360 365 Gly Ser Asn Thr Leu Thr Ile Ala Pro Gly Val Val Val Val Tyr Asn 370 375 380 Arg Asn Thr Ile Thr Asn Ala Ile Leu Glu Ser Lys Gly Leu Lys Leu 385 390 395 400 Ile Lys Ile His Gly Ser Glu Leu Val Arg Gly Arg Gly Gly Pro Arg 405 410 415 Cys Met Ser Met Pro Phe Glu Arg Glu Asp Ile 420 425 <![CDATA[<210> 27]]> <![CDATA[<211> 411]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> ADI (mut2) [全長] D277A nnAA (例如pAMF)突變體,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (123)..(123)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (247)..(247)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (316)..(316)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 27]]> Gly Thr Ala Gln Thr Pro Ile His Val Tyr Ser Glu Ile Gly Lys Leu 1 5 10 15 Lys Lys Val Leu Leu His Arg Pro Gly Lys Glu Ile Glu Asn Leu Met 20 25 30 Pro Asp Tyr Leu Glu Arg Leu Leu Phe Asp Asp Ile Pro Phe Leu Glu 35 40 45 Asp Ala Gln Lys Glu His Asp Ala Phe Ala Gln Ala Leu Arg Asp Glu 50 55 60 Gly Ile Glu Val Leu Tyr Leu Glu Thr Leu Ala Ala Glu Ser Leu Val 65 70 75 80 Thr Pro Glu Ile Arg Glu Ala Phe Ile Asp Glu Tyr Leu Ser Glu Ala 85 90 95 Asn Ile Arg Gly Arg Ala Thr Lys Lys Ala Ile Arg Glu Leu Leu Met 100 105 110 Ala Ile Glu Asp Asn Gln Glu Leu Ile Glu Xaa Thr Met Ala Gly Val 115 120 125 Gln Lys Ser Glu Leu Pro Glu Ile Pro Ala Ser Glu Lys Gly Leu Thr 130 135 140 Asp Leu Val Glu Ser Asn Tyr Pro Phe Ala Ile Asp Pro Met Pro Asn 145 150 155 160 Leu Tyr Phe Thr Arg Asp Pro Phe Ala Thr Ile Gly Thr Gly Val Ser 165 170 175 Leu Asn His Met Phe Ser Glu Thr Arg Asn Arg Glu Thr Leu Tyr Gly 180 185 190 Lys Tyr Ile Phe Thr His His Pro Ile Tyr Gly Gly Gly Lys Val Pro 195 200 205 Met Val Tyr Asp Arg Asn Glu Thr Thr Arg Ile Glu Gly Gly Asp Glu 210 215 220 Leu Val Leu Ser Lys Asp Val Leu Ala Val Gly Ile Ser Gln Arg Thr 225 230 235 240 Asp Ala Ala Ser Ile Glu Xaa Leu Leu Val Asn Ile Phe Lys Gln Asn 245 250 255 Leu Gly Phe Lys Lys Val Leu Ala Phe Glu Phe Ala Asn Asn Arg Lys 260 265 270 Phe Met His Leu Ala Thr Val Phe Thr Met Val Asp Tyr Asp Lys Phe 275 280 285 Thr Ile His Pro Glu Ile Glu Gly Asp Leu Arg Val Tyr Ser Val Thr 290 295 300 Tyr Asp Asn Glu Glu Leu His Ile Val Glu Glu Xaa Gly Asp Leu Ala 305 310 315 320 Glu Leu Leu Ala Ala Asn Leu Gly Val Glu Lys Val Asp Leu Ile Arg 325 330 335 Cys Gly Gly Asp Asn Leu Val Ala Ala Gly Arg Glu Gln Trp Asn Asp 340 345 350 Gly Ser Asn Thr Leu Thr Ile Ala Pro Gly Val Val Val Val Tyr Asn 355 360 365 Arg Asn Thr Ile Thr Asn Ala Ile Leu Glu Ser Lys Gly Leu Lys Leu 370 375 380 Ile Lys Ile His Gly Ser Glu Leu Val Arg Gly Arg Gly Gly Pro Arg 385 390 395 400 Cys Met Ser Met Pro Phe Glu Arg Glu Asp Ile 405 410 <![CDATA[<210> 28]]> <![CDATA[<211> 157]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 具有前導序列之Sfb1重複區]]> <![CDATA[<400> 28]]> Met His His His His His His Gly Ser Gly Val Glu Thr Glu Asp Thr 1 5 10 15 Lys Glu Pro Gly Val Leu Met Gly Gly Gln Ser Glu Ser Val Glu Phe 20 25 30 Thr Lys Asp Thr Gln Thr Gly Met Ser Gly Gln Thr Thr Pro Gln Val 35 40 45 Glu Thr Glu Asp Thr Lys Glu Pro Gly Val Leu Met Gly Gly Gln Ser 50 55 60 Glu Ser Val Glu Phe Thr Lys Asp Thr Gln Thr Gly Met Ser Gly Gln 65 70 75 80 Thr Ala Ser Gln Val Glu Thr Glu Asp Thr Lys Glu Pro Gly Val Leu 85 90 95 Met Gly Gly Gln Ser Glu Ser Val Glu Phe Thr Lys Asp Thr Gln Thr 100 105 110 Gly Met Ser Gly Gln Thr Thr Pro Gln Val Glu Thr Glu Asp Thr Lys 115 120 125 Glu Pro Gly Val Leu Met Gly Gly Gln Ser Glu Ser Val Glu Phe Thr 130 135 140 Lys Asp Thr Gln Thr Gly Met Ser Gly Phe Ser Glu Thr 145 150 155 <![CDATA[<210> 29]]> <![CDATA[<211> 946]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> C5a [90-1035片段] WT,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<400> 29]]> Gly Lys Thr Ala Asp Thr Pro Val Thr Ser Lys Ala Thr Ile Arg Asp 1 5 10 15 Leu Asn Asp Pro Ser Gln Val Lys Thr Leu Gln Glu Lys Ala Gly Lys 20 25 30 Gly Ala Gly Thr Val Val Ala Val Ile Asp Ala Gly Phe Asp Lys Asn 35 40 45 His Glu Ala Trp Arg Leu Thr Asp Lys Thr Lys Ala Arg Tyr Gln Ser 50 55 60 Lys Glu Asp Leu Glu Lys Ala Lys Lys Glu His Gly Ile Thr Tyr Gly 65 70 75 80 Glu Trp Val Asn Asp Lys Val Ala Tyr Tyr His Asp Tyr Ser Lys Asp 85 90 95 Gly Lys Thr Ala Val Asp Gln Glu His Gly Thr His Val Ser Gly Ile 100 105 110 Leu Ser Gly Asn Ala Pro Ser Glu Thr Lys Glu Pro Tyr Arg Leu Glu 115 120 125 Gly Ala Met Pro Glu Ala Gln Leu Leu Leu Met Arg Val Glu Ile Val 130 135 140 Asn Gly Leu Ala Asp Tyr Ala Arg Asn Tyr Ala Gln Ala Ile Arg Asp 145 150 155 160 Ala Val Asn Leu Gly Ala Lys Val Ile Asn Met Ser Phe Gly Asn Ala 165 170 175 Ala Leu Ala Tyr Ala Asn Leu Pro Asp Glu Thr Lys Lys Ala Phe Asp 180 185 190 Tyr Ala Lys Ser Lys Gly Val Ser Ile Val Thr Ser Ala Gly Asn Asp 195 200 205 Ser Ser Phe Gly Gly Lys Thr Arg Leu Pro Leu Ala Asp His Pro Asp 210 215 220 Tyr Gly Val Val Gly Thr Pro Ala Ala Ala Asp Ser Thr Leu Thr Val 225 230 235 240 Ala Ser Tyr Ser Pro Asp Lys Gln Leu Thr Glu Thr Ala Thr Val Lys 245 250 255 Thr Ala Asp Lys Gln Asp Lys Glu Met Pro Val Leu Ser Thr Asn Arg 260 265 270 Phe Glu Pro Asn Lys Ala Tyr Asp Tyr Ala Tyr Ala Asn Arg Gly Met 275 280 285 Lys Glu Asp Asp Phe Lys Asp Val Lys Gly Lys Ile Ala Leu Ile Glu 290 295 300 Arg Gly Asp Ile Asp Phe Lys Asp Lys Ile Ala Asn Ala Lys Lys Ala 305 310 315 320 Gly Ala Val Gly Val Leu Ile Tyr Asp Asn Gln Asp Lys Gly Phe Pro 325 330 335 Ile Glu Leu Pro Asn Val Asp Gln Met Pro Ala Ala Phe Ile Ser Arg 340 345 350 Lys Asp Gly Leu Leu Leu Lys Asp Asn Pro Lys Lys Thr Ile Thr Phe 355 360 365 Asn Ala Thr Pro Lys Val Leu Pro Thr Ala Ser Gly Thr Lys Leu Ser 370 375 380 Arg Phe Ser Ser Trp Gly Leu Thr Ala Asp Gly Asn Ile Lys Pro Asp 385 390 395 400 Ile Ala Ala Pro Gly Gln Asp Ile Leu Ser Ser Val Ala Asn Asn Lys 405 410 415 Tyr Ala Lys Leu Ser Gly Thr Ser Met Ser Ala Pro Leu Val Ala Gly 420 425 430 Ile Met Gly Leu Leu Gln Lys Gln Tyr Glu Thr Gln Tyr Pro Asp Met 435 440 445 Thr Pro Ser Glu Arg Leu Asp Leu Ala Lys Lys Val Leu Met Ser Ser 450 455 460 Ala Thr Ala Leu Tyr Asp Glu Asp Glu Lys Ala Tyr Phe Ser Pro Arg 465 470 475 480 Gln Gln Gly Ala Gly Ala Val Asp Ala Lys Lys Ala Ser Ala Ala Thr 485 490 495 Met Tyr Val Thr Asp Lys Asp Asn Thr Ser Ser Lys Val His Leu Asn 500 505 510 Asn Val Ser Asp Thr Phe Glu Val Thr Val Thr Val His Asn Lys Ser 515 520 525 Asp Lys Pro Gln Glu Leu Tyr Tyr Gln Ala Thr Val Gln Thr Asp Lys 530 535 540 Val Asp Gly Lys His Phe Ala Leu Ala Pro Lys Ala Leu Tyr Glu Thr 545 550 555 560 Ser Trp Gln Lys Ile Thr Ile Pro Ala Asn Ser Ser Lys Gln Val Thr 565 570 575 Val Pro Ile Asp Ala Ser Arg Phe Ser Lys Asp Leu Leu Ala Gln Met 580 585 590 Lys Asn Gly Tyr Phe Leu Glu Gly Phe Val Arg Phe Lys Gln Asp Pro 595 600 605 Thr Lys Glu Glu Leu Met Ser Ile Pro Tyr Ile Gly Phe Arg Gly Asp 610 615 620 Phe Gly Asn Leu Ser Ala Leu Glu Lys Pro Ile Tyr Asp Ser Lys Asp 625 630 635 640 Gly Ser Ser Tyr Tyr His Glu Ala Asn Ser Asp Ala Lys Asp Gln Leu 645 650 655 Asp Gly Asp Gly Leu Gln Phe Tyr Ala Leu Lys Asn Asn Phe Thr Ala 660 665 670 Leu Thr Thr Glu Ser Asn Pro Trp Thr Ile Ile Lys Ala Val Lys Glu 675 680 685 Gly Val Glu Asn Ile Glu Asp Ile Glu Ser Ser Glu Ile Thr Glu Thr 690 695 700 Ile Phe Ala Gly Thr Phe Ala Lys Gln Asp Asp Asp Ser His Tyr Tyr 705 710 715 720 Ile His Arg His Ala Asn Gly Lys Pro Tyr Ala Ala Ile Ser Pro Asn 725 730 735 Gly Asp Gly Asn Arg Asp Tyr Val Gln Phe Gln Gly Thr Phe Leu Arg 740 745 750 Asn Ala Lys Asn Leu Val Ala Glu Val Leu Asp Lys Glu Gly Asn Val 755 760 765 Val Trp Thr Ser Glu Val Thr Glu Gln Val Val Lys Asn Tyr Asn Asn 770 775 780 Asp Leu Ala Ser Thr Leu Gly Ser Thr Arg Phe Glu Lys Thr Arg Trp 785 790 795 800 Asp Gly Lys Asp Lys Asp Gly Lys Val Val Ala Asn Gly Thr Tyr Thr 805 810 815 Tyr Arg Val Arg Tyr Thr Pro Ile Ser Ser Gly Ala Lys Glu Gln His 820 825 830 Thr Asp Phe Asp Val Ile Val Asp Asn Thr Thr Pro Glu Val Ala Thr 835 840 845 Ser Ala Thr Phe Ser Thr Glu Asp Arg Arg Leu Thr Leu Ala Ser Lys 850 855 860 Pro Lys Thr Ser Gln Pro Val Tyr Arg Glu Arg Ile Ala Tyr Thr Tyr 865 870 875 880 Met Asp Glu Asp Leu Pro Thr Thr Glu Tyr Ile Ser Pro Asn Glu Asp 885 890 895 Gly Thr Phe Thr Leu Pro Glu Glu Ala Glu Thr Met Glu Gly Ala Thr 900 905 910 Val Pro Leu Lys Met Ser Asp Phe Thr Tyr Val Val Glu Asp Met Ala 915 920 925 Gly Asn Ile Thr Tyr Thr Pro Val Thr Lys Leu Leu Glu Gly His Ser 930 935 940 Asn Lys 945 <![CDATA[<210> 30]]> <![CDATA[<211> 946]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> C5a [90-1035片段] D131A/S513A,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<400> 30]]> Gly Lys Thr Ala Asp Thr Pro Val Thr Ser Lys Ala Thr Ile Arg Asp 1 5 10 15 Leu Asn Asp Pro Ser Gln Val Lys Thr Leu Gln Glu Lys Ala Gly Lys 20 25 30 Gly Ala Gly Thr Val Val Ala Val Ile Ala Ala Gly Phe Asp Lys Asn 35 40 45 His Glu Ala Trp Arg Leu Thr Asp Lys Thr Lys Ala Arg Tyr Gln Ser 50 55 60 Lys Glu Asp Leu Glu Lys Ala Lys Lys Glu His Gly Ile Thr Tyr Gly 65 70 75 80 Glu Trp Val Asn Asp Lys Val Ala Tyr Tyr His Asp Tyr Ser Lys Asp 85 90 95 Gly Lys Thr Ala Val Asp Gln Glu His Gly Thr His Val Ser Gly Ile 100 105 110 Leu Ser Gly Asn Ala Pro Ser Glu Thr Lys Glu Pro Tyr Arg Leu Glu 115 120 125 Gly Ala Met Pro Glu Ala Gln Leu Leu Leu Met Arg Val Glu Ile Val 130 135 140 Asn Gly Leu Ala Asp Tyr Ala Arg Asn Tyr Ala Gln Ala Ile Arg Asp 145 150 155 160 Ala Val Asn Leu Gly Ala Lys Val Ile Asn Met Ser Phe Gly Asn Ala 165 170 175 Ala Leu Ala Tyr Ala Asn Leu Pro Asp Glu Thr Lys Lys Ala Phe Asp 180 185 190 Tyr Ala Lys Ser Lys Gly Val Ser Ile Val Thr Ser Ala Gly Asn Asp 195 200 205 Ser Ser Phe Gly Gly Lys Thr Arg Leu Pro Leu Ala Asp His Pro Asp 210 215 220 Tyr Gly Val Val Gly Thr Pro Ala Ala Ala Asp Ser Thr Leu Thr Val 225 230 235 240 Ala Ser Tyr Ser Pro Asp Lys Gln Leu Thr Glu Thr Ala Thr Val Lys 245 250 255 Thr Ala Asp Lys Gln Asp Lys Glu Met Pro Val Leu Ser Thr Asn Arg 260 265 270 Phe Glu Pro Asn Lys Ala Tyr Asp Tyr Ala Tyr Ala Asn Arg Gly Met 275 280 285 Lys Glu Asp Asp Phe Lys Asp Val Lys Gly Lys Ile Ala Leu Ile Glu 290 295 300 Arg Gly Asp Ile Asp Phe Lys Asp Lys Ile Ala Asn Ala Lys Lys Ala 305 310 315 320 Gly Ala Val Gly Val Leu Ile Tyr Asp Asn Gln Asp Lys Gly Phe Pro 325 330 335 Ile Glu Leu Pro Asn Val Asp Gln Met Pro Ala Ala Phe Ile Ser Arg 340 345 350 Lys Asp Gly Leu Leu Leu Lys Asp Asn Pro Lys Lys Thr Ile Thr Phe 355 360 365 Asn Ala Thr Pro Lys Val Leu Pro Thr Ala Ser Gly Thr Lys Leu Ser 370 375 380 Arg Phe Ser Ser Trp Gly Leu Thr Ala Asp Gly Asn Ile Lys Pro Asp 385 390 395 400 Ile Ala Ala Pro Gly Gln Asp Ile Leu Ser Ser Val Ala Asn Asn Lys 405 410 415 Tyr Ala Lys Leu Ser Gly Thr Ala Met Ser Ala Pro Leu Val Ala Gly 420 425 430 Ile Met Gly Leu Leu Gln Lys Gln Tyr Glu Thr Gln Tyr Pro Asp Met 435 440 445 Thr Pro Ser Glu Arg Leu Asp Leu Ala Lys Lys Val Leu Met Ser Ser 450 455 460 Ala Thr Ala Leu Tyr Asp Glu Asp Glu Lys Ala Tyr Phe Ser Pro Arg 465 470 475 480 Gln Gln Gly Ala Gly Ala Val Asp Ala Lys Lys Ala Ser Ala Ala Thr 485 490 495 Met Tyr Val Thr Asp Lys Asp Asn Thr Ser Ser Lys Val His Leu Asn 500 505 510 Asn Val Ser Asp Thr Phe Glu Val Thr Val Thr Val His Asn Lys Ser 515 520 525 Asp Lys Pro Gln Glu Leu Tyr Tyr Gln Ala Thr Val Gln Thr Asp Lys 530 535 540 Val Asp Gly Lys His Phe Ala Leu Ala Pro Lys Ala Leu Tyr Glu Thr 545 550 555 560 Ser Trp Gln Lys Ile Thr Ile Pro Ala Asn Ser Ser Lys Gln Val Thr 565 570 575 Val Pro Ile Asp Ala Ser Arg Phe Ser Lys Asp Leu Leu Ala Gln Met 580 585 590 Lys Asn Gly Tyr Phe Leu Glu Gly Phe Val Arg Phe Lys Gln Asp Pro 595 600 605 Thr Lys Glu Glu Leu Met Ser Ile Pro Tyr Ile Gly Phe Arg Gly Asp 610 615 620 Phe Gly Asn Leu Ser Ala Leu Glu Lys Pro Ile Tyr Asp Ser Lys Asp 625 630 635 640 Gly Ser Ser Tyr Tyr His Glu Ala Asn Ser Asp Ala Lys Asp Gln Leu 645 650 655 Asp Gly Asp Gly Leu Gln Phe Tyr Ala Leu Lys Asn Asn Phe Thr Ala 660 665 670 Leu Thr Thr Glu Ser Asn Pro Trp Thr Ile Ile Lys Ala Val Lys Glu 675 680 685 Gly Val Glu Asn Ile Glu Asp Ile Glu Ser Ser Glu Ile Thr Glu Thr 690 695 700 Ile Phe Ala Gly Thr Phe Ala Lys Gln Asp Asp Asp Ser His Tyr Tyr 705 710 715 720 Ile His Arg His Ala Asn Gly Lys Pro Tyr Ala Ala Ile Ser Pro Asn 725 730 735 Gly Asp Gly Asn Arg Asp Tyr Val Gln Phe Gln Gly Thr Phe Leu Arg 740 745 750 Asn Ala Lys Asn Leu Val Ala Glu Val Leu Asp Lys Glu Gly Asn Val 755 760 765 Val Trp Thr Ser Glu Val Thr Glu Gln Val Val Lys Asn Tyr Asn Asn 770 775 780 Asp Leu Ala Ser Thr Leu Gly Ser Thr Arg Phe Glu Lys Thr Arg Trp 785 790 795 800 Asp Gly Lys Asp Lys Asp Gly Lys Val Val Ala Asn Gly Thr Tyr Thr 805 810 815 Tyr Arg Val Arg Tyr Thr Pro Ile Ser Ser Gly Ala Lys Glu Gln His 820 825 830 Thr Asp Phe Asp Val Ile Val Asp Asn Thr Thr Pro Glu Val Ala Thr 835 840 845 Ser Ala Thr Phe Ser Thr Glu Asp Arg Arg Leu Thr Leu Ala Ser Lys 850 855 860 Pro Lys Thr Ser Gln Pro Val Tyr Arg Glu Arg Ile Ala Tyr Thr Tyr 865 870 875 880 Met Asp Glu Asp Leu Pro Thr Thr Glu Tyr Ile Ser Pro Asn Glu Asp 885 890 895 Gly Thr Phe Thr Leu Pro Glu Glu Ala Glu Thr Met Glu Gly Ala Thr 900 905 910 Val Pro Leu Lys Met Ser Asp Phe Thr Tyr Val Val Glu Asp Met Ala 915 920 925 Gly Asn Ile Thr Tyr Thr Pro Val Thr Lys Leu Leu Glu Gly His Ser 930 935 940 Asn Lys 945 <![CDATA[<210> 31]]> <![CDATA[<211> 494]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO [79-571片段] WT,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<400> 31]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln Gly Ala Tyr Val Ala Gln Tyr 385 390 395 400 Glu Ile Leu Trp Asp Glu Ile Asn Tyr Asp Asp Lys Gly Lys Glu Val 405 410 415 Ile Thr Lys Arg Arg Trp Asp Asn Asn Trp Tyr Ser Lys Thr Ser Pro 420 425 430 Phe Ser Thr Val Ile Pro Leu Gly Ala Asn Ser Arg Asn Ile Arg Ile 435 440 445 Met Ala Arg Glu Cys Thr Gly Leu Ala Trp Glu Trp Trp Arg Lys Val 450 455 460 Ile Asp Glu Arg Asp Val Lys Leu Ser Lys Glu Ile Asn Val Asn Ile 465 470 475 480 Ser Gly Ser Thr Leu Ser Pro Tyr Gly Ser Ile Thr Tyr Lys 485 490 <![CDATA[<210> 32]]> <![CDATA[<211> 494]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO [79-571片段] W535A,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<400> 32]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln Gly Ala Tyr Val Ala Gln Tyr 385 390 395 400 Glu Ile Leu Trp Asp Glu Ile Asn Tyr Asp Asp Lys Gly Lys Glu Val 405 410 415 Ile Thr Lys Arg Arg Trp Asp Asn Asn Trp Tyr Ser Lys Thr Ser Pro 420 425 430 Phe Ser Thr Val Ile Pro Leu Gly Ala Asn Ser Arg Asn Ile Arg Ile 435 440 445 Met Ala Arg Glu Cys Thr Gly Leu Ala Ala Glu Trp Trp Arg Lys Val 450 455 460 Ile Asp Glu Arg Asp Val Lys Leu Ser Lys Glu Ile Asn Val Asn Ile 465 470 475 480 Ser Gly Ser Thr Leu Ser Pro Tyr Gly Ser Ile Thr Tyr Lys 485 490 <![CDATA[<210> 33]]> <![CDATA[<211> 818]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SpyAD [33-849片段] WT,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<400> 33]]> Gly Gln Val Lys Ala Asp Asp Arg Ala Ser Gly Glu Thr Lys Ala Ser 1 5 10 15 Asn Thr His Asp Asp Ser Leu Pro Lys Pro Glu Thr Ile Gln Glu Ala 20 25 30 Lys Ala Thr Ile Asp Ala Val Glu Lys Thr Leu Ser Gln Gln Lys Ala 35 40 45 Glu Leu Thr Glu Leu Ala Thr Ala Leu Thr Lys Thr Thr Ala Glu Ile 50 55 60 Asn His Leu Lys Glu Gln Gln Asp Asn Glu Gln Lys Ala Leu Thr Ser 65 70 75 80 Ala Gln Glu Ile Tyr Thr Asn Thr Leu Ala Ser Ser Glu Glu Thr Leu 85 90 95 Leu Ala Gln Gly Ala Glu His Gln Arg Glu Leu Thr Ala Thr Glu Thr 100 105 110 Glu Leu His Asn Ala Gln Ala Asp Gln His Ser Lys Glu Thr Ala Leu 115 120 125 Ser Glu Gln Lys Ala Ser Ile Ser Ala Glu Thr Thr Arg Ala Gln Asp 130 135 140 Leu Val Glu Gln Val Lys Thr Ser Glu Gln Asn Ile Ala Lys Leu Asn 145 150 155 160 Ala Met Ile Ser Asn Pro Asp Ala Ile Thr Lys Ala Ala Gln Thr Ala 165 170 175 Asn Asp Asn Thr Lys Ala Leu Ser Ser Glu Leu Glu Lys Ala Lys Ala 180 185 190 Asp Leu Glu Asn Gln Lys Ala Lys Val Lys Lys Gln Leu Thr Glu Glu 195 200 205 Leu Ala Ala Gln Lys Ala Ala Leu Ala Glu Lys Glu Ala Glu Leu Ser 210 215 220 Arg Leu Lys Ser Ser Ala Pro Ser Thr Gln Asp Ser Ile Val Gly Asn 225 230 235 240 Asn Thr Met Lys Ala Pro Gln Gly Tyr Pro Leu Glu Glu Leu Lys Lys 245 250 255 Leu Glu Ala Ser Gly Tyr Ile Gly Ser Ala Ser Tyr Asn Asn Tyr Tyr 260 265 270 Lys Glu His Ala Asp Gln Ile Ile Ala Lys Ala Ser Pro Gly Asn Gln 275 280 285 Leu Asn Gln Tyr Gln Asp Ile Pro Ala Asp Arg Asn Arg Phe Val Asp 290 295 300 Pro Asp Asn Leu Thr Pro Glu Val Gln Asn Glu Leu Ala Gln Phe Ala 305 310 315 320 Ala His Met Ile Asn Ser Val Arg Arg Gln Leu Gly Leu Pro Pro Val 325 330 335 Thr Val Thr Ala Gly Ser Gln Glu Phe Ala Arg Leu Leu Ser Thr Ser 340 345 350 Tyr Lys Lys Thr His Gly Asn Thr Arg Pro Ser Phe Val Tyr Gly Gln 355 360 365 Pro Gly Val Ser Gly His Tyr Gly Val Gly Pro His Asp Lys Thr Ile 370 375 380 Ile Glu Asp Ser Ala Gly Ala Ser Gly Leu Ile Arg Asn Asp Asp Asn 385 390 395 400 Met Tyr Glu Asn Ile Gly Ala Phe Asn Asp Val His Thr Val Asn Gly 405 410 415 Ile Lys Arg Gly Ile Tyr Asp Ser Ile Lys Tyr Met Leu Phe Thr Asp 420 425 430 His Leu His Gly Asn Thr Tyr Gly His Ala Ile Asn Phe Leu Arg Val 435 440 445 Asp Lys His Asn Pro Asn Ala Pro Val Tyr Leu Gly Phe Ser Thr Ser 450 455 460 Asn Val Gly Ser Leu Asn Glu His Phe Val Met Phe Pro Glu Ser Asn 465 470 475 480 Ile Ala Asn His Gln Arg Phe Asn Lys Thr Pro Ile Lys Ala Val Gly 485 490 495 Ser Thr Lys Asp Tyr Ala Gln Arg Val Gly Thr Val Ser Asp Thr Ile 500 505 510 Ala Ala Ile Lys Gly Lys Val Ser Ser Leu Glu Asn Arg Leu Ser Ala 515 520 525 Ile His Gln Glu Ala Asp Ile Met Ala Ala Gln Ala Lys Val Ser Gln 530 535 540 Leu Gln Gly Lys Leu Ala Ser Thr Leu Lys Gln Ser Asp Ser Leu Asn 545 550 555 560 Leu Gln Val Arg Gln Leu Asn Asp Thr Lys Gly Ser Leu Arg Thr Glu 565 570 575 Leu Leu Ala Ala Lys Ala Lys Gln Ala Gln Leu Glu Ala Thr Arg Asp 580 585 590 Gln Ser Leu Ala Lys Leu Ala Ser Leu Lys Ala Ala Leu His Gln Thr 595 600 605 Glu Ala Leu Ala Glu Gln Ala Ala Ala Arg Val Thr Ala Leu Val Ala 610 615 620 Lys Lys Ala His Leu Gln Tyr Leu Arg Asp Phe Lys Leu Asn Pro Asn 625 630 635 640 Arg Leu Gln Val Ile Arg Glu Arg Ile Asp Asn Thr Lys Gln Asp Leu 645 650 655 Ala Lys Thr Thr Ser Ser Leu Leu Asn Ala Gln Glu Ala Leu Ala Ala 660 665 670 Leu Gln Ala Lys Gln Ser Ser Leu Glu Ala Thr Ile Ala Thr Thr Glu 675 680 685 His Gln Leu Thr Leu Leu Lys Thr Leu Ala Asn Glu Lys Glu Tyr Arg 690 695 700 His Leu Asp Glu Asp Ile Ala Thr Val Pro Asp Leu Gln Val Ala Pro 705 710 715 720 Pro Leu Thr Gly Val Lys Pro Leu Ser Tyr Ser Lys Ile Asp Thr Thr 725 730 735 Pro Leu Val Gln Glu Met Val Lys Glu Thr Lys Gln Leu Leu Glu Ala 740 745 750 Ser Ala Arg Leu Ala Ala Glu Asn Thr Ser Leu Val Ala Glu Ala Leu 755 760 765 Val Gly Gln Thr Ser Glu Met Val Ala Ser Asn Ala Ile Val Ser Lys 770 775 780 Ile Thr Ser Ser Ile Thr Gln Pro Ser Ser Lys Thr Ser Tyr Gly Ser 785 790 795 800 Gly Ser Ser Thr Thr Ser Asn Leu Ile Ser Asp Val Asp Glu Ser Thr 805 810 815 Gln Arg <![CDATA[<210> 34]]> <![CDATA[<211> 818]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SpyAD [33-849片段] nnAA (例如pAMF)突變體,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (33)..(33)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (256)..(256)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (355)..(355)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (626)..(626)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 34]]> Gly Gln Val Lys Ala Asp Asp Arg Ala Ser Gly Glu Thr Lys Ala Ser 1 5 10 15 Asn Thr His Asp Asp Ser Leu Pro Lys Pro Glu Thr Ile Gln Glu Ala 20 25 30 Xaa Ala Thr Ile Asp Ala Val Glu Lys Thr Leu Ser Gln Gln Lys Ala 35 40 45 Glu Leu Thr Glu Leu Ala Thr Ala Leu Thr Lys Thr Thr Ala Glu Ile 50 55 60 Asn His Leu Lys Glu Gln Gln Asp Asn Glu Gln Lys Ala Leu Thr Ser 65 70 75 80 Ala Gln Glu Ile Tyr Thr Asn Thr Leu Ala Ser Ser Glu Glu Thr Leu 85 90 95 Leu Ala Gln Gly Ala Glu His Gln Arg Glu Leu Thr Ala Thr Glu Thr 100 105 110 Glu Leu His Asn Ala Gln Ala Asp Gln His Ser Lys Glu Thr Ala Leu 115 120 125 Ser Glu Gln Lys Ala Ser Ile Ser Ala Glu Thr Thr Arg Ala Gln Asp 130 135 140 Leu Val Glu Gln Val Lys Thr Ser Glu Gln Asn Ile Ala Lys Leu Asn 145 150 155 160 Ala Met Ile Ser Asn Pro Asp Ala Ile Thr Lys Ala Ala Gln Thr Ala 165 170 175 Asn Asp Asn Thr Lys Ala Leu Ser Ser Glu Leu Glu Lys Ala Lys Ala 180 185 190 Asp Leu Glu Asn Gln Lys Ala Lys Val Lys Lys Gln Leu Thr Glu Glu 195 200 205 Leu Ala Ala Gln Lys Ala Ala Leu Ala Glu Lys Glu Ala Glu Leu Ser 210 215 220 Arg Leu Lys Ser Ser Ala Pro Ser Thr Gln Asp Ser Ile Val Gly Asn 225 230 235 240 Asn Thr Met Lys Ala Pro Gln Gly Tyr Pro Leu Glu Glu Leu Lys Xaa 245 250 255 Leu Glu Ala Ser Gly Tyr Ile Gly Ser Ala Ser Tyr Asn Asn Tyr Tyr 260 265 270 Lys Glu His Ala Asp Gln Ile Ile Ala Lys Ala Ser Pro Gly Asn Gln 275 280 285 Leu Asn Gln Tyr Gln Asp Ile Pro Ala Asp Arg Asn Arg Phe Val Asp 290 295 300 Pro Asp Asn Leu Thr Pro Glu Val Gln Asn Glu Leu Ala Gln Phe Ala 305 310 315 320 Ala His Met Ile Asn Ser Val Arg Arg Gln Leu Gly Leu Pro Pro Val 325 330 335 Thr Val Thr Ala Gly Ser Gln Glu Phe Ala Arg Leu Leu Ser Thr Ser 340 345 350 Tyr Lys Xaa Thr His Gly Asn Thr Arg Pro Ser Phe Val Tyr Gly Gln 355 360 365 Pro Gly Val Ser Gly His Tyr Gly Val Gly Pro His Asp Lys Thr Ile 370 375 380 Ile Glu Asp Ser Ala Gly Ala Ser Gly Leu Ile Arg Asn Asp Asp Asn 385 390 395 400 Met Tyr Glu Asn Ile Gly Ala Phe Asn Asp Val His Thr Val Asn Gly 405 410 415 Ile Lys Arg Gly Ile Tyr Asp Ser Ile Lys Tyr Met Leu Phe Thr Asp 420 425 430 His Leu His Gly Asn Thr Tyr Gly His Ala Ile Asn Phe Leu Arg Val 435 440 445 Asp Lys His Asn Pro Asn Ala Pro Val Tyr Leu Gly Phe Ser Thr Ser 450 455 460 Asn Val Gly Ser Leu Asn Glu His Phe Val Met Phe Pro Glu Ser Asn 465 470 475 480 Ile Ala Asn His Gln Arg Phe Asn Lys Thr Pro Ile Lys Ala Val Gly 485 490 495 Ser Thr Lys Asp Tyr Ala Gln Arg Val Gly Thr Val Ser Asp Thr Ile 500 505 510 Ala Ala Ile Lys Gly Lys Val Ser Ser Leu Glu Asn Arg Leu Ser Ala 515 520 525 Ile His Gln Glu Ala Asp Ile Met Ala Ala Gln Ala Lys Val Ser Gln 530 535 540 Leu Gln Gly Lys Leu Ala Ser Thr Leu Lys Gln Ser Asp Ser Leu Asn 545 550 555 560 Leu Gln Val Arg Gln Leu Asn Asp Thr Lys Gly Ser Leu Arg Thr Glu 565 570 575 Leu Leu Ala Ala Lys Ala Lys Gln Ala Gln Leu Glu Ala Thr Arg Asp 580 585 590 Gln Ser Leu Ala Lys Leu Ala Ser Leu Lys Ala Ala Leu His Gln Thr 595 600 605 Glu Ala Leu Ala Glu Gln Ala Ala Ala Arg Val Thr Ala Leu Val Ala 610 615 620 Lys Xaa Ala His Leu Gln Tyr Leu Arg Asp Phe Lys Leu Asn Pro Asn 625 630 635 640 Arg Leu Gln Val Ile Arg Glu Arg Ile Asp Asn Thr Lys Gln Asp Leu 645 650 655 Ala Lys Thr Thr Ser Ser Leu Leu Asn Ala Gln Glu Ala Leu Ala Ala 660 665 670 Leu Gln Ala Lys Gln Ser Ser Leu Glu Ala Thr Ile Ala Thr Thr Glu 675 680 685 His Gln Leu Thr Leu Leu Lys Thr Leu Ala Asn Glu Lys Glu Tyr Arg 690 695 700 His Leu Asp Glu Asp Ile Ala Thr Val Pro Asp Leu Gln Val Ala Pro 705 710 715 720 Pro Leu Thr Gly Val Lys Pro Leu Ser Tyr Ser Lys Ile Asp Thr Thr 725 730 735 Pro Leu Val Gln Glu Met Val Lys Glu Thr Lys Gln Leu Leu Glu Ala 740 745 750 Ser Ala Arg Leu Ala Ala Glu Asn Thr Ser Leu Val Ala Glu Ala Leu 755 760 765 Val Gly Gln Thr Ser Glu Met Val Ala Ser Asn Ala Ile Val Ser Lys 770 775 780 Ile Thr Ser Ser Ile Thr Gln Pro Ser Ser Lys Thr Ser Tyr Gly Ser 785 790 795 800 Gly Ser Ser Thr Thr Ser Asn Leu Ile Ser Asp Val Asp Glu Ser Thr 805 810 815 Gln Arg <![CDATA[<210> 35]]> <![CDATA[<211> 411]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> ADI [全長] WT,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<400> 35]]> Gly Thr Ala Gln Thr Pro Ile His Val Tyr Ser Glu Ile Gly Lys Leu 1 5 10 15 Lys Lys Val Leu Leu His Arg Pro Gly Lys Glu Ile Glu Asn Leu Met 20 25 30 Pro Asp Tyr Leu Glu Arg Leu Leu Phe Asp Asp Ile Pro Phe Leu Glu 35 40 45 Asp Ala Gln Lys Glu His Asp Ala Phe Ala Gln Ala Leu Arg Asp Glu 50 55 60 Gly Ile Glu Val Leu Tyr Leu Glu Thr Leu Ala Ala Glu Ser Leu Val 65 70 75 80 Thr Pro Glu Ile Arg Glu Ala Phe Ile Asp Glu Tyr Leu Ser Glu Ala 85 90 95 Asn Ile Arg Gly Arg Ala Thr Lys Lys Ala Ile Arg Glu Leu Leu Met 100 105 110 Ala Ile Glu Asp Asn Gln Glu Leu Ile Glu Lys Thr Met Ala Gly Val 115 120 125 Gln Lys Ser Glu Leu Pro Glu Ile Pro Ala Ser Glu Lys Gly Leu Thr 130 135 140 Asp Leu Val Glu Ser Asn Tyr Pro Phe Ala Ile Asp Pro Met Pro Asn 145 150 155 160 Leu Tyr Phe Thr Arg Asp Pro Phe Ala Thr Ile Gly Thr Gly Val Ser 165 170 175 Leu Asn His Met Phe Ser Glu Thr Arg Asn Arg Glu Thr Leu Tyr Gly 180 185 190 Lys Tyr Ile Phe Thr His His Pro Ile Tyr Gly Gly Gly Lys Val Pro 195 200 205 Met Val Tyr Asp Arg Asn Glu Thr Thr Arg Ile Glu Gly Gly Asp Glu 210 215 220 Leu Val Leu Ser Lys Asp Val Leu Ala Val Gly Ile Ser Gln Arg Thr 225 230 235 240 Asp Ala Ala Ser Ile Glu Lys Leu Leu Val Asn Ile Phe Lys Gln Asn 245 250 255 Leu Gly Phe Lys Lys Val Leu Ala Phe Glu Phe Ala Asn Asn Arg Lys 260 265 270 Phe Met His Leu Asp Thr Val Phe Thr Met Val Asp Tyr Asp Lys Phe 275 280 285 Thr Ile His Pro Glu Ile Glu Gly Asp Leu Arg Val Tyr Ser Val Thr 290 295 300 Tyr Asp Asn Glu Glu Leu His Ile Val Glu Glu Lys Gly Asp Leu Ala 305 310 315 320 Glu Leu Leu Ala Ala Asn Leu Gly Val Glu Lys Val Asp Leu Ile Arg 325 330 335 Cys Gly Gly Asp Asn Leu Val Ala Ala Gly Arg Glu Gln Trp Asn Asp 340 345 350 Gly Ser Asn Thr Leu Thr Ile Ala Pro Gly Val Val Val Val Tyr Asn 355 360 365 Arg Asn Thr Ile Thr Asn Ala Ile Leu Glu Ser Lys Gly Leu Lys Leu 370 375 380 Ile Lys Ile His Gly Ser Glu Leu Val Arg Gly Arg Gly Gly Pro Arg 385 390 395 400 Cys Met Ser Met Pro Phe Glu Arg Glu Asp Ile 405 410 <![CDATA[<210> 36]]> <![CDATA[<211> 411]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> ADI [全長] D277A,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<400> 36]]> Gly Thr Ala Gln Thr Pro Ile His Val Tyr Ser Glu Ile Gly Lys Leu 1 5 10 15 Lys Lys Val Leu Leu His Arg Pro Gly Lys Glu Ile Glu Asn Leu Met 20 25 30 Pro Asp Tyr Leu Glu Arg Leu Leu Phe Asp Asp Ile Pro Phe Leu Glu 35 40 45 Asp Ala Gln Lys Glu His Asp Ala Phe Ala Gln Ala Leu Arg Asp Glu 50 55 60 Gly Ile Glu Val Leu Tyr Leu Glu Thr Leu Ala Ala Glu Ser Leu Val 65 70 75 80 Thr Pro Glu Ile Arg Glu Ala Phe Ile Asp Glu Tyr Leu Ser Glu Ala 85 90 95 Asn Ile Arg Gly Arg Ala Thr Lys Lys Ala Ile Arg Glu Leu Leu Met 100 105 110 Ala Ile Glu Asp Asn Gln Glu Leu Ile Glu Lys Thr Met Ala Gly Val 115 120 125 Gln Lys Ser Glu Leu Pro Glu Ile Pro Ala Ser Glu Lys Gly Leu Thr 130 135 140 Asp Leu Val Glu Ser Asn Tyr Pro Phe Ala Ile Asp Pro Met Pro Asn 145 150 155 160 Leu Tyr Phe Thr Arg Asp Pro Phe Ala Thr Ile Gly Thr Gly Val Ser 165 170 175 Leu Asn His Met Phe Ser Glu Thr Arg Asn Arg Glu Thr Leu Tyr Gly 180 185 190 Lys Tyr Ile Phe Thr His His Pro Ile Tyr Gly Gly Gly Lys Val Pro 195 200 205 Met Val Tyr Asp Arg Asn Glu Thr Thr Arg Ile Glu Gly Gly Asp Glu 210 215 220 Leu Val Leu Ser Lys Asp Val Leu Ala Val Gly Ile Ser Gln Arg Thr 225 230 235 240 Asp Ala Ala Ser Ile Glu Lys Leu Leu Val Asn Ile Phe Lys Gln Asn 245 250 255 Leu Gly Phe Lys Lys Val Leu Ala Phe Glu Phe Ala Asn Asn Arg Lys 260 265 270 Phe Met His Leu Ala Thr Val Phe Thr Met Val Asp Tyr Asp Lys Phe 275 280 285 Thr Ile His Pro Glu Ile Glu Gly Asp Leu Arg Val Tyr Ser Val Thr 290 295 300 Tyr Asp Asn Glu Glu Leu His Ile Val Glu Glu Lys Gly Asp Leu Ala 305 310 315 320 Glu Leu Leu Ala Ala Asn Leu Gly Val Glu Lys Val Asp Leu Ile Arg 325 330 335 Cys Gly Gly Asp Asn Leu Val Ala Ala Gly Arg Glu Gln Trp Asn Asp 340 345 350 Gly Ser Asn Thr Leu Thr Ile Ala Pro Gly Val Val Val Val Tyr Asn 355 360 365 Arg Asn Thr Ile Thr Asn Ala Ile Leu Glu Ser Lys Gly Leu Lys Leu 370 375 380 Ile Lys Ile His Gly Ser Glu Leu Val Arg Gly Arg Gly Gly Pro Arg 385 390 395 400 Cys Met Ser Met Pro Phe Glu Arg Glu Asp Ile 405 410 <![CDATA[<210> 37]]> <![CDATA[<211> 411]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> ADI [全長] nnAA (例如pAMF)突變體,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (15)..(15)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (193)..(193)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (316)..(316)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 37]]> Gly Thr Ala Gln Thr Pro Ile His Val Tyr Ser Glu Ile Gly Xaa Leu 1 5 10 15 Lys Lys Val Leu Leu His Arg Pro Gly Lys Glu Ile Glu Asn Leu Met 20 25 30 Pro Asp Tyr Leu Glu Arg Leu Leu Phe Asp Asp Ile Pro Phe Leu Glu 35 40 45 Asp Ala Gln Lys Glu His Asp Ala Phe Ala Gln Ala Leu Arg Asp Glu 50 55 60 Gly Ile Glu Val Leu Tyr Leu Glu Thr Leu Ala Ala Glu Ser Leu Val 65 70 75 80 Thr Pro Glu Ile Arg Glu Ala Phe Ile Asp Glu Tyr Leu Ser Glu Ala 85 90 95 Asn Ile Arg Gly Arg Ala Thr Lys Lys Ala Ile Arg Glu Leu Leu Met 100 105 110 Ala Ile Glu Asp Asn Gln Glu Leu Ile Glu Lys Thr Met Ala Gly Val 115 120 125 Gln Lys Ser Glu Leu Pro Glu Ile Pro Ala Ser Glu Lys Gly Leu Thr 130 135 140 Asp Leu Val Glu Ser Asn Tyr Pro Phe Ala Ile Asp Pro Met Pro Asn 145 150 155 160 Leu Tyr Phe Thr Arg Asp Pro Phe Ala Thr Ile Gly Thr Gly Val Ser 165 170 175 Leu Asn His Met Phe Ser Glu Thr Arg Asn Arg Glu Thr Leu Tyr Gly 180 185 190 Xaa Tyr Ile Phe Thr His His Pro Ile Tyr Gly Gly Gly Lys Val Pro 195 200 205 Met Val Tyr Asp Arg Asn Glu Thr Thr Arg Ile Glu Gly Gly Asp Glu 210 215 220 Leu Val Leu Ser Lys Asp Val Leu Ala Val Gly Ile Ser Gln Arg Thr 225 230 235 240 Asp Ala Ala Ser Ile Glu Lys Leu Leu Val Asn Ile Phe Lys Gln Asn 245 250 255 Leu Gly Phe Lys Lys Val Leu Ala Phe Glu Phe Ala Asn Asn Arg Lys 260 265 270 Phe Met His Leu Asp Thr Val Phe Thr Met Val Asp Tyr Asp Lys Phe 275 280 285 Thr Ile His Pro Glu Ile Glu Gly Asp Leu Arg Val Tyr Ser Val Thr 290 295 300 Tyr Asp Asn Glu Glu Leu His Ile Val Glu Glu Xaa Gly Asp Leu Ala 305 310 315 320 Glu Leu Leu Ala Ala Asn Leu Gly Val Glu Lys Val Asp Leu Ile Arg 325 330 335 Cys Gly Gly Asp Asn Leu Val Ala Ala Gly Arg Glu Gln Trp Asn Asp 340 345 350 Gly Ser Asn Thr Leu Thr Ile Ala Pro Gly Val Val Val Val Tyr Asn 355 360 365 Arg Asn Thr Ile Thr Asn Ala Ile Leu Glu Ser Lys Gly Leu Lys Leu 370 375 380 Ile Lys Ile His Gly Ser Glu Leu Val Arg Gly Arg Gly Gly Pro Arg 385 390 395 400 Cys Met Ser Met Pro Phe Glu Arg Glu Asp Ile 405 410 <![CDATA[<210> 38]]> <![CDATA[<211> 411]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> ADI (mut5) [全長] D277A nnAA (例如pAMF)突變體,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (15)..(15)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (193)..(193)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (316)..(316)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 38]]> Gly Thr Ala Gln Thr Pro Ile His Val Tyr Ser Glu Ile Gly Xaa Leu 1 5 10 15 Lys Lys Val Leu Leu His Arg Pro Gly Lys Glu Ile Glu Asn Leu Met 20 25 30 Pro Asp Tyr Leu Glu Arg Leu Leu Phe Asp Asp Ile Pro Phe Leu Glu 35 40 45 Asp Ala Gln Lys Glu His Asp Ala Phe Ala Gln Ala Leu Arg Asp Glu 50 55 60 Gly Ile Glu Val Leu Tyr Leu Glu Thr Leu Ala Ala Glu Ser Leu Val 65 70 75 80 Thr Pro Glu Ile Arg Glu Ala Phe Ile Asp Glu Tyr Leu Ser Glu Ala 85 90 95 Asn Ile Arg Gly Arg Ala Thr Lys Lys Ala Ile Arg Glu Leu Leu Met 100 105 110 Ala Ile Glu Asp Asn Gln Glu Leu Ile Glu Lys Thr Met Ala Gly Val 115 120 125 Gln Lys Ser Glu Leu Pro Glu Ile Pro Ala Ser Glu Lys Gly Leu Thr 130 135 140 Asp Leu Val Glu Ser Asn Tyr Pro Phe Ala Ile Asp Pro Met Pro Asn 145 150 155 160 Leu Tyr Phe Thr Arg Asp Pro Phe Ala Thr Ile Gly Thr Gly Val Ser 165 170 175 Leu Asn His Met Phe Ser Glu Thr Arg Asn Arg Glu Thr Leu Tyr Gly 180 185 190 Xaa Tyr Ile Phe Thr His His Pro Ile Tyr Gly Gly Gly Lys Val Pro 195 200 205 Met Val Tyr Asp Arg Asn Glu Thr Thr Arg Ile Glu Gly Gly Asp Glu 210 215 220 Leu Val Leu Ser Lys Asp Val Leu Ala Val Gly Ile Ser Gln Arg Thr 225 230 235 240 Asp Ala Ala Ser Ile Glu Lys Leu Leu Val Asn Ile Phe Lys Gln Asn 245 250 255 Leu Gly Phe Lys Lys Val Leu Ala Phe Glu Phe Ala Asn Asn Arg Lys 260 265 270 Phe Met His Leu Ala Thr Val Phe Thr Met Val Asp Tyr Asp Lys Phe 275 280 285 Thr Ile His Pro Glu Ile Glu Gly Asp Leu Arg Val Tyr Ser Val Thr 290 295 300 Tyr Asp Asn Glu Glu Leu His Ile Val Glu Glu Xaa Gly Asp Leu Ala 305 310 315 320 Glu Leu Leu Ala Ala Asn Leu Gly Val Glu Lys Val Asp Leu Ile Arg 325 330 335 Cys Gly Gly Asp Asn Leu Val Ala Ala Gly Arg Glu Gln Trp Asn Asp 340 345 350 Gly Ser Asn Thr Leu Thr Ile Ala Pro Gly Val Val Val Val Tyr Asn 355 360 365 Arg Asn Thr Ile Thr Asn Ala Ile Leu Glu Ser Lys Gly Leu Lys Leu 370 375 380 Ile Lys Ile His Gly Ser Glu Leu Val Arg Gly Arg Gly Gly Pro Arg 385 390 395 400 Cys Met Ser Met Pro Phe Glu Arg Glu Asp Ile 405 410 <![CDATA[<210> 39]]> <![CDATA[<211> 184]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> hFL [全長] WT,具有前導序列]]> <![CDATA[<400> 39]]> Met His His His His His His Gly Ser Gly Ser Ser Gln Ile Arg Gln 1 5 10 15 Asn Tyr Ser Thr Asp Val Glu Ala Ala Val Asn Ser Leu Val Asn Leu 20 25 30 Tyr Leu Gln Ala Ser Tyr Thr Tyr Leu Ser Leu Gly Phe Tyr Phe Asp 35 40 45 Arg Asp Asp Val Ala Leu Glu Gly Val Ser His Phe Phe Arg Glu Leu 50 55 60 Ala Glu Glu Lys Arg Glu Gly Tyr Glu Arg Leu Leu Lys Met Gln Asn 65 70 75 80 Gln Arg Gly Gly Arg Ala Leu Phe Gln Asp Ile Lys Lys Pro Ala Glu 85 90 95 Asp Glu Trp Gly Lys Thr Pro Asp Ala Met Lys Ala Ala Met Ala Leu 100 105 110 Glu Lys Lys Leu Asn Gln Ala Leu Leu Asp Leu His Ala Leu Gly Ser 115 120 125 Ala Arg Thr Asp Pro His Leu Cys Asp Phe Leu Glu Thr His Phe Leu 130 135 140 Asp Glu Glu Val Lys Leu Ile Lys Lys Met Gly Asp His Leu Thr Asn 145 150 155 160 Leu His Arg Leu Gly Gly Pro Glu Ala Gly Leu Gly Glu Tyr Leu Phe 165 170 175 Glu Arg Leu Thr Leu Lys His Asp 180 <![CDATA[<210> 40]]> <![CDATA[<211> 174]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 40]]> Ser Ser Gln Ile Arg Gln Asn Tyr Ser Thr Asp Val Glu Ala Ala Val 1 5 10 15 Asn Ser Leu Val Asn Leu Tyr Leu Gln Ala Ser Tyr Thr Tyr Leu Ser 20 25 30 Leu Gly Phe Tyr Phe Asp Arg Asp Asp Val Ala Leu Glu Gly Val Ser 35 40 45 His Phe Phe Arg Glu Leu Ala Glu Glu Lys Arg Glu Gly Tyr Glu Arg 50 55 60 Leu Leu Lys Met Gln Asn Gln Arg Gly Gly Arg Ala Leu Phe Gln Asp 65 70 75 80 Ile Lys Lys Pro Ala Glu Asp Glu Trp Gly Lys Thr Pro Asp Ala Met 85 90 95 Lys Ala Ala Met Ala Leu Glu Lys Lys Leu Asn Gln Ala Leu Leu Asp 100 105 110 Leu His Ala Leu Gly Ser Ala Arg Thr Asp Pro His Leu Cys Asp Phe 115 120 125 Leu Glu Thr His Phe Leu Asp Glu Glu Val Lys Leu Ile Lys Lys Met 130 135 140 Gly Asp His Leu Thr Asn Leu His Arg Leu Gly Gly Pro Glu Ala Gly 145 150 155 160 Leu Gly Glu Tyr Leu Phe Glu Arg Leu Thr Leu Lys His Asp 165 170 <![CDATA[<210> 41]]> <![CDATA[<211> 184]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> hFL [全長] nnAA (例如pAMF)突變體,具有前導序列]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (14)..(14)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 41]]> Met His His His His His His Gly Ser Gly Ser Ser Gln Xaa Arg Gln 1 5 10 15 Asn Tyr Ser Thr Asp Val Glu Ala Ala Val Asn Ser Leu Val Asn Leu 20 25 30 Tyr Leu Gln Ala Ser Tyr Thr Tyr Leu Ser Leu Gly Phe Tyr Phe Asp 35 40 45 Arg Asp Asp Val Ala Leu Glu Gly Val Ser His Phe Phe Arg Glu Leu 50 55 60 Ala Glu Glu Lys Arg Glu Gly Tyr Glu Arg Leu Leu Lys Met Gln Asn 65 70 75 80 Gln Arg Gly Gly Arg Ala Leu Phe Gln Asp Ile Lys Lys Pro Ala Glu 85 90 95 Asp Glu Trp Gly Lys Thr Pro Asp Ala Met Lys Ala Ala Met Ala Leu 100 105 110 Glu Lys Lys Leu Asn Gln Ala Leu Leu Asp Leu His Ala Leu Gly Ser 115 120 125 Ala Arg Thr Asp Pro His Leu Cys Asp Phe Leu Glu Thr His Phe Leu 130 135 140 Asp Glu Glu Val Lys Leu Ile Lys Lys Met Gly Asp His Leu Thr Asn 145 150 155 160 Leu His Arg Leu Gly Gly Pro Glu Ala Gly Leu Gly Glu Tyr Leu Phe 165 170 175 Glu Arg Leu Thr Leu Lys His Asp 180 <![CDATA[<210> 42]]> <![CDATA[<211> 174]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> hFL [全長] nnAA (例如pAMF)突變體,不具有前導序列]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (4)..(4)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 42]]> Ser Ser Gln Xaa Arg Gln Asn Tyr Ser Thr Asp Val Glu Ala Ala Val 1 5 10 15 Asn Ser Leu Val Asn Leu Tyr Leu Gln Ala Ser Tyr Thr Tyr Leu Ser 20 25 30 Leu Gly Phe Tyr Phe Asp Arg Asp Asp Val Ala Leu Glu Gly Val Ser 35 40 45 His Phe Phe Arg Glu Leu Ala Glu Glu Lys Arg Glu Gly Tyr Glu Arg 50 55 60 Leu Leu Lys Met Gln Asn Gln Arg Gly Gly Arg Ala Leu Phe Gln Asp 65 70 75 80 Ile Lys Lys Pro Ala Glu Asp Glu Trp Gly Lys Thr Pro Asp Ala Met 85 90 95 Lys Ala Ala Met Ala Leu Glu Lys Lys Leu Asn Gln Ala Leu Leu Asp 100 105 110 Leu His Ala Leu Gly Ser Ala Arg Thr Asp Pro His Leu Cys Asp Phe 115 120 125 Leu Glu Thr His Phe Leu Asp Glu Glu Val Lys Leu Ile Lys Lys Met 130 135 140 Gly Asp His Leu Thr Asn Leu His Arg Leu Gly Gly Pro Glu Ala Gly 145 150 155 160 Leu Gly Glu Tyr Leu Phe Glu Arg Leu Thr Leu Lys His Asp 165 170 <![CDATA[<210> 43]]> <![CDATA[<211> 535]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> eCRM-nnAA (例如pAMF)突變體]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (33)..(33)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (212)..(212)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (244)..(244)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (264)..(264)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (385)..(385)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (526)..(526)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 43]]> Gly Ala Asp Asp Val Val Asp Ser Ser Lys Ser Phe Val Met Glu Asn 1 5 10 15 Phe Ser Ser Tyr His Gly Thr Lys Pro Gly Tyr Val Asp Ser Ile Gln 20 25 30 Xaa Gly Ile Gln Lys Pro Lys Ser Gly Thr Gln Gly Asn Tyr Asp Asp 35 40 45 Asp Trp Lys Glu Phe Tyr Ser Thr Asp Asn Lys Tyr Asp Ala Ala Gly 50 55 60 Tyr Ser Val Asp Asn Glu Asn Pro Leu Ser Gly Lys Ala Gly Gly Val 65 70 75 80 Val Lys Val Thr Tyr Pro Gly Leu Thr Lys Val Leu Ala Leu Lys Val 85 90 95 Asp Asn Ala Glu Thr Ile Lys Lys Glu Leu Gly Leu Ser Leu Thr Glu 100 105 110 Pro Leu Met Glu Gln Val Gly Thr Glu Glu Phe Ile Lys Arg Phe Gly 115 120 125 Asp Gly Ala Ser Arg Val Val Leu Ser Leu Pro Phe Ala Glu Gly Ser 130 135 140 Ser Ser Val Glu Tyr Ile Asn Asn Trp Glu Gln Ala Lys Ala Leu Ser 145 150 155 160 Val Glu Leu Glu Ile Asn Phe Glu Thr Arg Gly Lys Arg Gly Gln Asp 165 170 175 Ala Met Tyr Glu Tyr Met Ala Gln Ala Cys Ala Gly Asn Arg Val Arg 180 185 190 Asn Ser Val Gly Ser Ser Leu Ser Cys Ile Asn Leu Asp Trp Asp Val 195 200 205 Ile Arg Asp Xaa Thr Lys Thr Lys Ile Glu Ser Leu Lys Glu His Gly 210 215 220 Pro Ile Lys Asn Lys Met Ser Glu Ser Pro Asn Lys Thr Val Ser Glu 225 230 235 240 Glu Lys Ala Xaa Gln Tyr Leu Glu Glu Phe His Gln Thr Ala Leu Glu 245 250 255 His Pro Glu Leu Ser Glu Leu Xaa Thr Val Thr Gly Thr Asn Pro Val 260 265 270 Phe Ala Gly Ala Asn Tyr Ala Ala Trp Ala Val Asn Val Ala Gln Val 275 280 285 Ile Asp Ser Glu Thr Ala Asp Asn Leu Glu Lys Thr Thr Ala Ala Leu 290 295 300 Ser Ile Leu Pro Gly Ile Gly Ser Val Met Gly Ile Ala Asp Gly Ala 305 310 315 320 Val His His Asn Thr Glu Glu Ile Val Ala Gln Ser Ile Ala Leu Ser 325 330 335 Ser Leu Met Val Ala Gln Ala Ile Pro Leu Val Gly Glu Leu Val Asp 340 345 350 Ile Gly Phe Ala Ala Tyr Asn Phe Val Glu Ser Ile Ile Asn Leu Phe 355 360 365 Gln Val Val His Asn Ser Tyr Asn Arg Pro Ala Tyr Ser Pro Gly His 370 375 380 Xaa Thr Gln Pro Phe Leu His Asp Gly Tyr Ala Val Ser Trp Asn Thr 385 390 395 400 Val Glu Asp Ser Ile Ile Arg Thr Gly Phe Gln Gly Glu Ser Gly His 405 410 415 Asp Ile Lys Ile Thr Ala Glu Asn Thr Pro Leu Pro Ile Ala Gly Val 420 425 430 Leu Leu Pro Thr Ile Pro Gly Lys Leu Asp Val Asn Lys Ser Lys Thr 435 440 445 His Ile Ser Val Asn Gly Arg Lys Ile Arg Met Arg Cys Arg Ala Ile 450 455 460 Asp Gly Asp Val Thr Phe Cys Arg Pro Lys Ser Pro Val Tyr Val Gly 465 470 475 480 Asn Gly Val His Ala Asn Leu His Val Ala Phe His Arg Ser Ser Ser 485 490 495 Glu Lys Ile His Ser Asn Glu Ile Ser Ser Asp Ser Ile Gly Val Leu 500 505 510 Gly Tyr Gln Lys Thr Val Asp His Thr Lys Val Asn Ser Xaa Leu Ser 515 520 525 Leu Phe Phe Glu Ile Lys Ser 530 535 <![CDATA[<210> 44]]> <![CDATA[<211> 483]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11) W535A,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<400> 44]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln Gly Ala Tyr Val Ala Gln Tyr 385 390 395 400 Glu Ile Leu Trp Asp Glu Ile Asn Tyr Asp Asp Lys Gly Lys Glu Val 405 410 415 Ile Thr Lys Arg Arg Trp Asp Asn Asn Trp Tyr Ser Lys Thr Ser Pro 420 425 430 Phe Ser Thr Val Ile Pro Leu Gly Ala Asn Ser Arg Asn Ile Arg Ile 435 440 445 Met Ala Arg Glu Cys Thr Gly Leu Ala Ala Glu Trp Trp Arg Lys Val 450 455 460 Ile Asp Glu Arg Asp Val Lys Leu Ser Lys Glu Ile Asn Val Asn Ile 465 470 475 480 Ser Gly Ser <![CDATA[<210> 45]]> <![CDATA[<211> 473]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC21)片段W535A,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<400> 45]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln Gly Ala Tyr Val Ala Gln Tyr 385 390 395 400 Glu Ile Leu Trp Asp Glu Ile Asn Tyr Asp Asp Lys Gly Lys Glu Val 405 410 415 Ile Thr Lys Arg Arg Trp Asp Asn Asn Trp Tyr Ser Lys Thr Ser Pro 420 425 430 Phe Ser Thr Val Ile Pro Leu Gly Ala Asn Ser Arg Asn Ile Arg Ile 435 440 445 Met Ala Arg Glu Cys Thr Gly Leu Ala Ala Glu Trp Trp Arg Lys Val 450 455 460 Ile Asp Glu Arg Asp Val Lys Leu Ser 465 470 <![CDATA[<210> 46]]> <![CDATA[<211> 463]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC31)片段W535A,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<400> 46]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln Gly Ala Tyr Val Ala Gln Tyr 385 390 395 400 Glu Ile Leu Trp Asp Glu Ile Asn Tyr Asp Asp Lys Gly Lys Glu Val 405 410 415 Ile Thr Lys Arg Arg Trp Asp Asn Asn Trp Tyr Ser Lys Thr Ser Pro 420 425 430 Phe Ser Thr Val Ile Pro Leu Gly Ala Asn Ser Arg Asn Ile Arg Ile 435 440 445 Met Ala Arg Glu Cys Thr Gly Leu Ala Ala Glu Trp Trp Arg Lys 450 455 460 <![CDATA[<210> 47]]> <![CDATA[<211> 453]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC41)片段,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<400> 47]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln Gly Ala Tyr Val Ala Gln Tyr 385 390 395 400 Glu Ile Leu Trp Asp Glu Ile Asn Tyr Asp Asp Lys Gly Lys Glu Val 405 410 415 Ile Thr Lys Arg Arg Trp Asp Asn Asn Trp Tyr Ser Lys Thr Ser Pro 420 425 430 Phe Ser Thr Val Ile Pro Leu Gly Ala Asn Ser Arg Asn Ile Arg Ile 435 440 445 Met Ala Arg Glu Cys 450 <![CDATA[<210> 48]]> <![CDATA[<211> 443]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC51)片段,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<400> 48]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln Gly Ala Tyr Val Ala Gln Tyr 385 390 395 400 Glu Ile Leu Trp Asp Glu Ile Asn Tyr Asp Asp Lys Gly Lys Glu Val 405 410 415 Ile Thr Lys Arg Arg Trp Asp Asn Asn Trp Tyr Ser Lys Thr Ser Pro 420 425 430 Phe Ser Thr Val Ile Pro Leu Gly Ala Asn Ser 435 440 <![CDATA[<210> 49]]> <![CDATA[<211> 433]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC61)片段,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<400> 49]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln Gly Ala Tyr Val Ala Gln Tyr 385 390 395 400 Glu Ile Leu Trp Asp Glu Ile Asn Tyr Asp Asp Lys Gly Lys Glu Val 405 410 415 Ile Thr Lys Arg Arg Trp Asp Asn Asn Trp Tyr Ser Lys Thr Ser Pro 420 425 430 Phe <![CDATA[<210> 50]]> <![CDATA[<211> 423]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC71)片段,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<400> 50]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln Gly Ala Tyr Val Ala Gln Tyr 385 390 395 400 Glu Ile Leu Trp Asp Glu Ile Asn Tyr Asp Asp Lys Gly Lys Glu Val 405 410 415 Ile Thr Lys Arg Arg Trp Asp 420 <![CDATA[<210> 51]]> <![CDATA[<211> 413]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC81)片段,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<400> 51]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln Gly Ala Tyr Val Ala Gln Tyr 385 390 395 400 Glu Ile Leu Trp Asp Glu Ile Asn Tyr Asp Asp Lys Gly 405 410 <![CDATA[<210> 52]]> <![CDATA[<211> 403]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC91)片段,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<400> 52]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln Gly Ala Tyr Val Ala Gln Tyr 385 390 395 400 Glu Ile Leu <![CDATA[<210> 53]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC101)片段W535A,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<400> 53]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 54]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (21)..(21)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (35)..(35)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (74)..(74)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (112)..(112)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (195)..(195)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (246)..(246)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (280)..(280)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (298)..(298)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (330)..(330)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (387)..(387)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 54]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Xaa Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Xaa Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Xaa Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Xaa 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Xaa Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Xaa Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Xaa Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Xaa Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Xaa Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Xaa Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 55]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體1,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (21)..(21)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (74)..(74)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (195)..(195)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (280)..(280)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 55]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Xaa Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Xaa Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Xaa Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Xaa Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 56]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體2,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (35)..(35)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (112)..(112)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (246)..(246)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (298)..(298)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 56]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Xaa Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Xaa 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Xaa Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Xaa Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 57]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體3,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (74)..(74)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (195)..(195)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (280)..(280)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (330)..(330)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 57]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Xaa Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Xaa Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Xaa Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Xaa Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 58]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體4,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (74)..(74)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (195)..(195)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (298)..(298)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (387)..(387)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 58]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Xaa Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Xaa Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Xaa Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Xaa Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 59]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體5,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (35)..(35)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (195)..(195)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (280)..(280)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (387)..(387)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 59]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Xaa Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Xaa Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Xaa Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Xaa Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 60]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體6,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (21)..(21)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (112)..(112)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (280)..(280)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 60]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Xaa Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Xaa 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Xaa Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 61]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體7,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (21)..(21)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (35)..(35)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (112)..(112)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (246)..(246)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 61]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Xaa Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Xaa Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Xaa 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Xaa Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 62]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體8,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (21)..(21)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (74)..(74)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (195)..(195)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 62]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Xaa Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Xaa Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Xaa Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 63]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體9,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (35)..(35)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (195)..(195)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (298)..(298)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 63]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Xaa Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Xaa Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Xaa Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 64]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體10,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (35)..(35)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (246)..(246)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (330)..(330)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 64]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Xaa Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Xaa Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Xaa Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 65]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體10,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (21)..(21)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (74)..(74)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (195)..(195)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (280)..(280)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (330)..(330)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 65]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Xaa Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Xaa Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Xaa Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Xaa Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Xaa Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 66]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體10,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (35)..(35)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (112)..(112)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (246)..(246)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (298)..(298)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (387)..(387)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 66]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Xaa Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Xaa 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Xaa Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Xaa Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Xaa Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 67]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體10,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (35)..(35)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (74)..(74)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (195)..(195)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (280)..(280)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (330)..(330)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 67]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Xaa Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Xaa Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Xaa Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Xaa Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Xaa Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 68]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體10,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (21)..(21)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (74)..(74)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (195)..(195)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (280)..(280)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (330)..(330)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (387)..(387)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 68]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Xaa Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Xaa Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Lys 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Xaa Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Xaa Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Xaa Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Xaa Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 69]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體10,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (35)..(35)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (74)..(74)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (112)..(112)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (246)..(246)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (298)..(298)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (387)..(387)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 69]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Xaa Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Xaa Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Xaa 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Xaa Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Xaa Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Xaa Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 70]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體10,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (21)..(21)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (35)..(35)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (112)..(112)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (246)..(246)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (298)..(298)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (387)..(387)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 70]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Xaa Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Xaa Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Xaa 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Xaa Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Xaa Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Xaa Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 71]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體10,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (35)..(35)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (74)..(74)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (112)..(112)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (195)..(195)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (280)..(280)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (330)..(330)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (387)..(387)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 71]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Xaa Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Xaa Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Xaa 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Xaa Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Xaa Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Xaa Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Xaa Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 72]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體10,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (21)..(21)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (74)..(74)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (112)..(112)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (246)..(246)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (298)..(298)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (330)..(330)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (387)..(387)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 72]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Xaa Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Xaa Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Xaa 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Lys Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Xaa Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Lys Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Xaa Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Xaa Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Xaa Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 73]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體10,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (35)..(35)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (112)..(112)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (195)..(195)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (280)..(280)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> misc_feature]]> <![CDATA[<222> (298)..(298)]]> <![CDATA[<223> Xaa可為任何天然胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (330)..(330)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (387)..(387)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 73]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Xaa Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Xaa 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Xaa Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Lys Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Xaa Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Xaa Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Xaa Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Xaa Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 74]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體10,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (21)..(21)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (35)..(35)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (74)..(74)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (112)..(112)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (195)..(195)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (246)..(246)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (280)..(280)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (298)..(298)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 74]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Xaa Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Xaa Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Xaa Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Xaa 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Xaa Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Xaa Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Xaa Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Xaa Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Lys Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Lys Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 75]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體10,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (21)..(21)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (74)..(74)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (112)..(112)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (195)..(195)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (246)..(246)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (280)..(280)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (330)..(330)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (387)..(387)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 75]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Xaa Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Lys Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Xaa Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Xaa 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Xaa Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Xaa Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Xaa Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Lys Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Xaa Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Xaa Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 76]]> <![CDATA[<211> 393]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SLO(ΔC11)之SLO(ΔC101)片段- nnAA (例如pAMF)突變體10,不具有前導序列且具有來自裂解之G懸突]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (35)..(35)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (112)..(112)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (195)..(195)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (246)..(246)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (280)..(280)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (298)..(298)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (330)..(330)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (387)..(387)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 76]]> Gly Ala Pro Lys Glu Met Pro Leu Glu Ser Ala Glu Lys Glu Glu Lys 1 5 10 15 Lys Ser Glu Asp Lys Lys Lys Ser Glu Glu Asp His Thr Glu Glu Ile 20 25 30 Asn Asp Xaa Ile Tyr Ser Leu Asn Tyr Asn Glu Leu Glu Val Leu Ala 35 40 45 Lys Asn Gly Glu Thr Ile Glu Asn Phe Val Pro Lys Glu Gly Val Lys 50 55 60 Lys Ala Asp Lys Phe Ile Val Ile Glu Arg Lys Lys Lys Asn Ile Asn 65 70 75 80 Thr Thr Pro Val Asp Ile Ser Ile Ile Asp Ser Val Thr Asp Arg Thr 85 90 95 Tyr Pro Ala Ala Leu Gln Leu Ala Asn Lys Gly Phe Thr Glu Asn Xaa 100 105 110 Pro Asp Ala Val Val Thr Lys Arg Asn Pro Gln Lys Ile His Ile Asp 115 120 125 Leu Pro Gly Met Gly Asp Lys Ala Thr Val Glu Val Asn Asp Pro Thr 130 135 140 Tyr Ala Asn Val Ser Thr Ala Ile Asp Asn Leu Val Asn Gln Trp His 145 150 155 160 Asp Asn Tyr Ser Gly Gly Asn Thr Leu Pro Ala Arg Thr Gln Tyr Thr 165 170 175 Glu Ser Met Val Tyr Ser Lys Ser Gln Ile Glu Ala Ala Leu Asn Val 180 185 190 Asn Ser Xaa Ile Leu Asp Gly Thr Leu Gly Ile Asp Phe Lys Ser Ile 195 200 205 Ser Lys Gly Glu Lys Lys Val Met Ile Ala Ala Tyr Lys Gln Ile Phe 210 215 220 Tyr Thr Val Ser Ala Asn Leu Pro Asn Asn Pro Ala Asp Val Phe Asp 225 230 235 240 Lys Ser Val Thr Phe Xaa Glu Leu Gln Arg Lys Gly Val Ser Asn Glu 245 250 255 Ala Pro Pro Leu Phe Val Ser Asn Val Ala Tyr Gly Arg Thr Val Phe 260 265 270 Val Lys Leu Glu Thr Ser Ser Xaa Ser Asn Asp Val Glu Ala Ala Phe 275 280 285 Ser Ala Ala Leu Lys Gly Thr Asp Val Xaa Thr Asn Gly Lys Tyr Ser 290 295 300 Asp Ile Leu Glu Asn Ser Ser Phe Thr Ala Val Val Leu Gly Gly Asp 305 310 315 320 Ala Ala Glu His Asn Lys Val Val Thr Xaa Asp Phe Asp Val Ile Arg 325 330 335 Asn Val Ile Lys Asp Asn Ala Thr Phe Ser Arg Lys Asn Pro Ala Tyr 340 345 350 Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys Asn Asn Lys Ile Ala Gly 355 360 365 Val Asn Asn Arg Thr Glu Tyr Val Glu Thr Thr Ser Thr Glu Tyr Thr 370 375 380 Ser Gly Xaa Ile Asn Leu Ser His Gln 385 390 <![CDATA[<210> 77]]> <![CDATA[<211> 683]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SpyAD [33-714片段] nnAA (例如pAMF)突變體,不具有前導序列]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (33)..(33)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (256)..(256)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (355)..(355)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (626)..(626)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 77]]> Gly Gln Val Lys Ala Asp Asp Arg Ala Ser Gly Glu Thr Lys Ala Ser 1 5 10 15 Asn Thr His Asp Asp Ser Leu Pro Lys Pro Glu Thr Ile Gln Glu Ala 20 25 30 Xaa Ala Thr Ile Asp Ala Val Glu Lys Thr Leu Ser Gln Gln Lys Ala 35 40 45 Glu Leu Thr Glu Leu Ala Thr Ala Leu Thr Lys Thr Thr Ala Glu Ile 50 55 60 Asn His Leu Lys Glu Gln Gln Asp Asn Glu Gln Lys Ala Leu Thr Ser 65 70 75 80 Ala Gln Glu Ile Tyr Thr Asn Thr Leu Ala Ser Ser Glu Glu Thr Leu 85 90 95 Leu Ala Gln Gly Ala Glu His Gln Arg Glu Leu Thr Ala Thr Glu Thr 100 105 110 Glu Leu His Asn Ala Gln Ala Asp Gln His Ser Lys Glu Thr Ala Leu 115 120 125 Ser Glu Gln Lys Ala Ser Ile Ser Ala Glu Thr Thr Arg Ala Gln Asp 130 135 140 Leu Val Glu Gln Val Lys Thr Ser Glu Gln Asn Ile Ala Lys Leu Asn 145 150 155 160 Ala Met Ile Ser Asn Pro Asp Ala Ile Thr Lys Ala Ala Gln Thr Ala 165 170 175 Asn Asp Asn Thr Lys Ala Leu Ser Ser Glu Leu Glu Lys Ala Lys Ala 180 185 190 Asp Leu Glu Asn Gln Lys Ala Lys Val Lys Lys Gln Leu Thr Glu Glu 195 200 205 Leu Ala Ala Gln Lys Ala Ala Leu Ala Glu Lys Glu Ala Glu Leu Ser 210 215 220 Arg Leu Lys Ser Ser Ala Pro Ser Thr Gln Asp Ser Ile Val Gly Asn 225 230 235 240 Asn Thr Met Lys Ala Pro Gln Gly Tyr Pro Leu Glu Glu Leu Lys Xaa 245 250 255 Leu Glu Ala Ser Gly Tyr Ile Gly Ser Ala Ser Tyr Asn Asn Tyr Tyr 260 265 270 Lys Glu His Ala Asp Gln Ile Ile Ala Lys Ala Ser Pro Gly Asn Gln 275 280 285 Leu Asn Gln Tyr Gln Asp Ile Pro Ala Asp Arg Asn Arg Phe Val Asp 290 295 300 Pro Asp Asn Leu Thr Pro Glu Val Gln Asn Glu Leu Ala Gln Phe Ala 305 310 315 320 Ala His Met Ile Asn Ser Val Arg Arg Gln Leu Gly Leu Pro Pro Val 325 330 335 Thr Val Thr Ala Gly Ser Gln Glu Phe Ala Arg Leu Leu Ser Thr Ser 340 345 350 Tyr Lys Xaa Thr His Gly Asn Thr Arg Pro Ser Phe Val Tyr Gly Gln 355 360 365 Pro Gly Val Ser Gly His Tyr Gly Val Gly Pro His Asp Lys Thr Ile 370 375 380 Ile Glu Asp Ser Ala Gly Ala Ser Gly Leu Ile Arg Asn Asp Asp Asn 385 390 395 400 Met Tyr Glu Asn Ile Gly Ala Phe Asn Asp Val His Thr Val Asn Gly 405 410 415 Ile Lys Arg Gly Ile Tyr Asp Ser Ile Lys Tyr Met Leu Phe Thr Asp 420 425 430 His Leu His Gly Asn Thr Tyr Gly His Ala Ile Asn Phe Leu Arg Val 435 440 445 Asp Lys His Asn Pro Asn Ala Pro Val Tyr Leu Gly Phe Ser Thr Ser 450 455 460 Asn Val Gly Ser Leu Asn Glu His Phe Val Met Phe Pro Glu Ser Asn 465 470 475 480 Ile Ala Asn His Gln Arg Phe Asn Lys Thr Pro Ile Lys Ala Val Gly 485 490 495 Ser Thr Lys Asp Tyr Ala Gln Arg Val Gly Thr Val Ser Asp Thr Ile 500 505 510 Ala Ala Ile Lys Gly Lys Val Ser Ser Leu Glu Asn Arg Leu Ser Ala 515 520 525 Ile His Gln Glu Ala Asp Ile Met Ala Ala Gln Ala Lys Val Ser Gln 530 535 540 Leu Gln Gly Lys Leu Ala Ser Thr Leu Lys Gln Ser Asp Ser Leu Asn 545 550 555 560 Leu Gln Val Arg Gln Leu Asn Asp Thr Lys Gly Ser Leu Arg Thr Glu 565 570 575 Leu Leu Ala Ala Lys Ala Lys Gln Ala Gln Leu Glu Ala Thr Arg Asp 580 585 590 Gln Ser Leu Ala Lys Leu Ala Ser Leu Lys Ala Ala Leu His Gln Thr 595 600 605 Glu Ala Leu Ala Glu Gln Ala Ala Ala Arg Val Thr Ala Leu Val Ala 610 615 620 Lys Xaa Ala His Leu Gln Tyr Leu Arg Asp Phe Lys Leu Asn Pro Asn 625 630 635 640 Arg Leu Gln Val Ile Arg Glu Arg Ile Asp Asn Thr Lys Gln Asp Leu 645 650 655 Ala Lys Thr Thr Ser Ser Leu Leu Asn Ala Gln Glu Ala Leu Ala Ala 660 665 670 Leu Gln Ala Lys Gln Ser Ser Leu Glu Ala Thr 675 680 <![CDATA[<210> 78]]> <![CDATA[<211> 668]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SpyAD [33-699片段] nnAA (例如pAMF)突變體,不具有前導序列]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (33)..(33)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (256)..(256)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (355)..(355)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (626)..(626)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 78]]> Gly Gln Val Lys Ala Asp Asp Arg Ala Ser Gly Glu Thr Lys Ala Ser 1 5 10 15 Asn Thr His Asp Asp Ser Leu Pro Lys Pro Glu Thr Ile Gln Glu Ala 20 25 30 Xaa Ala Thr Ile Asp Ala Val Glu Lys Thr Leu Ser Gln Gln Lys Ala 35 40 45 Glu Leu Thr Glu Leu Ala Thr Ala Leu Thr Lys Thr Thr Ala Glu Ile 50 55 60 Asn His Leu Lys Glu Gln Gln Asp Asn Glu Gln Lys Ala Leu Thr Ser 65 70 75 80 Ala Gln Glu Ile Tyr Thr Asn Thr Leu Ala Ser Ser Glu Glu Thr Leu 85 90 95 Leu Ala Gln Gly Ala Glu His Gln Arg Glu Leu Thr Ala Thr Glu Thr 100 105 110 Glu Leu His Asn Ala Gln Ala Asp Gln His Ser Lys Glu Thr Ala Leu 115 120 125 Ser Glu Gln Lys Ala Ser Ile Ser Ala Glu Thr Thr Arg Ala Gln Asp 130 135 140 Leu Val Glu Gln Val Lys Thr Ser Glu Gln Asn Ile Ala Lys Leu Asn 145 150 155 160 Ala Met Ile Ser Asn Pro Asp Ala Ile Thr Lys Ala Ala Gln Thr Ala 165 170 175 Asn Asp Asn Thr Lys Ala Leu Ser Ser Glu Leu Glu Lys Ala Lys Ala 180 185 190 Asp Leu Glu Asn Gln Lys Ala Lys Val Lys Lys Gln Leu Thr Glu Glu 195 200 205 Leu Ala Ala Gln Lys Ala Ala Leu Ala Glu Lys Glu Ala Glu Leu Ser 210 215 220 Arg Leu Lys Ser Ser Ala Pro Ser Thr Gln Asp Ser Ile Val Gly Asn 225 230 235 240 Asn Thr Met Lys Ala Pro Gln Gly Tyr Pro Leu Glu Glu Leu Lys Xaa 245 250 255 Leu Glu Ala Ser Gly Tyr Ile Gly Ser Ala Ser Tyr Asn Asn Tyr Tyr 260 265 270 Lys Glu His Ala Asp Gln Ile Ile Ala Lys Ala Ser Pro Gly Asn Gln 275 280 285 Leu Asn Gln Tyr Gln Asp Ile Pro Ala Asp Arg Asn Arg Phe Val Asp 290 295 300 Pro Asp Asn Leu Thr Pro Glu Val Gln Asn Glu Leu Ala Gln Phe Ala 305 310 315 320 Ala His Met Ile Asn Ser Val Arg Arg Gln Leu Gly Leu Pro Pro Val 325 330 335 Thr Val Thr Ala Gly Ser Gln Glu Phe Ala Arg Leu Leu Ser Thr Ser 340 345 350 Tyr Lys Xaa Thr His Gly Asn Thr Arg Pro Ser Phe Val Tyr Gly Gln 355 360 365 Pro Gly Val Ser Gly His Tyr Gly Val Gly Pro His Asp Lys Thr Ile 370 375 380 Ile Glu Asp Ser Ala Gly Ala Ser Gly Leu Ile Arg Asn Asp Asp Asn 385 390 395 400 Met Tyr Glu Asn Ile Gly Ala Phe Asn Asp Val His Thr Val Asn Gly 405 410 415 Ile Lys Arg Gly Ile Tyr Asp Ser Ile Lys Tyr Met Leu Phe Thr Asp 420 425 430 His Leu His Gly Asn Thr Tyr Gly His Ala Ile Asn Phe Leu Arg Val 435 440 445 Asp Lys His Asn Pro Asn Ala Pro Val Tyr Leu Gly Phe Ser Thr Ser 450 455 460 Asn Val Gly Ser Leu Asn Glu His Phe Val Met Phe Pro Glu Ser Asn 465 470 475 480 Ile Ala Asn His Gln Arg Phe Asn Lys Thr Pro Ile Lys Ala Val Gly 485 490 495 Ser Thr Lys Asp Tyr Ala Gln Arg Val Gly Thr Val Ser Asp Thr Ile 500 505 510 Ala Ala Ile Lys Gly Lys Val Ser Ser Leu Glu Asn Arg Leu Ser Ala 515 520 525 Ile His Gln Glu Ala Asp Ile Met Ala Ala Gln Ala Lys Val Ser Gln 530 535 540 Leu Gln Gly Lys Leu Ala Ser Thr Leu Lys Gln Ser Asp Ser Leu Asn 545 550 555 560 Leu Gln Val Arg Gln Leu Asn Asp Thr Lys Gly Ser Leu Arg Thr Glu 565 570 575 Leu Leu Ala Ala Lys Ala Lys Gln Ala Gln Leu Glu Ala Thr Arg Asp 580 585 590 Gln Ser Leu Ala Lys Leu Ala Ser Leu Lys Ala Ala Leu His Gln Thr 595 600 605 Glu Ala Leu Ala Glu Gln Ala Ala Ala Arg Val Thr Ala Leu Val Ala 610 615 620 Lys Xaa Ala His Leu Gln Tyr Leu Arg Asp Phe Lys Leu Asn Pro Asn 625 630 635 640 Arg Leu Gln Val Ile Arg Glu Arg Ile Asp Asn Thr Lys Gln Asp Leu 645 650 655 Ala Lys Thr Thr Ser Ser Leu Leu Asn Ala Gln Glu 660 665 <![CDATA[<210> 79]]> <![CDATA[<211> 653]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SpyAD [33-684片段] nnAA (例如pAMF)突變體,不具有前導序列]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (33)..(33)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (256)..(256)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (355)..(355)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (626)..(626)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 79]]> Gly Gln Val Lys Ala Asp Asp Arg Ala Ser Gly Glu Thr Lys Ala Ser 1 5 10 15 Asn Thr His Asp Asp Ser Leu Pro Lys Pro Glu Thr Ile Gln Glu Ala 20 25 30 Xaa Ala Thr Ile Asp Ala Val Glu Lys Thr Leu Ser Gln Gln Lys Ala 35 40 45 Glu Leu Thr Glu Leu Ala Thr Ala Leu Thr Lys Thr Thr Ala Glu Ile 50 55 60 Asn His Leu Lys Glu Gln Gln Asp Asn Glu Gln Lys Ala Leu Thr Ser 65 70 75 80 Ala Gln Glu Ile Tyr Thr Asn Thr Leu Ala Ser Ser Glu Glu Thr Leu 85 90 95 Leu Ala Gln Gly Ala Glu His Gln Arg Glu Leu Thr Ala Thr Glu Thr 100 105 110 Glu Leu His Asn Ala Gln Ala Asp Gln His Ser Lys Glu Thr Ala Leu 115 120 125 Ser Glu Gln Lys Ala Ser Ile Ser Ala Glu Thr Thr Arg Ala Gln Asp 130 135 140 Leu Val Glu Gln Val Lys Thr Ser Glu Gln Asn Ile Ala Lys Leu Asn 145 150 155 160 Ala Met Ile Ser Asn Pro Asp Ala Ile Thr Lys Ala Ala Gln Thr Ala 165 170 175 Asn Asp Asn Thr Lys Ala Leu Ser Ser Glu Leu Glu Lys Ala Lys Ala 180 185 190 Asp Leu Glu Asn Gln Lys Ala Lys Val Lys Lys Gln Leu Thr Glu Glu 195 200 205 Leu Ala Ala Gln Lys Ala Ala Leu Ala Glu Lys Glu Ala Glu Leu Ser 210 215 220 Arg Leu Lys Ser Ser Ala Pro Ser Thr Gln Asp Ser Ile Val Gly Asn 225 230 235 240 Asn Thr Met Lys Ala Pro Gln Gly Tyr Pro Leu Glu Glu Leu Lys Xaa 245 250 255 Leu Glu Ala Ser Gly Tyr Ile Gly Ser Ala Ser Tyr Asn Asn Tyr Tyr 260 265 270 Lys Glu His Ala Asp Gln Ile Ile Ala Lys Ala Ser Pro Gly Asn Gln 275 280 285 Leu Asn Gln Tyr Gln Asp Ile Pro Ala Asp Arg Asn Arg Phe Val Asp 290 295 300 Pro Asp Asn Leu Thr Pro Glu Val Gln Asn Glu Leu Ala Gln Phe Ala 305 310 315 320 Ala His Met Ile Asn Ser Val Arg Arg Gln Leu Gly Leu Pro Pro Val 325 330 335 Thr Val Thr Ala Gly Ser Gln Glu Phe Ala Arg Leu Leu Ser Thr Ser 340 345 350 Tyr Lys Xaa Thr His Gly Asn Thr Arg Pro Ser Phe Val Tyr Gly Gln 355 360 365 Pro Gly Val Ser Gly His Tyr Gly Val Gly Pro His Asp Lys Thr Ile 370 375 380 Ile Glu Asp Ser Ala Gly Ala Ser Gly Leu Ile Arg Asn Asp Asp Asn 385 390 395 400 Met Tyr Glu Asn Ile Gly Ala Phe Asn Asp Val His Thr Val Asn Gly 405 410 415 Ile Lys Arg Gly Ile Tyr Asp Ser Ile Lys Tyr Met Leu Phe Thr Asp 420 425 430 His Leu His Gly Asn Thr Tyr Gly His Ala Ile Asn Phe Leu Arg Val 435 440 445 Asp Lys His Asn Pro Asn Ala Pro Val Tyr Leu Gly Phe Ser Thr Ser 450 455 460 Asn Val Gly Ser Leu Asn Glu His Phe Val Met Phe Pro Glu Ser Asn 465 470 475 480 Ile Ala Asn His Gln Arg Phe Asn Lys Thr Pro Ile Lys Ala Val Gly 485 490 495 Ser Thr Lys Asp Tyr Ala Gln Arg Val Gly Thr Val Ser Asp Thr Ile 500 505 510 Ala Ala Ile Lys Gly Lys Val Ser Ser Leu Glu Asn Arg Leu Ser Ala 515 520 525 Ile His Gln Glu Ala Asp Ile Met Ala Ala Gln Ala Lys Val Ser Gln 530 535 540 Leu Gln Gly Lys Leu Ala Ser Thr Leu Lys Gln Ser Asp Ser Leu Asn 545 550 555 560 Leu Gln Val Arg Gln Leu Asn Asp Thr Lys Gly Ser Leu Arg Thr Glu 565 570 575 Leu Leu Ala Ala Lys Ala Lys Gln Ala Gln Leu Glu Ala Thr Arg Asp 580 585 590 Gln Ser Leu Ala Lys Leu Ala Ser Leu Lys Ala Ala Leu His Gln Thr 595 600 605 Glu Ala Leu Ala Glu Gln Ala Ala Ala Arg Val Thr Ala Leu Val Ala 610 615 620 Lys Xaa Ala His Leu Gln Tyr Leu Arg Asp Phe Lys Leu Asn Pro Asn 625 630 635 640 Arg Leu Gln Val Ile Arg Glu Arg Ile Asp Asn Thr Lys 645 650 <![CDATA[<210> 80]]> <![CDATA[<211> 840]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SpyAD [33-849片段] nnAA (例如pAMF)突變體,具有長前導序列]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (55)..(55)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (278)..(278)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (377)..(377)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (648)..(648)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 80]]> Met His His His His His His His His His His His His Gly Ser Gly 1 5 10 15 Glu Asn Leu Tyr Phe Gln Gly Gln Val Lys Ala Asp Asp Arg Ala Ser 20 25 30 Gly Glu Thr Lys Ala Ser Asn Thr His Asp Asp Ser Leu Pro Lys Pro 35 40 45 Glu Thr Ile Gln Glu Ala Xaa Ala Thr Ile Asp Ala Val Glu Lys Thr 50 55 60 Leu Ser Gln Gln Lys Ala Glu Leu Thr Glu Leu Ala Thr Ala Leu Thr 65 70 75 80 Lys Thr Thr Ala Glu Ile Asn His Leu Lys Glu Gln Gln Asp Asn Glu 85 90 95 Gln Lys Ala Leu Thr Ser Ala Gln Glu Ile Tyr Thr Asn Thr Leu Ala 100 105 110 Ser Ser Glu Glu Thr Leu Leu Ala Gln Gly Ala Glu His Gln Arg Glu 115 120 125 Leu Thr Ala Thr Glu Thr Glu Leu His Asn Ala Gln Ala Asp Gln His 130 135 140 Ser Lys Glu Thr Ala Leu Ser Glu Gln Lys Ala Ser Ile Ser Ala Glu 145 150 155 160 Thr Thr Arg Ala Gln Asp Leu Val Glu Gln Val Lys Thr Ser Glu Gln 165 170 175 Asn Ile Ala Lys Leu Asn Ala Met Ile Ser Asn Pro Asp Ala Ile Thr 180 185 190 Lys Ala Ala Gln Thr Ala Asn Asp Asn Thr Lys Ala Leu Ser Ser Glu 195 200 205 Leu Glu Lys Ala Lys Ala Asp Leu Glu Asn Gln Lys Ala Lys Val Lys 210 215 220 Lys Gln Leu Thr Glu Glu Leu Ala Ala Gln Lys Ala Ala Leu Ala Glu 225 230 235 240 Lys Glu Ala Glu Leu Ser Arg Leu Lys Ser Ser Ala Pro Ser Thr Gln 245 250 255 Asp Ser Ile Val Gly Asn Asn Thr Met Lys Ala Pro Gln Gly Tyr Pro 260 265 270 Leu Glu Glu Leu Lys Xaa Leu Glu Ala Ser Gly Tyr Ile Gly Ser Ala 275 280 285 Ser Tyr Asn Asn Tyr Tyr Lys Glu His Ala Asp Gln Ile Ile Ala Lys 290 295 300 Ala Ser Pro Gly Asn Gln Leu Asn Gln Tyr Gln Asp Ile Pro Ala Asp 305 310 315 320 Arg Asn Arg Phe Val Asp Pro Asp Asn Leu Thr Pro Glu Val Gln Asn 325 330 335 Glu Leu Ala Gln Phe Ala Ala His Met Ile Asn Ser Val Arg Arg Gln 340 345 350 Leu Gly Leu Pro Pro Val Thr Val Thr Ala Gly Ser Gln Glu Phe Ala 355 360 365 Arg Leu Leu Ser Thr Ser Tyr Lys Xaa Thr His Gly Asn Thr Arg Pro 370 375 380 Ser Phe Val Tyr Gly Gln Pro Gly Val Ser Gly His Tyr Gly Val Gly 385 390 395 400 Pro His Asp Lys Thr Ile Ile Glu Asp Ser Ala Gly Ala Ser Gly Leu 405 410 415 Ile Arg Asn Asp Asp Asn Met Tyr Glu Asn Ile Gly Ala Phe Asn Asp 420 425 430 Val His Thr Val Asn Gly Ile Lys Arg Gly Ile Tyr Asp Ser Ile Lys 435 440 445 Tyr Met Leu Phe Thr Asp His Leu His Gly Asn Thr Tyr Gly His Ala 450 455 460 Ile Asn Phe Leu Arg Val Asp Lys His Asn Pro Asn Ala Pro Val Tyr 465 470 475 480 Leu Gly Phe Ser Thr Ser Asn Val Gly Ser Leu Asn Glu His Phe Val 485 490 495 Met Phe Pro Glu Ser Asn Ile Ala Asn His Gln Arg Phe Asn Lys Thr 500 505 510 Pro Ile Lys Ala Val Gly Ser Thr Lys Asp Tyr Ala Gln Arg Val Gly 515 520 525 Thr Val Ser Asp Thr Ile Ala Ala Ile Lys Gly Lys Val Ser Ser Leu 530 535 540 Glu Asn Arg Leu Ser Ala Ile His Gln Glu Ala Asp Ile Met Ala Ala 545 550 555 560 Gln Ala Lys Val Ser Gln Leu Gln Gly Lys Leu Ala Ser Thr Leu Lys 565 570 575 Gln Ser Asp Ser Leu Asn Leu Gln Val Arg Gln Leu Asn Asp Thr Lys 580 585 590 Gly Ser Leu Arg Thr Glu Leu Leu Ala Ala Lys Ala Lys Gln Ala Gln 595 600 605 Leu Glu Ala Thr Arg Asp Gln Ser Leu Ala Lys Leu Ala Ser Leu Lys 610 615 620 Ala Ala Leu His Gln Thr Glu Ala Leu Ala Glu Gln Ala Ala Ala Arg 625 630 635 640 Val Thr Ala Leu Val Ala Lys Xaa Ala His Leu Gln Tyr Leu Arg Asp 645 650 655 Phe Lys Leu Asn Pro Asn Arg Leu Gln Val Ile Arg Glu Arg Ile Asp 660 665 670 Asn Thr Lys Gln Asp Leu Ala Lys Thr Thr Ser Ser Leu Leu Asn Ala 675 680 685 Gln Glu Ala Leu Ala Ala Leu Gln Ala Lys Gln Ser Ser Leu Glu Ala 690 695 700 Thr Ile Ala Thr Thr Glu His Gln Leu Thr Leu Leu Lys Thr Leu Ala 705 710 715 720 Asn Glu Lys Glu Tyr Arg His Leu Asp Glu Asp Ile Ala Thr Val Pro 725 730 735 Asp Leu Gln Val Ala Pro Pro Leu Thr Gly Val Lys Pro Leu Ser Tyr 740 745 750 Ser Lys Ile Asp Thr Thr Pro Leu Val Gln Glu Met Val Lys Glu Thr 755 760 765 Lys Gln Leu Leu Glu Ala Ser Ala Arg Leu Ala Ala Glu Asn Thr Ser 770 775 780 Leu Val Ala Glu Ala Leu Val Gly Gln Thr Ser Glu Met Val Ala Ser 785 790 795 800 Asn Ala Ile Val Ser Lys Ile Thr Ser Ser Ile Thr Gln Pro Ser Ser 805 810 815 Lys Thr Ser Tyr Gly Ser Gly Ser Ser Thr Thr Ser Asn Leu Ile Ser 820 825 830 Asp Val Asp Glu Ser Thr Gln Arg 835 840 <![CDATA[<210> 81]]> <![CDATA[<211> 562]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SpyAD [33-594片段] nnAA (例如pAMF)突變體,具有長前導序列]]> <![CDATA[<220>]]> <![CDATA[<221> misc_feature]]> <![CDATA[<222> (32)..(32)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> misc_feature]]> <![CDATA[<222> (255)..(255)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> misc_feature]]> <![CDATA[<222> (354)..(354)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 81]]> Gln Val Lys Ala Asp Asp Arg Ala Ser Gly Glu Thr Lys Ala Ser Asn 1 5 10 15 Thr His Asp Asp Ser Leu Pro Lys Pro Glu Thr Ile Gln Glu Ala Xaa 20 25 30 Ala Thr Ile Asp Ala Val Glu Lys Thr Leu Ser Gln Gln Lys Ala Glu 35 40 45 Leu Thr Glu Leu Ala Thr Ala Leu Thr Lys Thr Thr Ala Glu Ile Asn 50 55 60 His Leu Lys Glu Gln Gln Asp Asn Glu Gln Lys Ala Leu Thr Ser Ala 65 70 75 80 Gln Glu Ile Tyr Thr Asn Thr Leu Ala Ser Ser Glu Glu Thr Leu Leu 85 90 95 Ala Gln Gly Ala Glu His Gln Arg Glu Leu Thr Ala Thr Glu Thr Glu 100 105 110 Leu His Asn Ala Gln Ala Asp Gln His Ser Lys Glu Thr Ala Leu Ser 115 120 125 Glu Gln Lys Ala Ser Ile Ser Ala Glu Thr Thr Arg Ala Gln Asp Leu 130 135 140 Val Glu Gln Val Lys Thr Ser Glu Gln Asn Ile Ala Lys Leu Asn Ala 145 150 155 160 Met Ile Ser Asn Pro Asp Ala Ile Thr Lys Ala Ala Gln Thr Ala Asn 165 170 175 Asp Asn Thr Lys Ala Leu Ser Ser Glu Leu Glu Lys Ala Lys Ala Asp 180 185 190 Leu Glu Asn Gln Lys Ala Lys Val Lys Lys Gln Leu Thr Glu Glu Leu 195 200 205 Ala Ala Gln Lys Ala Ala Leu Ala Glu Lys Glu Ala Glu Leu Ser Arg 210 215 220 Leu Lys Ser Ser Ala Pro Ser Thr Gln Asp Ser Ile Val Gly Asn Asn 225 230 235 240 Thr Met Lys Ala Pro Gln Gly Tyr Pro Leu Glu Glu Leu Lys Xaa Leu 245 250 255 Glu Ala Ser Gly Tyr Ile Gly Ser Ala Ser Tyr Asn Asn Tyr Tyr Lys 260 265 270 Glu His Ala Asp Gln Ile Ile Ala Lys Ala Ser Pro Gly Asn Gln Leu 275 280 285 Asn Gln Tyr Gln Asp Ile Pro Ala Asp Arg Asn Arg Phe Val Asp Pro 290 295 300 Asp Asn Leu Thr Pro Glu Val Gln Asn Glu Leu Ala Gln Phe Ala Ala 305 310 315 320 His Met Ile Asn Ser Val Arg Arg Gln Leu Gly Leu Pro Pro Val Thr 325 330 335 Val Thr Ala Gly Ser Gln Glu Phe Ala Arg Leu Leu Ser Thr Ser Tyr 340 345 350 Lys Xaa Thr His Gly Asn Thr Arg Pro Ser Phe Val Tyr Gly Gln Pro 355 360 365 Gly Val Ser Gly His Tyr Gly Val Gly Pro His Asp Lys Thr Ile Ile 370 375 380 Glu Asp Ser Ala Gly Ala Ser Gly Leu Ile Arg Asn Asp Asp Asn Met 385 390 395 400 Tyr Glu Asn Ile Gly Ala Phe Asn Asp Val His Thr Val Asn Gly Ile 405 410 415 Lys Arg Gly Ile Tyr Asp Ser Ile Lys Tyr Met Leu Phe Thr Asp His 420 425 430 Leu His Gly Asn Thr Tyr Gly His Ala Ile Asn Phe Leu Arg Val Asp 435 440 445 Lys His Asn Pro Asn Ala Pro Val Tyr Leu Gly Phe Ser Thr Ser Asn 450 455 460 Val Gly Ser Leu Asn Glu His Phe Val Met Phe Pro Glu Ser Asn Ile 465 470 475 480 Ala Asn His Gln Arg Phe Asn Lys Thr Pro Ile Lys Ala Val Gly Ser 485 490 495 Thr Lys Asp Tyr Ala Gln Arg Val Gly Thr Val Ser Asp Thr Ile Ala 500 505 510 Ala Ile Lys Gly Lys Val Ser Ser Leu Glu Asn Arg Leu Ser Ala Ile 515 520 525 His Gln Glu Ala Asp Ile Met Ala Ala Gln Ala Lys Val Ser Gln Leu 530 535 540 Gln Gly Lys Leu Ala Ser Thr Leu Lys Gln Ser Asp Ser Leu Asn Leu 545 550 555 560 Gln Val <![CDATA[<210> 82]]> <![CDATA[<211> 625]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SpyAD [33-657片段] nnAA (例如pAMF)突變體,具有長前導序列]]> <![CDATA[<220>]]> <![CDATA[<221> misc_feature]]> <![CDATA[<222> (32)..(32)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> misc_feature]]> <![CDATA[<222> (255)..(255)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> misc_feature]]> <![CDATA[<222> (354)..(354)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> misc_feature]]> <![CDATA[<222> (625)..(625)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 82]]> Gln Val Lys Ala Asp Asp Arg Ala Ser Gly Glu Thr Lys Ala Ser Asn 1 5 10 15 Thr His Asp Asp Ser Leu Pro Lys Pro Glu Thr Ile Gln Glu Ala Xaa 20 25 30 Ala Thr Ile Asp Ala Val Glu Lys Thr Leu Ser Gln Gln Lys Ala Glu 35 40 45 Leu Thr Glu Leu Ala Thr Ala Leu Thr Lys Thr Thr Ala Glu Ile Asn 50 55 60 His Leu Lys Glu Gln Gln Asp Asn Glu Gln Lys Ala Leu Thr Ser Ala 65 70 75 80 Gln Glu Ile Tyr Thr Asn Thr Leu Ala Ser Ser Glu Glu Thr Leu Leu 85 90 95 Ala Gln Gly Ala Glu His Gln Arg Glu Leu Thr Ala Thr Glu Thr Glu 100 105 110 Leu His Asn Ala Gln Ala Asp Gln His Ser Lys Glu Thr Ala Leu Ser 115 120 125 Glu Gln Lys Ala Ser Ile Ser Ala Glu Thr Thr Arg Ala Gln Asp Leu 130 135 140 Val Glu Gln Val Lys Thr Ser Glu Gln Asn Ile Ala Lys Leu Asn Ala 145 150 155 160 Met Ile Ser Asn Pro Asp Ala Ile Thr Lys Ala Ala Gln Thr Ala Asn 165 170 175 Asp Asn Thr Lys Ala Leu Ser Ser Glu Leu Glu Lys Ala Lys Ala Asp 180 185 190 Leu Glu Asn Gln Lys Ala Lys Val Lys Lys Gln Leu Thr Glu Glu Leu 195 200 205 Ala Ala Gln Lys Ala Ala Leu Ala Glu Lys Glu Ala Glu Leu Ser Arg 210 215 220 Leu Lys Ser Ser Ala Pro Ser Thr Gln Asp Ser Ile Val Gly Asn Asn 225 230 235 240 Thr Met Lys Ala Pro Gln Gly Tyr Pro Leu Glu Glu Leu Lys Xaa Leu 245 250 255 Glu Ala Ser Gly Tyr Ile Gly Ser Ala Ser Tyr Asn Asn Tyr Tyr Lys 260 265 270 Glu His Ala Asp Gln Ile Ile Ala Lys Ala Ser Pro Gly Asn Gln Leu 275 280 285 Asn Gln Tyr Gln Asp Ile Pro Ala Asp Arg Asn Arg Phe Val Asp Pro 290 295 300 Asp Asn Leu Thr Pro Glu Val Gln Asn Glu Leu Ala Gln Phe Ala Ala 305 310 315 320 His Met Ile Asn Ser Val Arg Arg Gln Leu Gly Leu Pro Pro Val Thr 325 330 335 Val Thr Ala Gly Ser Gln Glu Phe Ala Arg Leu Leu Ser Thr Ser Tyr 340 345 350 Lys Xaa Thr His Gly Asn Thr Arg Pro Ser Phe Val Tyr Gly Gln Pro 355 360 365 Gly Val Ser Gly His Tyr Gly Val Gly Pro His Asp Lys Thr Ile Ile 370 375 380 Glu Asp Ser Ala Gly Ala Ser Gly Leu Ile Arg Asn Asp Asp Asn Met 385 390 395 400 Tyr Glu Asn Ile Gly Ala Phe Asn Asp Val His Thr Val Asn Gly Ile 405 410 415 Lys Arg Gly Ile Tyr Asp Ser Ile Lys Tyr Met Leu Phe Thr Asp His 420 425 430 Leu His Gly Asn Thr Tyr Gly His Ala Ile Asn Phe Leu Arg Val Asp 435 440 445 Lys His Asn Pro Asn Ala Pro Val Tyr Leu Gly Phe Ser Thr Ser Asn 450 455 460 Val Gly Ser Leu Asn Glu His Phe Val Met Phe Pro Glu Ser Asn Ile 465 470 475 480 Ala Asn His Gln Arg Phe Asn Lys Thr Pro Ile Lys Ala Val Gly Ser 485 490 495 Thr Lys Asp Tyr Ala Gln Arg Val Gly Thr Val Ser Asp Thr Ile Ala 500 505 510 Ala Ile Lys Gly Lys Val Ser Ser Leu Glu Asn Arg Leu Ser Ala Ile 515 520 525 His Gln Glu Ala Asp Ile Met Ala Ala Gln Ala Lys Val Ser Gln Leu 530 535 540 Gln Gly Lys Leu Ala Ser Thr Leu Lys Gln Ser Asp Ser Leu Asn Leu 545 550 555 560 Gln Val Arg Gln Leu Asn Asp Thr Lys Gly Ser Leu Arg Thr Glu Leu 565 570 575 Leu Ala Ala Lys Ala Lys Gln Ala Gln Leu Glu Ala Thr Arg Asp Gln 580 585 590 Ser Leu Ala Lys Leu Ala Ser Leu Lys Ala Ala Leu His Gln Thr Glu 595 600 605 Ala Leu Ala Glu Gln Ala Ala Ala Arg Val Thr Ala Leu Val Ala Lys 610 615 620 Xaa 625 <![CDATA[<210> 83]]> <![CDATA[<211> 635]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> SpyAD [33-667片段] nnAA (例如pAMF)突變體,具有長前導序列]]> <![CDATA[<220>]]> <![CDATA[<221> misc_feature]]> <![CDATA[<222> (32)..(32)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> misc_feature]]> <![CDATA[<222> (255)..(255)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> misc_feature]]> <![CDATA[<222> (354)..(354)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<220>]]> <![CDATA[<221> misc_feature]]> <![CDATA[<222> (625)..(625)]]> <![CDATA[<223> Xaa = nnAA (例如pAMF)]]> <![CDATA[<400> 83]]> Gln Val Lys Ala Asp Asp Arg Ala Ser Gly Glu Thr Lys Ala Ser Asn 1 5 10 15 Thr His Asp Asp Ser Leu Pro Lys Pro Glu Thr Ile Gln Glu Ala Xaa 20 25 30 Ala Thr Ile Asp Ala Val Glu Lys Thr Leu Ser Gln Gln Lys Ala Glu 35 40 45 Leu Thr Glu Leu Ala Thr Ala Leu Thr Lys Thr Thr Ala Glu Ile Asn 50 55 60 His Leu Lys Glu Gln Gln Asp Asn Glu Gln Lys Ala Leu Thr Ser Ala 65 70 75 80 Gln Glu Ile Tyr Thr Asn Thr Leu Ala Ser Ser Glu Glu Thr Leu Leu 85 90 95 Ala Gln Gly Ala Glu His Gln Arg Glu Leu Thr Ala Thr Glu Thr Glu 100 105 110 Leu His Asn Ala Gln Ala Asp Gln His Ser Lys Glu Thr Ala Leu Ser 115 120 125 Glu Gln Lys Ala Ser Ile Ser Ala Glu Thr Thr Arg Ala Gln Asp Leu 130 135 140 Val Glu Gln Val Lys Thr Ser Glu Gln Asn Ile Ala Lys Leu Asn Ala 145 150 155 160 Met Ile Ser Asn Pro Asp Ala Ile Thr Lys Ala Ala Gln Thr Ala Asn 165 170 175 Asp Asn Thr Lys Ala Leu Ser Ser Glu Leu Glu Lys Ala Lys Ala Asp 180 185 190 Leu Glu Asn Gln Lys Ala Lys Val Lys Lys Gln Leu Thr Glu Glu Leu 195 200 205 Ala Ala Gln Lys Ala Ala Leu Ala Glu Lys Glu Ala Glu Leu Ser Arg 210 215 220 Leu Lys Ser Ser Ala Pro Ser Thr Gln Asp Ser Ile Val Gly Asn Asn 225 230 235 240 Thr Met Lys Ala Pro Gln Gly Tyr Pro Leu Glu Glu Leu Lys Xaa Leu 245 250 255 Glu Ala Ser Gly Tyr Ile Gly Ser Ala Ser Tyr Asn Asn Tyr Tyr Lys 260 265 270 Glu His Ala Asp Gln Ile Ile Ala Lys Ala Ser Pro Gly Asn Gln Leu 275 280 285 Asn Gln Tyr Gln Asp Ile Pro Ala Asp Arg Asn Arg Phe Val Asp Pro 290 295 300 Asp Asn Leu Thr Pro Glu Val Gln Asn Glu Leu Ala Gln Phe Ala Ala 305 310 315 320 His Met Ile Asn Ser Val Arg Arg Gln Leu Gly Leu Pro Pro Val Thr 325 330 335 Val Thr Ala Gly Ser Gln Glu Phe Ala Arg Leu Leu Ser Thr Ser Tyr 340 345 350 Lys Xaa Thr His Gly Asn Thr Arg Pro Ser Phe Val Tyr Gly Gln Pro 355 360 365 Gly Val Ser Gly His Tyr Gly Val Gly Pro His Asp Lys Thr Ile Ile 370 375 380 Glu Asp Ser Ala Gly Ala Ser Gly Leu Ile Arg Asn Asp Asp Asn Met 385 390 395 400 Tyr Glu Asn Ile Gly Ala Phe Asn Asp Val His Thr Val Asn Gly Ile 405 410 415 Lys Arg Gly Ile Tyr Asp Ser Ile Lys Tyr Met Leu Phe Thr Asp His 420 425 430 Leu His Gly Asn Thr Tyr Gly His Ala Ile Asn Phe Leu Arg Val Asp 435 440 445 Lys His Asn Pro Asn Ala Pro Val Tyr Leu Gly Phe Ser Thr Ser Asn 450 455 460 Val Gly Ser Leu Asn Glu His Phe Val Met Phe Pro Glu Ser Asn Ile 465 470 475 480 Ala Asn His Gln Arg Phe Asn Lys Thr Pro Ile Lys Ala Val Gly Ser 485 490 495 Thr Lys Asp Tyr Ala Gln Arg Val Gly Thr Val Ser Asp Thr Ile Ala 500 505 510 Ala Ile Lys Gly Lys Val Ser Ser Leu Glu Asn Arg Leu Ser Ala Ile 515 520 525 His Gln Glu Ala Asp Ile Met Ala Ala Gln Ala Lys Val Ser Gln Leu 530 535 540 Gln Gly Lys Leu Ala Ser Thr Leu Lys Gln Ser Asp Ser Leu Asn Leu 545 550 555 560 Gln Val Arg Gln Leu Asn Asp Thr Lys Gly Ser Leu Arg Thr Glu Leu 565 570 575 Leu Ala Ala Lys Ala Lys Gln Ala Gln Leu Glu Ala Thr Arg Asp Gln 580 585 590 Ser Leu Ala Lys Leu Ala Ser Leu Lys Ala Ala Leu His Gln Thr Glu 595 600 605 Ala Leu Ala Glu Gln Ala Ala Ala Arg Val Thr Ala Leu Val Ala Lys 610 615 620 Xaa Ala His Leu Gln Tyr Leu Arg Asp Phe Lys 625 630 635
Claims (108)
- 一種多肽-多醣結合物,其包括: (a) GAS多肽抗原或非GAS載體多肽,其包括至少一個非天然胺基酸(nnAA),其中該nnAA包括點擊化學反應性基團;及 (b)經純化細胞壁多醣或結合肽聚醣之莢膜多醣,其分子量為至少約10 kDa至至少約40 kDa。
- 如請求項1之多肽-多醣結合物,其中該經純化細胞壁多醣缺乏免疫顯性N-乙醯基葡萄糖胺(GlcNAc)側鏈。
- 如請求項1至2之多肽-多醣結合物,其中該GAS多肽抗原係全長GAS多肽抗原或全長GAS多肽抗原之片段。
- 如請求項1至3中任一項之多肽-多醣結合物,其中該細胞壁多醣係GAS多醣或其變體。
- 如請求項4之多肽-多醣結合物,其中該GAS多醣或其變體之介於約8 mol%與約20 mol%之間之多醣重複單元由連接體衍生。
- 如請求項4至5之多肽-多醣結合物,其中該GAS多醣或其變體之介於約10 mol%與約20 mol%之間之多醣重複單元由連接體衍生。
- 如請求項4至6之多肽-多醣結合物,其中該GAS多醣或其變體之介於約10 mol%與約18 mol%之間之多醣重複單元由連接體衍生。
- 如請求項1至6中任一項之多肽-多醣結合物,其中平均分子量介於約185 kDa與約700 kDa之間。
- 如請求項1至7中任一項之多肽-多醣結合物,其中平均分子量介於約200 kDa與約700 kDa之間。
- 如請求項1至9中任一項之多肽-多醣結合物,其中該多肽-多醣結合物之平均分子量介於約300 kDa與約600 kDa之間。
- 如請求項1至10中任一項之多肽-多醣結合物,其中該多肽-多醣結合物之平均分子量介於約400 kDa與約500 kDa之間。
- 如請求項1至11中任一項之多肽-多醣結合物,其中該至少一個nnAA取代該GAS多肽抗原或該非GAS載體多肽中之離胺酸、白胺酸、異白胺酸或精胺酸。
- 如請求項1至12中任一項之多肽-多醣結合物,其中該至少一個nnAA係選自2-胺基-3-(4-疊氮基苯基)丙酸(pAF)、2-胺基-4-疊氮基丁酸、2-疊氮基-3-苯基丙酸、2-胺基-3-疊氮基丙酸、2-胺基-3-(4-(疊氮基甲基)苯基)丙酸(pAMF)、2-胺基-3-(5-(疊氮基甲基)吡啶-2-基)丙酸、2-胺基-3-(4-(疊氮基甲基)吡啶-2-基)丙酸、2-胺基-3-(6-(疊氮基甲基)吡啶-3-基)丙酸及2-胺基-5-疊氮基戊酸。
- 如請求項1至13中任一項之多肽-多醣結合物,其中該至少一個nnAA係pAMF。
- 如請求項1至14中任一項之多肽-多醣結合物,其中該GAS多肽抗原係選自C5a肽酶、鏈球菌溶血素O (SLO)、SpyAD、Sib35及Sfb1。
- 如請求項1至15中任一項之多肽-多醣結合物,其中該GAS多肽抗原係SpyAD多肽或其片段。
- 如請求項16之多肽-多醣結合物,其中該SpyAD多肽包括與SEQ ID NO: 33至少95%一致之胺基酸序列。
- 如請求項16之多肽-多醣結合物,其中該SpyAD多肽與SEQ ID NO: 33至少95%一致。
- 如請求項16至18中任一項之多肽-多醣結合物,其中該SpyAD多肽在SEQ ID NO: 33之位置K64、K287、K386及K657處包括pAMF取代。
- 如請求項16至19中任一項之多肽-多醣結合物,其中該SpyAD多肽包括SEQ ID NO: 34之胺基酸序列。
- 如請求項16至19中任一項之多肽-多醣結合物,其中該SpyAD多肽具有SEQ ID NO: 34之胺基酸序列。
- 如請求項16至19中任一項之多肽-多醣結合物,其中該SpyAD多肽包括SEQ ID NO: 77、SEQ ID NO: 78、SEQ ID NO: 79、SEQ ID NO: 81、SEQ ID NO: 82或SEQ ID NO: 83之胺基酸序列。
- 如請求項16至19中任一項之多肽-多醣結合物,其中該SpyAD多肽具有SEQ ID NO: 77、SEQ ID NO: 78、SEQ ID NO: 79、SEQ ID NO: 81、SEQ ID NO: 82或SEQ ID NO: 83之胺基酸序列。
- 如請求項1至2或4至14中任一項之多肽-多醣結合物,其中該非GAS載體多肽係選自ADI、鐵蛋白、蛋白質D及eCRM197。
- 如請求項24之多肽-多醣結合物,其中該非GAS載體多肽係eCRM197。
- 如請求項25之多肽-多醣結合物,其中該eCRM197具有SEQ ID NO: 25之序列。
- 如請求項1至13中任一項之多肽-多醣結合物,其中該GAS多肽抗原或非GAS載體多肽包括表1中所列示多肽之胺基酸序列或由其組成。
- 如請求項1至13中任一項之多肽-多醣結合物,其中該GAS多肽抗原或非GAS載體多肽包括表1A中所列示多肽之胺基酸序列或由其組成。
- 一種免疫原性組合物,其包括: (a) A型鏈球菌(GAS) C5a肽酶多肽抗原; (b) GAS鏈球菌溶血素O (SLO)多肽抗原;及 (c)多肽-多醣結合物,其包括 釀膿鏈球菌( Streptococcus pyogenes)黏附及分裂(SpyAD)結合多肽或其片段,其包括至少一個非天然胺基酸(nnAA),其中該至少一個nnAA包括點擊化學反應性基團,及 GAS多醣或其變體,其缺乏免疫顯性N-乙醯基葡萄糖胺(GlcNAc)側鏈; 其中該GAS多醣或其變體之介於約8 mol%與約20 mol%之間之多醣重複單元由連接體衍生;且 其中該多肽-多醣結合物之平均分子量介於約185 kDa與約700 kDa之間。
- 如請求項29之免疫原性組合物,其中該C5a肽酶多肽抗原包括SEQ ID NO: 29或SEQ ID NO: 30之胺基酸序列。
- 如請求項29或30之免疫原性組合物,其中該C5a肽酶多肽抗原包括與SEQ ID NO: 29或SEQ ID NO: 30至少95%一致之胺基酸序列。
- 如請求項29至31中任一項之免疫原性組合物,其中該C5a肽酶多肽抗原具有SEQ ID NO: 29或SEQ ID NO: 30之胺基酸序列。
- 如請求項29至32中任一項之免疫原性組合物,其中該SLO多肽抗原包括SEQ ID NO: 31、SEQ ID NO: 32、SEQ ID NO: 44、SEQ ID NO: 45、SEQ ID NO: 46、SEQ ID NO: 47、SEQ ID NO: 48、SEQ ID NO: 49、SEQ ID NO: 50、SEQ ID NO: 51、SEQ ID NO: 52或SEQ ID NO: 53之胺基酸序列。
- 如請求項29至33之免疫原性組合物,其中該SLO抗原包括與SEQ ID NO: 31、SEQ ID NO: 32、SEQ ID NO: 44、SEQ ID NO: 45、SEQ ID NO: 46、SEQ ID NO: 47、SEQ ID NO: 48、SEQ ID NO: 49、SEQ ID NO: 50、SEQ ID NO: 51、SEQ ID NO: 52或SEQ ID NO: 53至少95%一致之胺基酸序列。
- 如請求項29至34中任一項之免疫原性組合物,其中該SLO多肽抗原具有SEQ ID NO: 31、SEQ ID NO: 32、SEQ ID NO: 44、SEQ ID NO: 45、SEQ ID NO: 46、SEQ ID NO: 47、SEQ ID NO: 48、SEQ ID NO: 49、SEQ ID NO: 50、SEQ ID NO: 51、SEQ ID NO: 52或SEQ ID NO: 53之胺基酸序列。
- 如請求項29至35中任一項之免疫原性組合物,其中該至少一個nnAA係選自2-胺基-3-(4-疊氮基苯基)丙酸(pAF)、2-胺基-4-疊氮基丁酸、2-疊氮基-3-苯基丙酸、2-胺基-3-疊氮基丙酸、2-胺基-3-(4-(疊氮基甲基)苯基)丙酸(pAMF)、2-胺基-3-(5-(疊氮基甲基)吡啶-2-基)丙酸、2-胺基-3-(4-(疊氮基甲基)吡啶-2-基)丙酸、2-胺基-3-(6-(疊氮基甲基)吡啶-3-基)丙酸及2-胺基-5-疊氮基戊酸。
- 如請求項29至36中任一項之免疫原性組合物,其中該至少一個nnAA係pAMF。
- 如請求項29至37中任一項之免疫原性組合物,其中該SpyAD結合多肽或其片段包括與SEQ ID NO: 33至少95%一致之胺基酸序列。
- 如請求項29至38中任一項之免疫原性組合物,其中該SpyAD結合多肽包括作為SEQ ID NO: 33之片段之胺基酸序列。
- 如請求項29至38中任一項之免疫原性組合物,其中該SpyAD結合多肽具有作為SEQ ID NO: 33之片段之胺基酸序列。
- 如請求項29至40中任一項之免疫原性組合物,其中該SpyAD結合多肽在SEQ ID NO: 33之位置K64、K287、K386及K657處包括pAMF取代。
- 如請求項29至41中任一項之免疫原性組合物,其中該SpyAD結合多肽包括SEQ ID NO: 34、SEQ ID NO: 77、SEQ ID NO: 78、SEQ ID NO: 79、SEQ ID NO: 81、SEQ ID NO: 82或SEQ ID NO: 83之胺基酸序列。
- 如請求項29至42中任一項之免疫原性組合物,其中該SpyAD結合多肽包括與SEQ ID NO: 34、SEQ ID NO: 77、SEQ ID NO: 78、SEQ ID NO: 79、SEQ ID NO: 81、SEQ ID NO: 82或SEQ ID NO: 83至少95%一致之胺基酸序列。
- 如請求項29至43中任一項之免疫原性組合物,其中該SpyAD結合多肽具有SEQ ID NO: 34、SEQ ID NO: 77、SEQ ID NO: 78、SEQ ID NO: 79、SEQ ID NO: 81、SEQ ID NO: 82或SEQ ID NO: 83之胺基酸序列。
- 如請求項29至44中任一項之免疫原性組合物,其中該C5a肽酶多肽抗原包括與SEQ ID NO: 30至少95%一致之胺基酸序列;該SLO多肽抗原包括與SEQ ID NO: 53至少95%一致之胺基酸序列;且該SpyAD結合多肽包括與SEQ ID NO: 34至少95%一致之胺基酸序列。
- 如請求項29至45中任一項之免疫原性組合物,其中該C5a肽酶多肽抗原包括SEQ ID NO: 30之胺基酸序列;該SLO多肽抗原包括SEQ ID NO: 53之胺基酸序列;且該SpyAD結合多肽包括SEQ ID NO: 34之胺基酸序列。
- 如請求項29至46中任一項之免疫原性組合物,其中該C5a肽酶多肽抗原具有SEQ ID NO: 30之胺基酸序列;該SLO多肽抗原具有SEQ ID NO: 53之胺基酸序列;且該SpyAD結合多肽具有SEQ ID NO: 34之胺基酸序列。
- 如請求項29至47中任一項之免疫原性組合物,其中該GAS多醣或其變體之介於約15 mol%與約20 mol%之間之多醣重複單元由連接體衍生。
- 如請求項29至50中任一項之免疫原性組合物,其中該GAS多醣或其變體具有至少約10 kDa至至少約40 kDa之分子量。
- 如請求項29至51中任一項之免疫原性組合物,其中該多肽-多醣結合物之平均分子量介於約185 kDa與約700 kDa之間。
- 如請求項29至52中任一項之免疫原性組合物,其中該多肽-多醣結合物之平均分子量介於約200 kDa與約700 kDa之間。
- 如請求項29至53中任一項之免疫原性組合物,其中該多肽-多醣結合物之平均分子量介於約300 kDa與約700 kDa之間。
- 如請求項29至54中任一項之免疫原性組合物,其中該多肽-多醣結合物之平均分子量介於約300 kDa與約600 kDa之間。
- 如請求項29至55中任一項之免疫原性組合物,其進一步包括小於約60%之游離GAS多醣或其變體。
- 如請求項29至56中任一項之免疫原性組合物,其進一步包括小於約50%之游離GAS多醣或其變體。
- 如請求項29至57中任一項之免疫原性組合物,其進一步包括小於約25%之游離GAS多醣或其變體。
- 如請求項29至58中任一項之免疫原性組合物,其進一步包括小於約15%之游離GAS多醣或其變體。
- 如請求項29至59中任一項之免疫原性組合物,其進一步包括小於約10%之游離GAS多醣或其變體。
- 一種在個體中誘導針對A型鏈球菌(GAS)細菌之保護性免疫反應的方法,其包括向該個體投與如請求項29至60中任一項之免疫原性組合物。
- 如請求項61之方法,其中該免疫原性組合物在該個體中誘導針對該A型鏈球菌(GAS)細菌之抗體反應且並不在該個體中誘導針對人類組織之抗體反應。
- 一種如請求項29至60中任一項之免疫原性組合物之用途,其用以製造用於在個體中誘導針對GAS細菌之保護性免疫反應之藥劑。
- 一種如請求項29至60中任一項之免疫原性組合物之用途,其用於在個體中誘導針對GAS細菌之保護性免疫反應。
- 一種自細菌細胞純化細胞壁多醣或結合肽聚醣之莢膜多醣之方法,該方法包括: (a)在包括鹼及還原劑之溶液中水解該細菌細胞以形成包括多醣之溶解物;及 (b)將該包括多醣之溶解物與溶壁酶一起培育以形成游離多醣溶液。
- 如請求項65之方法,其中該細菌細胞係假單胞菌( Pseudomonas)細菌細胞、鏈球菌( Streptococcus)細菌細胞、葡萄球菌( Staphylococcus)細菌細胞、奈瑟菌( Neisseria)細菌細胞、嗜血桿菌( Haemophilus)細菌細胞、李斯特菌( Listeria)細菌細胞、腸球菌( Enterococcus)細菌細胞或梭菌( Clostridium)細菌細胞。
- 如請求項65或66之方法,其中該細菌細胞係選自銅綠假單胞菌( Pseudomonas aeruginosa)、草綠色鏈球菌( Streptococcus viridans)、變種鏈球菌( Streptococcus mutans)及釀膿鏈球菌。
- 如請求項67之方法,其中該釀膿鏈球菌細菌細胞屬選自M1、M2、M3、M4、M5、M6、M9、M11、M12、M13、M18、M22、M25、M28、M62、M71、M72、M74、M75、M77、M80、M81、M83、M87、M89或M92之血清型。
- 如請求項68之方法,其中該釀膿鏈球菌細菌細胞產生缺乏免疫顯性N-乙醯基葡萄糖胺(GlcNAc)側鏈之多醣或其變體。
- 如請求項65之方法,其用於自細菌細胞純化結合肽聚醣之莢膜多醣。
- 如請求項65至70中任一項之方法,其中步驟(a)之該鹼係NaOH、KOH或LiOH。
- 如請求項65至71中任一項之方法,其中步驟(a)之該鹼係NaOH。
- 如請求項65至72中任一項之方法,其中鹼濃度介於約2M至約8M之間。
- 如請求項65至73中任一項之方法,其中該包括鹼及還原劑之溶液為約pH 14。
- 如請求項65至72中任一項之方法,其中該還原劑係硼氫化鈉、氰基硼氫化鈉、三乙醯氧基硼氫化鈉、二硫蘇糖醇或β-巰基乙醇。
- 如請求項65至73中任一項之方法,其中該還原劑係硼氫化鈉。
- 如請求項65至76中任一項之方法,其中該還原劑之濃度介於約1 mM與500 mM之間。
- 如請求項65至75中任一項之方法,其中步驟(a)進一步包括在約30℃與約100℃之間培育該溶液。
- 如請求項65至78中任一項之方法,其中步驟(a)進一步包括將該溶液培育約0.5小時至約20小時。
- 如請求項65至79中任一項之方法,其中步驟(a)進一步包括 一或多個pH調節步驟。
- 如請求項80之方法,其中該一或多個pH調節步驟獨立地選自: (i)升高該包括多醣之溶解物之pH,或 (ii)降低該包括多醣之溶解物之pH。
- 如請求項81之方法,其包括將該包括多醣之溶解物之pH降至介於約3與7.0之間。
- 如請求項81或82之方法,其包括將該包括多醣之溶解物之pH降至約6.5。
- 如請求項81或82之方法,其包括將該包括多醣之溶解物之pH降至介於約3與約4之間。
- 如請求項80或81之方法,其包括 (i)將該包括多醣之溶解物之pH降至介於約5.5與7.0之間; (ii)將該包括多醣之溶解物之pH降至約3;及 (iii)將該包括多醣之溶解物之pH升至介於約5.5與7.0之間。
- 如請求項80至85中任一項之方法,其中在該一或多個pH調節步驟之後於約室溫(r.t.)下培育該包括多醣之溶解物。
- 如請求項81至84中任一項之方法,其中在該一或多個pH調節步驟之後於約4℃與約30℃之間培育該包括多醣之溶解物。
- 如請求項65至87中任一項之方法,其進一步包括自該包括多醣之溶解物去除固體。
- 如請求項88之方法,其中自該包括多醣之溶解物去除固體包括過濾、離心或其組合。
- 如請求項89之方法,其中該過濾包括深度過濾、切向流過濾(TFF)、無菌過濾或前述各項之組合。
- 如請求項89或90之方法,其中該過濾包括深度過濾及後續TFF。
- 如請求項88或89之方法,其中藉由離心自該包括多醣之溶解物去除固體。
- 如請求項65至92中任一項之方法,其中步驟(b)之該溶壁酶係變溶菌素(mutanolysin)、溶菌酶或噬菌體水解酶。
- 如請求項65至93中任一項之方法,其中步驟(b)進一步包括與蛋白酶一起培育。
- 如請求項94之方法,其中該蛋白酶係蛋白酶K、胰蛋白酶、胰凝乳蛋白酶、內蛋白酶Asp-N、內蛋白酶Arg-C、內蛋白酶Glu-C、內蛋白酶Lys-C、胃蛋白酶、嗜熱菌蛋白酶、彈性蛋白酶、木瓜酶、枯草桿菌蛋白酶(substilisin)、梭菌蛋白酶(clostripain)、羧肽酶A、羧肽酶B、羧肽酶P、羧肽酶Y、細胞自溶酶C、醯基胺基酸釋放酶或焦麩胺酸鹽。
- 如請求項65至95中任一項之方法,其中步驟(b)進一步包括將該包括多醣之溶解物與該溶壁酶升溫至介於約30℃與約65℃之間。
- 如請求項94至96中任一項之方法,其中將該包括多醣之溶解物與該蛋白酶升溫至介於約45℃與55℃之間。
- 如請求項96或97之方法,其中將該溶解物升溫約6小時至約20小時。
- 如請求項65至98中任一項之方法,其中進一步純化步驟(b)之該游離多醣溶液以減小核酸、酶、宿主細胞蛋白(HCP)或前述各項之組合之濃度。
- 如請求項65至99中任一項之方法,其中藉由沈澱進一步純化步驟(b)之該游離多醣溶液。
- 如請求項65至100中任一項之方法,其中使用鯨蠟基三甲基溴化銨(CTAB)處理步驟(b)之該游離多醣溶液。
- 如請求項101之方法,其中該游離多醣溶液中之CTAB濃度為約0.1%至約10%。
- 如請求項101或102之方法,CTAB之濃度介於約0.5%與約3%之間。
- 如請求項101至103中任一項之方法,其中使用碘化鉀(KI)處理步驟(b)之該游離多醣溶液。
- 如請求項104之方法,其中該游離多醣溶液中之KI濃度介於約20 mM至約400 mM之間。
- 如請求項65至105中任一項之方法,其中藉由過濾、離心、層析或前述各項之組合進一步純化該游離多醣溶液。
- 如請求項106之方法,其中該過濾包括深度過濾、切向流過濾(TFF)、無菌過濾或前述各項之組合。
- 如請求項106之方法,其中該層析包括疏水性相互作用層析(HIC)、陰離子交換層析(AEX)、陶瓷羥基磷灰石型層析或陽離子交換層析(CEX)。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163150516P | 2021-02-17 | 2021-02-17 | |
US63/150,516 | 2021-02-17 | ||
US202163288387P | 2021-12-10 | 2021-12-10 | |
US63/288,387 | 2021-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW202302152A true TW202302152A (zh) | 2023-01-16 |
Family
ID=82931694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW111105554A TW202302152A (zh) | 2021-02-17 | 2022-02-16 | 多醣及其多肽結合物之純化方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20240000926A1 (zh) |
EP (1) | EP4294452A1 (zh) |
JP (1) | JP2024506713A (zh) |
KR (1) | KR20230146620A (zh) |
AU (1) | AU2022221621A1 (zh) |
CA (1) | CA3208716A1 (zh) |
IL (1) | IL305201A (zh) |
TW (1) | TW202302152A (zh) |
WO (1) | WO2022178015A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12036276B2 (en) | 2021-09-09 | 2024-07-16 | Affinivax, Inc. | Multivalent pneumococcal vaccines |
CN115894604B (zh) * | 2022-12-16 | 2024-01-23 | 康日百奥生物科技(苏州)有限公司 | 重组蛋白澄清纯化方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2349520B1 (en) * | 2008-10-27 | 2016-05-25 | GlaxoSmithKline Biologicals SA | Purification method for carbohydrate from group a streptococcus |
EP2311947A1 (en) * | 2009-10-14 | 2011-04-20 | Ludwig-Maximilians-Universität München | Protein synthesis via click chemistry |
US20140294930A1 (en) * | 2011-08-04 | 2014-10-02 | The Regents Of The University Of California | STREPTOCOCCAL GlcNAc-LACKING GLYCOPOLYPEPTIDES, CELL WALL CARBOHYDRATES, STREPTOCOCCUS VACCINES, AND METHODS FOR MAKING AND USING THEM |
US11951165B2 (en) * | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
AU2017388891B2 (en) * | 2016-12-30 | 2024-10-17 | Vaxcyte, Inc. | Polypeptide-antigen conjugates with non-natural amino acids |
CN109045292A (zh) * | 2018-11-08 | 2018-12-21 | 山东大学 | 一种a群链球菌寡糖蛋白缀合物及其制备方法与应用 |
AU2020253332A1 (en) * | 2019-04-02 | 2021-11-25 | Vaxcyte, Inc. | Optimized cell-free synthesis of Invasion Plasmid Antigen B and related compositions and methods of use |
WO2021167996A1 (en) * | 2020-02-18 | 2021-08-26 | Vaxcyte, Inc. | Group a strep immunogenic compositions with polysaccharide-protein conjugates |
-
2022
- 2022-02-16 JP JP2023549595A patent/JP2024506713A/ja active Pending
- 2022-02-16 CA CA3208716A patent/CA3208716A1/en active Pending
- 2022-02-16 IL IL305201A patent/IL305201A/en unknown
- 2022-02-16 TW TW111105554A patent/TW202302152A/zh unknown
- 2022-02-16 AU AU2022221621A patent/AU2022221621A1/en active Pending
- 2022-02-16 KR KR1020237031748A patent/KR20230146620A/ko unknown
- 2022-02-16 WO PCT/US2022/016630 patent/WO2022178015A1/en active Application Filing
- 2022-02-16 EP EP22756854.0A patent/EP4294452A1/en active Pending
-
2023
- 2023-08-09 US US18/447,146 patent/US20240000926A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL305201A (en) | 2023-10-01 |
AU2022221621A9 (en) | 2024-10-17 |
US20240000926A1 (en) | 2024-01-04 |
EP4294452A1 (en) | 2023-12-27 |
JP2024506713A (ja) | 2024-02-14 |
KR20230146620A (ko) | 2023-10-19 |
WO2022178015A1 (en) | 2022-08-25 |
AU2022221621A1 (en) | 2023-08-17 |
CA3208716A1 (en) | 2022-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240000926A1 (en) | Purification processes for polysaccharides and polypeptide conjugates thereof | |
US20240358823A1 (en) | Conjugated vaccine carrier proteins | |
US10188719B2 (en) | Conjugation of Streptococcal capsular saccharides | |
Wang et al. | Synthesis of Neisseria meningitidis serogroup W135 capsular oligosaccharides for immunogenicity comparison and vaccine development | |
RU2636350C2 (ru) | МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021 | |
MX2007002094A (es) | Dominios y epitopos de proteina nmb1870 de meningococos. | |
MX2007009276A (es) | Purificacion de polisacarido capsular estreptococal. | |
EP2852414A1 (en) | Meningococcus serogroup x conjugate | |
US20230248839A1 (en) | Immunogenic compositions | |
US20230293658A1 (en) | Group a strep immunogenic compositions with polysaccharide-protein conjugates | |
US20130344104A1 (en) | Oligosaccharides and oligosaccharide-protein conjugates derived from clostridium difficile polysaccharide ps-ii, methods of synthesis and uses thereof, in particular as a vaccine | |
JP2018522978A (ja) | 免疫原性組成物 | |
CN117479961A (zh) | 多糖及其多肽缀合物的纯化方法 | |
KR20210042904A (ko) | 면역원성 접합체의 개선 | |
CA3192503A1 (en) | Pentavalent vaccine against neisseria meningitidis comprising a synthetic men a antigen | |
US11097000B2 (en) | Klebsiella pneumoniae capsule polysaccharide vaccines | |
CA2511084A1 (en) | Carbohydrate-phosphorylcholine conjugate molecules and their use in vaccinal, therapeutic and diagnostic applications |